|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
acanthoside B inhibits the reaction [Scopolamine results in increased expression of ACHE protein] |
CTD |
PMID:31077737 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
G |
Bdnf |
brain derived neurotrophic factor |
multiple interactions |
EXP |
[acanthoside B co-treated with Scopolamine] results in increased expression of BDNF protein |
CTD |
PMID:31077737 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
acanthoside B inhibits the reaction [Scopolamine results in decreased activity of CAT protein] |
CTD |
PMID:31077737 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
acanthoside B inhibits the reaction [Scopolamine results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:31077737 |
|
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
acanthoside B inhibits the reaction [Scopolamine results in decreased expression of IL10 protein] |
CTD |
PMID:31077737 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
acanthoside B inhibits the reaction [Scopolamine results in increased expression of IL1B protein] |
CTD |
PMID:31077737 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
acanthoside B inhibits the reaction [Scopolamine results in increased expression of IL6 protein] |
CTD |
PMID:31077737 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
EXP |
acanthoside B inhibits the reaction [Scopolamine results in increased expression of NOS2 protein] |
CTD |
PMID:31077737 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Ntrk2 |
neurotrophic tyrosine kinase, receptor, type 2 |
multiple interactions |
EXP |
[acanthoside B co-treated with Scopolamine] results in increased phosphorylation of NTRK2 protein |
CTD |
PMID:31077737 |
|
NCBI chr13:58,954,363...59,281,782
Ensembl chr13:58,954,383...59,281,784
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
acanthoside B inhibits the reaction [Scopolamine results in increased expression of PTGS2 protein] |
CTD |
PMID:31077737 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
acanthoside B inhibits the reaction [Scopolamine results in increased expression of TNF protein] |
CTD |
PMID:31077737 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
increases expression |
ISO |
ginsenoside Rh1 results in increased expression of FOS mRNA |
CTD |
PMID:16204943 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of IL1B mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1B mRNA] |
CTD |
PMID:16557482 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il4 |
interleukin 4 |
decreases expression |
EXP |
ginsenoside Rh1 results in decreased expression of IL4 |
CTD |
PMID:22855946 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Itga4 |
integrin alpha 4 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 2:79,084,767...79,163,458
Ensembl chr 2:79,085,770...79,163,467
|
|
G |
Itgal |
integrin alpha L |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 7:126,895,404...126,934,309
Ensembl chr 7:126,895,432...126,934,310
|
|
G |
Itgb1 |
integrin beta 1 (fibronectin receptor beta) |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681
|
|
G |
Itgb2 |
integrin beta 2 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr10:77,366,164...77,401,542
Ensembl chr10:77,366,086...77,401,542
|
|
G |
Jun |
jun proto-oncogene |
decreases activity |
EXP |
ginsenoside Rh1 results in decreased activity of JUN protein |
CTD |
PMID:22855946 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Lpl |
lipoprotein lipase |
increases secretion |
EXP |
ginsenoside Rh1 results in increased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
ginsenoside Rh1 results in increased expression of PGR protein |
CTD |
PMID:16204943 |
|
NCBI chr 9:8,890,017...8,968,612
Ensembl chr 9:8,899,834...8,968,612
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions |
EXP |
ginsenoside Rh1 inhibits the reaction [bisphenol A results in increased expression of PPARG mRNA]; ginsenoside Rh1 inhibits the reaction [bisphenol A results in increased expression of PPARG protein] |
CTD |
PMID:32623698 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of PTGS2 mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16557482 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Sele |
selectin, endothelial cell |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:21875580 |
|
NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
ginsenoside Rh1 results in increased expression of TFF1 mRNA |
CTD |
PMID:16204943 |
|
NCBI chr17:31,380,369...31,384,034
Ensembl chr17:31,380,369...31,384,251
|
|
G |
Tnf |
tumor necrosis factor |
decreases response to substance multiple interactions decreases expression |
ISO EXP |
ginsenoside Rh1 results in decreased susceptibility to TNF protein ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of TNF mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA] ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of SELE protein]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] ginsenoside Rh1 results in decreased expression of TNF |
CTD |
PMID:16557482 PMID:21875580 PMID:22855946 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337
|
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
decreases phosphorylation |
ISO |
ginsenoside Rh2 results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:32762018 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Bax |
BCL2-associated X protein |
increases expression |
ISO |
ginsenoside Rh2 results in increased expression of BAX protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of BCL2 protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Casp3 |
caspase 3 |
increases cleavage decreases expression |
ISO |
ginsenoside Rh2 results in increased cleavage of CASP3 protein ginsenoside Rh2 results in decreased expression of CASP3 protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp9 |
caspase 9 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of CASP9 protein |
CTD |
PMID:32762018 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of CCND1 protein |
CTD |
PMID:26482938 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Hdac1 |
histone deacetylase 1 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of HDAC1 protein |
CTD |
PMID:26482938 |
|
NCBI chr 4:129,409,897...129,436,516
Ensembl chr 4:129,409,897...129,436,506
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of HDAC2 protein |
CTD |
PMID:26482938 |
|
NCBI chr10:36,850,293...36,877,885
Ensembl chr10:36,850,540...36,877,885
|
|
G |
Hdac6 |
histone deacetylase 6 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of HDAC6 protein |
CTD |
PMID:26482938 |
|
NCBI chr X:7,796,355...7,814,284
Ensembl chr X:7,796,359...7,814,128
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside Rh2 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
decreases phosphorylation increases phosphorylation |
ISO |
ginsenoside Rh2 results in decreased phosphorylation of MAPK1 protein ginsenoside Rh2 results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
decreases phosphorylation increases phosphorylation |
ISO |
ginsenoside Rh2 results in decreased phosphorylation of MAPK3 protein ginsenoside Rh2 results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
ginsenoside Rh2 results in decreased phosphorylation of MTOR protein |
CTD |
PMID:32762018 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
increases expression |
ISO |
ginsenoside Rh2 results in increased expression of NFKBIA protein |
CTD |
PMID:32762018 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
ginsenoside Rh2 results in increased expression of and results in decreased phosphorylation of RELA protein |
CTD |
PMID:32762018 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle, aorta |
multiple interactions |
EXP ISO |
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:36457260 |
|
NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
EXP ISO |
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein] |
CTD |
PMID:36457260 |
|
NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359
|
|
G |
Hpse |
heparanase |
multiple interactions |
EXP ISO |
Amygdalin inhibits the reaction [Ovalbumin results in increased expression of HPSE protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of HPSE protein] |
CTD |
PMID:36457260 |
|
NCBI chr 5:100,827,350...100,867,582
Ensembl chr 5:100,827,350...100,867,582
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
[peoniflorin co-treated with benzoylpaeoniflorin co-treated with Amygdalin] inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS1 mRNA]; Amygdalin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS1 mRNA] |
CTD |
PMID:33149750 |
|
NCBI chr 2:36,106,758...36,142,287
Ensembl chr 2:36,120,438...36,142,284
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[peoniflorin co-treated with benzoylpaeoniflorin co-treated with Amygdalin] inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Amygdalin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:33149750 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO EXP |
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of HPSE protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased secretion of TGFB1 protein] Amygdalin inhibits the reaction [Ovalbumin results in increased secretion of TGFB1 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of HPSE protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased secretion of TGFB1 protein] |
CTD |
PMID:36457260 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Vim |
vimentin |
multiple interactions |
EXP ISO |
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] |
CTD |
PMID:36457260 |
|
NCBI chr 2:13,579,122...13,587,637
Ensembl chr 2:13,578,738...13,587,637
|
|
|
G |
Aacs |
acetoacetyl-CoA synthetase |
increases expression |
EXP |
Glucosamine results in increased expression of AACS mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:125,552,937...125,594,469
Ensembl chr 5:125,552,878...125,594,474
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
increases expression |
ISO |
Glucosamine results in increased expression of ABCG1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr17:31,276,668...31,336,958
Ensembl chr17:31,276,649...31,336,962
|
|
G |
Acaca |
acetyl-Coenzyme A carboxylase alpha |
increases expression |
ISO |
Glucosamine results in increased expression of ACACA mRNA |
CTD |
PMID:22096489 |
|
NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477
|
|
G |
Acan |
aggrecan |
multiple interactions increases expression decreases expression affects expression |
ISO EXP |
Glucosamine analog affects the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of ACAN mRNA]; Glucosamine results in decreased cleavage of and results in decreased secretion of ACAN protein Glucosamine results in increased expression of ACAN mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of ACAN mRNA] Glucosamine analog results in increased expression of ACAN protein; Glucosamine results in increased expression of ACAN mRNA; Glucosamine results in increased expression of ACAN protein Glucosamine analog results in decreased expression of ACAN mRNA Glucosamine analog affects the expression of ACAN mRNA |
CTD |
PMID:12801482 PMID:16300972 PMID:16872674 PMID:17109745 PMID:17337215 PMID:18321735 PMID:19909832 More...
|
|
NCBI chr 7:78,702,974...78,764,847
Ensembl chr 7:78,703,231...78,764,847
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression |
EXP |
Glucosamine results in increased expression of ACOT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:84,056,276...84,064,444
Ensembl chr12:84,056,264...84,065,145
|
|
G |
Acox2 |
acyl-Coenzyme A oxidase 2, branched chain |
decreases expression |
EXP |
Glucosamine results in decreased expression of ACOX2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:14,210,406...14,244,262
Ensembl chr14:14,210,420...14,244,262
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
increases expression |
EXP |
Glucosamine results in increased expression of ACSS2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:155,359,963...155,404,663
Ensembl chr 2:155,359,868...155,427,644
|
|
G |
Adam15 |
ADAM metallopeptidase domain 15 |
multiple interactions decreases expression |
ISO |
Glucosamine affects the reaction [IL1B results in decreased expression of ADAM15 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of ADAM15 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:89,246,947...89,257,589
Ensembl chr 3:89,245,849...89,257,303
|
|
G |
Adam17 |
a disintegrin and metallopeptidase domain 17 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr12:21,373,510...21,423,633
Ensembl chr12:21,373,510...21,423,633
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif 1 |
decreases expression multiple interactions |
ISO |
Glucosamine analog results in decreased expression of ADAMTS1 mRNA Glucosamine results in decreased expression of ADAMTS1 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of ADAMTS1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of ADAMTS1 mRNA] |
CTD |
PMID:16300972 PMID:17109745 |
|
NCBI chr16:85,590,715...85,600,001
Ensembl chr16:85,590,715...85,600,001
|
|
G |
Adamts20 |
ADAM metallopeptidase with thrombospondin type 1 motif 20 |
decreases cleavage |
ISO |
Glucosamine results in decreased cleavage of ADAMTS20 protein alternative form |
CTD |
PMID:19909832 |
|
NCBI chr15:94,166,177...94,329,966
Ensembl chr15:94,168,044...94,363,299
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif 4 |
increases expression |
ISO |
Glucosamine results in increased expression of ADAMTS4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:171,077,698...171,089,836
Ensembl chr 1:171,077,990...171,088,206
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif 5 |
decreases expression multiple interactions |
ISO |
Glucosamine analog results in decreased expression of ADAMTS5 mRNA Glucosamine results in decreased cleavage of and results in decreased activity of ADAMTS5 protein alternative form |
CTD |
PMID:16300972 PMID:19909832 |
|
NCBI chr16:85,655,045...85,698,013
Ensembl chr16:85,653,061...85,698,716
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif 9 |
decreases cleavage |
ISO |
Glucosamine results in decreased cleavage of ADAMTS9 protein alternative form |
CTD |
PMID:19909832 |
|
NCBI chr 6:92,749,680...92,921,431
Ensembl chr 6:92,749,680...92,920,473
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
EXP ISO |
Glucosamine results in increased expression of ADIPOQ mRNA |
CTD |
PMID:15694357 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Afp |
alpha fetoprotein |
increases expression |
EXP |
Glucosamine results in increased expression of AFP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:90,638,573...90,656,766
Ensembl chr 5:90,638,596...90,656,766
|
|
G |
Agt |
angiotensinogen |
increases expression |
EXP |
Glucosamine results in increased expression of AGT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445
|
|
G |
Ahi1 |
Abelson helper integration site 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of AHI1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:20,827,274...20,956,328
Ensembl chr10:20,828,446...20,956,328
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
affects phosphorylation multiple interactions |
ISO EXP |
Glucosamine analog affects the phosphorylation of AKT1 protein Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]] Glucosamine analog affects the reaction [IL1B results in increased phosphorylation of AKT1 protein]; Glucosamine promotes the reaction [IL1B results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:18080321 PMID:18340449 PMID:30602124 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
[LEPR protein affects the susceptibility to Glucosamine] which affects the expression of ALB protein |
CTD |
PMID:33345901 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Alg12 |
ALG12 alpha-1,6-mannosyltransferase |
decreases expression |
EXP |
Glucosamine results in decreased expression of ALG12 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:88,689,448...88,703,498
Ensembl chr15:88,689,447...88,703,521
|
|
G |
Alpl |
alkaline phosphatase, liver/bone/kidney |
multiple interactions increases expression increases activity |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased activity of ALPL protein] Glucosamine analog results in increased expression of ALPL mRNA |
CTD |
PMID:20458730 |
|
NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695
|
|
G |
Apoa1 |
apolipoprotein A-I |
increases secretion increases stability |
ISO |
Glucosamine results in increased secretion of APOA1 protein Glucosamine results in increased stability of APOA1 mRNA |
CTD |
PMID:15164326 |
|
NCBI chr 9:46,139,928...46,141,767
Ensembl chr 9:46,139,878...46,141,764
|
|
G |
Apob |
apolipoprotein B |
multiple interactions increases degradation increases ubiquitination decreases secretion decreases localization decreases expression |
ISO |
acetylleucyl-leucyl-norleucinal inhibits the reaction [Glucosamine results in decreased expression of and results in decreased secretion of APOB protein]; Glucosamine results in decreased expression of and results in decreased secretion of APOB protein; Oleic Acid inhibits the reaction [Glucosamine results in decreased secretion of APOB protein] Oleic Acid inhibits the reaction [Glucosamine results in increased degradation of APOB protein] Glucosamine results in increased ubiquitination of APOB protein Glucosamine results in decreased localization of APOB protein Glucosamine results in decreased expression of APOB protein |
CTD |
PMID:15618547 PMID:19383982 |
|
NCBI chr12:8,027,629...8,066,839
Ensembl chr12:8,027,648...8,066,835
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
EXP |
[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine; INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine] |
CTD |
PMID:16380481 |
|
NCBI chr 7:19,430,169...19,434,326
Ensembl chr 7:19,430,034...19,433,113
|
|
G |
Ass1 |
argininosuccinate synthetase 1 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of ASS1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:31,360,282...31,410,682
Ensembl chr 2:31,360,219...31,410,684
|
|
G |
Atf3 |
activating transcription factor 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of ATF3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
EXP ISO |
Glucosamine results in increased expression of ATF4 mRNA; Glucosamine results in increased expression of ATF4 protein NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF4 protein]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of ATF4 mRNA]; GSK2656157 inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA] |
CTD |
PMID:30602124 PMID:33812996 |
|
NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions increases expression decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA] ATF6 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA] Glucosamine results in increased expression of ATF6 protein 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA] Glucosamine results in decreased expression of ATF6 mRNA |
CTD |
PMID:17178593 PMID:19383982 PMID:20165829 PMID:30602124 PMID:33812996 |
|
NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340
|
|
G |
Atf7ip |
activating transcription factor 7 interacting protein |
increases expression |
EXP |
Glucosamine results in increased expression of ATF7IP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:136,495,787...136,587,848
Ensembl chr 6:136,483,165...136,587,860
|
|
G |
Atp2a2 |
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of ATP2A2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:122,591,576...122,640,288
Ensembl chr 5:122,591,576...122,640,288
|
|
G |
Azin1 |
antizyme inhibitor 1 |
decreases expression multiple interactions |
ISO |
Glucosamine results in decreased expression of AZIN1 mRNA IL1B promotes the reaction [Glucosamine results in increased expression of AZIN1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr15:38,487,674...38,523,506
Ensembl chr15:38,487,671...38,519,510
|
|
G |
B3gat3 |
beta-1,3-glucuronyltransferase 3 |
multiple interactions increases expression |
ISO |
[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased activity of B3GAT3 protein]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of B3GAT3 mRNA] |
CTD |
PMID:11229466 PMID:11801247 |
|
NCBI chr19:8,897,740...8,904,600
Ensembl chr19:8,897,738...8,904,600
|
|
G |
Bcl2l1 |
BCL2-like 1 |
decreases expression multiple interactions |
ISO |
Glucosamine results in decreased expression of BCL2L1 protein pepstatin inhibits the reaction [Glucosamine results in decreased expression of BCL2L1 protein] |
CTD |
PMID:15972124 PMID:16850161 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Bdnf |
brain derived neurotrophic factor |
decreases expression |
EXP |
Glucosamine results in decreased expression of BDNF mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Bglap |
bone gamma carboxyglutamate protein |
increases expression |
ISO |
Glucosamine analog results in increased expression of BGLAP mRNA |
CTD |
PMID:20458730 |
|
NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771
|
|
G |
Bgn |
biglycan |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of BGN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of BGN mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:72,527,207...72,539,542
Ensembl chr X:72,527,208...72,539,539
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of BMAL1 mRNA; Glucosamine results in decreased expression of BMAL1 protein |
CTD |
PMID:24442997 |
|
NCBI chr 7:112,777,820...112,913,333
Ensembl chr 7:112,806,672...112,913,333
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:133,394,079...133,404,816
Ensembl chr 2:133,394,079...133,404,805
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression multiple interactions |
ISO |
Glucosamine results in decreased expression of BMP4 mRNA Glucosamine promotes the reaction [IL1B results in decreased expression of BMP4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:46,620,982...46,628,126
Ensembl chr14:46,620,977...46,628,126
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP6 mRNA] Glucosamine results in decreased expression of BMP6 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:38,529,098...38,684,283
Ensembl chr13:38,529,083...38,684,278
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP7 mRNA] Glucosamine results in increased expression of BMP7 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:172,709,805...172,782,114
Ensembl chr 2:172,709,805...172,782,114
|
|
G |
Calr |
calreticulin |
decreases expression |
EXP |
Glucosamine results in decreased expression of CALR mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563
|
|
G |
Car3 |
carbonic anhydrase 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CAR3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:14,928,598...14,937,441
Ensembl chr 3:14,928,572...14,937,583
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
Glucosamine results in increased cleavage of CASP3 protein Glucosamine results in increased activity of and results in increased cleavage of CASP3 protein |
CTD |
PMID:16850161 PMID:22020377 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp4 |
caspase 4, apoptosis-related cysteine peptidase |
decreases expression |
EXP |
Glucosamine results in decreased expression of CASP4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:5,308,816...5,336,791
Ensembl chr 9:5,308,828...5,336,783
|
|
G |
Cbr2 |
carbonyl reductase 2 |
increases expression |
EXP |
Glucosamine results in increased expression of CBR2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:120,620,311...120,622,851
Ensembl chr11:120,620,315...120,622,940
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
EXP |
Glucosamine results in increased expression of CBR3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr16:93,480,107...93,487,879
Ensembl chr16:93,480,103...93,487,878
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 protein]]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL2 protein]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 protein] Glucosamine results in increased expression of CCL2 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of CCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL2 mRNA] |
CTD |
PMID:17109745 PMID:18080321 PMID:18949387 PMID:19020780 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL20 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL20 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:83,094,487...83,096,888
Ensembl chr 1:83,094,487...83,096,888
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL22 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 8:95,472,312...95,478,016
Ensembl chr 8:95,472,218...95,478,327
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL3 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL5 protein] Glucosamine inhibits the reaction [IL1B results in increased expression of CCL5 mRNA] |
CTD |
PMID:17109745 PMID:18080321 |
|
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL7 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr11:81,936,538...81,938,351
Ensembl chr11:81,936,538...81,938,351
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
ISO |
Glucosamine analog results in increased expression of CCN2 mRNA |
CTD |
PMID:21466783 |
|
NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CCNB1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:100,915,247...100,922,994
Ensembl chr13:100,915,158...100,923,078
|
|
G |
Cd24a |
CD24a antigen |
increases expression |
EXP |
Glucosamine results in increased expression of CD24A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:43,454,433...43,460,261
Ensembl chr10:43,454,280...43,460,261
|
|
G |
Cd28 |
CD28 antigen |
increases expression |
ISO |
Glucosamine results in increased expression of CD28 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:60,785,547...60,812,521
Ensembl chr 1:60,755,959...60,812,518
|
|
G |
Cdc20 |
cell division cycle 20 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CDC20 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:118,290,098...118,294,540
Ensembl chr 4:118,290,098...118,294,549
|
|
G |
Cdc23 |
CDC23 cell division cycle 23 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CDC23 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr18:34,761,401...34,784,802
Ensembl chr18:34,764,004...34,784,788
|
|
G |
Cdk1 |
cyclin dependent kinase 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CDK1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:69,170,976...69,188,742
Ensembl chr10:69,170,976...69,188,768
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
increases expression |
ISO EXP |
Glucosamine results in increased expression of CDKN1A protein Glucosamine results in increased expression of CDKN1A mRNA |
CTD |
PMID:15654767 PMID:17178593 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
decreases expression |
ISO |
Glucosamine results in decreased expression of CDKN1B protein |
CTD |
PMID:15654767 |
|
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Cdkn3 |
cyclin dependent kinase inhibitor 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CDKN3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr14:46,997,912...47,008,987
Ensembl chr14:46,997,998...47,009,126
|
|
G |
Cenpf |
centromere protein F |
decreases expression |
ISO |
Glucosamine results in decreased expression of CENPF mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:189,372,803...189,420,302
Ensembl chr 1:189,372,803...189,420,283
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of CHI3L1 mRNA |
CTD |
PMID:16142878 |
|
NCBI chr 1:134,109,894...134,117,769
Ensembl chr 1:134,109,914...134,117,919
|
|
G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
multiple interactions decreases activity |
ISO |
Glucosamine analog results in decreased activity of and results in decreased localization of CHUK protein Glucosamine analog results in decreased activity of CHUK protein |
CTD |
PMID:20113495 |
|
NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919
|
|
G |
Ckap2 |
cytoskeleton associated protein 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CKAP2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:22,658,168...22,675,835
Ensembl chr 8:22,658,176...22,675,835
|
|
G |
Clock |
clock circadian regulator |
decreases expression |
EXP |
Glucosamine results in decreased expression of CLOCK mRNA; Glucosamine results in decreased expression of CLOCK protein |
CTD |
PMID:24442997 |
|
NCBI chr 5:76,357,715...76,452,675
Ensembl chr 5:76,357,715...76,452,639
|
|
G |
Clta |
clathrin light chain A |
decreases expression |
ISO |
Glucosamine results in decreased expression of CLTA mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:44,003,816...44,032,846
Ensembl chr 4:44,004,452...44,032,846
|
|
G |
Col11a1 |
collagen, type XI, alpha 1 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of COL11A1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of COL11A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:113,823,933...114,014,405
Ensembl chr 3:113,824,189...114,014,367
|
|
G |
Col1a1 |
collagen, type I, alpha 1 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B protein results in increased expression of COL1A1 mRNA] Glucosamine results in decreased expression of COL1A1 mRNA |
CTD |
PMID:18321735 |
|
NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868
|
|
G |
Col2a1 |
collagen, type II, alpha 1 |
multiple interactions affects expression increases expression |
ISO |
Glucosamine analog affects the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of COL2A1 mRNA] Glucosamine inhibits the reaction [IL1B results in decreased expression of COL2A1 mRNA] Glucosamine analog affects the expression of COL2A1 mRNA Glucosamine analog results in increased expression of COL2A1 mRNA; Glucosamine results in increased expression of COL2A1 mRNA |
CTD |
PMID:16300972 PMID:17109745 PMID:17337215 PMID:18321735 |
|
NCBI chr15:97,873,483...97,902,525
Ensembl chr15:97,873,483...97,902,576
|
|
G |
Col3a1 |
collagen, type III, alpha 1 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of COL3A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:45,350,698...45,388,866
Ensembl chr 1:45,350,698...45,388,866
|
|
G |
Col8a1 |
collagen, type VIII, alpha 1 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of COL8A1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of COL8A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr16:57,444,619...57,575,100
Ensembl chr16:57,444,621...57,575,100
|
|
G |
Csf1 |
colony stimulating factor 1 (macrophage) |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CSF1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:107,648,364...107,668,048
Ensembl chr 3:107,648,364...107,667,785
|
|
G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF2 mRNA] Glucosamine results in increased expression of CSF2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493
|
|
G |
Csf3 |
colony stimulating factor 3 (granulocyte) |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF3 mRNA] Glucosamine results in increased expression of CSF3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr11:98,591,287...98,594,457
Ensembl chr11:98,592,089...98,594,455
|
|
G |
Ctsd |
cathepsin D |
affects localization multiple interactions increases activity decreases expression |
ISO |
Glucosamine affects the localization of CTSD protein pepstatin inhibits the reaction [Glucosamine results in decreased expression of CTSD protein alternative form] Glucosamine results in increased activity of CTSD protein |
CTD |
PMID:15972124 PMID:16850161 |
|
NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775
|
|
G |
Cul2 |
cullin 2 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CUL2 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr18:3,382,970...3,436,700
Ensembl chr18:3,382,988...3,436,377
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CXCL1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:91,039,104...91,040,980
Ensembl chr 5:91,039,100...91,040,974
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
EXP ISO |
Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA] Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL10 mRNA] |
CTD |
PMID:17109745 PMID:20737476 |
|
NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748
|
|
G |
Cxcl11 |
chemokine (C-X-C motif) ligand 11 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL11 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:92,507,403...92,511,155
Ensembl chr 5:92,507,403...92,513,344
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions decreases expression |
ISO |
Glucosamine promotes the reaction [IL1B results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of CXCL12 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [IL1B results in increased expression of CXCL8 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CXCL8 protein]; Glucosamine analog inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL8 protein]; Glucosamine inhibits the reaction [IL1B results in increased secretion of CXCL8 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CXCL8 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CXCL8 mRNA] |
CTD |
PMID:18026701 PMID:18080321 PMID:19626664 PMID:20113495 PMID:20307528 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL3 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459
|
|
G |
Cxcl5 |
C-X-C motif chemokine ligand 5 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL5 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:90,907,157...90,909,484
Ensembl chr 5:90,907,219...90,909,483
|
|
G |
Cyba |
cytochrome b-245, alpha polypeptide |
decreases expression |
ISO |
Glucosamine results in decreased expression of CYBA mRNA |
CTD |
PMID:18077487 |
|
NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
Glucosamine affects the localization of CYCS protein |
CTD |
PMID:15972124 PMID:22020377 |
|
NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
EXP |
Glucosamine results in increased expression of CYP51 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:4,130,674...4,154,697
Ensembl chr 5:4,131,145...4,154,746
|
|
G |
Dbi |
diazepam binding inhibitor |
increases expression |
EXP |
Glucosamine results in increased expression of DBI mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:120,041,010...120,048,826
Ensembl chr 1:120,041,010...120,048,808
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions decreases expression |
ISO EXP |
Glucosamine results in increased expression of DDIT3 mRNA; Glucosamine results in increased expression of DDIT3 protein NUS1 protein inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of DDIT3 protein] Glucosamine results in decreased expression of DDIT3 mRNA |
CTD |
PMID:16380481 PMID:17178593 PMID:30602124 PMID:33812996 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Ddit4l |
DNA-damage-inducible transcript 4-like |
increases expression |
ISO |
Glucosamine results in increased expression of DDIT4L mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:137,329,433...137,334,093
Ensembl chr 3:137,327,373...137,334,094
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
increases expression |
EXP |
Glucosamine results in increased expression of DHCR7 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:143,376,827...143,402,147
Ensembl chr 7:143,376,882...143,402,147
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
decreases expression |
EXP |
Glucosamine results in decreased expression of DNAJB11 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr16:22,676,595...22,698,384
Ensembl chr16:22,676,595...22,698,384
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
decreases expression |
EXP |
Glucosamine results in decreased expression of DNAJB9 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:44,252,680...44,256,851
Ensembl chr12:44,252,342...44,257,109
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of DNAJC3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:119,175,371...119,219,114
Ensembl chr14:119,175,388...119,219,109
|
|
G |
Dspp |
dentin sialophosphoprotein |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of DSPP mRNA |
CTD |
PMID:20458730 |
|
NCBI chr 5:104,318,569...104,327,993
Ensembl chr 5:104,318,578...104,327,993
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP5 mRNA] Glucosamine results in increased expression of DUSP5 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr19:53,517,576...53,530,240
Ensembl chr19:53,517,540...53,530,862
|
|
G |
Dusp7 |
dual specificity phosphatase 7 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP7 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of DUSP7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 9:106,245,831...106,252,923
Ensembl chr 9:106,245,831...106,252,923
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of DYNC1I1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 6:5,725,772...6,028,030
Ensembl chr 6:5,725,639...6,028,039
|
|
G |
Edem1 |
ER degradation enhancer, mannosidase alpha-like 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of EDEM1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:108,800,984...108,836,317
Ensembl chr 6:108,805,602...108,836,317
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases expression increases phosphorylation |
ISO EXP |
EIF2AK3 gene mutant form inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] NUS1 protein inhibits the reaction [Glucosamine results in increased expression of EIF2AK3 protein] EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of ATF4 mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] Glucosamine results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:16324875 PMID:19383982 PMID:30602124 PMID:33812996 |
|
NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2, subunit 1 alpha |
increases phosphorylation multiple interactions |
ISO EXP |
Glucosamine results in increased phosphorylation of EIF2S1 protein NUS1 protein inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 protein affects the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; GSK2656157 inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] EIF2AK3 gene mutant form inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:16324875 PMID:19383982 PMID:30602124 PMID:33812996 |
|
NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
increases expression |
EXP |
Glucosamine results in increased expression of ELOVL6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:129,326,035...129,432,144
Ensembl chr 3:129,326,004...129,432,144
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
decreases expression multiple interactions |
ISO |
Glucosamine results in decreased expression of EPAS1 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of EPAS1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of EPAS1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr17:87,061,292...87,140,838
Ensembl chr17:87,061,128...87,140,838
|
|
G |
Eprs1 |
glutamyl-prolyl-tRNA synthetase 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of EPRS1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:185,093,614...185,160,557
Ensembl chr 1:185,095,241...185,160,557
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signalling 1 |
multiple interactions increases expression |
EXP ISO |
ERN1 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased splicing of XBP1 mRNA] NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ERN1 mRNA] |
CTD |
PMID:30602124 PMID:33812996 |
|
NCBI chr11:106,285,474...106,378,701
Ensembl chr11:106,285,476...106,378,678
|
|
G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
increases expression |
EXP ISO |
Glucosamine results in increased expression of FABP4 mRNA |
CTD |
PMID:15694357 |
|
NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
Glucosamine results in increased expression of FASN mRNA |
CTD |
PMID:22096489 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Fbp2 |
fructose bisphosphatase 2 |
increases expression |
EXP |
Glucosamine results in increased expression of FBP2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:62,984,698...63,006,214
Ensembl chr13:62,984,691...63,006,236
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
Glucosamine promotes the reaction [Glucose results in increased expression of FGF2 mRNA] |
CTD |
PMID:1518840 |
|
NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
decreases expression multiple interactions |
ISO |
Glucosamine results in decreased expression of FGF7 mRNA IL1B inhibits the reaction [Glucosamine results in decreased expression of FGF7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:125,876,578...125,933,105
Ensembl chr 2:125,876,578...125,933,105
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of FGF9 mRNA] Glucosamine results in increased expression of FGF9 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr14:58,308,543...58,350,311
Ensembl chr14:58,308,004...58,350,177
|
|
G |
Fgfr1 |
fibroblast growth factor receptor 1 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of FGFR1 mRNA] Glucosamine results in increased expression of FGFR1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:26,008,808...26,067,819
Ensembl chr 8:26,003,670...26,065,734
|
|
G |
Fkbp11 |
FK506 binding protein 11 |
decreases expression |
EXP |
Glucosamine results in decreased expression of FKBP11 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:98,622,249...98,626,079
Ensembl chr15:98,622,247...98,626,079
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
EXP ISO |
Glucosamine results in decreased expression of FN1 protein |
CTD |
PMID:17178593 |
|
NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
multiple interactions |
EXP ISO |
Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of FOS mRNA] Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of FOS protein] |
CTD |
PMID:19375915 PMID:21825963 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Furin |
furin, paired basic amino acid cleaving enzyme |
decreases cleavage multiple interactions |
ISO |
Glucosamine results in decreased cleavage of FURIN protein alternative form Glucosamine results in decreased glycosylation of and results in decreased activity of FURIN protein |
CTD |
PMID:19909832 |
|
NCBI chr 7:80,038,942...80,055,188
Ensembl chr 7:80,038,333...80,055,184
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
increases expression |
ISO |
Glucosamine results in increased expression of FXYD2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 9:45,311,007...45,321,576
Ensembl chr 9:45,310,967...45,321,576
|
|
G |
Gatm |
glycine amidinotransferase (L-arginine:glycine amidinotransferase) |
decreases expression |
ISO |
Glucosamine results in decreased expression of GATM mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:122,424,954...122,441,758
Ensembl chr 2:122,424,948...122,441,784
|
|
G |
Gck |
glucokinase |
decreases expression |
ISO |
Glucosamine results in decreased expression of GCK mRNA |
CTD |
PMID:11893929 |
|
NCBI chr11:5,850,816...5,900,081
Ensembl chr11:5,850,820...5,900,081
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
EXP |
Glucosamine analog results in increased expression of GCLC mRNA |
CTD |
PMID:21825963 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gfpt1 |
glutamine fructose-6-phosphate transaminase 1 |
multiple interactions |
ISO |
[Glucosamine co-treated with INS1 protein] affects the localization of GFPT1 protein |
CTD |
PMID:9453242 |
|
NCBI chr 6:87,019,828...87,069,189
Ensembl chr 6:87,019,828...87,069,179
|
|
G |
Glrx |
glutaredoxin |
increases expression |
EXP |
Glucosamine results in increased expression of GLRX mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:75,988,004...75,998,270
Ensembl chr13:75,987,987...75,998,273
|
|
G |
Gnpnat1 |
glucosamine-phosphate N-acetyltransferase 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of GNPNAT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:45,613,897...45,626,972
Ensembl chr14:45,613,791...45,642,370
|
|
G |
Gnptab |
N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits |
increases expression |
EXP |
Glucosamine results in increased expression of GNPTAB mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:88,215,130...88,283,186
Ensembl chr10:88,214,994...88,283,191
|
|
G |
Gpd1l |
glycerol-3-phosphate dehydrogenase 1-like |
increases expression |
EXP |
Glucosamine results in increased expression of GPD1L mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:114,728,407...114,763,055
Ensembl chr 9:114,728,409...114,763,055
|
|
G |
Grem1 |
gremlin 1, DAN family BMP antagonist |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of GREM1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of GREM1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:113,579,020...113,588,993
Ensembl chr 2:113,576,509...113,588,991
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions decreases phosphorylation |
ISO |
Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]; NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] Glucosamine results in decreased phosphorylation of GSK3B protein |
CTD |
PMID:33812996 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
Gspt1 |
G1 to S phase transition 1 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of GSPT1 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr16:11,034,104...11,072,189
Ensembl chr16:11,037,156...11,072,189
|
|
G |
Gstt1 |
glutathione S-transferase, theta 1 |
increases expression |
EXP |
Glucosamine results in increased expression of GSTT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:75,619,647...75,634,418
Ensembl chr10:75,619,647...75,634,418
|
|
G |
H2-Bl |
histocompatibility 2, blastocyst |
decreases expression |
EXP |
Glucosamine results in decreased expression of H2-BL mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:36,391,002...36,395,141
Ensembl chr17:36,391,007...36,395,115
|
|
G |
Hapln1 |
hyaluronan and proteoglycan link protein 1 |
decreases expression multiple interactions |
ISO |
Glucosamine results in decreased expression of HAPLN1 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of HAPLN1 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of HAPLN1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr13:89,688,654...89,759,951
Ensembl chr13:89,687,915...89,759,771
|
|
G |
Herpud1 |
homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of HERPUD1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:95,113,057...95,121,999
Ensembl chr 8:95,113,066...95,122,005
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
multiple interactions decreases expression |
ISO |
Glucosamine affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein]; Glucosamine inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein] Glucosamine results in decreased expression of HIF1A mRNA; Glucosamine results in decreased expression of HIF1A protein |
CTD |
PMID:19254699 PMID:22020377 |
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Hk1 |
hexokinase 1 |
increases expression |
EXP ISO |
Glucosamine results in increased expression of HK1 mRNA |
CTD |
PMID:11893929 PMID:17178593 |
|
NCBI chr10:62,104,634...62,215,699
Ensembl chr10:62,104,634...62,215,687
|
|
G |
Hmga1 |
high mobility group AT-hook 1 |
increases expression |
ISO |
Glucosamine results in increased expression of HMGA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr17:27,774,798...27,782,649
Ensembl chr17:27,775,471...27,782,648
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 |
increases expression |
EXP |
Glucosamine results in increased expression of HMGCS1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:120,151,887...120,169,796
Ensembl chr13:120,151,915...120,169,796
|
|
G |
Hmmr |
hyaluronan mediated motility receptor (RHAMM) |
decreases expression |
ISO |
Glucosamine results in decreased expression of HMMR mRNA |
CTD |
PMID:17109745 |
|
NCBI chr11:40,592,215...40,624,290
Ensembl chr11:40,592,222...40,624,249
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 protein] Glucosamine results in increased expression of HMOX1 mRNA; Glucosamine results in increased expression of HMOX1 protein |
CTD |
PMID:18077487 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hoxa1 |
homeobox A1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of HOXA1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:52,132,573...52,135,299
Ensembl chr 6:52,132,570...52,135,297
|
|
G |
Hpgd |
hydroxyprostaglandin dehydrogenase 15 (NAD) |
decreases expression |
ISO |
Glucosamine results in decreased expression of HPGD mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:56,747,587...56,774,081
Ensembl chr 8:56,747,620...56,774,078
|
|
G |
Hsp90b1 |
heat shock protein 90, beta (Grp94), member 1 |
decreases expression increases expression |
EXP ISO |
Glucosamine results in decreased expression of HSP90B1 mRNA Glucosamine results in increased expression of HSP90B1 protein |
CTD |
PMID:15618547 PMID:17109745 PMID:17178593 |
|
NCBI chr10:86,526,705...86,541,308
Ensembl chr10:86,526,073...86,541,373
|
|
G |
Hspa5 |
heat shock protein 5 |
multiple interactions increases expression decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein] Glucosamine results in increased expression of HSPA5 mRNA; Glucosamine results in increased expression of HSPA5 protein 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA] Glucosamine results in decreased expression of HSPA5 mRNA |
CTD |
PMID:15618547 PMID:16380481 PMID:17178593 PMID:19383982 PMID:20165829 PMID:22020377 PMID:30602124 PMID:33812996 More...
|
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Hyou1 |
hypoxia up-regulated 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of HYOU1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:44,290,840...44,303,662
Ensembl chr 9:44,290,787...44,303,666
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases activity |
ISO |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL6 results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 protein] Glucosamine results in decreased activity of ICAM1 protein Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] |
CTD |
PMID:16431966 PMID:16822504 PMID:17238806 PMID:18949387 PMID:19020780 PMID:19098112 More...
|
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
increases expression |
EXP |
Glucosamine results in increased expression of ID1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:152,578,171...152,579,330
Ensembl chr 2:152,578,171...152,579,330
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
increases expression |
EXP |
Glucosamine results in increased expression of ID2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:25,143,798...25,146,091
Ensembl chr12:25,143,798...25,147,139
|
|
G |
Id3 |
inhibitor of DNA binding 3 |
increases expression |
EXP |
Glucosamine results in increased expression of ID3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:135,871,133...135,872,703
Ensembl chr 4:135,870,808...135,873,066
|
|
G |
Idh1 |
isocitrate dehydrogenase 1 (NADP+), soluble |
increases expression |
EXP |
Glucosamine results in increased expression of IDH1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:65,197,775...65,225,638
Ensembl chr 1:65,197,775...65,225,659
|
|
G |
Ifi204 |
interferon activated gene 204 |
increases expression |
EXP |
Glucosamine results in increased expression of IFI204 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:173,574,859...173,594,606
Ensembl chr 1:173,574,859...173,594,509
|
|
G |
Ifit1 |
interferon-induced protein with tetratricopeptide repeats 1 |
increases expression |
EXP |
Glucosamine results in increased expression of IFIT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:34,618,289...34,627,409
Ensembl chr19:34,618,271...34,627,409
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
increases expression |
EXP |
Glucosamine results in increased expression of IFIT3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:34,560,519...34,566,382
Ensembl chr19:34,560,931...34,566,131
|
|
G |
Ifng |
interferon gamma |
decreases secretion multiple interactions |
EXP ISO |
Glucosamine results in decreased secretion of IFNG protein Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG results in increased localization of STAT1 protein modified form]; Glucosamine inhibits the reaction [IFNG results in increased phosphorylation of and results in increased localization of STAT1 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]] |
CTD |
PMID:14507305 PMID:16431966 PMID:16822504 PMID:17238806 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP3 mRNA]; IL1B inhibits the reaction [Glucosamine results in increased expression of IGFBP3 mRNA] Glucosamine results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr11:7,156,086...7,165,498
Ensembl chr11:7,156,086...7,163,923
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
decreases expression |
EXP |
Glucosamine results in decreased expression of IGFBP4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:98,930,820...98,943,481
Ensembl chr11:98,932,070...98,945,218
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA] Glucosamine results in increased expression of IGFBP5 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:72,897,224...72,914,024
Ensembl chr 1:72,897,091...72,914,043
|
|
G |
Ikbkb |
inhibitor of kappaB kinase beta |
multiple interactions |
EXP |
Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of IKBKB protein] |
CTD |
PMID:18786831 |
|
NCBI chr 8:23,149,228...23,196,605
Ensembl chr 8:23,149,228...23,196,605
|
|
G |
Ikbkg |
inhibitor of kappaB kinase gamma |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of IKBKG mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of IKBKG mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:73,436,883...73,498,013
Ensembl chr X:73,436,896...73,497,460
|
|
G |
Il11 |
interleukin 11 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL11 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 7:4,775,372...4,785,877
Ensembl chr 7:4,775,372...4,785,858
|
|
G |
Il13ra1 |
interleukin 13 receptor, alpha 1 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL13RA1 mRNA] Glucosamine results in decreased expression of IL13RA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr X:35,375,761...35,434,915
Ensembl chr X:35,375,763...35,434,912
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL1A mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of IL1A mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression decreases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Nitrites]; Glucosamine analog affects the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Glucosamine analog affects the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine analog affects the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine analog affects the reaction [IL1B results in increased phosphorylation of AKT1 protein]; Glucosamine analog inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP13]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP1]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP3]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP1 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP13 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP3 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of CXCL8 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP1 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine analog inhibits the reaction [IL1B results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL2 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL5 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CXCL8 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in decreased methylation of IL1B promoter]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in increased expression of IL1B mRNA]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUN protein]; Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUND protein]; Glucosamine inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of COL1A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 protein]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Dinoprostone]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Nitric Oxide]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Nitrites]; Glucosamine inhibits the reaction [IL1B results in increased degradation of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL8 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PTGES mRNA]; Glucosamine inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK14 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [IL1B results in increased secretion of CXCL8 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine promotes the reaction [IL1B results in increased expression of PPARG]; Glucosamine promotes the reaction [IL1B results in increased phosphorylation of AKT1 protein] Glucosamine results in increased expression of IL1B mRNA Glucosamine results in decreased expression of IL1B mRNA [IL1B protein co-treated with Glucosamine] results in increased expression of IL1R2 mRNA; Glucosamine affects the reaction [IL1B results in decreased expression of ADAM15 mRNA]; Glucosamine affects the reaction [IL1B results in decreased expression of OAT mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased activity of B3GAT3 protein]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of B3GAT3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Glucosamine inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL11A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL3A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of FGFR1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HAPLN1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of LAMA4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of SDC2 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of SOX4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of THBS4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP2 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ADAMTS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ASS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BGN mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL20 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL22 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of COL8A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL10 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL11 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of EPAS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of FGF9 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of GREM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IKBKG mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL11 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL13RA1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL1A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL1B mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL23R mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of JAK2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of JUNB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP10 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP12 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIA mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NGF mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PDGFA mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G2A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G4A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of RELB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of SDC4 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of SLC7A8 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TIMP1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TNFAIP6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TNK2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of VCAN mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Glucosamine promotes the reaction [IL1B results in decreased expression of BMP4 mRNA]; Glucosamine promotes the reaction [IL1B results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine affects the expression of PDGFA mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of ADAM15 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of BGN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of COL11A1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of DUSP7 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of EPAS1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of IKBKG mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of JUNB mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of TNFAIP6 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of VCAN mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of IL1A mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of JAK2 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of LAMA4 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of MMP9 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of NFKBIB mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of TIMP3 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of ADAMTS1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of COL8A1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CSF1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CXCL1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of FGF7 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of GREM1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of NFKBIA mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G2A mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G5 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SDC4 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SLC7A8 mRNA]; IL1B inhibits the reaction [Glucosamine results in increased expression of IGFBP3 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of HAPLN1 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of SDC2 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of THBS4 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of AZIN1 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL20 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL7 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP10 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP12 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP13 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of NOS2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of TIMP1 mRNA] Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL1B protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:11229466 PMID:11801247 PMID:12681956 PMID:15144122 PMID:16822504 PMID:17109745 PMID:17238806 PMID:17337215 PMID:17605605 PMID:17925024 PMID:18026701 PMID:18077487 PMID:18080321 PMID:18321735 PMID:18340449 PMID:18786831 PMID:19626664 PMID:19656660 PMID:20737476 PMID:21219853 PMID:22089456 More...
|
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il1r2 |
interleukin 1 receptor, type II |
multiple interactions |
ISO |
[IL1B protein co-treated with Glucosamine] results in increased expression of IL1R2 mRNA |
CTD |
PMID:11801247 |
|
NCBI chr 1:40,123,872...40,164,390
Ensembl chr 1:40,113,239...40,164,391
|
|
G |
Il2 |
interleukin 2 |
decreases secretion |
EXP |
Glucosamine results in decreased secretion of IL2 protein |
CTD |
PMID:14507305 |
|
NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108
|
|
G |
Il23r |
interleukin 23 receptor |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL23R mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 6:67,399,906...67,468,838
Ensembl chr 6:67,399,916...67,468,839
|
|
G |
Il33 |
interleukin 33 |
decreases expression |
ISO |
Glucosamine results in decreased expression of IL33 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr19:29,902,513...29,938,118
Ensembl chr19:29,902,514...29,938,118
|
|
G |
Il4 |
interleukin 4 |
decreases secretion decreases expression |
EXP ISO |
Glucosamine results in decreased secretion of IL4 protein Glucosamine results in decreased expression of IL4 |
CTD |
PMID:14507305 PMID:21284687 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il5 |
interleukin 5 |
decreases secretion decreases expression |
EXP ISO |
Glucosamine results in decreased secretion of IL5 protein Glucosamine results in decreased expression of IL5 |
CTD |
PMID:14507305 PMID:21284687 |
|
NCBI chr11:53,611,621...53,615,930
Ensembl chr11:53,611,621...53,615,933
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL6 results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of IL6 mRNA] Glucosamine inhibits the reaction [IL1B results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] Glucosamine analog results in decreased expression of IL6 mRNA; Glucosamine results in decreased expression of IL6 mRNA Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:16822504 PMID:17109745 PMID:18786831 PMID:19098112 PMID:20093129 PMID:20113495 PMID:20307528 PMID:20737476 More...
|
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Inpp5k |
inositol polyphosphate 5-phosphatase K |
increases expression multiple interactions |
ISO |
Glucosamine results in increased expression of INPP5K mRNA NUS1 protein inhibits the reaction [Glucosamine results in increased expression of INPP5K mRNA] |
CTD |
PMID:33812996 |
|
NCBI chr11:75,519,893...75,539,691
Ensembl chr11:75,521,814...75,539,697
|
|
G |
Ins1 |
insulin I |
multiple interactions |
EXP ISO |
[INS1 protein co-treated with Glucosamine] results in increased expression of OSTN mRNA; Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]; INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] 4-phenylbutyric acid inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]]; [Glucosamine co-treated with INS1 protein] affects the localization of GFPT1 protein; Glucosamine inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Glucosamine inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]; ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]] |
CTD |
PMID:9453242 PMID:11893929 PMID:16380481 PMID:20165829 PMID:30602124 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Ins2 |
insulin II |
multiple interactions |
ISO |
4-phenylbutyric acid inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]]; Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]; Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]; NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]]; ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]] |
CTD |
PMID:20165829 PMID:33812996 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IRF1 mRNA] |
CTD |
PMID:20737476 |
|
NCBI chr11:53,660,841...53,669,200
Ensembl chr11:53,660,841...53,669,200
|
|
G |
Isyna1 |
myo-inositol 1-phosphate synthase A1 |
increases expression |
ISO |
Glucosamine results in increased expression of ISYNA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:71,047,131...71,049,940
Ensembl chr 8:71,047,023...71,049,940
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of JAK2 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of JAK2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr19:29,229,006...29,290,495
Ensembl chr19:29,229,228...29,290,480
|
|
G |
Jun |
jun proto-oncogene |
multiple interactions |
ISO EXP |
Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUN protein] Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of JUN mRNA] |
CTD |
PMID:17925024 PMID:21825963 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Junb |
jun B proto-oncogene |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of JUNB mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of JUNB mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 8:85,703,538...85,705,377
Ensembl chr 8:85,701,113...85,705,347
|
|
G |
Jund |
jun D proto-oncogene |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUND protein] |
CTD |
PMID:17925024 |
|
NCBI chr 8:71,150,389...71,153,265
Ensembl chr 8:71,151,599...71,153,265
|
|
G |
Kcnj16 |
potassium inwardly-rectifying channel, subfamily J, member 16 |
increases expression |
EXP |
Glucosamine results in increased expression of KCNJ16 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:110,858,859...110,918,794
Ensembl chr11:110,858,859...110,918,794
|
|
G |
Kif11 |
kinesin family member 11 |
decreases expression |
ISO |
Glucosamine results in decreased expression of KIF11 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr19:37,364,830...37,410,311
Ensembl chr19:37,364,851...37,410,307
|
|
G |
Kif4 |
kinesin family member 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of KIF4A mRNA |
CTD |
PMID:17109745 |
|
NCBI chr X:99,669,693...99,770,878
Ensembl chr X:99,669,343...99,770,820
|
|
G |
Klf10 |
Kruppel-like transcription factor 10 |
increases expression |
EXP |
Glucosamine results in increased expression of KLF10 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:38,291,702...38,300,950
Ensembl chr15:38,291,707...38,300,950
|
|
G |
Lama4 |
laminin, alpha 4 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of LAMA4 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of LAMA4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr10:38,841,511...38,986,184
Ensembl chr10:38,841,511...38,986,184
|
|
G |
Lamb1 |
laminin B1 |
multiple interactions |
EXP |
TXNIP promotes the reaction [Glucosamine results in increased expression of LAMB1 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr12:31,315,230...31,379,643
Ensembl chr12:31,315,233...31,379,643
|
|
G |
Lamc1 |
laminin, gamma 1 |
multiple interactions |
EXP |
TXNIP promotes the reaction [Glucosamine results in increased expression of LAMC1 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr 1:153,094,668...153,208,532
Ensembl chr 1:153,094,668...153,208,532
|
|
G |
Lcn2 |
lipocalin 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of LCN2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:32,274,649...32,277,751
Ensembl chr 2:32,274,645...32,278,264
|
|
G |
Lepr |
leptin receptor |
multiple interactions affects response to substance |
ISO |
[LEPR protein affects the susceptibility to Glucosamine] which affects the expression of ALB protein |
CTD |
PMID:33345901 |
|
NCBI chr 4:101,574,393...101,676,375
Ensembl chr 4:101,574,601...101,672,549
|
|
G |
Lpin1 |
lipin 1 |
increases expression |
EXP |
Glucosamine results in increased expression of LPIN1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:16,585,670...16,697,020
Ensembl chr12:16,585,670...16,696,967
|
|
G |
Ly6a |
lymphocyte antigen 6 family member A |
increases expression |
EXP |
Glucosamine results in increased expression of LY6A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:74,866,726...74,869,880
Ensembl chr15:74,866,726...74,869,880
|
|
G |
Mafb |
MAF bZIP transcription factor B |
increases expression |
ISO |
Glucosamine results in increased expression of MAFB mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:160,205,597...160,208,985
Ensembl chr 2:160,205,623...160,208,985
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MAPK1 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] Glucosamine analog results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:18080321 PMID:18340449 PMID:19375915 PMID:19626664 PMID:20307528 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk14 |
mitogen-activated protein kinase 14 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:19626664 |
|
NCBI chr17:28,910,316...28,967,379
Ensembl chr17:28,910,303...28,967,380
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MAPK3 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] Glucosamine analog results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:18080321 PMID:18340449 PMID:19375915 PMID:19626664 PMID:20307528 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein] Glucosamine analog results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:18080321 PMID:19626664 PMID:20307528 |
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mcl1 |
myeloid cell leukemia sequence 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of MCL1 mRNA; Glucosamine results in decreased expression of MCL1 protein |
CTD |
PMID:22020377 |
|
NCBI chr 3:95,564,017...95,583,553
Ensembl chr 3:95,566,099...95,570,487
|
|
G |
Mef2a |
myocyte enhancer factor 2A |
multiple interactions decreases expression |
ISO |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein] Glucosamine results in decreased expression of MEF2A mRNA; Glucosamine results in decreased expression of MEF2A protein |
CTD |
PMID:20165829 |
|
NCBI chr 7:66,880,911...67,026,435
Ensembl chr 7:66,880,911...67,022,606
|
|
G |
Mettl1 |
methyltransferase 1, tRNA methylguanosine |
decreases expression |
EXP |
Glucosamine results in decreased expression of METTL1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:126,877,287...126,882,234
Ensembl chr10:126,877,283...126,882,234
|
|
G |
Mfap3l |
microfibrillar-associated protein 3-like |
increases expression |
EXP |
Glucosamine results in increased expression of MFAP3L mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:61,085,859...61,129,765
Ensembl chr 8:61,085,861...61,129,763
|
|
G |
Mki67 |
antigen identified by monoclonal antibody Ki 67 |
decreases expression |
ISO |
Glucosamine results in decreased expression of MKI67 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
increases expression multiple interactions |
ISO |
Glucosamine results in increased expression of MMP10 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of MMP10 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP10 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 9:7,502,343...7,510,243
Ensembl chr 9:7,502,353...7,510,241
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of MMP12 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP12 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 9:7,344,397...7,360,461
Ensembl chr 9:7,344,381...7,369,499
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
affects expression multiple interactions increases expression |
ISO |
Glucosamine analog affects the expression of MMP13 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP13 mRNA] Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP13]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP13 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein] |
CTD |
PMID:15144122 PMID:17109745 PMID:17337215 PMID:17925024 PMID:18080321 PMID:19656660 More...
|
|
NCBI chr 9:7,272,514...7,283,333
Ensembl chr 9:7,272,514...7,283,331
|
|
G |
Mmp1b |
matrix metallopeptidase 1b (interstitial collagenase) |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP1]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP1 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein] |
CTD |
PMID:15144122 PMID:17925024 PMID:18080321 |
|
NCBI chr 9:7,367,670...7,388,026
Ensembl chr 9:7,368,239...7,388,047
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions increases expression |
ISO |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of MMP2 protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 protein] IL1B promotes the reaction [Glucosamine results in increased expression of MMP2 mRNA] |
CTD |
PMID:17109745 PMID:17498959 PMID:19375915 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions increases expression decreases expression |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of MMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] results in decreased secretion of MMP3 protein; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP3]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP3 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 protein]; Glucosamine results in decreased expression of and results in decreased activity of MMP3 protein Glucosamine results in increased expression of MMP3 mRNA Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP3 mRNA] Glucosamine analog results in decreased expression of MMP3 mRNA |
CTD |
PMID:11229466 PMID:12801482 PMID:15144122 PMID:16300972 PMID:17109745 PMID:17925024 PMID:18080321 PMID:18340449 PMID:20110869 More...
|
|
NCBI chr 9:7,445,845...7,455,975
Ensembl chr 9:7,445,822...7,455,975
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of MMP9 protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 protein] Glucosamine results in increased expression of MMP9 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of MMP9 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of MMP9 mRNA] |
CTD |
PMID:17109745 PMID:17498959 PMID:19375915 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mpo |
myeloperoxidase |
decreases activity |
ISO |
Glucosamine results in decreased activity of MPO protein |
CTD |
PMID:19098112 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Mvd |
mevalonate (diphospho) decarboxylase |
increases expression |
EXP |
Glucosamine results in increased expression of MVD mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:123,160,335...123,170,161
Ensembl chr 8:123,160,340...123,170,161
|
|
G |
Ndufa4 |
Ndufa4, mitochondrial complex associated |
increases expression |
ISO |
Glucosamine results in increased expression of NDUFA4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 6:11,900,371...11,907,449
Ensembl chr 6:11,900,291...11,907,496
|
|
G |
Nedd4 |
neural precursor cell expressed, developmentally down-regulated 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of NEDD4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 9:72,569,613...72,657,133
Ensembl chr 9:72,569,628...72,657,134
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions decreases activity |
ISO EXP |
Glucosamine inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B results in increased degradation of NFKB1 protein]; Glucosamine inhibits the reaction [NFKB1 results in increased degradation of RELA protein]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of NFKB1 protein] Glucosamine results in decreased activity of NFKB1 protein Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NFKB1 protein] |
CTD |
PMID:12681956 PMID:16431966 PMID:16822504 PMID:17498959 PMID:18036590 PMID:18205790 PMID:20737476 More...
|
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions decreases phosphorylation decreases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [IL1B results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein] Glucosamine results in decreased phosphorylation of NFKBIA protein Glucosamine results in decreased expression of NFKBIA mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIA mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]; IL1B inhibits the reaction [Glucosamine results in decreased expression of NFKBIA mRNA] Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NFKBIA protein modified form]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:12681956 PMID:17109745 PMID:18080321 PMID:18205790 PMID:19098112 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nfkbib |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, beta |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIB mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of NFKBIB mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 7:28,457,676...28,466,069
Ensembl chr 7:28,457,676...28,466,937
|
|
G |
Ngef |
neuronal guanine nucleotide exchange factor |
increases expression |
EXP |
Glucosamine results in increased expression of NGEF mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:87,404,551...87,501,661
Ensembl chr 1:87,404,556...87,501,592
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of NGF mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions increases expression decreases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA] Glucosamine results in increased expression of NOS2 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of NOS2 mRNA] Glucosamine results in decreased expression of NOS2 mRNA Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to NOS2 promoter]]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:17109745 PMID:17440993 PMID:17605605 PMID:18077487 PMID:18205790 PMID:19098112 PMID:20737476 More...
|
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
affects expression |
ISO |
Glucosamine affects the expression of NR1H4 |
CTD |
PMID:19373748 |
|
NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
increases expression |
EXP |
Glucosamine results in increased expression of NSDHL mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:71,962,127...72,002,134
Ensembl chr X:71,962,163...72,002,120
|
|
G |
Nucb2 |
nucleobindin 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of NUCB2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:116,103,579...116,139,823
Ensembl chr 7:116,103,604...116,139,819
|
|
G |
Nuf2 |
NUF2, NDC80 kinetochore complex component |
decreases expression |
ISO |
Glucosamine results in decreased expression of NUF2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:169,325,503...169,359,033
Ensembl chr 1:169,325,503...169,359,033
|
|
G |
Nus1 |
NUS1 dehydrodolichyl diphosphate synthase subunit |
multiple interactions |
ISO |
NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of EIF2AK3 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ERN1 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of INPP5K mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] |
CTD |
PMID:33812996 |
|
NCBI chr10:52,293,643...52,316,288
Ensembl chr10:52,293,643...52,316,279
|
|
G |
Oasl2 |
2'-5' oligoadenylate synthetase-like 2 |
increases expression |
EXP |
Glucosamine results in increased expression of OASL2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:115,034,995...115,050,306
Ensembl chr 5:115,034,997...115,050,295
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
ISO |
Glucosamine affects the reaction [IL1B results in decreased expression of OAT mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 7:132,159,204...132,178,127
Ensembl chr 7:132,159,207...132,178,127
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase) |
decreases expression |
EXP |
Glucosamine results in decreased expression of OGT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:100,683,617...100,727,957
Ensembl chr X:100,683,666...100,727,957
|
|
G |
Orc2 |
origin recognition complex, subunit 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of ORC2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:58,501,933...58,544,114
Ensembl chr 1:58,501,930...58,544,268
|
|
G |
Osm |
oncostatin M |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in decreased methylation of IL1B promoter]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in increased expression of IL1B mRNA] |
CTD |
PMID:21219853 |
|
NCBI chr11:4,186,831...4,191,027
Ensembl chr11:4,186,420...4,191,026
|
|
G |
Ostn |
osteocrin |
multiple interactions increases expression |
EXP |
4-methylumbelliferone 8-carbaldehyde inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; [INS1 protein co-treated with Glucosamine] results in increased expression of OSTN mRNA; ATF6 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; GSK2656157 inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] |
CTD |
PMID:30602124 |
|
NCBI chr16:27,125,733...27,169,959
Ensembl chr16:27,126,239...27,169,962
|
|
G |
Oxr1 |
oxidation resistance 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of OXR1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:41,310,745...41,724,447
Ensembl chr15:41,310,878...41,724,444
|
|
G |
Pank1 |
pantothenate kinase 1 |
increases expression |
EXP |
Glucosamine results in increased expression of PANK1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:34,784,335...34,862,420
Ensembl chr19:34,784,340...34,856,855
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
increases cleavage multiple interactions |
ISO |
Glucosamine results in increased cleavage of PARP1 protein pepstatin inhibits the reaction [Glucosamine results in increased cleavage of PARP1 protein] |
CTD |
PMID:16850161 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Pdgfa |
platelet derived growth factor, alpha |
affects expression multiple interactions |
ISO |
Glucosamine affects the expression of PDGFA mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of PDGFA mRNA]; IL1B affects the reaction [Glucosamine affects the expression of PDGFA mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:138,961,761...138,986,336
Ensembl chr 5:138,961,769...138,983,125
|
|
G |
Pdia4 |
protein disulfide isomerase associated 4 |
decreases expression |
EXP |
Glucosamine results in decreased expression of PDIA4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:47,773,075...47,790,446
Ensembl chr 6:47,773,075...47,790,364
|
|
G |
Pdia6 |
protein disulfide isomerase associated 6 |
decreases expression |
EXP |
Glucosamine results in decreased expression of PDIA6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:17,316,590...17,334,786
Ensembl chr12:17,316,546...17,334,771
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase, isoenzyme 4 |
increases expression |
EXP |
Glucosamine results in increased expression of PDK4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:5,483,351...5,496,278
Ensembl chr 6:5,483,351...5,496,309
|
|
G |
Pfkp |
phosphofructokinase, platelet |
increases expression |
EXP |
Glucosamine results in increased expression of PFKP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:6,629,910...6,699,096
Ensembl chr13:6,629,804...6,698,813
|
|
G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
decreases expression |
EXP |
Glucosamine results in decreased expression of PIGA mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:163,202,814...163,216,912
Ensembl chr X:163,202,783...163,216,912
|
|
G |
Pla2g2a |
phospholipase A2, group IIA (platelets, synovial fluid) |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G2A mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G2A mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 4:138,559,168...138,562,500
Ensembl chr 4:138,559,171...138,562,497
|
|
G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
affects expression multiple interactions |
ISO |
Glucosamine affects the expression of PLA2G4A mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G4A mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:149,705,369...149,837,041
Ensembl chr 1:149,705,369...149,837,041
|
|
G |
Pla2g5 |
phospholipase A2, group V |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G5 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G5 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 4:138,526,558...138,590,784
Ensembl chr 4:138,526,555...138,590,793
|
|
G |
Plat |
plasminogen activator, tissue |
increases expression |
EXP |
Glucosamine results in increased expression of PLAT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:23,247,655...23,272,864
Ensembl chr 8:23,247,743...23,272,860
|
|
G |
Plk1 |
polo like kinase 1 |
increases expression decreases expression |
EXP ISO |
Glucosamine results in increased expression of PLK1 mRNA Glucosamine results in decreased expression of PLK1 mRNA |
CTD |
PMID:17109745 PMID:17178593 |
|
NCBI chr 7:121,758,658...121,769,107
Ensembl chr 7:121,758,662...121,769,096
|
|
G |
Plpp3 |
phospholipid phosphatase 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of PLPP3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:105,014,544...105,089,964
Ensembl chr 4:105,014,544...105,089,961
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions increases expression |
ISO EXP |
Glucosamine promotes the reaction [IL1B results in increased expression of PPARG] Glucosamine results in increased expression of PPARG mRNA |
CTD |
PMID:15694357 PMID:22089456 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
multiple interactions decreases expression |
ISO |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein] Glucosamine results in decreased expression of PPARGC1A mRNA; Glucosamine results in decreased expression of PPARGC1A protein |
CTD |
PMID:20165829 |
|
NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068
|
|
G |
Ppm1a |
protein phosphatase 1A, magnesium dependent, alpha isoform |
decreases expression |
EXP |
Glucosamine results in decreased expression of PPM1A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:72,804,231...72,846,593
Ensembl chr12:72,804,229...72,846,593
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
decreases expression |
EXP |
Glucosamine results in decreased expression of PPP1R15A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:45,172,341...45,175,692
Ensembl chr 7:45,172,340...45,175,692
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of PRC1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 7:79,944,224...79,966,007
Ensembl chr 7:79,944,198...79,966,007
|
|
G |
Prkaa1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
multiple interactions |
ISO |
PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] |
CTD |
PMID:33812996 |
|
NCBI chr15:5,172,641...5,211,380
Ensembl chr15:5,173,343...5,211,380
|
|
G |
Psme3 |
proteaseome (prosome, macropain) activator subunit 3 (PA28 gamma, Ki) |
decreases expression |
ISO |
Glucosamine results in decreased expression of PSME3 |
CTD |
PMID:21697645 |
|
NCBI chr11:101,206,090...101,214,363
Ensembl chr11:101,207,039...101,214,363
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein; Glucosamine inhibits the reaction [IL1B results in increased expression of PTGES mRNA] |
CTD |
PMID:17605605 PMID:22089456 |
|
NCBI chr 2:30,779,483...30,793,309
Ensembl chr 2:30,779,483...30,819,875
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression decreases expression multiple interactions decreases glycosylation |
ISO EXP |
Glucosamine analog results in increased expression of PTGS2 protein alternative form Glucosamine results in decreased expression of PTGS2 mRNA Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Glucosamine inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] Glucosamine results in decreased glycosylation of PTGS2 protein [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:12681956 PMID:17440993 PMID:17605605 PMID:18205790 PMID:19656660 PMID:20737476 PMID:22089456 More...
|
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Pttg1 |
pituitary tumor-transforming gene 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of PTTG1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr11:43,311,097...43,317,417
Ensembl chr11:43,311,077...43,317,078
|
|
G |
Rab32 |
RAB32, member RAS oncogene family |
increases expression |
EXP |
Glucosamine results in increased expression of RAB32 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:10,420,783...10,433,951
Ensembl chr10:10,420,746...10,434,009
|
|
G |
Racgap1 |
Rac GTPase-activating protein 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of RACGAP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr15:99,518,377...99,549,504
Ensembl chr15:99,518,377...99,549,537
|
|
G |
Rbm39 |
RNA binding motif protein 39 |
decreases expression |
EXP |
Glucosamine results in decreased expression of RBM39 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:155,989,159...156,022,649
Ensembl chr 2:155,989,159...156,022,158
|
|
G |
Recql4 |
RecQ protein-like 4 |
increases expression |
EXP |
Glucosamine results in increased expression of RECQL4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:76,587,753...76,594,820
Ensembl chr15:76,587,753...76,594,748
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions decreases activity increases localization |
ISO EXP |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein]]; Glucosamine analog inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of RELA protein]; Glucosamine inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine inhibits the reaction [NFKB1 results in increased degradation of RELA protein]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased localization of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein] Glucosamine results in decreased activity of RELA protein Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]; Glucosamine inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to NOS2 promoter]]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of RELA mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein] Glucosamine results in increased localization of RELA protein |
CTD |
PMID:12681956 PMID:16431966 PMID:16822504 PMID:17238806 PMID:17498959 PMID:18036590 PMID:18080321 PMID:18205790 PMID:18340449 PMID:18786831 PMID:19020780 PMID:19375915 PMID:20307528 PMID:20737476 More...
|
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Relb |
avian reticuloendotheliosis viral (v-rel) oncogene related B |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of RELB mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 7:19,340,142...19,363,352
Ensembl chr 7:19,340,142...19,363,363
|
|
G |
Rhob |
ras homolog family member B |
increases expression |
EXP |
Glucosamine results in increased expression of RHOB mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:8,547,661...8,550,009
Ensembl chr12:8,547,661...8,550,009
|
|
G |
Rhoc |
ras homolog family member C |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of RHOC mRNA |
CTD |
PMID:16142878 |
|
NCBI chr 3:104,696,350...104,701,775
Ensembl chr 3:104,695,691...104,701,775
|
|
G |
Rnd1 |
Rho family GTPase 1 |
multiple interactions decreases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of RND1 mRNA] Glucosamine results in decreased expression of RND1 mRNA |
CTD |
PMID:17178593 PMID:18173918 |
|
NCBI chr15:98,567,086...98,575,342
Ensembl chr15:98,561,302...98,575,342
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Glucosamine results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:19254699 |
|
NCBI chr 4:86,772,336...86,775,604
Ensembl chr 4:86,772,897...86,775,649
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase, polypeptide 1 |
decreases phosphorylation |
ISO |
Glucosamine results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:19254699 |
|
NCBI chr11:86,389,695...86,435,711
Ensembl chr11:86,389,697...86,435,631
|
|
G |
Runx2 |
runt related transcription factor 2 |
increases phosphorylation increases expression multiple interactions |
ISO |
Glucosamine analog results in increased phosphorylation of RUNX2 protein Glucosamine analog results in increased expression of RUNX2 mRNA 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of RUNX2 protein] |
CTD |
PMID:20458730 |
|
NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684
|
|
G |
Scd2 |
stearoyl-Coenzyme A desaturase 2 |
increases expression |
EXP |
Glucosamine results in increased expression of SCD2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:44,282,115...44,295,303
Ensembl chr19:44,282,113...44,295,303
|
|
G |
Sdc2 |
syndecan 2 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of SDC2 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of SDC2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr15:32,920,869...33,034,867
Ensembl chr15:32,920,869...33,035,081
|
|
G |
Sdc4 |
syndecan 4 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of SDC4 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SDC4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:164,266,167...164,285,512
Ensembl chr 2:164,266,167...164,285,807
|
|
G |
Selenbp1 |
selenium binding protein 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SELENBP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:94,840,394...94,852,069
Ensembl chr 3:94,840,367...94,852,069
|
|
G |
Serpinb2 |
serine (or cysteine) peptidase inhibitor, clade B, member 2 |
increases expression |
ISO |
Glucosamine results in increased expression of SERPINB2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:107,439,153...107,453,330
Ensembl chr 1:107,439,153...107,463,208
|
|
G |
Serpinh1 |
serine (or cysteine) peptidase inhibitor, clade H, member 1 |
increases expression |
ISO |
Glucosamine results in increased expression of SERPINH1 protein |
CTD |
PMID:16380481 |
|
NCBI chr 7:98,994,583...99,002,321
Ensembl chr 7:98,994,583...99,002,446
|
|
G |
Sfrp2 |
secreted frizzled-related protein 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SFRP2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:83,673,628...83,681,621
Ensembl chr 3:83,673,628...83,681,623
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SGK1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:21,758,083...21,875,802
Ensembl chr10:21,758,083...21,875,802
|
|
G |
Shcbp1 |
Shc SH2-domain binding protein 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SHCBP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:4,785,976...4,829,549
Ensembl chr 8:4,785,976...4,829,567
|
|
G |
Slc17a1 |
solute carrier family 17 (sodium phosphate), member 1 |
increases expression |
EXP |
Glucosamine results in increased expression of SLC17A1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:24,051,607...24,079,713
Ensembl chr13:24,051,733...24,079,713
|
|
G |
Slc23a2 |
solute carrier family 23 (nucleobase transporters), member 2 |
increases expression |
ISO |
Glucosamine results in increased expression of SLC23A2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:131,894,416...131,987,287
Ensembl chr 2:131,894,416...131,987,028
|
|
G |
Slc2a2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SLC2A2 mRNA |
CTD |
PMID:11893929 |
|
NCBI chr 3:28,752,052...28,782,510
Ensembl chr 3:28,752,052...28,785,508
|
|
G |
Slc2a4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
multiple interactions decreases expression increases uptake |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein] Glucosamine results in decreased expression of SLC2A4 mRNA; Glucosamine results in decreased expression of SLC2A4 protein SLC2A4 protein results in increased uptake of Glucosamine Glucosamine inhibits the reaction [SLC2A4 protein results in increased uptake of Glucose]; Glucose inhibits the reaction [SLC2A4 protein results in increased uptake of Glucosamine] |
CTD |
PMID:19373748 PMID:20165829 |
|
NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014
|
|
G |
Slc2a6 |
solute carrier family 2 (facilitated glucose transporter), member 6 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SLC2A6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:26,911,375...26,918,011
Ensembl chr 2:26,911,375...26,918,010
|
|
G |
Slc37a4 |
solute carrier family 37 (glucose-6-phosphate transporter), member 4 |
increases expression |
EXP |
Glucosamine results in increased expression of SLC37A4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:44,308,243...44,314,263
Ensembl chr 9:44,308,149...44,314,265
|
|
G |
Slc4a4 |
solute carrier family 4 (anion exchanger), member 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SLC4A4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 5:88,941,717...89,387,515
Ensembl chr 5:89,034,345...89,387,512
|
|
G |
Slc7a8 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 8 |
increases expression multiple interactions |
ISO |
Glucosamine results in increased expression of SLC7A8 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of SLC7A8 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SLC7A8 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:54,959,672...55,019,343
Ensembl chr14:54,959,666...55,019,403
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions increases phosphorylation |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:20458730 |
|
NCBI chr18:76,369,898...76,444,819
Ensembl chr18:76,374,651...76,444,034
|
|
G |
Smpd3 |
sphingomyelin phosphodiesterase 3, neutral |
decreases expression |
ISO |
Glucosamine results in decreased expression of SMPD3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:106,979,180...107,064,597
Ensembl chr 8:106,979,180...107,064,620
|
|
G |
Sox4 |
SRY (sex determining region Y)-box 4 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of SOX4 mRNA] Glucosamine results in decreased expression of SOX4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:29,132,902...29,137,682
Ensembl chr13:29,132,902...29,137,696
|
|
G |
Srsf3 |
serine and arginine-rich splicing factor 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SRSF3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:29,251,634...29,262,346
Ensembl chr17:29,251,602...29,262,347
|
|
G |
St6gal1 |
beta galactoside alpha 2,6 sialyltransferase 1 |
increases expression |
EXP |
Glucosamine results in increased expression of ST6GAL1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr16:23,043,478...23,179,100
Ensembl chr16:23,043,490...23,179,100
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IFNG results in increased localization of STAT1 protein modified form]; Glucosamine inhibits the reaction [IFNG results in increased phosphorylation of and results in increased localization of STAT1 protein] |
CTD |
PMID:16431966 PMID:17238806 |
|
NCBI chr 1:52,158,588...52,201,024
Ensembl chr 1:52,158,599...52,201,024
|
|
G |
Tacc3 |
transforming, acidic coiled-coil containing protein 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of TACC3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 5:33,814,808...33,836,331
Ensembl chr 5:33,815,472...33,836,339
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
ISO |
[Glucose co-treated with Glucosamine] results in increased expression of TGFA protein; Glucosamine promotes the reaction [Glucose results in increased expression of TGFA mRNA] |
CTD |
PMID:1518840 |
|
NCBI chr 6:86,172,020...86,252,726
Ensembl chr 6:86,172,205...86,252,701
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
Glucosamine analog results in increased expression of TGFB1 mRNA |
CTD |
PMID:21466783 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor I |
multiple interactions increases expression |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased expression of TGFBR1 protein] |
CTD |
PMID:20458730 |
|
NCBI chr 4:47,353,258...47,414,926
Ensembl chr 4:47,353,222...47,414,931
|
|
G |
Thbs4 |
thrombospondin 4 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of THBS4 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of THBS4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr13:92,888,094...92,931,326
Ensembl chr13:92,888,098...92,931,326
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of TIMP1 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of TIMP1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974
|
|
G |
Timp2 |
tissue inhibitor of metalloproteinase 2 |
affects expression multiple interactions |
ISO |
Glucosamine affects the expression of TIMP2 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr11:118,191,887...118,246,237
Ensembl chr11:118,191,887...118,246,566
|
|
G |
Timp3 |
tissue inhibitor of metalloproteinase 3 |
multiple interactions increases expression |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA Glucosamine results in increased expression of TIMP3 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP3 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of TIMP3 mRNA] |
CTD |
PMID:17109745 PMID:17605605 |
|
NCBI chr10:86,136,276...86,185,369
Ensembl chr10:86,136,236...86,185,370
|
|
G |
Tinag |
tubulointerstitial nephritis antigen |
increases expression |
EXP |
Glucosamine results in increased expression of TINAG mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:76,858,980...76,953,084
Ensembl chr 9:76,858,975...76,953,076
|
|
G |
Tk1 |
thymidine kinase 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of TK1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr11:117,706,345...117,716,913
Ensembl chr11:117,706,352...117,716,918
|
|
G |
Tlr1 |
toll-like receptor 1 |
increases expression |
EXP |
Glucosamine results in increased expression of TLR1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:65,082,023...65,090,945
Ensembl chr 5:65,082,022...65,090,906
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion multiple interactions decreases expression |
EXP ISO |
Glucosamine results in decreased secretion of TNF protein Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Glucosamine analog results in decreased expression of TNF mRNA; Glucosamine results in decreased expression of TNF mRNA Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] [Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of TNF; Alloxan inhibits the reaction [Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein]]; Glucosamine analog inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased localization of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein] |
CTD |
PMID:14507305 PMID:16431966 PMID:16445576 PMID:16822504 PMID:17238806 PMID:18173918 PMID:18205790 PMID:18786831 PMID:19020780 PMID:19098112 PMID:20093129 PMID:20110869 PMID:20113495 PMID:20737476 More...
|
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfaip6 |
tumor necrosis factor alpha induced protein 6 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of TNFAIP6 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of TNFAIP6 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:51,928,125...51,946,693
Ensembl chr 2:51,928,021...51,946,698
|
|
G |
Tnfrsf11b |
tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) |
multiple interactions |
ISO |
[Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B protein; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B protein |
CTD |
PMID:17996099 |
|
NCBI chr15:54,114,014...54,141,700
Ensembl chr15:54,114,015...54,141,880
|
|
G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447
|
|
G |
Tnfrsf1b |
tumor necrosis factor receptor superfamily, member 1b |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr 4:144,938,938...144,973,453
Ensembl chr 4:144,940,033...144,973,440
|
|
G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
multiple interactions increases expression |
ISO |
[Chondroitin Sulfates co-treated with Glucosamine] inhibits the reaction [Cholecalciferol results in increased expression of TNFSF11 mRNA]; Chondroitin Sulfates inhibits the reaction [Glucosamine results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:17996099 |
|
NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483
|
|
G |
Tnk2 |
tyrosine kinase, non-receptor, 2 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of TNK2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr16:32,462,699...32,502,311
Ensembl chr16:32,462,692...32,502,311
|
|
G |
Top2a |
topoisomerase (DNA) II alpha |
decreases expression |
ISO |
Glucosamine results in decreased expression of TOP2A mRNA |
CTD |
PMID:17109745 |
|
NCBI chr11:98,883,773...98,915,037
Ensembl chr11:98,883,769...98,915,015
|
|
G |
Traf6 |
TNF receptor-associated factor 6 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TRAF6 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr 2:101,508,765...101,532,013
Ensembl chr 2:101,508,774...101,532,014
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
increases expression |
EXP |
Glucosamine results in increased expression of TRPV4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:114,760,213...114,796,497
Ensembl chr 5:114,760,213...114,796,482
|
|
G |
Txn1 |
thioredoxin 1 |
decreases expression |
ISO EXP |
Glucosamine results in decreased expression of TXN1 protein |
CTD |
PMID:17178593 |
|
NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411
|
|
G |
Txnip |
thioredoxin interacting protein |
multiple interactions increases expression |
EXP ISO |
Glucosamine promotes the reaction [TXNIP results in increased abundance of Reactive Oxygen Species]; TXNIP promotes the reaction [Glucosamine results in increased expression of LAMB1 mRNA]; TXNIP promotes the reaction [Glucosamine results in increased expression of LAMC1 mRNA] Glucosamine results in increased expression of TXNIP protein Glucosamine results in increased expression of TXNIP mRNA; Glucosamine results in increased expression of TXNIP protein |
CTD |
PMID:17178593 |
|
NCBI chr 3:96,465,273...96,469,173
Ensembl chr 3:96,465,273...96,469,199
|
|
G |
Ucp2 |
uncoupling protein 2 (mitochondrial, proton carrier) |
decreases expression |
ISO |
Glucosamine results in decreased expression of UCP2 mRNA |
CTD |
PMID:11893929 |
|
NCBI chr 7:100,142,565...100,148,832
Ensembl chr 7:100,142,544...100,151,227
|
|
G |
Uqcrh |
ubiquinol-cytochrome c reductase hinge protein |
increases expression |
EXP |
Glucosamine results in increased expression of UQCRH mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:115,924,162...115,932,267
Ensembl chr 4:115,924,162...115,932,268
|
|
G |
Vamp1 |
vesicle-associated membrane protein 1 |
increases expression |
ISO |
Glucosamine results in increased expression of VAMP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 6:125,192,544...125,199,269
Ensembl chr 6:125,192,514...125,222,927
|
|
G |
Vcan |
versican |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of VCAN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of VCAN mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr13:89,803,429...89,891,146
Ensembl chr13:89,803,431...89,890,628
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression decreases expression |
ISO |
Glucosamine inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA protein] Glucosamine results in increased expression of VEGFA protein Glucosamine results in decreased expression of VEGFA protein |
CTD |
PMID:16324875 PMID:19254699 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Vegfd |
vascular endothelial growth factor D |
increases expression decreases expression |
EXP ISO |
Glucosamine results in increased expression of VEGFD mRNA Glucosamine results in decreased expression of VEGFD mRNA |
CTD |
PMID:17109745 PMID:17178593 |
|
NCBI chr X:163,156,282...163,185,643
Ensembl chr X:163,156,374...163,185,646
|
|
G |
Vnn1 |
vanin 1 |
increases expression |
EXP |
Glucosamine results in increased expression of VNN1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:23,770,586...23,781,242
Ensembl chr10:23,770,586...23,781,241
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions increases splicing increases expression decreases splicing |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA] 4-methylumbelliferone 8-carbaldehyde affects the reaction [Glucosamine results in increased expression of XBP1 protein alternative form]; 4-methylumbelliferone 8-carbaldehyde inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 protein alternative form]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased splicing of XBP1 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA] Glucosamine results in decreased splicing of XBP1 mRNA |
CTD |
PMID:19383982 PMID:20165829 PMID:30602124 PMID:33812996 |
|
NCBI chr11:5,470,641...5,475,993
Ensembl chr11:5,470,659...5,475,893
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
ISO |
[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased abundance of Proteoglycans]; [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA] |
CTD |
PMID:11801247 |
|
NCBI chr17:74,190,890...74,257,191
Ensembl chr17:74,190,890...74,257,191
|
|
G |
Zfp467 |
zinc finger protein 467 |
increases expression |
EXP |
Glucosamine results in increased expression of ZFP467 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:48,404,626...48,422,926
Ensembl chr 6:48,404,631...48,422,759
|
|
|
G |
4921524L21Rik |
RIKEN cDNA 4921524L21 gene |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of CCDC144NL mRNA |
CTD |
PMID:33770205 |
|
NCBI chr18:6,603,629...6,638,970
Ensembl chr18:6,603,629...6,638,970
|
|
G |
A2m |
alpha-2-macroglobulin |
increases uptake multiple interactions |
ISO |
A2M protein modified form results in increased uptake of Deoxyglucose HSPA5 protein affects the reaction [A2M protein modified form results in increased uptake of Deoxyglucose] |
CTD |
PMID:25720493 |
|
NCBI chr 6:121,612,920...121,656,197
Ensembl chr 6:121,612,335...121,656,186
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [ABCB1 protein results in increased export of Diazinon] |
CTD |
PMID:16221533 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcc9 |
ATP-binding cassette, sub-family C member 9 |
multiple interactions |
EXP |
[Oligomycins co-treated with Deoxyglucose] results in increased activity of [KCNJ11 protein binds to ABCC9 protein]; Glyburide inhibits the reaction [[Oligomycins co-treated with Deoxyglucose] results in increased activity of [KCNJ11 protein binds to ABCC9 protein]] |
CTD |
PMID:28842488 |
|
NCBI chr 6:142,533,592...142,648,472
Ensembl chr 6:142,533,588...142,648,041
|
|
G |
Abra |
actin-binding Rho activating protein |
multiple interactions increases uptake |
ISO |
CCG 1423 promotes the reaction [ABRA mutant form promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; CCG 1423 promotes the reaction [ABRA mutant form results in increased uptake of Deoxyglucose]; CCG 1423 promotes the reaction [INS1 protein promotes the reaction [ABRA mutant form results in increased uptake of Deoxyglucose]]; INS1 protein promotes the reaction [ABRA mutant form results in increased uptake of Deoxyglucose] |
CTD |
PMID:21393865 |
|
NCBI chr15:41,728,689...41,733,116
Ensembl chr15:41,727,472...41,733,116
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases uptake multiple interactions |
ISO |
ADIPOQ protein modified form results in increased uptake of Deoxyglucose Indinavir inhibits the reaction [ADIPOQ protein modified form results in increased uptake of Deoxyglucose] |
CTD |
PMID:29991592 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Agrp |
agouti related neuropeptide |
increases expression |
ISO |
Deoxyglucose results in increased expression of AGRP mRNA |
CTD |
PMID:10683841 |
|
NCBI chr 8:106,293,327...106,306,477
Ensembl chr 8:106,293,330...106,364,025
|
|
G |
Ap5s1 |
adaptor-related protein 5 complex, sigma 1 subunit |
increases expression |
ISO |
Deoxyglucose results in increased expression of AP5S1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 2:131,052,280...131,055,434
Ensembl chr 2:131,048,998...131,055,434
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
[Sodium Azide co-treated with Deoxyglucose] affects the cleavage of and affects the localization of APP protein |
CTD |
PMID:17405930 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Atg3 |
autophagy related 3 |
multiple interactions |
ISO |
Deoxyglucose affects the reaction [demycarosyl-3D-digitoxosylmithramycin SK affects the expression of ATG3 mRNA] |
CTD |
PMID:26079942 |
|
NCBI chr16:44,979,192...45,008,901
Ensembl chr16:44,979,148...45,008,901
|
|
G |
Atg4b |
autophagy related 4B, cysteine peptidase |
multiple interactions |
ISO |
[demycarosyl-3D-digitoxosylmithramycin SK co-treated with Deoxyglucose] results in increased expression of ATG4B mRNA |
CTD |
PMID:26079942 |
|
NCBI chr 1:93,682,627...93,717,328
Ensembl chr 1:93,679,222...93,718,332
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions |
ISO |
ATG7 protein inhibits the reaction [Deoxyglucose results in increased cleavage of CASP3 protein]; ATG7 protein inhibits the reaction [Deoxyglucose results in increased expression of DDIT3 protein]; ATG7 protein inhibits the reaction [Deoxyglucose results in increased expression of HSPA5 protein]; ATG7 protein promotes the reaction [Deoxyglucose results in increased prenylation of MAP1LC3B protein] |
CTD |
PMID:20593179 |
|
NCBI chr 6:114,620,075...114,837,565
Ensembl chr 6:114,620,058...114,837,575
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions decreases expression |
ISO |
Deoxyglucose promotes the reaction [arsenic trioxide results in increased localization of and results in increased activity of BAX protein]; Deoxyglucose results in increased localization of and results in increased activity of BAX protein Deoxyglucose results in decreased expression of BAX mRNA |
CTD |
PMID:23041229 PMID:26079942 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
ISO |
Deoxyglucose affects the reaction [demycarosyl-3D-digitoxosylmithramycin SK affects the expression of BCL2 mRNA] |
CTD |
PMID:26079942 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l1 |
BCL2-like 1 |
decreases response to substance |
EXP |
BCL2L1 protein results in decreased susceptibility to Deoxyglucose |
CTD |
PMID:10679475 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Becn1 |
beclin 1, autophagy related |
multiple interactions |
ISO |
[bafilomycin A co-treated with Deoxyglucose co-treated with demycarosyl-3D-digitoxosylmithramycin SK] results in decreased expression of BECN1 protein; [demycarosyl-3D-digitoxosylmithramycin SK co-treated with Deoxyglucose] results in increased expression of BECN1 mRNA |
CTD |
PMID:26079942 |
|
NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
Deoxyglucose promotes the reaction [arsenic trioxide results in increased cleavage of and results in increased activity of BID protein]; Deoxyglucose results in increased cleavage of and results in increased activity of BID protein |
CTD |
PMID:23041229 |
|
NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases cleavage |
ISO EXP |
ATG7 protein inhibits the reaction [Deoxyglucose results in increased cleavage of CASP3 protein]; Deoxyglucose promotes the reaction [arsenic trioxide results in increased cleavage of and results in increased activity of CASP3 protein]; Deoxyglucose results in increased cleavage of and results in increased activity of CASP3 protein Deoxyglucose promotes the reaction [Metformin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 protein modified form]] Deoxyglucose results in increased activity of CASP3 protein Corticosterone inhibits the reaction [Deoxyglucose results in increased activity of CASP3 protein]; GPX4 protein inhibits the reaction [Deoxyglucose results in increased activity of CASP3 protein] |
CTD |
PMID:10506188 PMID:15755911 PMID:20593179 PMID:23041229 PMID:29095437 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[Deoxyglucose co-treated with Cisplatin] results in increased activity of CASP9 protein; Deoxyglucose promotes the reaction [arsenic trioxide results in increased cleavage of and results in increased activity of CASP9 protein]; Deoxyglucose results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:20138251 PMID:23041229 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[demycarosyl-3D-digitoxosylmithramycin SK co-treated with Deoxyglucose] results in increased expression of CDKN1A mRNA |
CTD |
PMID:26079942 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cemip2 |
cell migration inducing hyaluronidase 2 |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of CEMIP2 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr19:21,755,704...21,835,724
Ensembl chr19:21,755,706...21,835,724
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3, cardiac |
affects response to substance |
EXP |
CHRM3 protein affects the susceptibility to Deoxyglucose |
CTD |
PMID:14724830 |
|
NCBI chr13:9,925,522...10,411,131
Ensembl chr13:9,925,522...10,410,883
|
|
G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
affects localization |
ISO |
Deoxyglucose analog affects the localization of CHUK protein |
CTD |
PMID:27931795 |
|
NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919
|
|
G |
Ctsd |
cathepsin D |
increases expression |
ISO |
Deoxyglucose results in increased expression of CTSD protein |
CTD |
PMID:20026095 |
|
NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775
|
|
G |
Cul7 |
cullin 7 |
multiple interactions |
EXP |
[INS1 protein co-treated with CUL7 mutant form] results in increased uptake of Deoxyglucose |
CTD |
PMID:24219910 |
|
NCBI chr17:46,961,264...46,975,290
Ensembl chr17:46,961,263...46,975,290
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
ATG7 protein inhibits the reaction [Deoxyglucose results in increased expression of DDIT3 protein]; Mannose inhibits the reaction [Deoxyglucose results in increased expression of DDIT3 protein] |
CTD |
PMID:20593179 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases import |
ISO |
AICA ribonucleotide inhibits the reaction [EGFR protein results in increased import of Deoxyglucose] EGFR protein mutant form results in increased import of Deoxyglucose |
CTD |
PMID:19625624 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
Deoxyglucose results in decreased phosphorylation of and results in increased expression of EIF4EBP1 protein |
CTD |
PMID:23363784 |
|
NCBI chr 8:27,750,355...27,765,684
Ensembl chr 8:27,750,357...27,766,702
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[Deoxyglucose co-treated with Quercetin] results in increased ubiquitination of ERBB2 protein; Deoxyglucose inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:18655187 |
|
NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542
|
|
G |
Errfi1 |
ERBB receptor feedback inhibitor 1 |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of ERRFI1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 4:150,938,253...150,953,346
Ensembl chr 4:150,938,376...150,953,349
|
|
G |
Fam117a |
family with sequence similarity 117, member A |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of FAM117A mRNA |
CTD |
PMID:33770205 |
|
NCBI chr11:95,227,844...95,272,698
Ensembl chr11:95,227,844...95,272,698
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
multiple interactions increases transport |
ISO |
Calcium inhibits the reaction [FXYD2 protein results in increased transport of Deoxyglucose] |
CTD |
PMID:11533133 |
|
NCBI chr 9:45,311,007...45,321,576
Ensembl chr 9:45,310,967...45,321,576
|
|
G |
G3bp1 |
G3BP stress granule assembly factor 1 |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [G3BP1 protein results in increased abundance of Lactic Acid]; Deoxyglucose inhibits the reaction [G3BP1 protein results in increased expression of HK2 protein]; Deoxyglucose inhibits the reaction [G3BP1 protein results in increased expression of LDHA protein]; Deoxyglucose inhibits the reaction [G3BP1 protein results in increased expression of PKM protein]; Deoxyglucose inhibits the reaction [G3BP1 protein results in increased uptake of Glucose] |
CTD |
PMID:35945655 |
|
NCBI chr11:55,360,521...55,391,722
Ensembl chr11:55,360,511...55,395,664
|
|
G |
Galr1 |
galanin receptor 1 |
increases expression |
ISO |
Deoxyglucose results in increased expression of GALR1 mRNA |
CTD |
PMID:9858361 PMID:9928191 |
|
NCBI chr18:82,410,621...82,424,902
Ensembl chr18:82,410,505...82,424,902
|
|
G |
Gcg |
glucagon |
multiple interactions increases secretion |
EXP |
Capsaicin inhibits the reaction [Deoxyglucose results in increased secretion of GCG protein] |
CTD |
PMID:1378463 |
|
NCBI chr 2:62,304,874...62,313,997
Ensembl chr 2:62,304,874...62,313,994
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions |
ISO |
GPX4 protein inhibits the reaction [Deoxyglucose results in increased activity of CASP3 protein] |
CTD |
PMID:10506188 |
|
NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [arsenic trioxide results in increased phosphorylation of GSK3B protein]; Deoxyglucose inhibits the reaction [Fenretinide results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:25246272 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
H2ax |
H2A.X variant histone |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of H2AX protein |
CTD |
PMID:23363784 |
|
NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374
|
|
G |
Hk2 |
hexokinase 2 |
multiple interactions |
ISO |
[Lactic Acid co-treated with Deoxyglucose] inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of HK2 protein]; Deoxyglucose inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of HK2 protein]; Deoxyglucose inhibits the reaction [G3BP1 protein results in increased expression of HK2 protein]; Deoxyglucose inhibits the reaction [HMGA2 protein results in increased expression of HK2 protein]; Deoxyglucose results in decreased expression of and results in decreased activity of HK2 protein |
CTD |
PMID:32619556 PMID:34481905 PMID:35945655 PMID:36336208 |
|
NCBI chr 6:82,702,004...82,751,437
Ensembl chr 6:82,702,006...82,751,435
|
|
G |
Hmga2 |
high mobility group AT-hook 2 |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [HMGA2 protein results in decreased expression of COX4 protein]; Deoxyglucose inhibits the reaction [HMGA2 protein results in decreased expression of ND1 protein]; Deoxyglucose inhibits the reaction [HMGA2 protein results in increased expression of HK2 protein]; Deoxyglucose inhibits the reaction [HMGA2 protein results in increased expression of MMP2 protein]; Deoxyglucose inhibits the reaction [HMGA2 protein results in increased expression of MMP9 protein] |
CTD |
PMID:34481905 |
|
NCBI chr10:120,197,173...120,312,374
Ensembl chr10:120,197,180...120,312,374
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [arsenic trioxide results in increased expression of HMOX1 protein]; Deoxyglucose inhibits the reaction [Fenretinide results in increased expression of HMOX1 protein] |
CTD |
PMID:25246272 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hsp90aa1 |
heat shock protein 90, alpha (cytosolic), class A member 1 |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:18655187 |
|
NCBI chr12:110,657,470...110,662,829
Ensembl chr12:110,657,039...110,669,162
|
|
G |
Hsp90b1 |
heat shock protein 90, beta (Grp94), member 1 |
multiple interactions increases expression |
ISO |
4-Quinolones analog inhibits the reaction [Deoxyglucose results in increased expression of HSP90B1 protein] |
CTD |
PMID:31022492 |
|
NCBI chr10:86,526,705...86,541,308
Ensembl chr10:86,526,073...86,541,373
|
|
G |
Hspa5 |
heat shock protein 5 |
multiple interactions increases expression |
ISO |
4-Quinolones analog inhibits the reaction [Deoxyglucose results in increased expression of HSPA5 mRNA]; 4-Quinolones analog inhibits the reaction [Deoxyglucose results in increased expression of HSPA5 protein]; ATG7 protein inhibits the reaction [Deoxyglucose results in increased expression of HSPA5 protein]; HSPA5 protein affects the reaction [A2M protein modified form results in increased uptake of Deoxyglucose]; HSPA5 protein affects the reaction [INS protein results in increased uptake of Deoxyglucose]; Mannose inhibits the reaction [Deoxyglucose results in increased expression of HSPA5 protein]; Oxygen deficiency inhibits the reaction [Deoxyglucose results in increased expression of HSPA5 protein] Deoxyglucose results in increased expression of HSPA5 mRNA; Deoxyglucose results in increased expression of HSPA5 protein |
CTD |
PMID:20593179 PMID:25720493 PMID:31022492 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
multiple interactions decreases localization |
ISO |
Deoxyglucose promotes the reaction [arsenic trioxide results in decreased localization of HTRA2 protein] Deoxyglucose results in decreased localization of HTRA2 protein |
CTD |
PMID:23041229 |
|
NCBI chr 6:83,028,247...83,031,552
Ensembl chr 6:83,028,247...83,032,254
|
|
G |
Igf1r |
insulin-like growth factor I receptor |
multiple interactions |
ISO |
Deoxyglucose results in increased phosphorylation of and results in increased activity of IGF1R protein |
CTD |
PMID:23041229 |
|
NCBI chr 7:67,601,486...67,883,416
Ensembl chr 7:67,602,575...67,883,416
|
|
G |
Il1b |
interleukin 1 beta |
decreases response to substance multiple interactions |
ISO EXP |
Deoxyglucose results in decreased susceptibility to IL1B protein Deoxyglucose inhibits the reaction [bisphenol F results in increased secretion of IL1B protein] Deoxyglucose inhibits the reaction [IL1B protein results in increased expression of MMP13 protein] |
CTD |
PMID:21211511 PMID:34147605 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Deoxyglucose inhibits the reaction [bisphenol F results in increased secretion of IL6 protein] |
CTD |
PMID:34147605 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ins1 |
insulin I |
increases uptake multiple interactions increases transport affects transport increases secretion |
EXP ISO |
INS1 protein results in increased uptake of Deoxyglucose; INS1 results in increased uptake of Deoxyglucose 4-phenylbutyric acid inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]]; CCG 1423 promotes the reaction [ABRA mutant form promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; CCG 1423 promotes the reaction [INS1 protein promotes the reaction [ABRA mutant form results in increased uptake of Deoxyglucose]]; CCG 1423 promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Diethylhexyl Phthalate inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Glucosamine inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]; Glucose inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; INS1 protein promotes the reaction [ABRA mutant form results in increased uptake of Deoxyglucose]; INS1 protein promotes the reaction [CCG 1423 results in increased uptake of Deoxyglucose]; mono-(2-ethylhexyl)phthalate inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; oxophenylarsine inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Quercetin inhibits the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; Quercetin inhibits the reaction [TNF protein inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; Quercetin promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Raffinose promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; SLC2A4 promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; TNF protein inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]] [INS1 protein co-treated with CUL7 mutant form] results in increased uptake of Deoxyglucose; acetylaminophenylarsine oxide inhibits the reaction [INS1 protein results in increased transport of Deoxyglucose]; Apigenin inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Dimercaprol inhibits the reaction [oxophenylarsine inhibits the reaction [INS1 protein results in increased transport of Deoxyglucose]]; Dimercaprol inhibits the reaction [oxophenylarsine inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; Dimercaprol inhibits the reaction [p-aminophenylarsine oxide inhibits the reaction [INS1 protein results in increased transport of Deoxyglucose]]; dorsomorphin inhibits the reaction [Quercetin inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; epigallocatechin gallate inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; fisetin inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Genistein inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Genistein inhibits the reaction [Raffinose promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; kaempferol inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Luteolin inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; oxophenylarsine inhibits the reaction [INS1 protein results in increased transport of Deoxyglucose]; oxophenylarsine inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; p-aminophenylarsine oxide inhibits the reaction [INS1 protein results in increased transport of Deoxyglucose]; Quercetin inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Quercetin inhibits the reaction [TNF protein inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; Raffinose promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Ro 31-8220 inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Silybin inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; theaflavin inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; TNF protein inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; tyrphostin 25 inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Wortmannin inhibits the reaction [Raffinose promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]] INS1 protein affects the transport of Deoxyglucose Deoxyglucose results in increased secretion of INS1 protein |
CTD |
PMID:1378463 PMID:1536656 PMID:1847587 PMID:1918056 PMID:2202293 PMID:2877896 PMID:3882699 PMID:9453242 PMID:14511371 PMID:18591783 PMID:20165829 PMID:20206685 PMID:21393865 PMID:22713545 PMID:23439570 PMID:24219910 PMID:24287560 PMID:24343960 PMID:26627467 PMID:28298333 PMID:28526321 PMID:29458019 PMID:31408376 More...
|
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Ins2 |
insulin II |
increases uptake multiple interactions |
ISO EXP |
INS protein results in increased uptake of Deoxyglucose; INS results in increased uptake of Deoxyglucose METRNL protein inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]; PPARA protein promotes the reaction [GW 7647 promotes the reaction [INS protein results in increased uptake of Deoxyglucose]] 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Palmitic Acid inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]]; 4-phenylbutyric acid inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]]; Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]; GW 7647 promotes the reaction [INS protein results in increased uptake of Deoxyglucose]; HSPA5 protein affects the reaction [INS protein results in increased uptake of Deoxyglucose]; Palmitates inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]; Palmitic Acid inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]; SLC2A1 protein inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]; tin protoporphyrin IX inhibits the reaction [3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Palmitic Acid inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]]]; TNF protein inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]; Troglitazone inhibits the reaction [TNF protein inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]]; ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]] |
CTD |
PMID:2173694 PMID:16483873 PMID:20165829 PMID:21324916 PMID:25720493 PMID:25815690 PMID:30213948 PMID:31877369 More...
|
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Itgb1 |
integrin beta 1 (fibronectin receptor beta) |
decreases expression |
ISO |
Deoxyglucose analog results in decreased expression of ITGB1 protein |
CTD |
PMID:27931795 |
|
NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681
|
|
G |
Jade2 |
jade family PHD finger 2 |
increases expression |
ISO |
Deoxyglucose results in increased expression of JADE2 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr11:51,704,278...51,749,835
Ensembl chr11:51,704,282...51,748,480
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
multiple interactions decreases activity |
ISO |
[Deoxyglucose co-treated with Glucose deficiency] results in decreased activity of KCNH2 protein; Deoxyglucose inhibits the reaction [Glucose results in decreased activity of KCNH2 protein]; Deoxyglucose promotes the reaction [Glucose deficiency results in decreased activity of KCNH2 protein]; Pyruvic Acid inhibits the reaction [[Deoxyglucose co-treated with Glucose deficiency] results in decreased activity of KCNH2 protein] Deoxyglucose results in decreased activity of KCNH2 protein |
CTD |
PMID:12531891 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Kcnj11 |
potassium inwardly rectifying channel, subfamily J, member 11 |
multiple interactions |
EXP |
[Oligomycins co-treated with Deoxyglucose] results in increased activity of [KCNJ11 protein binds to ABCC9 protein]; Glyburide inhibits the reaction [[Oligomycins co-treated with Deoxyglucose] results in increased activity of [KCNJ11 protein binds to ABCC9 protein]] |
CTD |
PMID:28842488 |
|
NCBI chr 7:45,746,545...45,750,215
Ensembl chr 7:45,743,377...45,750,188
|
|
G |
Klhl42 |
kelch-like 42 |
increases expression |
ISO |
Deoxyglucose results in increased expression of KLHL42 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 6:146,990,783...147,014,276
Ensembl chr 6:146,992,877...147,014,276
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [G3BP1 protein results in increased expression of LDHA protein] |
CTD |
PMID:35945655 |
|
NCBI chr 7:46,491,698...46,505,051
Ensembl chr 7:46,490,899...46,505,051
|
|
G |
Lep |
leptin |
multiple interactions decreases secretion |
ISO |
[Deoxyglucose results in decreased abundance of Adenosine Triphosphate] which results in decreased secretion of LEP protein Deoxyglucose results in decreased secretion of LEP protein |
CTD |
PMID:10780946 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Liph |
lipase, member H |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of LIPH mRNA |
CTD |
PMID:33770205 |
|
NCBI chr16:21,772,567...21,814,408
Ensembl chr16:21,772,567...21,814,413
|
|
G |
Map1lc3a |
microtubule-associated protein 1 light chain 3 alpha |
multiple interactions |
ISO |
Deoxyglucose affects the reaction [demycarosyl-3D-digitoxosylmithramycin SK affects the expression of MAP1LC3A mRNA] |
CTD |
PMID:26079942 |
|
NCBI chr 2:155,118,284...155,119,993
Ensembl chr 2:155,118,217...155,119,993
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases prenylation |
ISO |
ATG7 protein promotes the reaction [Deoxyglucose results in increased prenylation of MAP1LC3B protein]; Mannose inhibits the reaction [Deoxyglucose results in increased prenylation of MAP1LC3B protein]; Oxygen deficiency inhibits the reaction [Deoxyglucose results in increased prenylation of MAP1LC3B protein] |
CTD |
PMID:20593179 |
|
NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions |
ISO |
arsenic trioxide inhibits the reaction [Deoxyglucose results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Deoxyglucose results in increased phosphorylation of and results in increased activity of MAPK1 protein; PQ 401 inhibits the reaction [Deoxyglucose results in increased phosphorylation of and results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [Deoxyglucose results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:23041229 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions |
ISO |
MAPK3 protein affects the reaction [AICA ribonucleotide results in increased uptake of Deoxyglucose] arsenic trioxide inhibits the reaction [Deoxyglucose results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Deoxyglucose results in increased phosphorylation of and results in increased activity of MAPK3 protein; PQ 401 inhibits the reaction [Deoxyglucose results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [Deoxyglucose results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:11978788 PMID:23041229 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mepce |
methylphosphate capping enzyme |
increases expression |
ISO |
Deoxyglucose results in increased expression of MEPCE mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 5:137,780,168...137,785,915
Ensembl chr 5:137,780,168...137,785,917
|
|
G |
Metrnl |
meteorin, glial cell differentiation regulator-like |
multiple interactions |
EXP |
METRNL protein inhibits the reaction [INS protein results in increased uptake of Deoxyglucose] |
CTD |
PMID:30213948 |
|
NCBI chr11:121,593,253...121,608,215
Ensembl chr11:121,592,370...121,607,132
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions decreases expression |
ISO |
Deoxyglucose inhibits the reaction [IL1B protein results in increased expression of MMP13 protein]; Deoxyglucose inhibits the reaction [TNF protein results in increased expression of MMP13 protein] Deoxyglucose analog results in decreased expression of MMP13 protein |
CTD |
PMID:21211511 PMID:27931795 |
|
NCBI chr 9:7,272,514...7,283,333
Ensembl chr 9:7,272,514...7,283,331
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of MMP2 protein]; Deoxyglucose inhibits the reaction [HMGA2 protein results in increased expression of MMP2 protein] |
CTD |
PMID:34481905 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions |
ISO |
Deoxyglucose analog results in decreased expression of MMP9 protein Deoxyglucose inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of MMP9 protein]; Deoxyglucose inhibits the reaction [HMGA2 protein results in increased expression of MMP9 protein] |
CTD |
PMID:27931795 PMID:34481905 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
mt-Nd1 |
NADH dehydrogenase 1, mitochondrial |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of ND1 protein]; Deoxyglucose inhibits the reaction [HMGA2 protein results in decreased expression of ND1 protein] |
CTD |
PMID:34481905 |
|
NCBI chr MT:2,751...3,707
Ensembl chr MT:2,751...3,707
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
Deoxyglucose results in decreased phosphorylation of and results in increased expression of MTOR protein; Deoxyglucose results in increased phosphorylation of and results in increased activity of MTOR protein |
CTD |
PMID:23041229 PMID:23363784 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Mxi1 |
MAX interactor 1, dimerization protein |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of MXI1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr19:53,298,509...53,361,724
Ensembl chr19:53,298,949...53,364,241
|
|
G |
Myo1e |
myosin IE |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of MYO1E mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 9:70,114,632...70,307,349
Ensembl chr 9:70,114,632...70,307,048
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions decreases expression |
ISO |
[demycarosyl-3D-digitoxosylmithramycin SK co-treated with Deoxyglucose] affects the expression of NFKB1 mRNA Deoxyglucose results in decreased expression of NFKB1 mRNA |
CTD |
PMID:26079942 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
ISO |
Deoxyglucose promotes the reaction [STO 609 inhibits the reaction [Histamine results in increased phosphorylation of NOS2 protein]] |
CTD |
PMID:21145922 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Npy |
neuropeptide Y |
increases expression |
ISO |
Deoxyglucose results in increased expression of NPY mRNA |
CTD |
PMID:10683841 |
|
NCBI chr 6:49,799,690...49,806,487
Ensembl chr 6:49,799,690...49,806,487
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein] |
CTD |
PMID:2827574 |
|
NCBI chr 7:132,159,204...132,178,127
Ensembl chr 7:132,159,207...132,178,127
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
multiple interactions increases cleavage |
ISO EXP |
Deoxyglucose inhibits the reaction [arsenic trioxide results in increased cleavage of PARP1 protein]; Deoxyglucose inhibits the reaction [Fenretinide results in increased cleavage of PARP1 protein] Deoxyglucose promotes the reaction [Metformin inhibits the reaction [Arsenic Trioxide results in increased expression of PARP1 protein modified form]] Deoxyglucose results in increased cleavage of PARP1 protein |
CTD |
PMID:25246272 PMID:29095437 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Pkm |
pyruvate kinase, muscle |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [G3BP1 protein results in increased expression of PKM protein] |
CTD |
PMID:35945655 |
|
NCBI chr 9:59,563,859...59,586,655
Ensembl chr 9:59,563,651...59,586,658
|
|
G |
Pmch |
pro-melanin-concentrating hormone |
increases expression |
ISO |
Deoxyglucose results in increased expression of PMCH mRNA |
CTD |
PMID:10683841 |
|
NCBI chr10:87,926,934...87,928,236
Ensembl chr10:87,926,934...87,928,237
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
PPARA protein promotes the reaction [GW 7647 promotes the reaction [INS protein results in increased uptake of Deoxyglucose]] |
CTD |
PMID:21324916 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
affects uptake increases uptake |
EXP |
PPARG protein affects the uptake of Deoxyglucose PPARG gene polymorphism results in increased uptake of Deoxyglucose |
CTD |
PMID:18083318 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ppp3ca |
protein phosphatase 3, catalytic subunit, alpha isoform |
decreases response to substance |
EXP |
PPP3CA protein results in decreased susceptibility to Deoxyglucose |
CTD |
PMID:10679475 |
|
NCBI chr 3:136,375,778...136,643,488
Ensembl chr 3:136,375,885...136,643,488
|
|
G |
Pym1 |
PYM homolog 1, exon junction complex associated factor |
increases expression |
ISO |
Deoxyglucose results in increased expression of PYM1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr10:128,579,989...128,602,437
Ensembl chr10:128,583,758...128,602,433
|
|
G |
Raf1 |
v-raf-leukemia viral oncogene 1 |
multiple interactions |
ISO |
RAF1 protein affects the reaction [AICA ribonucleotide results in increased uptake of Deoxyglucose] |
CTD |
PMID:11978788 |
|
NCBI chr 6:115,595,530...115,653,596
Ensembl chr 6:115,595,028...115,653,596
|
|
G |
Rnf24 |
ring finger protein 24 |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of RNF24 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 2:131,139,984...131,194,766
Ensembl chr 2:131,139,984...131,194,812
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Deoxyglucose results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:23363784 |
|
NCBI chr 4:86,772,336...86,775,604
Ensembl chr 4:86,772,897...86,775,649
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase, polypeptide 1 |
decreases phosphorylation multiple interactions |
ISO |
Deoxyglucose results in decreased phosphorylation of RPS6KB1 protein Deoxyglucose results in increased phosphorylation of and results in increased activity of RPS6KB1 protein; oxophenylarsine inhibits the reaction [Deoxyglucose results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:16183647 PMID:23041229 |
|
NCBI chr11:86,389,695...86,435,711
Ensembl chr11:86,389,697...86,435,631
|
|
G |
Serpinb5 |
serine (or cysteine) peptidase inhibitor, clade B, member 5 |
increases expression |
ISO |
Deoxyglucose analog results in increased expression of SERPINB5 protein |
CTD |
PMID:27931795 |
|
NCBI chr 1:106,788,905...106,811,078
Ensembl chr 1:106,788,903...106,811,078
|
|
G |
Slc16a1 |
solute carrier family 16 (monocarboxylic acid transporters), member 1 |
multiple interactions |
ISO |
[Lactic Acid co-treated with Deoxyglucose] promotes the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of SLC16A1 protein] |
CTD |
PMID:36336208 |
|
NCBI chr 3:104,545,980...104,565,778
Ensembl chr 3:104,545,984...104,565,778
|
|
G |
Slc2a1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
multiple interactions increases uptake |
EXP ISO |
[arsenite affects the localization of SLC2A1 protein] which results in increased uptake of Deoxyglucose SLC2A1 protein results in increased uptake of Deoxyglucose [Deoxyglucose results in increased abundance of Glucose] which affects the localization of SLC2A1 protein; [sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [[Deoxyglucose results in increased abundance of Glucose] which affects the localization of SLC2A1 protein]; SLC2A1 protein inhibits the reaction [INS protein results in increased uptake of Deoxyglucose] |
CTD |
PMID:2173694 PMID:14511371 PMID:31398423 |
|
NCBI chr 4:118,966,001...118,994,527
Ensembl chr 4:118,965,908...118,995,180
|
|
G |
Slc2a2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
multiple interactions increases transport |
ISO |
Cytochalasin B inhibits the reaction [SLC2A2 protein results in increased transport of Deoxyglucose]; Fructose inhibits the reaction [SLC2A2 protein results in increased transport of Deoxyglucose]; Glucose inhibits the reaction [SLC2A2 protein results in increased transport of Deoxyglucose]; Maltose inhibits the reaction [SLC2A2 protein results in increased transport of Deoxyglucose] |
CTD |
PMID:8457197 |
|
NCBI chr 3:28,752,052...28,782,510
Ensembl chr 3:28,752,052...28,785,508
|
|
G |
Slc2a3 |
solute carrier family 2 (facilitated glucose transporter), member 3 |
multiple interactions increases transport |
ISO |
Cytochalasin B inhibits the reaction [SLC2A3 protein results in increased transport of Deoxyglucose]; Galactose inhibits the reaction [SLC2A3 protein results in increased transport of Deoxyglucose]; Glucose inhibits the reaction [SLC2A3 protein results in increased transport of Deoxyglucose]; Maltose inhibits the reaction [SLC2A3 protein results in increased transport of Deoxyglucose] |
CTD |
PMID:8457197 |
|
NCBI chr 6:122,704,783...122,779,149
Ensembl chr 6:122,704,768...122,778,599
|
|
G |
Slc2a4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
multiple interactions increases uptake |
EXP ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [mangiferin promotes the reaction [SLC2A4 protein results in increased uptake of Deoxyglucose]]; [arsenite affects the localization of SLC2A4 protein] which results in increased uptake of Deoxyglucose; mangiferin promotes the reaction [SLC2A4 protein results in increased uptake of Deoxyglucose]; Plant Extracts promotes the reaction [SLC2A4 protein results in increased uptake of Deoxyglucose] [Indinavir results in decreased activity of SLC2A4 protein] inhibits the reaction [resveratrol results in increased uptake of Deoxyglucose]; SLC2A4 promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; SLC2A4 protein promotes the reaction [resveratrol results in increased uptake of Deoxyglucose] |
CTD |
PMID:14511371 PMID:18601907 PMID:19477051 PMID:20206685 |
|
NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014
|
|
G |
Slc2a8 |
solute carrier family 2, (facilitated glucose transporter), member 8 |
increases uptake |
EXP ISO |
SLC2A8 protein results in increased uptake of Deoxyglucose |
CTD |
PMID:23396969 |
|
NCBI chr 2:32,862,993...32,872,088
Ensembl chr 2:32,863,002...32,872,095
|
|
G |
Slc7a11 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of SLC7A11 protein |
CTD |
PMID:37927237 |
|
NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063
|
|
G |
Smim14 |
small integral membrane protein 14 |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of SMIM14 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 5:65,604,187...65,694,492
Ensembl chr 5:65,604,187...65,694,527
|
|
G |
Snd1 |
staphylococcal nuclease and tudor domain containing 1 |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of SND1 protein |
CTD |
PMID:37927237 |
|
NCBI chr 6:28,480,332...28,935,161
Ensembl chr 6:28,475,138...28,935,161
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [manganese chloride results in increased expression of SOD2 mRNA]; Deoxyglucose inhibits the reaction [manganese chloride results in increased expression of SOD2 protein] |
CTD |
PMID:10328827 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[bafilomycin A co-treated with Deoxyglucose co-treated with demycarosyl-3D-digitoxosylmithramycin SK] affects the expression of SQSTM1 protein; [bafilomycin A co-treated with Deoxyglucose] affects the expression of SQSTM1 protein; Deoxyglucose inhibits the reaction [demycarosyl-3D-digitoxosylmithramycin SK results in decreased expression of SQSTM1 mRNA]; Deoxyglucose promotes the reaction [demycarosyl-3D-digitoxosylmithramycin SK results in decreased expression of SQSTM1 mRNA] |
CTD |
PMID:26079942 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
increases expression |
EXP |
Deoxyglucose results in increased expression of SREBF1 mRNA |
CTD |
PMID:10913129 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
G |
Srgap3 |
SLIT-ROBO Rho GTPase activating protein 3 |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of SRGAP3 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 6:112,694,932...112,924,466
Ensembl chr 6:112,694,932...112,924,227
|
|
G |
Stk11 |
serine/threonine kinase 11 |
decreases phosphorylation |
ISO |
Deoxyglucose results in decreased phosphorylation of STK11 protein |
CTD |
PMID:23041229 |
|
NCBI chr10:79,951,602...79,966,513
Ensembl chr10:79,951,637...79,966,516
|
|
G |
Tent4b |
terminal nucleotidyltransferase 4B |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of TENT4B mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 8:88,925,229...88,989,942
Ensembl chr 8:88,925,837...88,986,355
|
|
G |
Tmcc3 |
transmembrane and coiled coil domains 3 |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of TMCC3 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr10:94,147,544...94,426,816
Ensembl chr10:94,147,811...94,426,818
|
|
G |
Tmem250 |
transmembrane protein 250 |
increases expression |
ISO |
Deoxyglucose results in increased expression of TMEM250 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 2:26,026,819...26,030,518
Ensembl chr 2:26,026,826...26,030,533
|
|
G |
Tmem87a |
transmembrane protein 87A |
increases expression |
ISO |
Deoxyglucose results in increased expression of TMEM87A mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 2:120,185,790...120,234,597
Ensembl chr 2:120,185,793...120,234,594
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions decreases response to substance |
EXP ISO |
Deoxyglucose results in decreased expression of TNF protein Quercetin inhibits the reaction [TNF protein inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; TNF protein inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose] Deoxyglucose inhibits the reaction [bisphenol F results in increased secretion of TNF protein]; Quercetin inhibits the reaction [TNF protein inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; TNF protein inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose] Deoxyglucose results in decreased susceptibility to TNF protein Deoxyglucose inhibits the reaction [TNF protein results in increased expression of MMP13 protein]; TNF protein inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]; troglitazone inhibits the reaction [TNF protein inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]] |
CTD |
PMID:16483873 PMID:21211511 PMID:21778228 PMID:22713545 PMID:23439570 PMID:34147605 More...
|
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions |
ISO |
[Deoxyglucose co-treated with demycarosyl-3D-digitoxosylmithramycin SK] results in increased expression of TP53 mRNA; Deoxyglucose promotes the reaction [demycarosyl-3D-digitoxosylmithramycin SK results in increased expression of TP53 mRNA]; TP53 protein inhibits the reaction [Deoxyglucose results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:21042727 PMID:26079942 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Deoxyglucose] results in decreased expression of XIAP protein |
CTD |
PMID:23041229 |
|
NCBI chr X:41,148,483...41,198,541
Ensembl chr X:41,148,556...41,198,533
|
|
G |
Yars2 |
tyrosyl-tRNA synthetase 2 (mitochondrial) |
increases expression |
ISO |
Deoxyglucose results in increased expression of YARS2 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr16:16,120,829...16,127,504
Ensembl chr16:16,120,829...16,127,504
|
|
G |
Yes1 |
YES proto-oncogene 1, Src family tyrosine kinase |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of YES1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 5:32,768,502...32,844,410
Ensembl chr 5:32,768,515...32,844,401
|
|
G |
Zbtb1 |
zinc finger and BTB domain containing 1 |
increases expression |
ISO |
Deoxyglucose results in increased expression of ZBTB1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr12:76,416,825...76,443,729
Ensembl chr12:76,417,040...76,443,724
|
|
G |
Zfx |
zinc finger protein X-linked |
increases expression |
ISO |
Deoxyglucose results in increased expression of ZFX mRNA |
CTD |
PMID:33770205 |
|
NCBI chr X:93,118,237...93,194,250
Ensembl chr X:93,118,237...93,167,308
|
|
|
G |
Gaa |
glucosidase, alpha, acid |
multiple interactions increases metabolic processing |
ISO |
GAA gene SNP inhibits the reaction [GAA protein results in increased metabolism of 4-methylumbelliferyl glucoside] |
CTD |
PMID:21963784 |
|
NCBI chr11:119,158,789...119,176,284
Ensembl chr11:119,158,713...119,176,280
|
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions |
ISO |
albiflorin inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:37523837 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Drd2 |
dopamine receptor D2 |
affects expression |
ISO |
albiflorin affects the expression of DRD2 |
CTD |
PMID:26475043 |
|
NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
albiflorin inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased phosphorylation of EGFR protein] |
CTD |
PMID:37523837 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A |
affects expression |
ISO |
albiflorin affects the expression of HTR1A |
CTD |
PMID:26475043 |
|
NCBI chr13:105,580,040...105,584,630
Ensembl chr13:105,580,147...105,584,630
|
|
G |
Htr2a |
5-hydroxytryptamine (serotonin) receptor 2A |
affects expression |
ISO |
albiflorin affects the expression of HTR2A |
CTD |
PMID:26475043 |
|
NCBI chr14:74,878,314...74,944,299
Ensembl chr14:74,878,280...74,946,934
|
|
G |
Map3k7 |
mitogen-activated protein kinase kinase kinase 7 |
multiple interactions |
ISO |
Albiflorin inhibits the reaction [oxidized LDL increases phosphorylation of MAP3K7 protein in umbilical vein endothelial cells] |
RGD |
PMID:35601145 |
RGD:155804296 |
NCBI chr 4:31,963,659...32,023,470
Ensembl chr 4:31,964,097...32,023,467
|
|
G |
Slc6a3 |
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
affects expression |
ISO |
albiflorin affects the expression of SLC6A3 |
CTD |
PMID:26475043 |
|
NCBI chr13:73,684,270...73,726,791
Ensembl chr13:73,684,866...73,726,791
|
|
G |
Th |
tyrosine hydroxylase |
affects expression |
ISO |
albiflorin affects the expression of TH |
CTD |
PMID:26475043 |
|
NCBI chr 7:142,446,516...142,453,732
Ensembl chr 7:142,446,489...142,484,865
|
|
|
G |
Idh2 |
isocitrate dehydrogenase 2 (NADP+), mitochondrial |
increases abundance multiple interactions |
EXP |
IDH2 protein mutant form results in increased abundance of glucose-1-phosphate Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of glucose-1-phosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140
|
|
|
G |
Abcc3 |
ATP-binding cassette, sub-family C member 3 |
decreases expression |
ISO |
Amikacin results in decreased expression of ABCC3 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823
|
|
G |
Abcc4 |
ATP-binding cassette, sub-family C member 4 |
decreases expression |
ISO |
Amikacin results in decreased expression of ABCC4 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631
|
|
G |
Casr |
calcium-sensing receptor |
increases activity |
ISO |
Amikacin results in increased activity of CASR protein |
CTD |
PMID:19884751 |
|
NCBI chr16:36,310,947...36,382,605
Ensembl chr16:36,314,058...36,382,503
|
|
G |
Cat |
catalase |
decreases activity multiple interactions |
EXP ISO |
Amikacin results in decreased activity of CAT protein cefepime inhibits the reaction [Amikacin results in decreased activity of CAT protein] |
CTD |
PMID:18781908 PMID:23416261 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
decreases expression |
ISO |
Amikacin results in decreased expression of CXCL8 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Il1a |
interleukin 1 alpha |
decreases expression |
ISO |
Amikacin results in decreased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
Amikacin results in decreased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il24 |
interleukin 24 |
decreases expression |
ISO |
Amikacin results in decreased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 1:130,809,801...130,815,153
Ensembl chr 1:130,809,811...130,815,191
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
ISO |
Amikacin results in decreased activity of PGD protein |
CTD |
PMID:15558954 |
|
NCBI chr 4:149,234,448...149,251,162
Ensembl chr 4:149,234,448...149,251,228
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
increases expression |
ISO |
Amikacin results in increased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 1:84,014,014...84,317,550
Ensembl chr 1:84,014,017...84,341,901
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
Amikacin results in decreased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Slc7a11 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 |
decreases expression |
ISO |
Amikacin results in decreased expression of SLC7A11 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
Amikacin results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:164,195,990...164,231,086
Ensembl chr 2:164,195,990...164,231,015
|
|
G |
Tyr |
tyrosinase |
decreases activity |
ISO |
Amikacin results in decreased activity of TYR protein |
CTD |
PMID:23416261 |
|
NCBI chr 7:87,073,979...87,142,637
Ensembl chr 7:87,073,979...87,142,720
|
|
|
G |
Gypa |
glycophorin A |
increases expression |
ISO |
apigetrin results in increased expression of GYPA protein |
CTD |
PMID:25058688 |
|
NCBI chr 8:81,220,674...81,237,414
Ensembl chr 8:81,220,410...81,237,171
|
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
[lipopolysaccharide, E coli O55-B5 co-treated with asperuloside] results in increased expression of HMOX1 protein; asperuloside inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 protein] |
CTD |
PMID:33974900 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
asperuloside inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein] |
CTD |
PMID:33974900 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
asperuloside inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 protein] |
CTD |
PMID:33974900 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
asperuloside inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein] |
CTD |
PMID:33974900 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
affects localization multiple interactions |
EXP |
asperuloside affects the localization of NFE2L2 protein [asperuloside co-treated with Dextran Sulfate] results in increased expression of NFE2L2 protein; [lipopolysaccharide, E coli O55-B5 co-treated with asperuloside] results in increased expression of NFE2L2 protein; asperuloside affects the reaction [NFE2L2 protein affects the expression of NQO1 mRNA]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of NFE2L2 protein] |
CTD |
PMID:33974900 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions |
EXP |
asperuloside affects the reaction [NFE2L2 protein affects the expression of NQO1 mRNA] |
CTD |
PMID:33974900 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
EXP |
asperuloside inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein] |
CTD |
PMID:33974900 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
asperuloside inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF mRNA]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; asperuloside inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:16508180 PMID:33974900 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
EXP |
ganglioside, GD1b analog inhibits the reaction [[lipopolysaccharide, E. coli O26-B6 results in increased activity of NOS2 protein] which results in increased secretion of Nitrites]; ganglioside, GD1b inhibits the reaction [[lipopolysaccharide, E. coli O26-B6 results in increased activity of NOS2 protein] which results in increased secretion of Nitrites] |
CTD |
PMID:31202640 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
|
G |
Aacs |
acetoacetyl-CoA synthetase |
increases expression |
EXP |
Glucosamine results in increased expression of AACS mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:125,552,937...125,594,469
Ensembl chr 5:125,552,878...125,594,474
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
increases expression |
ISO |
Glucosamine results in increased expression of ABCG1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr17:31,276,668...31,336,958
Ensembl chr17:31,276,649...31,336,962
|
|
G |
Acaca |
acetyl-Coenzyme A carboxylase alpha |
increases expression |
ISO |
Glucosamine results in increased expression of ACACA mRNA |
CTD |
PMID:22096489 |
|
NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477
|
|
G |
Acan |
aggrecan |
multiple interactions increases expression decreases expression affects expression |
ISO EXP |
Glucosamine analog affects the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of ACAN mRNA]; Glucosamine results in decreased cleavage of and results in decreased secretion of ACAN protein Glucosamine results in increased expression of ACAN mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of ACAN mRNA] Glucosamine analog results in increased expression of ACAN protein; Glucosamine results in increased expression of ACAN mRNA; Glucosamine results in increased expression of ACAN protein Glucosamine analog results in decreased expression of ACAN mRNA Glucosamine analog affects the expression of ACAN mRNA |
CTD |
PMID:12801482 PMID:16300972 PMID:16872674 PMID:17109745 PMID:17337215 PMID:18321735 PMID:19909832 More...
|
|
NCBI chr 7:78,702,974...78,764,847
Ensembl chr 7:78,703,231...78,764,847
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression |
EXP |
Glucosamine results in increased expression of ACOT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:84,056,276...84,064,444
Ensembl chr12:84,056,264...84,065,145
|
|
G |
Acox2 |
acyl-Coenzyme A oxidase 2, branched chain |
decreases expression |
EXP |
Glucosamine results in decreased expression of ACOX2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:14,210,406...14,244,262
Ensembl chr14:14,210,420...14,244,262
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
increases expression |
EXP |
Glucosamine results in increased expression of ACSS2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:155,359,963...155,404,663
Ensembl chr 2:155,359,868...155,427,644
|
|
G |
Adam15 |
ADAM metallopeptidase domain 15 |
multiple interactions decreases expression |
ISO |
Glucosamine affects the reaction [IL1B results in decreased expression of ADAM15 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of ADAM15 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:89,246,947...89,257,589
Ensembl chr 3:89,245,849...89,257,303
|
|
G |
Adam17 |
a disintegrin and metallopeptidase domain 17 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr12:21,373,510...21,423,633
Ensembl chr12:21,373,510...21,423,633
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif 1 |
decreases expression multiple interactions |
ISO |
Glucosamine analog results in decreased expression of ADAMTS1 mRNA Glucosamine results in decreased expression of ADAMTS1 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of ADAMTS1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of ADAMTS1 mRNA] |
CTD |
PMID:16300972 PMID:17109745 |
|
NCBI chr16:85,590,715...85,600,001
Ensembl chr16:85,590,715...85,600,001
|
|
G |
Adamts20 |
ADAM metallopeptidase with thrombospondin type 1 motif 20 |
decreases cleavage |
ISO |
Glucosamine results in decreased cleavage of ADAMTS20 protein alternative form |
CTD |
PMID:19909832 |
|
NCBI chr15:94,166,177...94,329,966
Ensembl chr15:94,168,044...94,363,299
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif 4 |
increases expression |
ISO |
Glucosamine results in increased expression of ADAMTS4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:171,077,698...171,089,836
Ensembl chr 1:171,077,990...171,088,206
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif 5 |
decreases expression multiple interactions |
ISO |
Glucosamine analog results in decreased expression of ADAMTS5 mRNA Glucosamine results in decreased cleavage of and results in decreased activity of ADAMTS5 protein alternative form |
CTD |
PMID:16300972 PMID:19909832 |
|
NCBI chr16:85,655,045...85,698,013
Ensembl chr16:85,653,061...85,698,716
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif 9 |
decreases cleavage |
ISO |
Glucosamine results in decreased cleavage of ADAMTS9 protein alternative form |
CTD |
PMID:19909832 |
|
NCBI chr 6:92,749,680...92,921,431
Ensembl chr 6:92,749,680...92,920,473
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
EXP ISO |
Glucosamine results in increased expression of ADIPOQ mRNA |
CTD |
PMID:15694357 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Afp |
alpha fetoprotein |
increases expression |
EXP |
Glucosamine results in increased expression of AFP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:90,638,573...90,656,766
Ensembl chr 5:90,638,596...90,656,766
|
|
G |
Agt |
angiotensinogen |
increases expression |
EXP |
Glucosamine results in increased expression of AGT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445
|
|
G |
Ahi1 |
Abelson helper integration site 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of AHI1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:20,827,274...20,956,328
Ensembl chr10:20,828,446...20,956,328
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
affects phosphorylation multiple interactions |
ISO EXP |
Glucosamine analog affects the phosphorylation of AKT1 protein Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]] Glucosamine analog affects the reaction [IL1B results in increased phosphorylation of AKT1 protein]; Glucosamine promotes the reaction [IL1B results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:18080321 PMID:18340449 PMID:30602124 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
[LEPR protein affects the susceptibility to Glucosamine] which affects the expression of ALB protein |
CTD |
PMID:33345901 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Alg12 |
ALG12 alpha-1,6-mannosyltransferase |
decreases expression |
EXP |
Glucosamine results in decreased expression of ALG12 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:88,689,448...88,703,498
Ensembl chr15:88,689,447...88,703,521
|
|
G |
Alpl |
alkaline phosphatase, liver/bone/kidney |
multiple interactions increases expression increases activity |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased activity of ALPL protein] Glucosamine analog results in increased expression of ALPL mRNA |
CTD |
PMID:20458730 |
|
NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695
|
|
G |
Apoa1 |
apolipoprotein A-I |
increases secretion increases stability |
ISO |
Glucosamine results in increased secretion of APOA1 protein Glucosamine results in increased stability of APOA1 mRNA |
CTD |
PMID:15164326 |
|
NCBI chr 9:46,139,928...46,141,767
Ensembl chr 9:46,139,878...46,141,764
|
|
G |
Apob |
apolipoprotein B |
multiple interactions increases degradation increases ubiquitination decreases secretion decreases localization decreases expression |
ISO |
acetylleucyl-leucyl-norleucinal inhibits the reaction [Glucosamine results in decreased expression of and results in decreased secretion of APOB protein]; Glucosamine results in decreased expression of and results in decreased secretion of APOB protein; Oleic Acid inhibits the reaction [Glucosamine results in decreased secretion of APOB protein] Oleic Acid inhibits the reaction [Glucosamine results in increased degradation of APOB protein] Glucosamine results in increased ubiquitination of APOB protein Glucosamine results in decreased localization of APOB protein Glucosamine results in decreased expression of APOB protein |
CTD |
PMID:15618547 PMID:19383982 |
|
NCBI chr12:8,027,629...8,066,839
Ensembl chr12:8,027,648...8,066,835
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
EXP |
[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine; INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine] |
CTD |
PMID:16380481 |
|
NCBI chr 7:19,430,169...19,434,326
Ensembl chr 7:19,430,034...19,433,113
|
|
G |
Ass1 |
argininosuccinate synthetase 1 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of ASS1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:31,360,282...31,410,682
Ensembl chr 2:31,360,219...31,410,684
|
|
G |
Atf3 |
activating transcription factor 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of ATF3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
EXP ISO |
Glucosamine results in increased expression of ATF4 mRNA; Glucosamine results in increased expression of ATF4 protein NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF4 protein]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of ATF4 mRNA]; GSK2656157 inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA] |
CTD |
PMID:30602124 PMID:33812996 |
|
NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions increases expression decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA] Glucosamine results in increased expression of ATF6 protein ATF6 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA] Glucosamine results in decreased expression of ATF6 mRNA |
CTD |
PMID:17178593 PMID:19383982 PMID:20165829 PMID:30602124 PMID:33812996 |
|
NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340
|
|
G |
Atf7ip |
activating transcription factor 7 interacting protein |
increases expression |
EXP |
Glucosamine results in increased expression of ATF7IP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:136,495,787...136,587,848
Ensembl chr 6:136,483,165...136,587,860
|
|
G |
Atp2a2 |
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of ATP2A2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:122,591,576...122,640,288
Ensembl chr 5:122,591,576...122,640,288
|
|
G |
Azin1 |
antizyme inhibitor 1 |
decreases expression multiple interactions |
ISO |
Glucosamine results in decreased expression of AZIN1 mRNA IL1B promotes the reaction [Glucosamine results in increased expression of AZIN1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr15:38,487,674...38,523,506
Ensembl chr15:38,487,671...38,519,510
|
|
G |
B3gat3 |
beta-1,3-glucuronyltransferase 3 |
multiple interactions increases expression |
ISO |
[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased activity of B3GAT3 protein]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of B3GAT3 mRNA] |
CTD |
PMID:11229466 PMID:11801247 |
|
NCBI chr19:8,897,740...8,904,600
Ensembl chr19:8,897,738...8,904,600
|
|
G |
Bcl2l1 |
BCL2-like 1 |
decreases expression multiple interactions |
ISO |
Glucosamine results in decreased expression of BCL2L1 protein pepstatin inhibits the reaction [Glucosamine results in decreased expression of BCL2L1 protein] |
CTD |
PMID:15972124 PMID:16850161 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Bdnf |
brain derived neurotrophic factor |
decreases expression |
EXP |
Glucosamine results in decreased expression of BDNF mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Bglap |
bone gamma carboxyglutamate protein |
increases expression |
ISO |
Glucosamine analog results in increased expression of BGLAP mRNA |
CTD |
PMID:20458730 |
|
NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771
|
|
G |
Bgn |
biglycan |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of BGN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of BGN mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:72,527,207...72,539,542
Ensembl chr X:72,527,208...72,539,539
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of BMAL1 mRNA; Glucosamine results in decreased expression of BMAL1 protein |
CTD |
PMID:24442997 |
|
NCBI chr 7:112,777,820...112,913,333
Ensembl chr 7:112,806,672...112,913,333
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:133,394,079...133,404,816
Ensembl chr 2:133,394,079...133,404,805
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression multiple interactions |
ISO |
Glucosamine results in decreased expression of BMP4 mRNA Glucosamine promotes the reaction [IL1B results in decreased expression of BMP4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:46,620,982...46,628,126
Ensembl chr14:46,620,977...46,628,126
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP6 mRNA] Glucosamine results in decreased expression of BMP6 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:38,529,098...38,684,283
Ensembl chr13:38,529,083...38,684,278
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP7 mRNA] Glucosamine results in increased expression of BMP7 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:172,709,805...172,782,114
Ensembl chr 2:172,709,805...172,782,114
|
|
G |
Calr |
calreticulin |
decreases expression |
EXP |
Glucosamine results in decreased expression of CALR mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563
|
|
G |
Car3 |
carbonic anhydrase 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CAR3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:14,928,598...14,937,441
Ensembl chr 3:14,928,572...14,937,583
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
Glucosamine results in increased cleavage of CASP3 protein Glucosamine results in increased activity of and results in increased cleavage of CASP3 protein |
CTD |
PMID:16850161 PMID:22020377 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp4 |
caspase 4, apoptosis-related cysteine peptidase |
decreases expression |
EXP |
Glucosamine results in decreased expression of CASP4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:5,308,816...5,336,791
Ensembl chr 9:5,308,828...5,336,783
|
|
G |
Cbr2 |
carbonyl reductase 2 |
increases expression |
EXP |
Glucosamine results in increased expression of CBR2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:120,620,311...120,622,851
Ensembl chr11:120,620,315...120,622,940
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
EXP |
Glucosamine results in increased expression of CBR3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr16:93,480,107...93,487,879
Ensembl chr16:93,480,103...93,487,878
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 protein]]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL2 protein]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 protein] Glucosamine results in increased expression of CCL2 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of CCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL2 mRNA] |
CTD |
PMID:17109745 PMID:18080321 PMID:18949387 PMID:19020780 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL20 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL20 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:83,094,487...83,096,888
Ensembl chr 1:83,094,487...83,096,888
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL22 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 8:95,472,312...95,478,016
Ensembl chr 8:95,472,218...95,478,327
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL3 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL5 protein] Glucosamine inhibits the reaction [IL1B results in increased expression of CCL5 mRNA] |
CTD |
PMID:17109745 PMID:18080321 |
|
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL7 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr11:81,936,538...81,938,351
Ensembl chr11:81,936,538...81,938,351
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
ISO |
Glucosamine analog results in increased expression of CCN2 mRNA |
CTD |
PMID:21466783 |
|
NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CCNB1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:100,915,247...100,922,994
Ensembl chr13:100,915,158...100,923,078
|
|
G |
Cd24a |
CD24a antigen |
increases expression |
EXP |
Glucosamine results in increased expression of CD24A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:43,454,433...43,460,261
Ensembl chr10:43,454,280...43,460,261
|
|
G |
Cd28 |
CD28 antigen |
increases expression |
ISO |
Glucosamine results in increased expression of CD28 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:60,785,547...60,812,521
Ensembl chr 1:60,755,959...60,812,518
|
|
G |
Cdc20 |
cell division cycle 20 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CDC20 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:118,290,098...118,294,540
Ensembl chr 4:118,290,098...118,294,549
|
|
G |
Cdc23 |
CDC23 cell division cycle 23 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CDC23 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr18:34,761,401...34,784,802
Ensembl chr18:34,764,004...34,784,788
|
|
G |
Cdk1 |
cyclin dependent kinase 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CDK1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:69,170,976...69,188,742
Ensembl chr10:69,170,976...69,188,768
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
increases expression |
ISO EXP |
Glucosamine results in increased expression of CDKN1A protein Glucosamine results in increased expression of CDKN1A mRNA |
CTD |
PMID:15654767 PMID:17178593 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
decreases expression |
ISO |
Glucosamine results in decreased expression of CDKN1B protein |
CTD |
PMID:15654767 |
|
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Cdkn3 |
cyclin dependent kinase inhibitor 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CDKN3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr14:46,997,912...47,008,987
Ensembl chr14:46,997,998...47,009,126
|
|
G |
Cenpf |
centromere protein F |
decreases expression |
ISO |
Glucosamine results in decreased expression of CENPF mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:189,372,803...189,420,302
Ensembl chr 1:189,372,803...189,420,283
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of CHI3L1 mRNA |
CTD |
PMID:16142878 |
|
NCBI chr 1:134,109,894...134,117,769
Ensembl chr 1:134,109,914...134,117,919
|
|
G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
multiple interactions decreases activity |
ISO |
Glucosamine analog results in decreased activity of and results in decreased localization of CHUK protein Glucosamine analog results in decreased activity of CHUK protein |
CTD |
PMID:20113495 |
|
NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919
|
|
G |
Ckap2 |
cytoskeleton associated protein 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CKAP2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:22,658,168...22,675,835
Ensembl chr 8:22,658,176...22,675,835
|
|
G |
Clock |
clock circadian regulator |
decreases expression |
EXP |
Glucosamine results in decreased expression of CLOCK mRNA; Glucosamine results in decreased expression of CLOCK protein |
CTD |
PMID:24442997 |
|
NCBI chr 5:76,357,715...76,452,675
Ensembl chr 5:76,357,715...76,452,639
|
|
G |
Clta |
clathrin light chain A |
decreases expression |
ISO |
Glucosamine results in decreased expression of CLTA mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:44,003,816...44,032,846
Ensembl chr 4:44,004,452...44,032,846
|
|
G |
Col11a1 |
collagen, type XI, alpha 1 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of COL11A1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of COL11A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:113,823,933...114,014,405
Ensembl chr 3:113,824,189...114,014,367
|
|
G |
Col1a1 |
collagen, type I, alpha 1 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B protein results in increased expression of COL1A1 mRNA] Glucosamine results in decreased expression of COL1A1 mRNA |
CTD |
PMID:18321735 |
|
NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868
|
|
G |
Col2a1 |
collagen, type II, alpha 1 |
multiple interactions affects expression increases expression |
ISO |
Glucosamine analog affects the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of COL2A1 mRNA] Glucosamine inhibits the reaction [IL1B results in decreased expression of COL2A1 mRNA] Glucosamine analog affects the expression of COL2A1 mRNA Glucosamine analog results in increased expression of COL2A1 mRNA; Glucosamine results in increased expression of COL2A1 mRNA |
CTD |
PMID:16300972 PMID:17109745 PMID:17337215 PMID:18321735 |
|
NCBI chr15:97,873,483...97,902,525
Ensembl chr15:97,873,483...97,902,576
|
|
G |
Col3a1 |
collagen, type III, alpha 1 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of COL3A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:45,350,698...45,388,866
Ensembl chr 1:45,350,698...45,388,866
|
|
G |
Col8a1 |
collagen, type VIII, alpha 1 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of COL8A1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of COL8A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr16:57,444,619...57,575,100
Ensembl chr16:57,444,621...57,575,100
|
|
G |
Csf1 |
colony stimulating factor 1 (macrophage) |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CSF1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:107,648,364...107,668,048
Ensembl chr 3:107,648,364...107,667,785
|
|
G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF2 mRNA] Glucosamine results in increased expression of CSF2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493
|
|
G |
Csf3 |
colony stimulating factor 3 (granulocyte) |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF3 mRNA] Glucosamine results in increased expression of CSF3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr11:98,591,287...98,594,457
Ensembl chr11:98,592,089...98,594,455
|
|
G |
Ctsd |
cathepsin D |
affects localization multiple interactions increases activity decreases expression |
ISO |
Glucosamine affects the localization of CTSD protein pepstatin inhibits the reaction [Glucosamine results in decreased expression of CTSD protein alternative form] Glucosamine results in increased activity of CTSD protein |
CTD |
PMID:15972124 PMID:16850161 |
|
NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775
|
|
G |
Cul2 |
cullin 2 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CUL2 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr18:3,382,970...3,436,700
Ensembl chr18:3,382,988...3,436,377
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CXCL1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:91,039,104...91,040,980
Ensembl chr 5:91,039,100...91,040,974
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
EXP ISO |
Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA] Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL10 mRNA] |
CTD |
PMID:17109745 PMID:20737476 |
|
NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748
|
|
G |
Cxcl11 |
chemokine (C-X-C motif) ligand 11 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL11 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:92,507,403...92,511,155
Ensembl chr 5:92,507,403...92,513,344
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions decreases expression |
ISO |
Glucosamine promotes the reaction [IL1B results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of CXCL12 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [IL1B results in increased expression of CXCL8 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CXCL8 protein]; Glucosamine analog inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL8 protein]; Glucosamine inhibits the reaction [IL1B results in increased secretion of CXCL8 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CXCL8 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CXCL8 mRNA] |
CTD |
PMID:18026701 PMID:18080321 PMID:19626664 PMID:20113495 PMID:20307528 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL3 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459
|
|
G |
Cxcl5 |
C-X-C motif chemokine ligand 5 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL5 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:90,907,157...90,909,484
Ensembl chr 5:90,907,219...90,909,483
|
|
G |
Cyba |
cytochrome b-245, alpha polypeptide |
decreases expression |
ISO |
Glucosamine results in decreased expression of CYBA mRNA |
CTD |
PMID:18077487 |
|
NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
Glucosamine affects the localization of CYCS protein |
CTD |
PMID:15972124 PMID:22020377 |
|
NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
EXP |
Glucosamine results in increased expression of CYP51 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:4,130,674...4,154,697
Ensembl chr 5:4,131,145...4,154,746
|
|
G |
Dbi |
diazepam binding inhibitor |
increases expression |
EXP |
Glucosamine results in increased expression of DBI mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:120,041,010...120,048,826
Ensembl chr 1:120,041,010...120,048,808
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions decreases expression |
ISO EXP |
Glucosamine results in increased expression of DDIT3 mRNA; Glucosamine results in increased expression of DDIT3 protein NUS1 protein inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of DDIT3 protein] Glucosamine results in decreased expression of DDIT3 mRNA |
CTD |
PMID:16380481 PMID:17178593 PMID:30602124 PMID:33812996 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Ddit4l |
DNA-damage-inducible transcript 4-like |
increases expression |
ISO |
Glucosamine results in increased expression of DDIT4L mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:137,329,433...137,334,093
Ensembl chr 3:137,327,373...137,334,094
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
increases expression |
EXP |
Glucosamine results in increased expression of DHCR7 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:143,376,827...143,402,147
Ensembl chr 7:143,376,882...143,402,147
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
decreases expression |
EXP |
Glucosamine results in decreased expression of DNAJB11 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr16:22,676,595...22,698,384
Ensembl chr16:22,676,595...22,698,384
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
decreases expression |
EXP |
Glucosamine results in decreased expression of DNAJB9 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:44,252,680...44,256,851
Ensembl chr12:44,252,342...44,257,109
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of DNAJC3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:119,175,371...119,219,114
Ensembl chr14:119,175,388...119,219,109
|
|
G |
Dspp |
dentin sialophosphoprotein |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of DSPP mRNA |
CTD |
PMID:20458730 |
|
NCBI chr 5:104,318,569...104,327,993
Ensembl chr 5:104,318,578...104,327,993
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP5 mRNA] Glucosamine results in increased expression of DUSP5 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr19:53,517,576...53,530,240
Ensembl chr19:53,517,540...53,530,862
|
|
G |
Dusp7 |
dual specificity phosphatase 7 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP7 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of DUSP7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 9:106,245,831...106,252,923
Ensembl chr 9:106,245,831...106,252,923
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of DYNC1I1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 6:5,725,772...6,028,030
Ensembl chr 6:5,725,639...6,028,039
|
|
G |
Edem1 |
ER degradation enhancer, mannosidase alpha-like 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of EDEM1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:108,800,984...108,836,317
Ensembl chr 6:108,805,602...108,836,317
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases expression increases phosphorylation |
ISO EXP |
EIF2AK3 gene mutant form inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] NUS1 protein inhibits the reaction [Glucosamine results in increased expression of EIF2AK3 protein] EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of ATF4 mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] Glucosamine results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:16324875 PMID:19383982 PMID:30602124 PMID:33812996 |
|
NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2, subunit 1 alpha |
increases phosphorylation multiple interactions |
ISO EXP |
Glucosamine results in increased phosphorylation of EIF2S1 protein NUS1 protein inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 protein affects the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; GSK2656157 inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] EIF2AK3 gene mutant form inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:16324875 PMID:19383982 PMID:30602124 PMID:33812996 |
|
NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
increases expression |
EXP |
Glucosamine results in increased expression of ELOVL6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:129,326,035...129,432,144
Ensembl chr 3:129,326,004...129,432,144
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
decreases expression multiple interactions |
ISO |
Glucosamine results in decreased expression of EPAS1 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of EPAS1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of EPAS1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr17:87,061,292...87,140,838
Ensembl chr17:87,061,128...87,140,838
|
|
G |
Eprs1 |
glutamyl-prolyl-tRNA synthetase 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of EPRS1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:185,093,614...185,160,557
Ensembl chr 1:185,095,241...185,160,557
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signalling 1 |
multiple interactions increases expression |
EXP ISO |
ERN1 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased splicing of XBP1 mRNA] NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ERN1 mRNA] |
CTD |
PMID:30602124 PMID:33812996 |
|
NCBI chr11:106,285,474...106,378,701
Ensembl chr11:106,285,476...106,378,678
|
|
G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
increases expression |
EXP ISO |
Glucosamine results in increased expression of FABP4 mRNA |
CTD |
PMID:15694357 |
|
NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
Glucosamine results in increased expression of FASN mRNA |
CTD |
PMID:22096489 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Fbp2 |
fructose bisphosphatase 2 |
increases expression |
EXP |
Glucosamine results in increased expression of FBP2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:62,984,698...63,006,214
Ensembl chr13:62,984,691...63,006,236
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
Glucosamine promotes the reaction [Glucose results in increased expression of FGF2 mRNA] |
CTD |
PMID:1518840 |
|
NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
decreases expression multiple interactions |
ISO |
Glucosamine results in decreased expression of FGF7 mRNA IL1B inhibits the reaction [Glucosamine results in decreased expression of FGF7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:125,876,578...125,933,105
Ensembl chr 2:125,876,578...125,933,105
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of FGF9 mRNA] Glucosamine results in increased expression of FGF9 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr14:58,308,543...58,350,311
Ensembl chr14:58,308,004...58,350,177
|
|
G |
Fgfr1 |
fibroblast growth factor receptor 1 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of FGFR1 mRNA] Glucosamine results in increased expression of FGFR1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:26,008,808...26,067,819
Ensembl chr 8:26,003,670...26,065,734
|
|
G |
Fkbp11 |
FK506 binding protein 11 |
decreases expression |
EXP |
Glucosamine results in decreased expression of FKBP11 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:98,622,249...98,626,079
Ensembl chr15:98,622,247...98,626,079
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
EXP ISO |
Glucosamine results in decreased expression of FN1 protein |
CTD |
PMID:17178593 |
|
NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
multiple interactions |
EXP ISO |
Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of FOS mRNA] Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of FOS protein] |
CTD |
PMID:19375915 PMID:21825963 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Furin |
furin, paired basic amino acid cleaving enzyme |
decreases cleavage multiple interactions |
ISO |
Glucosamine results in decreased cleavage of FURIN protein alternative form Glucosamine results in decreased glycosylation of and results in decreased activity of FURIN protein |
CTD |
PMID:19909832 |
|
NCBI chr 7:80,038,942...80,055,188
Ensembl chr 7:80,038,333...80,055,184
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
increases expression |
ISO |
Glucosamine results in increased expression of FXYD2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 9:45,311,007...45,321,576
Ensembl chr 9:45,310,967...45,321,576
|
|
G |
Gatm |
glycine amidinotransferase (L-arginine:glycine amidinotransferase) |
decreases expression |
ISO |
Glucosamine results in decreased expression of GATM mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:122,424,954...122,441,758
Ensembl chr 2:122,424,948...122,441,784
|
|
G |
Gck |
glucokinase |
decreases expression |
ISO |
Glucosamine results in decreased expression of GCK mRNA |
CTD |
PMID:11893929 |
|
NCBI chr11:5,850,816...5,900,081
Ensembl chr11:5,850,820...5,900,081
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
EXP |
Glucosamine analog results in increased expression of GCLC mRNA |
CTD |
PMID:21825963 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gfpt1 |
glutamine fructose-6-phosphate transaminase 1 |
multiple interactions |
ISO |
[Glucosamine co-treated with INS1 protein] affects the localization of GFPT1 protein |
CTD |
PMID:9453242 |
|
NCBI chr 6:87,019,828...87,069,189
Ensembl chr 6:87,019,828...87,069,179
|
|
G |
Glrx |
glutaredoxin |
increases expression |
EXP |
Glucosamine results in increased expression of GLRX mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:75,988,004...75,998,270
Ensembl chr13:75,987,987...75,998,273
|
|
G |
Gnpnat1 |
glucosamine-phosphate N-acetyltransferase 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of GNPNAT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:45,613,897...45,626,972
Ensembl chr14:45,613,791...45,642,370
|
|
G |
Gnptab |
N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits |
increases expression |
EXP |
Glucosamine results in increased expression of GNPTAB mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:88,215,130...88,283,186
Ensembl chr10:88,214,994...88,283,191
|
|
G |
Gpd1l |
glycerol-3-phosphate dehydrogenase 1-like |
increases expression |
EXP |
Glucosamine results in increased expression of GPD1L mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:114,728,407...114,763,055
Ensembl chr 9:114,728,409...114,763,055
|
|
G |
Grem1 |
gremlin 1, DAN family BMP antagonist |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of GREM1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of GREM1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:113,579,020...113,588,993
Ensembl chr 2:113,576,509...113,588,991
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions decreases phosphorylation |
ISO |
Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]; NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] Glucosamine results in decreased phosphorylation of GSK3B protein |
CTD |
PMID:33812996 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
Gspt1 |
G1 to S phase transition 1 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of GSPT1 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr16:11,034,104...11,072,189
Ensembl chr16:11,037,156...11,072,189
|
|
G |
Gstt1 |
glutathione S-transferase, theta 1 |
increases expression |
EXP |
Glucosamine results in increased expression of GSTT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:75,619,647...75,634,418
Ensembl chr10:75,619,647...75,634,418
|
|
G |
H2-Bl |
histocompatibility 2, blastocyst |
decreases expression |
EXP |
Glucosamine results in decreased expression of H2-BL mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:36,391,002...36,395,141
Ensembl chr17:36,391,007...36,395,115
|
|
G |
Hapln1 |
hyaluronan and proteoglycan link protein 1 |
decreases expression multiple interactions |
ISO |
Glucosamine results in decreased expression of HAPLN1 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of HAPLN1 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of HAPLN1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr13:89,688,654...89,759,951
Ensembl chr13:89,687,915...89,759,771
|
|
G |
Herpud1 |
homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of HERPUD1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:95,113,057...95,121,999
Ensembl chr 8:95,113,066...95,122,005
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
multiple interactions decreases expression |
ISO |
Glucosamine affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein]; Glucosamine inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein] Glucosamine results in decreased expression of HIF1A mRNA; Glucosamine results in decreased expression of HIF1A protein |
CTD |
PMID:19254699 PMID:22020377 |
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Hk1 |
hexokinase 1 |
increases expression |
EXP ISO |
Glucosamine results in increased expression of HK1 mRNA |
CTD |
PMID:11893929 PMID:17178593 |
|
NCBI chr10:62,104,634...62,215,699
Ensembl chr10:62,104,634...62,215,687
|
|
G |
Hmga1 |
high mobility group AT-hook 1 |
increases expression |
ISO |
Glucosamine results in increased expression of HMGA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr17:27,774,798...27,782,649
Ensembl chr17:27,775,471...27,782,648
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 |
increases expression |
EXP |
Glucosamine results in increased expression of HMGCS1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:120,151,887...120,169,796
Ensembl chr13:120,151,915...120,169,796
|
|
G |
Hmmr |
hyaluronan mediated motility receptor (RHAMM) |
decreases expression |
ISO |
Glucosamine results in decreased expression of HMMR mRNA |
CTD |
PMID:17109745 |
|
NCBI chr11:40,592,215...40,624,290
Ensembl chr11:40,592,222...40,624,249
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 protein] Glucosamine results in increased expression of HMOX1 mRNA; Glucosamine results in increased expression of HMOX1 protein |
CTD |
PMID:18077487 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hoxa1 |
homeobox A1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of HOXA1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:52,132,573...52,135,299
Ensembl chr 6:52,132,570...52,135,297
|
|
G |
Hpgd |
hydroxyprostaglandin dehydrogenase 15 (NAD) |
decreases expression |
ISO |
Glucosamine results in decreased expression of HPGD mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:56,747,587...56,774,081
Ensembl chr 8:56,747,620...56,774,078
|
|
G |
Hsp90b1 |
heat shock protein 90, beta (Grp94), member 1 |
decreases expression increases expression |
EXP ISO |
Glucosamine results in decreased expression of HSP90B1 mRNA Glucosamine results in increased expression of HSP90B1 protein |
CTD |
PMID:15618547 PMID:17109745 PMID:17178593 |
|
NCBI chr10:86,526,705...86,541,308
Ensembl chr10:86,526,073...86,541,373
|
|
G |
Hspa5 |
heat shock protein 5 |
multiple interactions increases expression decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA] Glucosamine results in increased expression of HSPA5 mRNA; Glucosamine results in increased expression of HSPA5 protein 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA] Glucosamine results in decreased expression of HSPA5 mRNA |
CTD |
PMID:15618547 PMID:16380481 PMID:17178593 PMID:19383982 PMID:20165829 PMID:22020377 PMID:30602124 PMID:33812996 More...
|
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Hyou1 |
hypoxia up-regulated 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of HYOU1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:44,290,840...44,303,662
Ensembl chr 9:44,290,787...44,303,666
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases activity |
ISO |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL6 results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 protein] Glucosamine results in decreased activity of ICAM1 protein Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] |
CTD |
PMID:16431966 PMID:16822504 PMID:17238806 PMID:18949387 PMID:19020780 PMID:19098112 More...
|
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
increases expression |
EXP |
Glucosamine results in increased expression of ID1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:152,578,171...152,579,330
Ensembl chr 2:152,578,171...152,579,330
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
increases expression |
EXP |
Glucosamine results in increased expression of ID2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:25,143,798...25,146,091
Ensembl chr12:25,143,798...25,147,139
|
|
G |
Id3 |
inhibitor of DNA binding 3 |
increases expression |
EXP |
Glucosamine results in increased expression of ID3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:135,871,133...135,872,703
Ensembl chr 4:135,870,808...135,873,066
|
|
G |
Idh1 |
isocitrate dehydrogenase 1 (NADP+), soluble |
increases expression |
EXP |
Glucosamine results in increased expression of IDH1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:65,197,775...65,225,638
Ensembl chr 1:65,197,775...65,225,659
|
|
G |
Ifi204 |
interferon activated gene 204 |
increases expression |
EXP |
Glucosamine results in increased expression of IFI204 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:173,574,859...173,594,606
Ensembl chr 1:173,574,859...173,594,509
|
|
G |
Ifit1 |
interferon-induced protein with tetratricopeptide repeats 1 |
increases expression |
EXP |
Glucosamine results in increased expression of IFIT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:34,618,289...34,627,409
Ensembl chr19:34,618,271...34,627,409
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
increases expression |
EXP |
Glucosamine results in increased expression of IFIT3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:34,560,519...34,566,382
Ensembl chr19:34,560,931...34,566,131
|
|
G |
Ifng |
interferon gamma |
decreases secretion multiple interactions |
EXP ISO |
Glucosamine results in decreased secretion of IFNG protein Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG results in increased localization of STAT1 protein modified form]; Glucosamine inhibits the reaction [IFNG results in increased phosphorylation of and results in increased localization of STAT1 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]] |
CTD |
PMID:14507305 PMID:16431966 PMID:16822504 PMID:17238806 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP3 mRNA]; IL1B inhibits the reaction [Glucosamine results in increased expression of IGFBP3 mRNA] Glucosamine results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr11:7,156,086...7,165,498
Ensembl chr11:7,156,086...7,163,923
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
decreases expression |
EXP |
Glucosamine results in decreased expression of IGFBP4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:98,930,820...98,943,481
Ensembl chr11:98,932,070...98,945,218
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA] Glucosamine results in increased expression of IGFBP5 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:72,897,224...72,914,024
Ensembl chr 1:72,897,091...72,914,043
|
|
G |
Ikbkb |
inhibitor of kappaB kinase beta |
multiple interactions |
EXP |
Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of IKBKB protein] |
CTD |
PMID:18786831 |
|
NCBI chr 8:23,149,228...23,196,605
Ensembl chr 8:23,149,228...23,196,605
|
|
G |
Ikbkg |
inhibitor of kappaB kinase gamma |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of IKBKG mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of IKBKG mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:73,436,883...73,498,013
Ensembl chr X:73,436,896...73,497,460
|
|
G |
Il11 |
interleukin 11 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL11 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 7:4,775,372...4,785,877
Ensembl chr 7:4,775,372...4,785,858
|
|
G |
Il13ra1 |
interleukin 13 receptor, alpha 1 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL13RA1 mRNA] Glucosamine results in decreased expression of IL13RA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr X:35,375,761...35,434,915
Ensembl chr X:35,375,763...35,434,912
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL1A mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of IL1A mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression decreases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Nitrites]; Glucosamine analog affects the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Glucosamine analog affects the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine analog affects the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine analog affects the reaction [IL1B results in increased phosphorylation of AKT1 protein]; Glucosamine analog inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP13]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP1]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP3]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP1 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP13 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP3 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of CXCL8 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP1 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine analog inhibits the reaction [IL1B results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL2 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL5 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CXCL8 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in decreased methylation of IL1B promoter]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in increased expression of IL1B mRNA]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUN protein]; Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUND protein]; Glucosamine inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of COL1A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 protein]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Dinoprostone]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Nitric Oxide]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Nitrites]; Glucosamine inhibits the reaction [IL1B results in increased degradation of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL8 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PTGES mRNA]; Glucosamine inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK14 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [IL1B results in increased secretion of CXCL8 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine promotes the reaction [IL1B results in increased expression of PPARG]; Glucosamine promotes the reaction [IL1B results in increased phosphorylation of AKT1 protein] Glucosamine results in increased expression of IL1B mRNA Glucosamine results in decreased expression of IL1B mRNA [IL1B protein co-treated with Glucosamine] results in increased expression of IL1R2 mRNA; Glucosamine affects the reaction [IL1B results in decreased expression of ADAM15 mRNA]; Glucosamine affects the reaction [IL1B results in decreased expression of OAT mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased activity of B3GAT3 protein]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of B3GAT3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Glucosamine inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL11A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL3A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of FGFR1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HAPLN1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of LAMA4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of SDC2 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of SOX4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of THBS4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP2 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ADAMTS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ASS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BGN mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL20 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL22 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of COL8A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL10 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL11 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of EPAS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of FGF9 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of GREM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IKBKG mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL11 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL13RA1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL1A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL1B mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL23R mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of JAK2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of JUNB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP10 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP12 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIA mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NGF mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PDGFA mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G2A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G4A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of RELB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of SDC4 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of SLC7A8 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TIMP1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TNFAIP6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TNK2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of VCAN mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Glucosamine promotes the reaction [IL1B results in decreased expression of BMP4 mRNA]; Glucosamine promotes the reaction [IL1B results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine affects the expression of PDGFA mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of ADAM15 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of BGN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of COL11A1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of DUSP7 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of EPAS1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of IKBKG mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of JUNB mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of TNFAIP6 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of VCAN mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of IL1A mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of JAK2 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of LAMA4 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of MMP9 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of NFKBIB mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of TIMP3 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of ADAMTS1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of COL8A1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CSF1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CXCL1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of FGF7 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of GREM1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of NFKBIA mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G2A mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G5 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SDC4 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SLC7A8 mRNA]; IL1B inhibits the reaction [Glucosamine results in increased expression of IGFBP3 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of HAPLN1 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of SDC2 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of THBS4 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of AZIN1 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL20 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL7 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP10 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP12 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP13 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of NOS2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of TIMP1 mRNA] Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL1B protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:11229466 PMID:11801247 PMID:12681956 PMID:15144122 PMID:16822504 PMID:17109745 PMID:17238806 PMID:17337215 PMID:17605605 PMID:17925024 PMID:18026701 PMID:18077487 PMID:18080321 PMID:18321735 PMID:18340449 PMID:18786831 PMID:19626664 PMID:19656660 PMID:20737476 PMID:21219853 PMID:22089456 More...
|
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il1r2 |
interleukin 1 receptor, type II |
multiple interactions |
ISO |
[IL1B protein co-treated with Glucosamine] results in increased expression of IL1R2 mRNA |
CTD |
PMID:11801247 |
|
NCBI chr 1:40,123,872...40,164,390
Ensembl chr 1:40,113,239...40,164,391
|
|
G |
Il2 |
interleukin 2 |
decreases secretion |
EXP |
Glucosamine results in decreased secretion of IL2 protein |
CTD |
PMID:14507305 |
|
NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108
|
|
G |
Il23r |
interleukin 23 receptor |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL23R mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 6:67,399,906...67,468,838
Ensembl chr 6:67,399,916...67,468,839
|
|
G |
Il33 |
interleukin 33 |
decreases expression |
ISO |
Glucosamine results in decreased expression of IL33 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr19:29,902,513...29,938,118
Ensembl chr19:29,902,514...29,938,118
|
|
G |
Il4 |
interleukin 4 |
decreases secretion decreases expression |
EXP ISO |
Glucosamine results in decreased secretion of IL4 protein Glucosamine results in decreased expression of IL4 |
CTD |
PMID:14507305 PMID:21284687 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il5 |
interleukin 5 |
decreases secretion decreases expression |
EXP ISO |
Glucosamine results in decreased secretion of IL5 protein Glucosamine results in decreased expression of IL5 |
CTD |
PMID:14507305 PMID:21284687 |
|
NCBI chr11:53,611,621...53,615,930
Ensembl chr11:53,611,621...53,615,933
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL6 results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of IL6 mRNA] Glucosamine inhibits the reaction [IL1B results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] Glucosamine analog results in decreased expression of IL6 mRNA; Glucosamine results in decreased expression of IL6 mRNA Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:16822504 PMID:17109745 PMID:18786831 PMID:19098112 PMID:20093129 PMID:20113495 PMID:20307528 PMID:20737476 More...
|
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Inpp5k |
inositol polyphosphate 5-phosphatase K |
increases expression multiple interactions |
ISO |
Glucosamine results in increased expression of INPP5K mRNA NUS1 protein inhibits the reaction [Glucosamine results in increased expression of INPP5K mRNA] |
CTD |
PMID:33812996 |
|
NCBI chr11:75,519,893...75,539,691
Ensembl chr11:75,521,814...75,539,697
|
|
G |
Ins1 |
insulin I |
multiple interactions |
EXP ISO |
[INS1 protein co-treated with Glucosamine] results in increased expression of OSTN mRNA; Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]; INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] 4-phenylbutyric acid inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]]; [Glucosamine co-treated with INS1 protein] affects the localization of GFPT1 protein; Glucosamine inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Glucosamine inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]; ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]] |
CTD |
PMID:9453242 PMID:11893929 PMID:16380481 PMID:20165829 PMID:30602124 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Ins2 |
insulin II |
multiple interactions |
ISO |
4-phenylbutyric acid inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]]; Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]; Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]; NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]]; ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]] |
CTD |
PMID:20165829 PMID:33812996 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IRF1 mRNA] |
CTD |
PMID:20737476 |
|
NCBI chr11:53,660,841...53,669,200
Ensembl chr11:53,660,841...53,669,200
|
|
G |
Isyna1 |
myo-inositol 1-phosphate synthase A1 |
increases expression |
ISO |
Glucosamine results in increased expression of ISYNA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:71,047,131...71,049,940
Ensembl chr 8:71,047,023...71,049,940
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of JAK2 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of JAK2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr19:29,229,006...29,290,495
Ensembl chr19:29,229,228...29,290,480
|
|
G |
Jun |
jun proto-oncogene |
multiple interactions |
ISO EXP |
Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUN protein] Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of JUN mRNA] |
CTD |
PMID:17925024 PMID:21825963 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Junb |
jun B proto-oncogene |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of JUNB mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of JUNB mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 8:85,703,538...85,705,377
Ensembl chr 8:85,701,113...85,705,347
|
|
G |
Jund |
jun D proto-oncogene |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUND protein] |
CTD |
PMID:17925024 |
|
NCBI chr 8:71,150,389...71,153,265
Ensembl chr 8:71,151,599...71,153,265
|
|
G |
Kcnj16 |
potassium inwardly-rectifying channel, subfamily J, member 16 |
increases expression |
EXP |
Glucosamine results in increased expression of KCNJ16 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:110,858,859...110,918,794
Ensembl chr11:110,858,859...110,918,794
|
|
G |
Kif11 |
kinesin family member 11 |
decreases expression |
ISO |
Glucosamine results in decreased expression of KIF11 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr19:37,364,830...37,410,311
Ensembl chr19:37,364,851...37,410,307
|
|
G |
Kif4 |
kinesin family member 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of KIF4A mRNA |
CTD |
PMID:17109745 |
|
NCBI chr X:99,669,693...99,770,878
Ensembl chr X:99,669,343...99,770,820
|
|
G |
Klf10 |
Kruppel-like transcription factor 10 |
increases expression |
EXP |
Glucosamine results in increased expression of KLF10 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:38,291,702...38,300,950
Ensembl chr15:38,291,707...38,300,950
|
|
G |
Lama4 |
laminin, alpha 4 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of LAMA4 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of LAMA4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr10:38,841,511...38,986,184
Ensembl chr10:38,841,511...38,986,184
|
|
G |
Lamb1 |
laminin B1 |
multiple interactions |
EXP |
TXNIP promotes the reaction [Glucosamine results in increased expression of LAMB1 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr12:31,315,230...31,379,643
Ensembl chr12:31,315,233...31,379,643
|
|
G |
Lamc1 |
laminin, gamma 1 |
multiple interactions |
EXP |
TXNIP promotes the reaction [Glucosamine results in increased expression of LAMC1 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr 1:153,094,668...153,208,532
Ensembl chr 1:153,094,668...153,208,532
|
|
G |
Lcn2 |
lipocalin 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of LCN2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:32,274,649...32,277,751
Ensembl chr 2:32,274,645...32,278,264
|
|
G |
Lepr |
leptin receptor |
multiple interactions affects response to substance |
ISO |
[LEPR protein affects the susceptibility to Glucosamine] which affects the expression of ALB protein |
CTD |
PMID:33345901 |
|
NCBI chr 4:101,574,393...101,676,375
Ensembl chr 4:101,574,601...101,672,549
|
|
G |
Lpin1 |
lipin 1 |
increases expression |
EXP |
Glucosamine results in increased expression of LPIN1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:16,585,670...16,697,020
Ensembl chr12:16,585,670...16,696,967
|
|
G |
Ly6a |
lymphocyte antigen 6 family member A |
increases expression |
EXP |
Glucosamine results in increased expression of LY6A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:74,866,726...74,869,880
Ensembl chr15:74,866,726...74,869,880
|
|
G |
Mafb |
MAF bZIP transcription factor B |
increases expression |
ISO |
Glucosamine results in increased expression of MAFB mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:160,205,597...160,208,985
Ensembl chr 2:160,205,623...160,208,985
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MAPK1 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] Glucosamine analog results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:18080321 PMID:18340449 PMID:19375915 PMID:19626664 PMID:20307528 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk14 |
mitogen-activated protein kinase 14 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:19626664 |
|
NCBI chr17:28,910,316...28,967,379
Ensembl chr17:28,910,303...28,967,380
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MAPK3 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] Glucosamine analog results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:18080321 PMID:18340449 PMID:19375915 PMID:19626664 PMID:20307528 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein] Glucosamine analog results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:18080321 PMID:19626664 PMID:20307528 |
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mcl1 |
myeloid cell leukemia sequence 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of MCL1 mRNA; Glucosamine results in decreased expression of MCL1 protein |
CTD |
PMID:22020377 |
|
NCBI chr 3:95,564,017...95,583,553
Ensembl chr 3:95,566,099...95,570,487
|
|
G |
Mef2a |
myocyte enhancer factor 2A |
multiple interactions decreases expression |
ISO |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein] Glucosamine results in decreased expression of MEF2A mRNA; Glucosamine results in decreased expression of MEF2A protein |
CTD |
PMID:20165829 |
|
NCBI chr 7:66,880,911...67,026,435
Ensembl chr 7:66,880,911...67,022,606
|
|
G |
Mettl1 |
methyltransferase 1, tRNA methylguanosine |
decreases expression |
EXP |
Glucosamine results in decreased expression of METTL1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:126,877,287...126,882,234
Ensembl chr10:126,877,283...126,882,234
|
|
G |
Mfap3l |
microfibrillar-associated protein 3-like |
increases expression |
EXP |
Glucosamine results in increased expression of MFAP3L mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:61,085,859...61,129,765
Ensembl chr 8:61,085,861...61,129,763
|
|
G |
Mki67 |
antigen identified by monoclonal antibody Ki 67 |
decreases expression |
ISO |
Glucosamine results in decreased expression of MKI67 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
increases expression multiple interactions |
ISO |
Glucosamine results in increased expression of MMP10 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of MMP10 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP10 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 9:7,502,343...7,510,243
Ensembl chr 9:7,502,353...7,510,241
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of MMP12 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP12 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 9:7,344,397...7,360,461
Ensembl chr 9:7,344,381...7,369,499
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
affects expression multiple interactions increases expression |
ISO |
Glucosamine analog affects the expression of MMP13 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP13 mRNA] Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP13]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP13 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein] |
CTD |
PMID:15144122 PMID:17109745 PMID:17337215 PMID:17925024 PMID:18080321 PMID:19656660 More...
|
|
NCBI chr 9:7,272,514...7,283,333
Ensembl chr 9:7,272,514...7,283,331
|
|
G |
Mmp1b |
matrix metallopeptidase 1b (interstitial collagenase) |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP1]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP1 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein] |
CTD |
PMID:15144122 PMID:17925024 PMID:18080321 |
|
NCBI chr 9:7,367,670...7,388,026
Ensembl chr 9:7,368,239...7,388,047
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions increases expression |
ISO |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of MMP2 protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 protein] IL1B promotes the reaction [Glucosamine results in increased expression of MMP2 mRNA] |
CTD |
PMID:17109745 PMID:17498959 PMID:19375915 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions increases expression decreases expression |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of MMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] results in decreased secretion of MMP3 protein; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP3]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP3 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 protein]; Glucosamine results in decreased expression of and results in decreased activity of MMP3 protein Glucosamine results in increased expression of MMP3 mRNA Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP3 mRNA] Glucosamine analog results in decreased expression of MMP3 mRNA |
CTD |
PMID:11229466 PMID:12801482 PMID:15144122 PMID:16300972 PMID:17109745 PMID:17925024 PMID:18080321 PMID:18340449 PMID:20110869 More...
|
|
NCBI chr 9:7,445,845...7,455,975
Ensembl chr 9:7,445,822...7,455,975
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of MMP9 protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 protein] Glucosamine results in increased expression of MMP9 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of MMP9 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of MMP9 mRNA] |
CTD |
PMID:17109745 PMID:17498959 PMID:19375915 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mpo |
myeloperoxidase |
decreases activity |
ISO |
Glucosamine results in decreased activity of MPO protein |
CTD |
PMID:19098112 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Mvd |
mevalonate (diphospho) decarboxylase |
increases expression |
EXP |
Glucosamine results in increased expression of MVD mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:123,160,335...123,170,161
Ensembl chr 8:123,160,340...123,170,161
|
|
G |
Ndufa4 |
Ndufa4, mitochondrial complex associated |
increases expression |
ISO |
Glucosamine results in increased expression of NDUFA4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 6:11,900,371...11,907,449
Ensembl chr 6:11,900,291...11,907,496
|
|
G |
Nedd4 |
neural precursor cell expressed, developmentally down-regulated 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of NEDD4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 9:72,569,613...72,657,133
Ensembl chr 9:72,569,628...72,657,134
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions decreases activity |
ISO EXP |
Glucosamine inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B results in increased degradation of NFKB1 protein]; Glucosamine inhibits the reaction [NFKB1 results in increased degradation of RELA protein]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of NFKB1 protein] Glucosamine results in decreased activity of NFKB1 protein Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NFKB1 protein] |
CTD |
PMID:12681956 PMID:16431966 PMID:16822504 PMID:17498959 PMID:18036590 PMID:18205790 PMID:20737476 More...
|
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions decreases phosphorylation decreases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [IL1B results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein] Glucosamine results in decreased phosphorylation of NFKBIA protein Glucosamine results in decreased expression of NFKBIA mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIA mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]; IL1B inhibits the reaction [Glucosamine results in decreased expression of NFKBIA mRNA] Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NFKBIA protein modified form]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:12681956 PMID:17109745 PMID:18080321 PMID:18205790 PMID:19098112 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nfkbib |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, beta |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIB mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of NFKBIB mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 7:28,457,676...28,466,069
Ensembl chr 7:28,457,676...28,466,937
|
|
G |
Ngef |
neuronal guanine nucleotide exchange factor |
increases expression |
EXP |
Glucosamine results in increased expression of NGEF mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:87,404,551...87,501,661
Ensembl chr 1:87,404,556...87,501,592
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of NGF mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions increases expression decreases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA] Glucosamine results in increased expression of NOS2 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of NOS2 mRNA] Glucosamine results in decreased expression of NOS2 mRNA Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to NOS2 promoter]]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:17109745 PMID:17440993 PMID:17605605 PMID:18077487 PMID:18205790 PMID:19098112 PMID:20737476 More...
|
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
affects expression |
ISO |
Glucosamine affects the expression of NR1H4 |
CTD |
PMID:19373748 |
|
NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
increases expression |
EXP |
Glucosamine results in increased expression of NSDHL mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:71,962,127...72,002,134
Ensembl chr X:71,962,163...72,002,120
|
|
G |
Nucb2 |
nucleobindin 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of NUCB2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:116,103,579...116,139,823
Ensembl chr 7:116,103,604...116,139,819
|
|
G |
Nuf2 |
NUF2, NDC80 kinetochore complex component |
decreases expression |
ISO |
Glucosamine results in decreased expression of NUF2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:169,325,503...169,359,033
Ensembl chr 1:169,325,503...169,359,033
|
|
G |
Nus1 |
NUS1 dehydrodolichyl diphosphate synthase subunit |
multiple interactions |
ISO |
NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of EIF2AK3 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ERN1 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of INPP5K mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] |
CTD |
PMID:33812996 |
|
NCBI chr10:52,293,643...52,316,288
Ensembl chr10:52,293,643...52,316,279
|
|
G |
Oasl2 |
2'-5' oligoadenylate synthetase-like 2 |
increases expression |
EXP |
Glucosamine results in increased expression of OASL2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:115,034,995...115,050,306
Ensembl chr 5:115,034,997...115,050,295
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
ISO |
Glucosamine affects the reaction [IL1B results in decreased expression of OAT mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 7:132,159,204...132,178,127
Ensembl chr 7:132,159,207...132,178,127
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase) |
decreases expression |
EXP |
Glucosamine results in decreased expression of OGT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:100,683,617...100,727,957
Ensembl chr X:100,683,666...100,727,957
|
|
G |
Orc2 |
origin recognition complex, subunit 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of ORC2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:58,501,933...58,544,114
Ensembl chr 1:58,501,930...58,544,268
|
|
G |
Osm |
oncostatin M |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in decreased methylation of IL1B promoter]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in increased expression of IL1B mRNA] |
CTD |
PMID:21219853 |
|
NCBI chr11:4,186,831...4,191,027
Ensembl chr11:4,186,420...4,191,026
|
|
G |
Ostn |
osteocrin |
increases expression multiple interactions |
EXP |
Glucosamine results in increased expression of OSTN mRNA 4-methylumbelliferone 8-carbaldehyde inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; [INS1 protein co-treated with Glucosamine] results in increased expression of OSTN mRNA; ATF6 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; GSK2656157 inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] |
CTD |
PMID:30602124 |
|
NCBI chr16:27,125,733...27,169,959
Ensembl chr16:27,126,239...27,169,962
|
|
G |
Oxr1 |
oxidation resistance 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of OXR1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:41,310,745...41,724,447
Ensembl chr15:41,310,878...41,724,444
|
|
G |
Pank1 |
pantothenate kinase 1 |
increases expression |
EXP |
Glucosamine results in increased expression of PANK1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:34,784,335...34,862,420
Ensembl chr19:34,784,340...34,856,855
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
increases cleavage multiple interactions |
ISO |
Glucosamine results in increased cleavage of PARP1 protein pepstatin inhibits the reaction [Glucosamine results in increased cleavage of PARP1 protein] |
CTD |
PMID:16850161 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Pdgfa |
platelet derived growth factor, alpha |
affects expression multiple interactions |
ISO |
Glucosamine affects the expression of PDGFA mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of PDGFA mRNA]; IL1B affects the reaction [Glucosamine affects the expression of PDGFA mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:138,961,761...138,986,336
Ensembl chr 5:138,961,769...138,983,125
|
|
G |
Pdia4 |
protein disulfide isomerase associated 4 |
decreases expression |
EXP |
Glucosamine results in decreased expression of PDIA4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:47,773,075...47,790,446
Ensembl chr 6:47,773,075...47,790,364
|
|
G |
Pdia6 |
protein disulfide isomerase associated 6 |
decreases expression |
EXP |
Glucosamine results in decreased expression of PDIA6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:17,316,590...17,334,786
Ensembl chr12:17,316,546...17,334,771
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase, isoenzyme 4 |
increases expression |
EXP |
Glucosamine results in increased expression of PDK4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:5,483,351...5,496,278
Ensembl chr 6:5,483,351...5,496,309
|
|
G |
Pfkp |
phosphofructokinase, platelet |
increases expression |
EXP |
Glucosamine results in increased expression of PFKP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:6,629,910...6,699,096
Ensembl chr13:6,629,804...6,698,813
|
|
G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
decreases expression |
EXP |
Glucosamine results in decreased expression of PIGA mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:163,202,814...163,216,912
Ensembl chr X:163,202,783...163,216,912
|
|
G |
Pla2g2a |
phospholipase A2, group IIA (platelets, synovial fluid) |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G2A mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G2A mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 4:138,559,168...138,562,500
Ensembl chr 4:138,559,171...138,562,497
|
|
G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
affects expression multiple interactions |
ISO |
Glucosamine affects the expression of PLA2G4A mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G4A mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:149,705,369...149,837,041
Ensembl chr 1:149,705,369...149,837,041
|
|
G |
Pla2g5 |
phospholipase A2, group V |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G5 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G5 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 4:138,526,558...138,590,784
Ensembl chr 4:138,526,555...138,590,793
|
|
G |
Plat |
plasminogen activator, tissue |
increases expression |
EXP |
Glucosamine results in increased expression of PLAT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:23,247,655...23,272,864
Ensembl chr 8:23,247,743...23,272,860
|
|
G |
Plk1 |
polo like kinase 1 |
increases expression decreases expression |
EXP ISO |
Glucosamine results in increased expression of PLK1 mRNA Glucosamine results in decreased expression of PLK1 mRNA |
CTD |
PMID:17109745 PMID:17178593 |
|
NCBI chr 7:121,758,658...121,769,107
Ensembl chr 7:121,758,662...121,769,096
|
|
G |
Plpp3 |
phospholipid phosphatase 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of PLPP3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:105,014,544...105,089,964
Ensembl chr 4:105,014,544...105,089,961
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions increases expression |
ISO EXP |
Glucosamine promotes the reaction [IL1B results in increased expression of PPARG] Glucosamine results in increased expression of PPARG mRNA |
CTD |
PMID:15694357 PMID:22089456 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
multiple interactions decreases expression |
ISO |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein] Glucosamine results in decreased expression of PPARGC1A mRNA; Glucosamine results in decreased expression of PPARGC1A protein |
CTD |
PMID:20165829 |
|
NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068
|
|
G |
Ppm1a |
protein phosphatase 1A, magnesium dependent, alpha isoform |
decreases expression |
EXP |
Glucosamine results in decreased expression of PPM1A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:72,804,231...72,846,593
Ensembl chr12:72,804,229...72,846,593
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
decreases expression |
EXP |
Glucosamine results in decreased expression of PPP1R15A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:45,172,341...45,175,692
Ensembl chr 7:45,172,340...45,175,692
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of PRC1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 7:79,944,224...79,966,007
Ensembl chr 7:79,944,198...79,966,007
|
|
G |
Prkaa1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
multiple interactions |
ISO |
PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] |
CTD |
PMID:33812996 |
|
NCBI chr15:5,172,641...5,211,380
Ensembl chr15:5,173,343...5,211,380
|
|
G |
Psme3 |
proteaseome (prosome, macropain) activator subunit 3 (PA28 gamma, Ki) |
decreases expression |
ISO |
Glucosamine results in decreased expression of PSME3 |
CTD |
PMID:21697645 |
|
NCBI chr11:101,206,090...101,214,363
Ensembl chr11:101,207,039...101,214,363
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein; Glucosamine inhibits the reaction [IL1B results in increased expression of PTGES mRNA] |
CTD |
PMID:17605605 PMID:22089456 |
|
NCBI chr 2:30,779,483...30,793,309
Ensembl chr 2:30,779,483...30,819,875
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression decreases expression multiple interactions decreases glycosylation |
ISO EXP |
Glucosamine analog results in increased expression of PTGS2 protein alternative form Glucosamine results in decreased expression of PTGS2 mRNA Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Glucosamine inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] Glucosamine results in decreased glycosylation of PTGS2 protein [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:12681956 PMID:17440993 PMID:17605605 PMID:18205790 PMID:19656660 PMID:20737476 PMID:22089456 More...
|
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Pttg1 |
pituitary tumor-transforming gene 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of PTTG1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr11:43,311,097...43,317,417
Ensembl chr11:43,311,077...43,317,078
|
|
G |
Rab32 |
RAB32, member RAS oncogene family |
increases expression |
EXP |
Glucosamine results in increased expression of RAB32 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:10,420,783...10,433,951
Ensembl chr10:10,420,746...10,434,009
|
|
G |
Racgap1 |
Rac GTPase-activating protein 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of RACGAP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr15:99,518,377...99,549,504
Ensembl chr15:99,518,377...99,549,537
|
|
G |
Rbm39 |
RNA binding motif protein 39 |
decreases expression |
EXP |
Glucosamine results in decreased expression of RBM39 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:155,989,159...156,022,649
Ensembl chr 2:155,989,159...156,022,158
|
|
G |
Recql4 |
RecQ protein-like 4 |
increases expression |
EXP |
Glucosamine results in increased expression of RECQL4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:76,587,753...76,594,820
Ensembl chr15:76,587,753...76,594,748
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions decreases activity increases localization |
ISO EXP |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein]]; Glucosamine analog inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of RELA protein]; Glucosamine inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine inhibits the reaction [NFKB1 results in increased degradation of RELA protein]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased localization of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein] Glucosamine results in decreased activity of RELA protein Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]; Glucosamine inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to NOS2 promoter]]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of RELA mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein] Glucosamine results in increased localization of RELA protein |
CTD |
PMID:12681956 PMID:16431966 PMID:16822504 PMID:17238806 PMID:17498959 PMID:18036590 PMID:18080321 PMID:18205790 PMID:18340449 PMID:18786831 PMID:19020780 PMID:19375915 PMID:20307528 PMID:20737476 More...
|
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Relb |
avian reticuloendotheliosis viral (v-rel) oncogene related B |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of RELB mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 7:19,340,142...19,363,352
Ensembl chr 7:19,340,142...19,363,363
|
|
G |
Rhob |
ras homolog family member B |
increases expression |
EXP |
Glucosamine results in increased expression of RHOB mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:8,547,661...8,550,009
Ensembl chr12:8,547,661...8,550,009
|
|
G |
Rhoc |
ras homolog family member C |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of RHOC mRNA |
CTD |
PMID:16142878 |
|
NCBI chr 3:104,696,350...104,701,775
Ensembl chr 3:104,695,691...104,701,775
|
|
G |
Rnd1 |
Rho family GTPase 1 |
multiple interactions decreases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of RND1 mRNA] Glucosamine results in decreased expression of RND1 mRNA |
CTD |
PMID:17178593 PMID:18173918 |
|
NCBI chr15:98,567,086...98,575,342
Ensembl chr15:98,561,302...98,575,342
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Glucosamine results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:19254699 |
|
NCBI chr 4:86,772,336...86,775,604
Ensembl chr 4:86,772,897...86,775,649
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase, polypeptide 1 |
decreases phosphorylation |
ISO |
Glucosamine results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:19254699 |
|
NCBI chr11:86,389,695...86,435,711
Ensembl chr11:86,389,697...86,435,631
|
|
G |
Runx2 |
runt related transcription factor 2 |
increases phosphorylation increases expression multiple interactions |
ISO |
Glucosamine analog results in increased phosphorylation of RUNX2 protein Glucosamine analog results in increased expression of RUNX2 mRNA 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of RUNX2 protein] |
CTD |
PMID:20458730 |
|
NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684
|
|
G |
Scd2 |
stearoyl-Coenzyme A desaturase 2 |
increases expression |
EXP |
Glucosamine results in increased expression of SCD2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:44,282,115...44,295,303
Ensembl chr19:44,282,113...44,295,303
|
|
G |
Sdc2 |
syndecan 2 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of SDC2 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of SDC2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr15:32,920,869...33,034,867
Ensembl chr15:32,920,869...33,035,081
|
|
G |
Sdc4 |
syndecan 4 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of SDC4 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SDC4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:164,266,167...164,285,512
Ensembl chr 2:164,266,167...164,285,807
|
|
G |
Selenbp1 |
selenium binding protein 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SELENBP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:94,840,394...94,852,069
Ensembl chr 3:94,840,367...94,852,069
|
|
G |
Serpinb2 |
serine (or cysteine) peptidase inhibitor, clade B, member 2 |
increases expression |
ISO |
Glucosamine results in increased expression of SERPINB2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:107,439,153...107,453,330
Ensembl chr 1:107,439,153...107,463,208
|
|
G |
Serpinh1 |
serine (or cysteine) peptidase inhibitor, clade H, member 1 |
increases expression |
ISO |
Glucosamine results in increased expression of SERPINH1 protein |
CTD |
PMID:16380481 |
|
NCBI chr 7:98,994,583...99,002,321
Ensembl chr 7:98,994,583...99,002,446
|
|
G |
Sfrp2 |
secreted frizzled-related protein 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SFRP2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:83,673,628...83,681,621
Ensembl chr 3:83,673,628...83,681,623
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SGK1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:21,758,083...21,875,802
Ensembl chr10:21,758,083...21,875,802
|
|
G |
Shcbp1 |
Shc SH2-domain binding protein 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SHCBP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:4,785,976...4,829,549
Ensembl chr 8:4,785,976...4,829,567
|
|
G |
Slc17a1 |
solute carrier family 17 (sodium phosphate), member 1 |
increases expression |
EXP |
Glucosamine results in increased expression of SLC17A1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:24,051,607...24,079,713
Ensembl chr13:24,051,733...24,079,713
|
|
G |
Slc23a2 |
solute carrier family 23 (nucleobase transporters), member 2 |
increases expression |
ISO |
Glucosamine results in increased expression of SLC23A2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:131,894,416...131,987,287
Ensembl chr 2:131,894,416...131,987,028
|
|
G |
Slc2a2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SLC2A2 mRNA |
CTD |
PMID:11893929 |
|
NCBI chr 3:28,752,052...28,782,510
Ensembl chr 3:28,752,052...28,785,508
|
|
G |
Slc2a4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
multiple interactions decreases expression increases uptake |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein] Glucosamine results in decreased expression of SLC2A4 mRNA; Glucosamine results in decreased expression of SLC2A4 protein SLC2A4 protein results in increased uptake of Glucosamine Glucosamine inhibits the reaction [SLC2A4 protein results in increased uptake of Glucose]; Glucose inhibits the reaction [SLC2A4 protein results in increased uptake of Glucosamine] |
CTD |
PMID:19373748 PMID:20165829 |
|
NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014
|
|
G |
Slc2a6 |
solute carrier family 2 (facilitated glucose transporter), member 6 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SLC2A6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:26,911,375...26,918,011
Ensembl chr 2:26,911,375...26,918,010
|
|
G |
Slc37a4 |
solute carrier family 37 (glucose-6-phosphate transporter), member 4 |
increases expression |
EXP |
Glucosamine results in increased expression of SLC37A4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:44,308,243...44,314,263
Ensembl chr 9:44,308,149...44,314,265
|
|
G |
Slc4a4 |
solute carrier family 4 (anion exchanger), member 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SLC4A4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 5:88,941,717...89,387,515
Ensembl chr 5:89,034,345...89,387,512
|
|
G |
Slc7a8 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 8 |
increases expression multiple interactions |
ISO |
Glucosamine results in increased expression of SLC7A8 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of SLC7A8 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SLC7A8 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:54,959,672...55,019,343
Ensembl chr14:54,959,666...55,019,403
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions increases phosphorylation |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:20458730 |
|
NCBI chr18:76,369,898...76,444,819
Ensembl chr18:76,374,651...76,444,034
|
|
G |
Smpd3 |
sphingomyelin phosphodiesterase 3, neutral |
decreases expression |
ISO |
Glucosamine results in decreased expression of SMPD3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:106,979,180...107,064,597
Ensembl chr 8:106,979,180...107,064,620
|
|
G |
Sox4 |
SRY (sex determining region Y)-box 4 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of SOX4 mRNA] Glucosamine results in decreased expression of SOX4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:29,132,902...29,137,682
Ensembl chr13:29,132,902...29,137,696
|
|
G |
Srsf3 |
serine and arginine-rich splicing factor 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SRSF3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:29,251,634...29,262,346
Ensembl chr17:29,251,602...29,262,347
|
|
G |
St6gal1 |
beta galactoside alpha 2,6 sialyltransferase 1 |
increases expression |
EXP |
Glucosamine results in increased expression of ST6GAL1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr16:23,043,478...23,179,100
Ensembl chr16:23,043,490...23,179,100
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IFNG results in increased localization of STAT1 protein modified form]; Glucosamine inhibits the reaction [IFNG results in increased phosphorylation of and results in increased localization of STAT1 protein] |
CTD |
PMID:16431966 PMID:17238806 |
|
NCBI chr 1:52,158,588...52,201,024
Ensembl chr 1:52,158,599...52,201,024
|
|
G |
Tacc3 |
transforming, acidic coiled-coil containing protein 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of TACC3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 5:33,814,808...33,836,331
Ensembl chr 5:33,815,472...33,836,339
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
ISO |
[Glucose co-treated with Glucosamine] results in increased expression of TGFA protein; Glucosamine promotes the reaction [Glucose results in increased expression of TGFA mRNA] |
CTD |
PMID:1518840 |
|
NCBI chr 6:86,172,020...86,252,726
Ensembl chr 6:86,172,205...86,252,701
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
Glucosamine analog results in increased expression of TGFB1 mRNA |
CTD |
PMID:21466783 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor I |
multiple interactions increases expression |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased expression of TGFBR1 protein] |
CTD |
PMID:20458730 |
|
NCBI chr 4:47,353,258...47,414,926
Ensembl chr 4:47,353,222...47,414,931
|
|
G |
Thbs4 |
thrombospondin 4 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of THBS4 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of THBS4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr13:92,888,094...92,931,326
Ensembl chr13:92,888,098...92,931,326
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of TIMP1 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of TIMP1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974
|
|
G |
Timp2 |
tissue inhibitor of metalloproteinase 2 |
affects expression multiple interactions |
ISO |
Glucosamine affects the expression of TIMP2 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr11:118,191,887...118,246,237
Ensembl chr11:118,191,887...118,246,566
|
|
G |
Timp3 |
tissue inhibitor of metalloproteinase 3 |
multiple interactions increases expression |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA Glucosamine results in increased expression of TIMP3 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP3 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of TIMP3 mRNA] |
CTD |
PMID:17109745 PMID:17605605 |
|
NCBI chr10:86,136,276...86,185,369
Ensembl chr10:86,136,236...86,185,370
|
|
G |
Tinag |
tubulointerstitial nephritis antigen |
increases expression |
EXP |
Glucosamine results in increased expression of TINAG mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:76,858,980...76,953,084
Ensembl chr 9:76,858,975...76,953,076
|
|
G |
Tk1 |
thymidine kinase 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of TK1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr11:117,706,345...117,716,913
Ensembl chr11:117,706,352...117,716,918
|
|
G |
Tlr1 |
toll-like receptor 1 |
increases expression |
EXP |
Glucosamine results in increased expression of TLR1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:65,082,023...65,090,945
Ensembl chr 5:65,082,022...65,090,906
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion multiple interactions decreases expression |
EXP ISO |
Glucosamine results in decreased secretion of TNF protein Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Glucosamine analog results in decreased expression of TNF mRNA; Glucosamine results in decreased expression of TNF mRNA Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] [Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of TNF; Alloxan inhibits the reaction [Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein]]; Glucosamine analog inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased localization of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein] |
CTD |
PMID:14507305 PMID:16431966 PMID:16445576 PMID:16822504 PMID:17238806 PMID:18173918 PMID:18205790 PMID:18786831 PMID:19020780 PMID:19098112 PMID:20093129 PMID:20110869 PMID:20113495 PMID:20737476 More...
|
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfaip6 |
tumor necrosis factor alpha induced protein 6 |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of TNFAIP6 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of TNFAIP6 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:51,928,125...51,946,693
Ensembl chr 2:51,928,021...51,946,698
|
|
G |
Tnfrsf11b |
tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) |
multiple interactions |
ISO |
[Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B protein; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B protein |
CTD |
PMID:17996099 |
|
NCBI chr15:54,114,014...54,141,700
Ensembl chr15:54,114,015...54,141,880
|
|
G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447
|
|
G |
Tnfrsf1b |
tumor necrosis factor receptor superfamily, member 1b |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr 4:144,938,938...144,973,453
Ensembl chr 4:144,940,033...144,973,440
|
|
G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
multiple interactions increases expression |
ISO |
[Chondroitin Sulfates co-treated with Glucosamine] inhibits the reaction [Cholecalciferol results in increased expression of TNFSF11 mRNA]; Chondroitin Sulfates inhibits the reaction [Glucosamine results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:17996099 |
|
NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483
|
|
G |
Tnk2 |
tyrosine kinase, non-receptor, 2 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of TNK2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr16:32,462,699...32,502,311
Ensembl chr16:32,462,692...32,502,311
|
|
G |
Top2a |
topoisomerase (DNA) II alpha |
decreases expression |
ISO |
Glucosamine results in decreased expression of TOP2A mRNA |
CTD |
PMID:17109745 |
|
NCBI chr11:98,883,773...98,915,037
Ensembl chr11:98,883,769...98,915,015
|
|
G |
Traf6 |
TNF receptor-associated factor 6 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TRAF6 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr 2:101,508,765...101,532,013
Ensembl chr 2:101,508,774...101,532,014
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
increases expression |
EXP |
Glucosamine results in increased expression of TRPV4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:114,760,213...114,796,497
Ensembl chr 5:114,760,213...114,796,482
|
|
G |
Txn1 |
thioredoxin 1 |
decreases expression |
ISO EXP |
Glucosamine results in decreased expression of TXN1 protein |
CTD |
PMID:17178593 |
|
NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411
|
|
G |
Txnip |
thioredoxin interacting protein |
multiple interactions increases expression |
EXP ISO |
Glucosamine promotes the reaction [TXNIP results in increased abundance of Reactive Oxygen Species]; TXNIP promotes the reaction [Glucosamine results in increased expression of LAMB1 mRNA]; TXNIP promotes the reaction [Glucosamine results in increased expression of LAMC1 mRNA] Glucosamine results in increased expression of TXNIP protein Glucosamine results in increased expression of TXNIP mRNA; Glucosamine results in increased expression of TXNIP protein |
CTD |
PMID:17178593 |
|
NCBI chr 3:96,465,273...96,469,173
Ensembl chr 3:96,465,273...96,469,199
|
|
G |
Ucp2 |
uncoupling protein 2 (mitochondrial, proton carrier) |
decreases expression |
ISO |
Glucosamine results in decreased expression of UCP2 mRNA |
CTD |
PMID:11893929 |
|
NCBI chr 7:100,142,565...100,148,832
Ensembl chr 7:100,142,544...100,151,227
|
|
G |
Uqcrh |
ubiquinol-cytochrome c reductase hinge protein |
increases expression |
EXP |
Glucosamine results in increased expression of UQCRH mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:115,924,162...115,932,267
Ensembl chr 4:115,924,162...115,932,268
|
|
G |
Vamp1 |
vesicle-associated membrane protein 1 |
increases expression |
ISO |
Glucosamine results in increased expression of VAMP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 6:125,192,544...125,199,269
Ensembl chr 6:125,192,514...125,222,927
|
|
G |
Vcan |
versican |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased expression of VCAN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of VCAN mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr13:89,803,429...89,891,146
Ensembl chr13:89,803,431...89,890,628
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression decreases expression |
ISO |
Glucosamine inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA protein] Glucosamine results in increased expression of VEGFA protein Glucosamine results in decreased expression of VEGFA protein |
CTD |
PMID:16324875 PMID:19254699 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Vegfd |
vascular endothelial growth factor D |
increases expression decreases expression |
EXP ISO |
Glucosamine results in increased expression of VEGFD mRNA Glucosamine results in decreased expression of VEGFD mRNA |
CTD |
PMID:17109745 PMID:17178593 |
|
NCBI chr X:163,156,282...163,185,643
Ensembl chr X:163,156,374...163,185,646
|
|
G |
Vnn1 |
vanin 1 |
increases expression |
EXP |
Glucosamine results in increased expression of VNN1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:23,770,586...23,781,242
Ensembl chr10:23,770,586...23,781,241
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions increases splicing increases expression decreases splicing |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA] Glucosamine results in increased expression of XBP1 protein alternative form 4-methylumbelliferone 8-carbaldehyde affects the reaction [Glucosamine results in increased expression of XBP1 protein alternative form]; 4-methylumbelliferone 8-carbaldehyde inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 protein alternative form]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased splicing of XBP1 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA] Glucosamine results in decreased splicing of XBP1 mRNA |
CTD |
PMID:19383982 PMID:20165829 PMID:30602124 PMID:33812996 |
|
NCBI chr11:5,470,641...5,475,993
Ensembl chr11:5,470,659...5,475,893
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
ISO |
[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased abundance of Proteoglycans]; [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA] |
CTD |
PMID:11801247 |
|
NCBI chr17:74,190,890...74,257,191
Ensembl chr17:74,190,890...74,257,191
|
|
G |
Zfp467 |
zinc finger protein 467 |
increases expression |
EXP |
Glucosamine results in increased expression of ZFP467 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:48,404,626...48,422,926
Ensembl chr 6:48,404,631...48,422,759
|
|
|
G |
Bax |
BCL2-associated X protein |
increases expression multiple interactions |
ISO EXP |
calycosin-7-O-beta-D-glucoside results in increased expression of BAX mRNA; calycosin-7-O-beta-D-glucoside results in increased expression of BAX protein TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of BAX mRNA]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of BAX protein] |
CTD |
PMID:36812960 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
decreases expression multiple interactions |
EXP ISO |
calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 mRNA; calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 protein TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 mRNA]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 protein] |
CTD |
PMID:36812960 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases expression |
ISO EXP |
TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased cleavage of CASP3 protein]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of CASP3 mRNA] |
CTD |
PMID:36812960 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cat |
catalase |
decreases expression |
EXP ISO |
calycosin-7-O-beta-D-glucoside results in decreased expression of CAT protein |
CTD |
PMID:36812960 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Epo |
erythropoietin |
increases expression |
ISO |
calycosin-7-O-beta-D-glucoside results in increased expression of EPO mRNA |
CTD |
PMID:21309574 PMID:37348668 |
|
NCBI chr 5:137,481,282...137,484,078
Ensembl chr 5:137,481,282...137,531,504
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
decreases expression |
EXP |
calycosin-7-O-beta-D-glucoside results in decreased expression of GPT protein |
CTD |
PMID:36812960 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
multiple interactions increases expression |
ISO |
calycosin-7-O-beta-D-glucoside results in decreased degradation of and results in increased expression of HIF1A protein modified form; calycosin-7-O-beta-D-glucoside results in increased expression of and results in decreased degradation of HIF1A protein calycosin-7-O-beta-D-glucoside results in increased expression of HIF1A mRNA; calycosin-7-O-beta-D-glucoside results in increased expression of HIF1A protein |
CTD |
PMID:21309574 PMID:37348668 |
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Txn1 |
thioredoxin 1 |
decreases expression multiple interactions |
EXP ISO |
calycosin-7-O-beta-D-glucoside results in decreased expression of TXN mRNA; calycosin-7-O-beta-D-glucoside results in decreased expression of TXN protein TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 mRNA]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 protein]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased cleavage of CASP3 protein]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of BAX mRNA]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of BAX protein]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of CASP3 mRNA] |
CTD |
PMID:36812960 |
|
NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411
|
|
|
G |
Fbp1 |
fructose bisphosphatase 1 |
multiple interactions |
EXP |
[Enzyme Inhibitors results in decreased activity of FBP1 protein] which results in decreased abundance of Glucose-6-Phosphate |
CTD |
PMID:31974165 |
|
NCBI chr13:63,012,567...63,036,112
Ensembl chr13:63,012,567...63,036,096
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
EXP |
[Fluoxetine results in decreased expression of G6PC1 protein] which results in increased abundance of Glucose-6-Phosphate |
CTD |
PMID:33179799 |
|
NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729
|
|
G |
G6pc2 |
glucose-6-phosphatase, catalytic, 2 |
increases hydrolysis |
ISO |
G6PC2 protein results in increased hydrolysis of Glucose-6-Phosphate |
CTD |
PMID:14722102 |
|
NCBI chr 2:69,041,417...69,058,337
Ensembl chr 2:69,041,417...69,058,185
|
|
G |
Gpd2 |
glycerol phosphate dehydrogenase 2, mitochondrial |
multiple interactions |
EXP |
GPD2 protein inhibits the reaction [Dihydroxyacetone results in increased abundance of Glucose-6-Phosphate]; GPD2 protein inhibits the reaction [Glucose results in increased abundance of Glucose-6-Phosphate]; GPD2 protein inhibits the reaction [Glycerol results in increased abundance of Glucose-6-Phosphate] |
CTD |
PMID:31974165 |
|
NCBI chr 2:57,127,690...57,260,731
Ensembl chr 2:57,127,647...57,260,731
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
EXP |
[Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA |
CTD |
PMID:20505214 |
|
NCBI chr15:101,151,783...101,172,676
Ensembl chr15:101,152,150...101,172,676
|
|
G |
Pfkfb1 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 |
increases abundance multiple interactions |
EXP |
PFKFB1 gene mutant form results in increased abundance of Glucose-6-Phosphate PFKFB1 gene mutant form inhibits the reaction [Metformin results in decreased abundance of Glucose-6-Phosphate metabolite] |
CTD |
PMID:31974165 |
|
NCBI chr X:149,370,441...149,426,874
Ensembl chr X:149,371,225...149,426,874
|
|
G |
Prkaa1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
multiple interactions |
EXP |
[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to 4-hydroxy-3-(4-(2-hydroxyphenyl)phenyl)-6-oxo-7H-thieno(2,3-b)pyridine-5-carbonitrile] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to Metformin] which results in increased abundance of Glucose-6-Phosphate |
CTD |
PMID:31974165 |
|
NCBI chr15:5,172,641...5,211,380
Ensembl chr15:5,173,343...5,211,380
|
|
G |
Prkaa2 |
protein kinase, AMP-activated, alpha 2 catalytic subunit |
multiple interactions |
EXP |
[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to 4-hydroxy-3-(4-(2-hydroxyphenyl)phenyl)-6-oxo-7H-thieno(2,3-b)pyridine-5-carbonitrile] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to Metformin] which results in increased abundance of Glucose-6-Phosphate |
CTD |
PMID:31974165 |
|
NCBI chr 4:104,886,846...104,967,095
Ensembl chr 4:104,887,071...104,967,087
|
|
|
G |
Ache |
acetylcholinesterase |
increases expression multiple interactions |
ISO |
daidzin results in increased expression of ACHE mRNA 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [daidzin results in increased expression of ACHE mRNA]; 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [daidzin results in increased expression of and results in increased activity of ACHE protein]; daidzin results in increased expression of and results in increased activity of ACHE protein |
CTD |
PMID:31034797 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of ACSL3 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:78,635,600...78,685,462
Ensembl chr 1:78,635,542...78,685,460
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase family 1, subfamily A2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ALDH1A2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:71,123,071...71,203,525
Ensembl chr 9:71,123,071...71,203,525
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2, mitochondrial |
multiple interactions |
ISO |
daidzin inhibits the reaction [ALDH2 protein results in increased hydrolysis of 4-nitrophenyl acetate]; daidzin inhibits the reaction [ALDH2 protein results in increased oxidation of propionaldehyde] |
CTD |
PMID:21349255 |
|
NCBI chr 5:121,704,090...121,731,887
Ensembl chr 5:121,704,090...121,731,887
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ANPEP mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:79,471,551...79,497,958
Ensembl chr 7:79,471,551...79,510,807
|
|
G |
Atoh8 |
atonal bHLH transcription factor 8 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of ATOH8 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:72,183,158...72,212,765
Ensembl chr 6:72,183,161...72,212,561
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of BCKDK mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:127,503,245...127,508,836
Ensembl chr 7:127,503,254...127,509,393
|
|
G |
Bdnf |
brain derived neurotrophic factor |
multiple interactions |
EXP |
daidzin inhibits the reaction [Pentylenetetrazole results in decreased expression of BDNF protein] |
CTD |
PMID:32450180 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Bpgm |
2,3-bisphosphoglycerate mutase |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of BPGM mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:34,453,291...34,482,071
Ensembl chr 6:34,453,142...34,482,548
|
|
G |
Cabp5 |
calcium binding protein 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CABP5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:13,119,885...13,142,812
Ensembl chr 7:13,132,057...13,142,812
|
|
G |
Cacybp |
calcyclin binding protein |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CACYBP mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:160,029,171...160,040,391
Ensembl chr 1:160,029,937...160,040,445
|
|
G |
Casp8ap2 |
caspase 8 associated protein 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CASP8AP2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:32,615,462...32,653,271
Ensembl chr 4:32,615,451...32,653,265
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
daidzin inhibits the reaction [Pentylenetetrazole results in decreased activity of CAT protein] |
CTD |
PMID:32450180 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cd200r1 |
CD200 receptor 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CD200R1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr16:44,586,141...44,615,341
Ensembl chr16:44,586,099...44,615,341
|
|
G |
Cfap251 |
cilia and flagella associated protein 251 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CFAP251 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:123,390,196...123,465,547
Ensembl chr 5:123,390,165...123,465,547
|
|
G |
Cybrd1 |
cytochrome b reductase 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CYBRD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:70,948,398...70,973,270
Ensembl chr 2:70,948,267...70,973,270
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306
|
|
G |
Dennd2d |
DENN domain containing 2D |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of DENND2D mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:106,389,745...106,410,346
Ensembl chr 3:106,389,721...106,410,346
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 9:20,818,501...20,871,084
Ensembl chr 9:20,818,505...20,871,184
|
|
G |
Dnmt3a |
DNA methyltransferase 3A |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT3A mRNA |
CTD |
PMID:28964809 |
|
NCBI chr12:3,851,559...3,964,442
Ensembl chr12:3,856,007...3,964,443
|
|
G |
Dpp9 |
dipeptidylpeptidase 9 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of DPP9 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr17:56,493,674...56,525,927
Ensembl chr17:56,493,807...56,525,905
|
|
G |
Edrf1 |
erythroid differentiation regulatory factor 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of EDRF1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:133,239,422...133,274,710
Ensembl chr 7:133,239,272...133,274,700
|
|
G |
Efhd1 |
EF hand domain containing 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of EFHD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:87,192,075...87,238,563
Ensembl chr 1:87,192,085...87,238,561
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of ESR2 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
Fam171a2 |
family with sequence similarity 171, member A2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FAM171A2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr11:102,327,807...102,338,551
Ensembl chr11:102,327,807...102,338,508
|
|
G |
Fam180a |
family with sequence similarity 180, member A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM180A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:35,289,678...35,303,076
Ensembl chr 6:35,289,603...35,303,076
|
|
G |
Fam210b |
family with sequence similarity 210, member B |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM210B mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:172,187,444...172,197,669
Ensembl chr 2:172,187,485...172,197,669
|
|
G |
Fam241b |
family with sequence similarity 241, member B |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of FAM241B mRNA |
CTD |
PMID:27424125 |
|
NCBI chr10:61,943,435...61,946,829
Ensembl chr10:61,943,434...61,979,699
|
|
G |
Fgd6 |
FYVE, RhoGEF and PH domain containing 6 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FGD6 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr10:93,871,862...93,981,201
Ensembl chr10:93,871,863...93,981,201
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FHL2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:43,162,233...43,237,501
Ensembl chr 1:43,162,234...43,236,144
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
increases expression |
ISO |
daidzin results in increased expression of FOS mRNA |
CTD |
PMID:17142977 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Galnt15 |
polypeptide N-acetylgalactosaminyltransferase 15 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of GALNT15 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr14:31,750,739...31,784,161
Ensembl chr14:31,750,946...31,784,154
|
|
G |
Gng5 |
G protein subunit gamma 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of GNG5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:146,205,591...146,211,298
Ensembl chr 3:146,205,562...146,211,327
|
|
G |
Hipk4 |
homeodomain interacting protein kinase 4 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of HIPK4 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:27,222,686...27,230,605
Ensembl chr 7:27,222,692...27,230,600
|
|
G |
Hmcn1 |
hemicentin 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of HMCN1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:150,438,251...150,869,568
Ensembl chr 1:150,438,275...150,869,186
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
daidzin inhibits the reaction [Pentylenetetrazole results in decreased expression of HMOX1 protein] |
CTD |
PMID:32450180 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of HSD3B1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 3:98,749,672...98,767,110
Ensembl chr 3:98,759,510...98,767,110
|
|
G |
Il6ra |
interleukin 6 receptor, alpha |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of IL6R mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:89,776,631...89,820,503
Ensembl chr 3:89,771,366...89,820,503
|
|
G |
Isg20l2 |
interferon stimulated exonuclease gene 20-like 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ISG20L2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:87,837,602...87,847,994
Ensembl chr 3:87,837,621...87,847,993
|
|
G |
Kdm5a |
lysine demethylase 5A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of KDM5A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:120,341,060...120,421,535
Ensembl chr 6:120,341,085...120,421,535
|
|
G |
Kitl |
kit ligand |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KITLG mRNA |
CTD |
PMID:27424125 |
|
NCBI chr10:99,851,477...99,936,278
Ensembl chr10:99,851,492...99,936,278
|
|
G |
Knstrn |
kinetochore-localized astrin/SPAG5 binding |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KNSTRN mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:118,644,470...118,667,691
Ensembl chr 2:118,644,484...118,684,438
|
|
G |
Ldlrap1 |
low density lipoprotein receptor adaptor protein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LDLRAP1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:134,468,865...134,495,342
Ensembl chr 4:134,468,865...134,495,335
|
|
G |
Lmod1 |
leiomodin 1 (smooth muscle) |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LMOD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:135,252,551...135,295,803
Ensembl chr 1:135,252,545...135,295,803
|
|
G |
Lrg1 |
leucine-rich alpha-2-glycoprotein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of LRG1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr17:56,426,678...56,428,946
Ensembl chr17:56,426,678...56,429,001
|
|
G |
Lsr |
lipolysis stimulated lipoprotein receptor |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LSR mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:30,657,195...30,672,894
Ensembl chr 7:30,657,195...30,672,889
|
|
G |
Mrpl33 |
mitochondrial ribosomal protein L33 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of MRPL33 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:31,771,295...31,779,988
Ensembl chr 5:31,754,279...31,821,728
|
|
G |
Mtmr11 |
myotubularin related protein 11 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of MTMR11 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:96,069,287...96,079,034
Ensembl chr 3:96,069,321...96,079,034
|
|
G |
Myof |
myoferlin |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of MYOF mRNA |
CTD |
PMID:27424125 |
|
NCBI chr19:37,887,484...38,032,025
Ensembl chr19:37,887,484...38,032,025
|
|
G |
Nefh |
neurofilament, heavy polypeptide |
increases expression |
ISO |
daidzin results in increased expression of NEFH mRNA; daidzin results in increased expression of NEFH protein |
CTD |
PMID:31034797 |
|
NCBI chr11:4,888,754...4,898,064
Ensembl chr11:4,888,754...4,898,064
|
|
G |
Nefl |
neurofilament, light polypeptide |
increases expression |
ISO |
daidzin results in increased expression of NEFL mRNA; daidzin results in increased expression of NEFL protein |
CTD |
PMID:31034797 |
|
NCBI chr14:68,321,312...68,326,544
Ensembl chr14:68,321,312...68,326,544
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of NR4A1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr15:101,151,783...101,172,676
Ensembl chr15:101,152,150...101,172,676
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 protein; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased methylation of NR5A1 promoter; decitabine inhibits the reaction [[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA] |
CTD |
PMID:28964809 |
|
NCBI chr 2:38,582,668...38,604,554
Ensembl chr 2:38,582,668...38,604,554
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
daidzin results in increased expression of PGR protein |
CTD |
PMID:17142977 |
|
NCBI chr 9:8,890,017...8,968,612
Ensembl chr 9:8,899,834...8,968,612
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
multiple interactions increases expression |
ISO |
4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [daidzin results in increased expression of PRIMA1 mRNA] |
CTD |
PMID:31034797 |
|
NCBI chr12:103,160,712...103,208,967
Ensembl chr12:103,163,167...103,208,409
|
|
G |
Prkaca |
protein kinase, cAMP dependent, catalytic, alpha |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of PRKACA mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 8:84,699,607...84,723,073
Ensembl chr 8:84,699,622...84,723,072
|
|
G |
Prpf40a |
pre-mRNA processing factor 40A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PRPF40A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:53,024,714...53,081,450
Ensembl chr 2:53,024,716...53,081,714
|
|
G |
Pspc1 |
paraspeckle protein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PSPC1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr14:56,959,898...57,015,775
Ensembl chr14:56,958,167...57,015,773
|
|
G |
Pth1r |
parathyroid hormone 1 receptor |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of PTH1R mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:110,551,132...110,576,213
Ensembl chr 9:110,551,153...110,576,213
|
|
G |
Rassf5 |
Ras association (RalGDS/AF-6) domain family member 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of RASSF5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:131,104,147...131,172,915
Ensembl chr 1:131,104,147...131,172,995
|
|
G |
Rgs22 |
regulator of G-protein signalling 22 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of RGS22 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr15:35,960,664...36,140,718
Ensembl chr15:36,009,625...36,140,546
|
|
G |
S1pr3 |
sphingosine-1-phosphate receptor 3 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of S1PR3 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:51,562,654...51,576,833
Ensembl chr13:51,562,675...51,576,833
|
|
G |
Selplg |
selectin, platelet (p-selectin) ligand |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SELPLG mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:113,955,859...113,970,576
Ensembl chr 5:113,956,597...113,970,705
|
|
G |
Slc16a1 |
solute carrier family 16 (monocarboxylic acid transporters), member 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SLC16A1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:104,545,980...104,565,778
Ensembl chr 3:104,545,984...104,565,778
|
|
G |
Snx30 |
sorting nexin family member 30 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SNX30 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:59,805,137...59,904,740
Ensembl chr 4:59,805,840...59,904,737
|
|
G |
Ssc5d |
scavenger receptor cysteine rich family, 5 domains |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SSC5D mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:4,928,820...4,947,827
Ensembl chr 7:4,928,784...4,947,825
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR protein |
CTD |
PMID:28964809 |
|
NCBI chr 8:26,298,502...26,306,010
Ensembl chr 8:26,296,583...26,306,010
|
|
G |
Styxl1 |
serine/threonine/tyrosine interacting-like 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of STYXL1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:135,776,074...135,807,277
Ensembl chr 5:135,776,074...135,807,239
|
|
G |
Sumo1 |
small ubiquitin-like modifier 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of SUMO1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:59,678,593...59,709,993
Ensembl chr 1:59,625,717...59,709,993
|
|
G |
Tc2n |
tandem C2 domains, nuclear |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of TC2N mRNA |
CTD |
PMID:27424125 |
|
NCBI chr12:101,611,705...101,685,178
Ensembl chr12:101,611,702...101,684,782
|
|
G |
Trp53i11 |
transformation related protein 53 inducible protein 11 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of TP53I11 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:93,017,694...93,032,102
Ensembl chr 2:93,017,893...93,032,104
|
|
G |
Vcpip1 |
valosin containing protein (p97)/p47 complex interacting protein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of VCPIP1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:9,788,847...9,818,607
Ensembl chr 1:9,788,847...9,818,607
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
daidzin inhibits the reaction [Pentylenetetrazole results in increased expression of VEGFA protein] |
CTD |
PMID:32450180 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
|
G |
0610040J01Rik |
RIKEN cDNA 0610040J01 gene |
affects response to substance |
ISO |
C4ORF19 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:63,969,833...64,056,968
Ensembl chr 5:63,969,706...64,056,968
|
|
G |
6030458C11Rik |
RIKEN cDNA 6030458C11 gene |
affects response to substance |
ISO |
C5ORF22 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:12,806,012...12,824,767
Ensembl chr15:12,808,263...12,824,735
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
affects response to substance increases expression multiple interactions |
ISO |
ABCB1 exon polymorphism affects the susceptibility to Etoposide Etoposide results in increased expression of ABCB1 mRNA; Etoposide results in increased expression of ABCB1 protein [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [Celecoxib results in decreased expression of ABCB1] which results in increased susceptibility to Etoposide |
CTD |
PMID:12969965 PMID:15239124 PMID:19047049 PMID:19562670 PMID:27570640 PMID:27840903 More...
|
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcc1 |
ATP-binding cassette, sub-family C member 1 |
affects response to substance multiple interactions increases expression decreases uptake decreases response to substance |
ISO EXP |
ABCC1 protein affects the susceptibility to Etoposide Glucose inhibits the reaction [Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide]]; Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide]; Verapamil inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Verapamil inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide] Etoposide results in increased expression of ABCC1 mRNA ABCC1 protein results in decreased susceptibility to Etoposide; ABCC1 results in decreased susceptibility to Etoposide [GCLC protein co-treated with GCLM protein] promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; [MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Etoposide; GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; hesperetin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; naringenin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; resveratrol inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Silymarin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Tocopherols inhibits the reaction [ABCC1 protein affects the export of Etoposide]; verlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:7954421 PMID:8968083 PMID:9334814 PMID:10348353 PMID:10856430 PMID:10900222 PMID:11778547 PMID:15180633 PMID:15460906 PMID:15617835 PMID:15999103 PMID:16156793 PMID:16217747 More...
|
|
NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
affects transport multiple interactions |
ISO |
ABCC2 protein affects the transport of Etoposide Probenecid promotes the reaction [ABCC2 protein affects the transport of Etoposide] |
CTD |
PMID:15751272 PMID:15849751 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcc3 |
ATP-binding cassette, sub-family C member 3 |
decreases response to substance |
ISO |
ABCC3 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:15884115 |
|
NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
multiple interactions |
ISO |
[ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Etoposide; ABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide] |
CTD |
PMID:21712253 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Abhd4 |
abhydrolase domain containing 4 |
increases expression |
EXP |
Etoposide results in increased expression of ABHD4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr14:54,491,586...54,506,626
Ensembl chr14:54,491,645...54,508,094
|
|
G |
Abra |
actin-binding Rho activating protein |
increases expression |
ISO |
Etoposide results in increased expression of ABRA mRNA |
CTD |
PMID:29397400 |
|
NCBI chr15:41,728,689...41,733,116
Ensembl chr15:41,727,472...41,733,116
|
|
G |
Acadm |
acyl-Coenzyme A dehydrogenase, medium chain |
affects response to substance |
ISO |
ACADM protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:153,627,990...153,650,280
Ensembl chr 3:153,627,994...153,650,269
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
increases expression decreases expression |
ISO |
Etoposide results in increased expression of ACE2 mRNA Etoposide results in decreased expression of ACE2 mRNA |
CTD |
PMID:29397400 PMID:32808185 |
|
NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416
|
|
G |
Aco1 |
aconitase 1 |
increases expression |
EXP |
Etoposide results in increased expression of ACO1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:40,143,429...40,199,011
Ensembl chr 4:40,143,081...40,198,338
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
affects response to substance |
ISO |
ACSL3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:78,635,600...78,685,462
Ensembl chr 1:78,635,542...78,685,460
|
|
G |
Acta1 |
actin alpha 1, skeletal muscle |
decreases expression |
ISO |
Etoposide results in decreased expression of ACTA1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 8:124,618,497...124,621,514
Ensembl chr 8:124,618,508...124,621,490
|
|
G |
Agrn |
agrin |
increases expression |
ISO |
Etoposide results in increased expression of AGRN mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 4:156,249,747...156,281,997
Ensembl chr 4:156,249,747...156,281,945
|
|
G |
Ahcyl1 |
S-adenosylhomocysteine hydrolase-like 1 |
affects response to substance |
ISO |
AHCYL1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:107,570,436...107,603,876
Ensembl chr 3:107,570,434...107,603,876
|
|
G |
Ahi1 |
Abelson helper integration site 1 |
increases expression |
ISO |
Etoposide results in increased expression of AHI1 protein alternative form |
CTD |
PMID:19379585 |
|
NCBI chr10:20,827,274...20,956,328
Ensembl chr10:20,828,446...20,956,328
|
|
G |
Akap12 |
A kinase anchor protein 12 |
affects response to substance |
ISO |
AKAP12 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:4,216,329...4,309,471
Ensembl chr10:4,216,380...4,309,470
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
increases response to substance increases phosphorylation multiple interactions |
ISO |
AKT1 protein modified form results in increased susceptibility to Etoposide Etoposide results in increased phosphorylation of AKT1 protein Etoposide results in increased phosphorylation of and results in increased activity of AKT1 protein; NFKB1 protein affects the reaction [Etoposide results in increased phosphorylation of AKT1 protein]; pepstatin inhibits the reaction [AKT1 protein modified form results in increased susceptibility to Etoposide]; PTEN protein inhibits the reaction [Etoposide results in increased phosphorylation of and results in increased activity of AKT1 protein] |
CTD |
PMID:17699715 PMID:17935137 PMID:23396362 PMID:27769712 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Alad |
aminolevulinate, delta-, dehydratase |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with Carmustine co-treated with Etoposide] results in decreased activity of ALAD protein |
CTD |
PMID:19162187 |
|
NCBI chr 4:62,422,762...62,438,300
Ensembl chr 4:62,427,406...62,438,155
|
|
G |
Alas1 |
aminolevulinic acid synthase 1 |
increases expression |
EXP |
Etoposide results in increased expression of ALAS1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:106,110,654...106,125,153
Ensembl chr 9:106,110,654...106,125,853
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase family 1, subfamily A1 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of ALDH1A1 mRNA; Etoposide results in increased expression of ALDH1A1 protein FTL protein affects the reaction [Etoposide results in increased expression of ALDH1A1 protein] |
CTD |
PMID:33969609 |
|
NCBI chr19:20,469,947...20,620,827
Ensembl chr19:20,470,079...20,620,829
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase family 3, subfamily A1 |
affects response to substance |
ISO |
ALDH3A1 protein affects the susceptibility to Etoposide |
CTD |
PMID:15905174 |
|
NCBI chr11:61,099,336...61,109,244
Ensembl chr11:61,098,363...61,109,247
|
|
G |
Aldoc |
aldolase C, fructose-bisphosphate |
affects response to substance multiple interactions |
ISO EXP |
ALDOC protein affects the susceptibility to Etoposide [Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ALDOC protein |
CTD |
PMID:16217747 PMID:29733421 |
|
NCBI chr11:78,213,899...78,218,607
Ensembl chr11:78,213,794...78,218,607
|
|
G |
Alppl2 |
alkaline phosphatase, placental-like 2 |
affects response to substance |
ISO |
ALPG protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:87,014,412...87,023,656
Ensembl chr 1:87,014,416...87,017,650
|
|
G |
Ank1 |
ankyrin 1, erythroid |
increases expression |
ISO |
Etoposide results in increased expression of ANK1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 8:23,464,852...23,640,517
Ensembl chr 8:23,464,860...23,640,513
|
|
G |
Ankrd10 |
ankyrin repeat domain 10 |
decreases expression |
ISO |
Etoposide results in decreased expression of ANKRD10 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 8:11,661,581...11,694,617
Ensembl chr 8:11,661,583...11,685,757
|
|
G |
Ankrd27 |
ankyrin repeat domain 27 |
decreases expression |
EXP |
Etoposide results in decreased expression of ANKRD27 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:35,285,652...35,338,662
Ensembl chr 7:35,285,669...35,338,651
|
|
G |
Ankrd28 |
ankyrin repeat domain 28 |
affects response to substance |
ISO |
ANKRD28 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:31,418,687...31,552,374
Ensembl chr14:31,420,725...31,552,608
|
|
G |
Anxa4 |
annexin A4 |
increases expression |
ISO |
Etoposide results in increased expression of ANXA4 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:86,713,822...86,770,616
Ensembl chr 6:86,713,822...86,770,566
|
|
G |
Anxa7 |
annexin A7 |
multiple interactions |
EXP |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ANXA7 protein |
CTD |
PMID:29733421 |
|
NCBI chr14:20,505,344...20,530,009
Ensembl chr14:20,505,328...20,530,201
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
EXP |
Etoposide results in increased expression of APAF1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:90,825,173...90,918,688
Ensembl chr10:90,825,173...90,918,632
|
|
G |
Apex1 |
apurinic/apyrimidinic endonuclease 1 |
decreases response to substance |
ISO |
APEX1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:20856196 |
|
NCBI chr14:51,162,406...51,164,645
Ensembl chr14:51,162,425...51,164,596
|
|
G |
Aplp1 |
amyloid beta precursor like protein 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of APLP1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:30,134,405...30,144,960
Ensembl chr 7:30,134,407...30,144,960
|
|
G |
Apol8 |
apolipoprotein L 8 |
increases expression |
EXP |
Etoposide results in increased expression of APOL8 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr15:77,629,309...77,641,306
Ensembl chr15:77,631,998...77,641,203
|
|
G |
Aqp1 |
aquaporin 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of AQP1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 6:55,313,284...55,325,540
Ensembl chr 6:55,313,417...55,325,540
|
|
G |
Ar |
androgen receptor |
multiple interactions increases degradation |
ISO |
calpain inhibitor 2 inhibits the reaction [Etoposide results in increased degradation of AR protein]; CAST inhibits the reaction [Etoposide results in increased degradation of AR protein]; Etoposide inhibits the reaction [Androgens results in increased activity of AR protein]; Etoposide inhibits the reaction [Metribolone results in increased activity of AR protein] |
CTD |
PMID:18726991 PMID:28377212 PMID:30818834 |
|
NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821
|
|
G |
Areg |
amphiregulin |
increases expression decreases expression |
ISO EXP |
Etoposide results in increased expression of AREG mRNA; Etoposide results in increased expression of AREG protein Etoposide results in decreased expression of AREG mRNA |
CTD |
PMID:15228094 PMID:25270620 |
|
NCBI chr 5:91,287,458...91,296,291
Ensembl chr 5:91,287,458...91,296,291
|
|
G |
Arg2 |
arginase type II |
decreases expression |
ISO |
Etoposide results in decreased expression of ARG2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr12:79,177,562...79,203,075
Ensembl chr12:79,177,551...79,203,075
|
|
G |
Arhgdib |
Rho, GDP dissociation inhibitor beta |
increases expression |
ISO |
Etoposide results in increased expression of ARHGDIB mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 6:136,900,653...136,918,895
Ensembl chr 6:136,900,653...136,918,897
|
|
G |
Arih1 |
ariadne RBR E3 ubiquitin protein ligase 1 |
increases response to substance |
EXP |
ARIH1 mutant form results in increased susceptibility to Etoposide |
CTD |
PMID:25624349 |
|
NCBI chr 9:59,295,837...59,395,469
Ensembl chr 9:59,295,541...59,393,901
|
|
G |
Arl6ip5 |
ADP-ribosylation factor-like 6 interacting protein 5 |
increases response to substance decreases expression |
ISO |
ARL6IP5 protein results in increased susceptibility to Etoposide Etoposide results in decreased expression of ARL6IP5 |
CTD |
PMID:19492242 |
|
NCBI chr 6:97,187,753...97,210,276
Ensembl chr 6:97,187,650...97,210,276
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
ARNT protein affects the reaction [Etoposide results in increased expression of FTL protein] |
CTD |
PMID:33969609 |
|
NCBI chr 3:95,341,674...95,404,551
Ensembl chr 3:95,341,699...95,404,551
|
|
G |
Arsa |
arylsulfatase A |
decreases expression |
EXP |
Etoposide results in decreased expression of ARSA mRNA |
CTD |
PMID:25270620 |
|
NCBI chr15:89,356,679...89,361,627
Ensembl chr15:89,356,679...89,361,628
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
affects response to substance |
ISO |
ASAH1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:41,793,683...41,850,681
Ensembl chr 8:41,793,234...41,827,810
|
|
G |
Atf2 |
activating transcription factor 2 |
multiple interactions |
ISO |
Etoposide results in increased phosphorylation of and results in increased activity of ATF2 protein |
CTD |
PMID:12663670 |
|
NCBI chr 2:73,646,853...73,723,094
Ensembl chr 2:73,646,853...73,722,983
|
|
G |
Atf4 |
activating transcription factor 4 |
decreases expression |
EXP |
Etoposide results in decreased expression of ATF4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742
|
|
G |
Atm |
ataxia telangiectasia mutated |
multiple interactions increases phosphorylation |
EXP ISO |
Etoposide results in increased phosphorylation of and results in increased activity of ATM protein Etoposide results in increased phosphorylation of ATM protein Etoposide results in increased phosphorylation of and affects the localization of ATM protein; pifithrin inhibits the reaction [Etoposide results in increased phosphorylation of and affects the localization of ATM protein] |
CTD |
PMID:22242153 PMID:26259609 PMID:37451322 |
|
NCBI chr 9:53,348,422...53,448,125
Ensembl chr 9:53,350,449...53,448,040
|
|
G |
Atp13a4 |
ATPase type 13A4 |
decreases expression |
EXP |
Etoposide results in decreased expression of ATP13A4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr16:29,208,685...29,363,682
Ensembl chr16:29,214,671...29,363,682
|
|
G |
Atp1a1 |
ATPase, Na+/K+ transporting, alpha 1 polypeptide |
affects response to substance |
ISO |
ATP1A1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:101,483,535...101,512,023
Ensembl chr 3:101,483,535...101,512,000
|
|
G |
Atp1a2 |
ATPase, Na+/K+ transporting, alpha 2 polypeptide |
decreases expression |
ISO |
Etoposide results in decreased expression of ATP1A2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:172,099,276...172,125,631
Ensembl chr 1:172,099,276...172,125,631
|
|
G |
Atp1b4 |
ATPase Na+/K+ transporting, beta 4 polypeptide |
increases expression |
ISO |
Etoposide results in increased expression of ATP1B4 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr X:37,404,999...37,425,661
Ensembl chr X:37,405,061...37,425,646
|
|
G |
Atp5me |
ATP synthase membrane subunit e |
multiple interactions |
EXP |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in increased expression of ATP5ME protein |
CTD |
PMID:29733421 |
|
NCBI chr 5:108,581,112...108,582,265
Ensembl chr 5:108,581,110...108,582,314
|
|
G |
Atp5po |
ATP synthase peripheral stalk subunit OSCP |
decreases expression |
EXP |
Etoposide results in decreased expression of ATP5PO protein |
CTD |
PMID:29733421 |
|
NCBI chr16:91,722,111...91,728,518
Ensembl chr16:91,722,102...91,728,575 Ensembl chr16:91,722,102...91,728,575
|
|
G |
Atp6v0a4 |
ATPase, H+ transporting, lysosomal V0 subunit A4 |
affects response to substance |
ISO |
ATP6V0A4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:38,025,418...38,101,521
Ensembl chr 6:38,025,418...38,101,521
|
|
G |
Atp6v1a |
ATPase, H+ transporting, lysosomal V1 subunit A |
decreases expression multiple interactions |
EXP |
Etoposide results in decreased expression of ATP6V1A protein [Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ATP6V1A protein |
CTD |
PMID:29733421 |
|
NCBI chr16:43,905,765...43,960,055
Ensembl chr16:43,905,765...43,960,068
|
|
G |
Atp7a |
ATPase, Cu++ transporting, alpha polypeptide |
decreases response to substance |
ISO |
ATP7A protein results in decreased susceptibility to Etoposide |
CTD |
PMID:17510416 |
|
NCBI chr X:105,070,830...105,171,766
Ensembl chr X:105,070,882...105,168,532
|
|
G |
Atr |
ataxia telangiectasia and Rad3 related |
increases phosphorylation |
EXP |
Etoposide results in increased phosphorylation of ATR protein |
CTD |
PMID:22242153 |
|
NCBI chr 9:95,739,655...95,834,813
Ensembl chr 9:95,739,650...95,833,834
|
|
G |
Atxn1 |
ataxin 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of ATXN1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr13:45,703,231...46,118,467
Ensembl chr13:45,703,231...46,118,484
|
|
G |
Aurka |
aurora kinase A |
decreases expression |
EXP |
Etoposide results in decreased expression of AURKA mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:172,198,116...172,212,825
Ensembl chr 2:172,198,110...172,212,455
|
|
G |
Avpi1 |
arginine vasopressin-induced 1 |
affects response to substance |
ISO |
AVPI1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr19:42,111,714...42,117,432
Ensembl chr19:42,111,712...42,117,498
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
increases expression |
ISO |
Etoposide results in increased expression of AVPR1A mRNA |
CTD |
PMID:29397400 |
|
NCBI chr10:122,284,404...122,289,358
Ensembl chr10:122,284,404...122,289,357
|
|
G |
Axl |
AXL receptor tyrosine kinase |
increases expression |
ISO |
Etoposide results in increased expression of AXL mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 7:25,455,925...25,488,502
Ensembl chr 7:25,456,698...25,488,130
|
|
G |
Bace2 |
beta-site APP-cleaving enzyme 2 |
affects response to substance |
ISO |
BACE2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:97,157,928...97,244,136
Ensembl chr16:97,157,942...97,244,136
|
|
G |
Bag2 |
BCL2-associated athanogene 2 |
affects response to substance |
ISO |
BAG2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:33,784,565...33,796,831
Ensembl chr 1:33,784,565...33,796,876
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases activity increases response to substance affects response to substance multiple interactions affects expression |
ISO EXP |
Etoposide results in increased activity of BAK1 protein BAK1 protein results in increased susceptibility to Etoposide BAK1 protein affects the susceptibility to Etoposide nimesulide inhibits the reaction [Etoposide results in increased activity of BAK1 protein] Etoposide affects the expression of BAK1 protein |
CTD |
PMID:15215046 PMID:16077961 PMID:17688235 PMID:21745461 |
|
NCBI chr17:27,238,786...27,247,601
Ensembl chr17:27,238,784...27,247,983
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
affects response to substance |
ISO |
BAMBI protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr18:3,507,011...3,516,404
Ensembl chr18:3,507,923...3,516,404
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions increases expression decreases folding affects response to substance |
ISO EXP |
[ABT-737 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [Cisplatin co-treated with Etoposide] affects the localization of BAX protein; [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of BAX protein; [IL4 protein co-treated with VCAM1 protein] inhibits the reaction [Etoposide results in decreased folding of BAX protein]; [RASSF1 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [trigonelline co-treated with Etoposide] results in increased expression of BAX protein; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]; Etoposide results in increased activity of and affects the localization of BAX protein; Etoposide results in increased cleavage of and results in increased expression of BAX protein; Nicotine inhibits the reaction [[Cisplatin co-treated with Etoposide] affects the localization of BAX protein]; nimesulide inhibits the reaction [Etoposide results in increased activity of and affects the localization of BAX protein] Etoposide results in increased expression of BAX mRNA; Etoposide results in increased expression of BAX protein BAX protein affects the susceptibility to Etoposide |
CTD |
PMID:9815696 PMID:10620629 PMID:15131059 PMID:16077961 PMID:16120219 PMID:18676776 PMID:21527772 PMID:21745461 PMID:21880625 PMID:29397400 PMID:33148531 More...
|
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bbc3 |
BCL2 binding component 3 |
increases expression multiple interactions affects response to substance |
ISO EXP |
Etoposide results in increased expression of BBC3 mRNA; Etoposide results in increased expression of BBC3 protein entinostat promotes the reaction [Etoposide results in increased expression of BBC3 protein]; Etoposide promotes the reaction [entinostat results in increased expression of BBC3 protein]; Etoposide promotes the reaction [trichostatin A results in increased expression of BBC3 protein]; Etoposide promotes the reaction [UF010 compound results in increased expression of BBC3 protein]; TP53 protein modified form inhibits the reaction [Etoposide results in increased expression of BBC3 protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of BBC3 protein]; UF010 compound promotes the reaction [Etoposide results in increased expression of BBC3 protein] BBC3 protein affects the susceptibility to Etoposide |
CTD |
PMID:20477944 PMID:21801448 PMID:25699604 PMID:37956312 |
|
NCBI chr 7:16,042,307...16,052,130
Ensembl chr 7:16,042,318...16,052,130
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions decreases expression |
ISO EXP |
[Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of BCL2 protein; [Etoposide co-treated with Ciprofloxacin] results in decreased expression of BCL2 protein; [trigonelline co-treated with Etoposide] results in decreased expression of BCL2 protein; BCL2 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide] Etoposide results in decreased expression of BCL2 mRNA; Etoposide results in decreased expression of BCL2 protein [G(M3) Ganglioside results in increased expression of BCL2 protein] which results in decreased susceptibility to Etoposide; BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein]; Lithium Chloride inhibits the reaction [Etoposide results in decreased expression of BCL2 mRNA]; Lithium Chloride inhibits the reaction [Etoposide results in decreased expression of BCL2 protein] |
CTD |
PMID:8840993 PMID:9815696 PMID:12063570 PMID:15917659 PMID:16571667 PMID:19408126 PMID:33148531 More...
|
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l1 |
BCL2-like 1 |
multiple interactions affects expression decreases response to substance |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; BCL2L1 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2L1 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide]; Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein] Etoposide affects the expression of BCL2L1 protein BCL2L1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:8840993 PMID:10620629 PMID:11468182 PMID:15215046 PMID:15917659 PMID:19047049 More...
|
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Bcl2l2 |
BCL2-like 2 |
decreases response to substance |
ISO |
BCL2L2 results in decreased susceptibility to Etoposide |
CTD |
PMID:14973057 |
|
NCBI chr14:55,120,900...55,125,691
Ensembl chr14:55,120,834...55,125,691
|
|
G |
Bcl6b |
B cell CLL/lymphoma 6, member B |
multiple interactions |
EXP |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of BCL6B mRNA |
CTD |
PMID:29733421 |
|
NCBI chr11:70,114,953...70,120,624
Ensembl chr11:70,114,954...70,120,624
|
|
G |
Bdnf |
brain derived neurotrophic factor |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of BDNF mRNA HIPK2 mutant form inhibits the reaction [Etoposide results in increased expression of BDNF mRNA] |
CTD |
PMID:20573984 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions increases expression increases cleavage |
ISO |
CASP9 mutant form inhibits the reaction [Etoposide results in increased cleavage of BID protein]; Estradiol inhibits the reaction [Etoposide results in increased expression of BID mRNA] |
CTD |
PMID:19426747 PMID:21801448 |
|
NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814
|
|
G |
Bik |
BCL2-interacting killer |
increases response to substance |
ISO |
BIK protein results in increased susceptibility to Etoposide |
CTD |
PMID:16007125 |
|
NCBI chr15:83,410,992...83,428,836
Ensembl chr15:83,411,063...83,428,835
|
|
G |
Bin1 |
bridging integrator 1 |
increases response to substance |
ISO |
BIN1 protein results in increased susceptibility to Etoposide |
CTD |
PMID:21447800 |
|
NCBI chr18:32,509,671...32,568,793
Ensembl chr18:32,510,283...32,568,790
|
|
G |
Bin3 |
bridging integrator 3 |
affects response to substance |
ISO |
BIN3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:70,337,538...70,375,413
Ensembl chr14:70,337,554...70,375,655
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
affects response to substance decreases response to substance increases expression |
ISO |
BIRC2 protein affects the susceptibility to Etoposide BIRC2 protein results in decreased susceptibility to Etoposide Etoposide results in increased expression of BIRC2 mRNA |
CTD |
PMID:10815900 PMID:14970392 PMID:15050749 PMID:16217747 |
|
NCBI chr 9:7,818,227...7,837,123
Ensembl chr 9:7,818,228...7,837,065
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases response to substance decreases expression multiple interactions |
ISO |
BIRC3 protein results in decreased susceptibility to Etoposide Etoposide results in decreased expression of BIRC3 mRNA [Etoposide co-treated with KN 62] results in decreased expression of BIRC3 protein |
CTD |
PMID:14666661 PMID:15050749 PMID:16120219 |
|
NCBI chr 9:7,848,698...7,873,199
Ensembl chr 9:7,848,700...7,873,187
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases response to substance increases expression |
ISO |
[FOXO3 protein results in decreased expression of BIRC5 protein] which results in increased susceptibility to Etoposide; BIRC5 protein inhibits the reaction [FOXO3 protein results in increased susceptibility to Etoposide]; BIRC5 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide]; Estradiol inhibits the reaction [Etoposide results in increased expression of BIRC5 mRNA] BIRC5 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:15917659 PMID:16322251 PMID:16364925 PMID:16382892 PMID:19211844 PMID:19426747 More...
|
|
NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
|
|
G |
Birc7 |
baculoviral IAP repeat-containing 7 |
decreases response to substance |
ISO |
BIRC7 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:17437058 |
|
NCBI chr 2:180,570,402...180,575,803
Ensembl chr 2:180,570,816...180,575,803
|
|
G |
Blm |
Bloom syndrome, RecQ like helicase |
decreases expression |
ISO |
Etoposide results in decreased expression of BLM mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 7:80,104,839...80,184,896
Ensembl chr 7:80,104,481...80,184,867
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
ISO |
Etoposide inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25633564 |
|
NCBI chr13:38,529,098...38,684,283
Ensembl chr13:38,529,083...38,684,278
|
|
G |
Brca1 |
breast cancer 1, early onset |
multiple interactions increases expression decreases expression |
ISO |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of CDK2 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD52 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD54L protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC2 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC3 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC4 protein]; pifithrin inhibits the reaction [Etoposide results in increased expression of and affects the localization of BRCA1 protein] Etoposide results in increased expression of BRCA1 protein Etoposide results in decreased expression of BRCA1 mRNA |
CTD |
PMID:15607317 PMID:16417649 PMID:26259609 |
|
NCBI chr11:101,379,587...101,442,808
Ensembl chr11:101,379,590...101,442,781
|
|
G |
Bscl2 |
BSCL2 lipid droplet biogenesis associated, seipin |
increases expression |
EXP |
Etoposide results in increased expression of BSCL2 mRNA |
CTD |
PMID:22003191 PMID:25270620 |
|
NCBI chr19:8,814,831...8,826,047
Ensembl chr19:8,814,831...8,826,047
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
multiple interactions increases expression |
EXP ISO |
TRP53 protein affects the reaction [Etoposide results in increased expression of BTG2 mRNA] TP53 promotes the reaction [Etoposide results in increased expression of BTG2 protein] Etoposide results in increased expression of BTG2 mRNA; Etoposide results in increased expression of BTG2 protein |
CTD |
PMID:21382384 PMID:22003191 PMID:24211769 PMID:27358234 |
|
NCBI chr 1:134,002,603...134,006,893
Ensembl chr 1:134,002,908...134,006,858
|
|
G |
Btg3 |
BTG anti-proliferation factor 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of BTG3 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr16:78,156,748...78,174,069
Ensembl chr16:78,129,525...78,174,080
|
|
G |
Bub1 |
BUB1, mitotic checkpoint serine/threonine kinase |
decreases expression |
ISO |
Etoposide results in decreased expression of BUB1 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 2:127,642,117...127,673,790
Ensembl chr 2:127,643,036...127,673,785
|
|
G |
Bub1b |
BUB1B, mitotic checkpoint serine/threonine kinase |
decreases expression |
ISO |
Etoposide results in decreased expression of BUB1B mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 2:118,428,684...118,472,073
Ensembl chr 2:118,428,692...118,472,072
|
|
G |
C1qbp |
complement component 1, q subcomponent binding protein |
decreases response to substance |
ISO |
C1QBP protein results in decreased susceptibility to Etoposide |
CTD |
PMID:25354864 |
|
NCBI chr11:70,868,672...70,873,852
Ensembl chr11:70,868,662...70,873,852
|
|
G |
Cab39 |
calcium binding protein 39 |
decreases expression |
ISO |
Etoposide results in decreased expression of CAB39 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:85,707,796...85,779,298
Ensembl chr 1:85,721,162...85,779,297
|
|
G |
Cadps2 |
Ca2+-dependent activator protein for secretion 2 |
affects response to substance |
ISO |
CADPS2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:23,262,765...23,840,662
Ensembl chr 6:23,262,772...23,839,420
|
|
G |
Calca |
calcitonin/calcitonin-related polypeptide, alpha |
multiple interactions decreases response to substance |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [CALCA protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:16222118 |
|
NCBI chr 7:114,225,223...114,236,145
Ensembl chr 7:114,230,713...114,235,592
|
|
G |
Calm1 |
calmodulin 1 |
increases expression |
ISO |
Etoposide results in increased expression of CALM1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr12:100,165,694...100,176,083
Ensembl chr12:100,165,694...100,176,073
|
|
G |
Card10 |
caspase recruitment domain family, member 10 |
multiple interactions increases expression |
ISO |
Estradiol inhibits the reaction [Etoposide results in increased expression of CARD10 mRNA] |
CTD |
PMID:19426747 |
|
NCBI chr15:78,659,323...78,687,261
Ensembl chr15:78,659,338...78,687,242
|
|
G |
Casp2 |
caspase 2 |
increases expression increases splicing |
ISO |
Etoposide results in increased expression of CASP2 mRNA alternative form Etoposide results in increased splicing of CASP2 mRNA |
CTD |
PMID:14757846 |
|
NCBI chr 6:42,241,942...42,259,442
Ensembl chr 6:42,241,919...42,259,442
|
|
G |
Casp3 |
caspase 3 |
affects expression increases cleavage multiple interactions increases activity increases expression |
ISO EXP |
Etoposide affects the expression of CASP3 protein Etoposide results in increased cleavage of CASP3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; 3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of CASP3 protein]; [Etoposide co-treated with Mifepristone] results in increased activity of CASP3 protein; [RASSF1 co-treated with Etoposide] results in increased cleavage of CASP3 protein; [STAT1 protein results in increased activity of CASP3 protein] which results in increased susceptibility to Etoposide; [trigonelline co-treated with Etoposide] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; Aspirin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; CD40LG protein inhibits the reaction [Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; CDKN1A mutant form inhibits the reaction [Aspirin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]]; Dehydroascorbic Acid promotes the reaction [Etoposide results in increased activity of CASP3 protein]; Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]; Etoposide promotes the reaction [Gold results in increased activity of CASP3 protein]; Etoposide promotes the reaction [Nanotubes, Carbon results in increased activity of CASP3 protein]; Etoposide promotes the reaction [Silver results in increased activity of CASP3 protein]; Etoposide results in increased cleavage of and results in increased activity of CASP3 protein; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; nimesulide inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; Oxygen deficiency inhibits the reaction [Etoposide results in increased expression of CASP3 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; pifithrin promotes the reaction [Etoposide results in increased activity of CASP3 protein]; pifithrin promotes the reaction [Etoposide results in increased cleavage of CASP3 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TMSB4X protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; Wortmannin promotes the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP3 protein] Etoposide results in increased expression of CASP3 protein; Etoposide results in increased expression of CASP3 protein modified form [Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein; Etoposide results in increased activity of CASP3 protein 2-tert-butylhydroquinone inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP3 protein]; BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein]; Etoposide results in increased cleavage of and results in increased activity of CASP3 protein; HIPK2 gene mutant form promotes the reaction [Etoposide results in increased activity of CASP3 protein]; Metoclopramide inhibits the reaction [Etoposide results in increased activity of CASP3 protein] |
CTD |
PMID:8840993 PMID:10759716 PMID:12871656 PMID:15215046 PMID:15924153 PMID:16014620 PMID:16192531 PMID:16364925 PMID:16545138 PMID:16844113 PMID:16951922 PMID:17516866 PMID:17935137 PMID:18056177 PMID:18649362 PMID:19047049 PMID:19408126 PMID:19662097 PMID:19760634 PMID:20299546 PMID:20573984 PMID:21617849 PMID:21745461 PMID:21745629 PMID:21801448 PMID:21880625 PMID:22275372 PMID:22302033 PMID:23144690 PMID:25447644 PMID:26259609 PMID:29027213 PMID:30217652 PMID:30890322 PMID:33148531 PMID:35065218 More...
|
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases activity |
ISO EXP |
[STAT1 protein results in increased activity of CASP7 protein] which results in increased susceptibility to Etoposide; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; pifithrin promotes the reaction [Etoposide results in increased activity of CASP7 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP7 protein] 2-tert-butylhydroquinone inhibits the reaction [Etoposide results in increased activity of CASP7 protein] |
CTD |
PMID:18056177 PMID:18649362 PMID:20299546 PMID:21801448 PMID:22275372 PMID:22302033 PMID:26259609 More...
|
|
NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases response to substance increases cleavage increases activity decreases response to substance |
ISO |
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Etoposide results in increased activity of CASP8 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of CASP3 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of PARP1 protein]; [CASP8 co-treated with TP53] inhibits the reaction [CASP8 protein mutant form results in decreased susceptibility to Etoposide]; acetyl-leucyl-glutamyl-histidyl-aspartal inhibits the reaction [Etoposide results in increased activity of CASP8 protein]; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP9 protein]; Etoposide results in increased cleavage of and results in increased activity of CASP8 protein; Etoposide results in increased expression of and results in increased cleavage of CASP8 protein; Lithium inhibits the reaction [Etoposide results in increased activity of CASP8 protein]; nimesulide inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP8 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP8 protein] CASP8 protein results in increased susceptibility to Etoposide |
CTD |
PMID:15475000 PMID:21745461 PMID:21801448 PMID:22010212 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage increases activity affects expression |
ISO |
[CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; [Cisplatin co-treated with Etoposide] results in increased activity of CASP9 protein; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP9 protein]; CASP9 mutant form inhibits the reaction [Etoposide results in increased cleavage of BID protein]; Etoposide results in increased cleavage of and results in increased activity of CASP9 protein; HTATIP2 protein promotes the reaction [Etoposide results in increased activity of CASP9 protein]; MYC protein promotes the reaction [Etoposide results in increased cleavage of CASP9 protein]; Nicotine inhibits the reaction [[Cisplatin co-treated with Etoposide] results in increased activity of CASP9 protein]; nimesulide inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; TMSB4X protein inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; wortmannin promotes the reaction [Etoposide results in increased cleavage of CASP9 protein] Etoposide affects the expression of CASP9 protein |
CTD |
PMID:12925536 PMID:15215046 PMID:16364925 PMID:16799960 PMID:17935137 PMID:18056177 PMID:18676776 PMID:21324178 PMID:21745461 PMID:21801448 More...
|
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Casq2 |
calsequestrin 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of CASQ2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 3:101,993,731...102,053,830
Ensembl chr 3:101,993,731...102,053,830
|
|
G |
Cast |
calpastatin |
multiple interactions |
ISO |
CAST inhibits the reaction [Etoposide results in increased degradation of AR protein] |
CTD |
PMID:18726991 |
|
NCBI chr13:74,840,485...74,956,993
Ensembl chr13:74,840,487...74,956,929
|
|
G |
Cat |
catalase |
increases response to substance multiple interactions increases activity |
ISO |
CAT results in increased susceptibility to Etoposide EPO protein inhibits the reaction [Etoposide results in increased activity of CAT protein] |
CTD |
PMID:21689642 PMID:25451571 PMID:29069929 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccdc51 |
coiled-coil domain containing 51 |
decreases expression |
ISO |
Etoposide results in decreased expression of CCDC51 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 9:108,911,564...108,922,431
Ensembl chr 9:108,911,561...108,921,557
|
|
G |
Ccdc6 |
coiled-coil domain containing 6 |
increases response to substance decreases response to substance |
ISO |
CCDC6 results in increased susceptibility to Etoposide CCDC6 results in decreased susceptibility to Etoposide |
CTD |
PMID:22363533 PMID:22655027 |
|
NCBI chr10:69,932,709...70,029,030
Ensembl chr10:69,932,951...70,029,030
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression |
ISO |
Etoposide results in increased expression of CCL3 protein |
CTD |
PMID:10540334 |
|
NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
ISO |
Etoposide results in increased expression of CCN2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
Etoposide affects the expression of and affects the localization of CCNA2 protein Etoposide results in decreased expression of CCNA2 mRNA; Etoposide results in decreased expression of CCNA2 protein |
CTD |
PMID:16120219 PMID:17390037 |
|
NCBI chr 3:36,619,014...36,627,187
Ensembl chr 3:36,619,014...36,626,299
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
Etoposide results in decreased expression of CCNB1 mRNA; Etoposide results in decreased expression of CCNB1 protein |
CTD |
PMID:16120219 |
|
NCBI chr13:100,915,247...100,922,994
Ensembl chr13:100,915,158...100,923,078
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO |
Etoposide results in increased expression of CCND1 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Ccng1 |
cyclin G1 |
increases expression |
EXP |
Etoposide results in increased expression of CCNG1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:40,639,379...40,646,044
Ensembl chr11:40,639,379...40,646,138
|
|
G |
Ccng2 |
cyclin G2 |
increases expression |
ISO |
Etoposide results in increased expression of CCNG2 mRNA |
CTD |
PMID:18754885 |
|
NCBI chr 5:93,415,432...93,424,090
Ensembl chr 5:93,415,116...93,424,090
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
increases expression |
ISO |
Etoposide results in increased expression of CCS mRNA |
CTD |
PMID:21527772 |
|
NCBI chr19:4,875,394...4,889,326
Ensembl chr19:4,875,394...4,889,360
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
multiple interactions |
EXP |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of CCT8 protein |
CTD |
PMID:29733421 |
|
NCBI chr16:87,280,213...87,292,757
Ensembl chr16:87,280,214...87,292,761
|
|
G |
Cd274 |
CD274 antigen |
increases expression |
ISO |
Etoposide results in increased expression of CD274 protein |
CTD |
PMID:17920123 |
|
NCBI chr19:29,339,428...29,365,495
Ensembl chr19:29,344,855...29,365,495
|
|
G |
Cd40lg |
CD40 ligand |
multiple interactions decreases response to substance |
ISO |
CD40LG protein inhibits the reaction [Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]] CD40LG protein results in decreased susceptibility to Etoposide |
CTD |
PMID:16545138 |
|
NCBI chr X:56,257,448...56,269,402
Ensembl chr X:56,257,503...56,269,402
|
|
G |
Cd44 |
CD44 antigen |
affects response to substance multiple interactions |
ISO |
CD44 protein affects the susceptibility to Etoposide [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide] |
CTD |
PMID:15215046 PMID:19047049 |
|
NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010
|
|
G |
Cd55 |
CD55 molecule, decay accelerating factor for complement |
affects response to substance |
ISO |
CD55 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:130,357,526...130,390,513
Ensembl chr 1:130,366,764...130,390,481
|
|
G |
Cd59b |
CD59b antigen |
multiple interactions |
ISO |
[Cisplatin co-treated with Etoposide] results in decreased expression of CD59 protein |
CTD |
PMID:21826740 |
|
NCBI chr 2:103,900,127...103,920,619
Ensembl chr 2:103,896,142...103,921,534
|
|
G |
Cdc25a |
cell division cycle 25A |
decreases expression |
ISO |
Etoposide results in decreased expression of CDC25A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 9:109,704,545...109,722,963
Ensembl chr 9:109,704,647...109,722,963
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression |
ISO |
Etoposide results in decreased expression of CDC25C mRNA |
CTD |
PMID:16120219 |
|
NCBI chr18:34,866,046...34,884,644
Ensembl chr18:34,866,046...34,884,586
|
|
G |
Cdc42bpg |
CDC42 binding protein kinase gamma |
increases expression |
EXP |
Etoposide results in increased expression of CDC42BPG mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:6,356,465...6,375,682
Ensembl chr19:6,356,486...6,375,682
|
|
G |
Cdc45 |
cell division cycle 45 |
decreases expression |
ISO |
Etoposide results in decreased expression of CDC45 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr16:18,599,202...18,632,371
Ensembl chr16:18,599,197...18,630,737
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression |
ISO |
Etoposide results in decreased expression of CDC6 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr11:98,798,627...98,814,768
Ensembl chr11:98,798,627...98,814,766
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions increases expression affects response to substance |
ISO |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of CDK2 protein]; CDK2 affects the reaction [Etoposide results in increased phosphorylation of TPI1 protein] CDK2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 PMID:16417649 PMID:20149834 |
|
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO EXP |
[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein; [RASSF1 co-treated with Etoposide] results in increased expression of CDKN1A protein; CDKN1A mutant form inhibits the reaction [Aspirin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]]; CDKN1A protein affects the reaction [Etoposide results in decreased expression of UBE2C protein]; entinostat promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [entinostat results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [trichostatin A results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [UF010 compound results in increased expression of CDKN1A protein]; KEAP1 protein affects the reaction [Etoposide results in increased expression of CDKN1A protein]; resveratrol inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TP53 promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; UF010 compound promotes the reaction [Etoposide results in increased expression of CDKN1A protein] Etoposide results in increased expression of CDKN1A mRNA; Etoposide results in increased expression of CDKN1A protein [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of CDKN1A protein]; TRP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA] cordycepin inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]; Etoposide promotes the reaction [Niacin deficiency results in increased expression of CDKN1A protein]; mithramycin A inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]; salubrinal inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA] |
CTD |
PMID:14601052 PMID:16120219 PMID:16882877 PMID:17516866 PMID:21212465 PMID:21526190 PMID:21527772 PMID:21617849 PMID:21801448 PMID:21880625 PMID:23690541 PMID:24067374 PMID:24211769 PMID:25078064 PMID:25699604 PMID:25914138 PMID:26055805 PMID:27129209 PMID:27358234 PMID:27982581 PMID:29471073 More...
|
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of CDKN1B protein wortmannin promotes the reaction [Etoposide results in increased expression of CDKN1B protein] |
CTD |
PMID:17935137 |
|
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Cdkn2a |
cyclin dependent kinase inhibitor 2A |
increases expression multiple interactions |
ISO EXP |
Etoposide results in increased expression of CDKN2A mRNA [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of CDKN1A protein]; [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of TRP53 protein] cordycepin inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]; mithramycin A inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]; salubrinal inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA] |
CTD |
PMID:21526190 PMID:23690541 |
|
NCBI chr 4:89,192,710...89,212,856
Ensembl chr 4:89,192,708...89,212,890
|
|
G |
Cdkn3 |
cyclin dependent kinase inhibitor 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of CDKN3 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr14:46,997,912...47,008,987
Ensembl chr14:46,997,998...47,009,126
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
increases expression |
ISO |
Etoposide results in increased expression of CEACAM1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 7:25,161,127...25,177,072
Ensembl chr 7:25,161,132...25,177,028
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases expression increases degradation |
ISO |
Etoposide results in decreased expression of CEBPA mRNA; Etoposide results in decreased expression of CEBPA protein Etoposide results in increased degradation of CEBPA protein |
CTD |
PMID:19662097 |
|
NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353
|
|
G |
Cebpz |
CCAAT/enhancer binding protein zeta |
decreases expression |
ISO |
Etoposide results in decreased expression of CEBPZ mRNA |
CTD |
PMID:17374387 |
|
NCBI chr17:79,226,432...79,244,499
Ensembl chr17:79,226,435...79,244,495
|
|
G |
Cel |
carboxyl ester lipase |
increases expression |
ISO |
Etoposide results in increased expression of CEL mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:28,445,831...28,453,415
Ensembl chr 2:28,445,807...28,453,415
|
|
G |
Cenpf |
centromere protein F |
decreases expression |
ISO |
Etoposide results in decreased expression of CENPF mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 1:189,372,803...189,420,302
Ensembl chr 1:189,372,803...189,420,283
|
|
G |
Cercam |
cerebral endothelial cell adhesion molecule |
increases expression |
EXP |
Etoposide results in increased expression of CERCAM mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:29,735,442...29,772,857
Ensembl chr 2:29,759,176...29,772,852
|
|
G |
Ces1d |
carboxylesterase 1D |
increases expression |
EXP |
Etoposide results in increased expression of CES1D mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:93,892,700...93,924,432
Ensembl chr 8:93,892,696...93,924,466
|
|
G |
Ces2a |
carboxylesterase 2A |
increases expression |
EXP |
Etoposide results in increased expression of CES2A mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:105,460,635...105,468,266
Ensembl chr 8:105,460,635...105,468,266
|
|
G |
Ces2e |
carboxylesterase 2E |
increases expression |
EXP |
Etoposide results in increased expression of CES2E mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:105,652,892...105,661,304
Ensembl chr 8:105,652,892...105,661,304
|
|
G |
Ces2g |
carboxylesterase 2G |
increases expression |
EXP |
Etoposide results in increased expression of CES2G mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:105,688,350...105,696,169
Ensembl chr 8:105,688,350...105,696,169
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
increases expression |
ISO |
Etoposide results in increased expression of CFLAR protein |
CTD |
PMID:14601052 |
|
NCBI chr 1:58,750,353...58,798,043
Ensembl chr 1:58,750,667...58,798,043
|
|
G |
Cgref1 |
cell growth regulator with EF hand domain 1 |
increases expression |
EXP |
Etoposide results in increased expression of CGREF1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 5:31,090,487...31,102,771
Ensembl chr 5:31,090,487...31,102,935
|
|
G |
Chac1 |
ChaC, cation transport regulator 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of CHAC1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:119,181,723...119,184,807
Ensembl chr 2:119,181,710...119,184,862
|
|
G |
Chaf1a |
chromatin assembly factor 1, subunit A |
decreases expression |
ISO |
Etoposide results in decreased expression of CHAF1A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr17:56,347,404...56,375,027
Ensembl chr17:56,347,439...56,379,289
|
|
G |
Chek1 |
checkpoint kinase 1 |
affects response to substance multiple interactions |
ISO |
CHEK1 protein affects the susceptibility to Etoposide TP53 protein affects the reaction [CHEK1 protein affects the susceptibility to Etoposide] |
CTD |
PMID:18698031 |
|
NCBI chr 9:36,619,935...36,637,897
Ensembl chr 9:36,619,778...36,638,361
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases phosphorylation multiple interactions |
EXP ISO |
Etoposide results in increased phosphorylation of CHEK2 protein 4-fluoro-2-(4-(4-(2-hydroxypropan-2-yl)pyrrolidin-3-ylamino)-6,7-dimethoxyquinazolin-2-yl)phenol inhibits the reaction [Etoposide results in increased phosphorylation of CHEK2 protein]; pifithrin inhibits the reaction [Etoposide results in increased phosphorylation of CHEK2 protein] |
CTD |
PMID:21186793 PMID:22242153 PMID:26259609 |
|
NCBI chr 5:110,987,668...111,022,006
Ensembl chr 5:110,987,845...111,022,011
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
decreases response to substance |
ISO |
CHI3L1 results in decreased susceptibility to Etoposide |
CTD |
PMID:20506295 |
|
NCBI chr 1:134,109,894...134,117,769
Ensembl chr 1:134,109,914...134,117,919
|
|
G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
decreases expression |
ISO |
Etoposide results in decreased expression of CHUK protein |
CTD |
PMID:30177839 |
|
NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919
|
|
G |
Ciapin1 |
cytokine induced apoptosis inhibitor 1 |
decreases response to substance |
ISO |
CIAPIN1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:18389626 |
|
NCBI chr 8:95,546,446...95,565,454
Ensembl chr 8:95,546,432...95,564,986
|
|
G |
Ckm |
creatine kinase, muscle |
decreases expression |
ISO |
Etoposide results in decreased expression of CKM mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 7:19,145,019...19,155,508
Ensembl chr 7:19,138,701...19,156,766
|
|
G |
Ckmt1 |
creatine kinase, mitochondrial 1, ubiquitous |
affects response to substance |
ISO |
CKMT1B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:121,188,257...121,194,218
Ensembl chr 2:121,188,195...121,194,218
|
|
G |
Coa7 |
cytochrome c oxidase assembly factor 7 |
decreases expression |
ISO |
Etoposide results in decreased expression of COA7 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 4:108,185,349...108,197,915
Ensembl chr 4:108,185,337...108,198,741
|
|
G |
Cobl |
cordon-bleu WH2 repeat |
decreases expression |
EXP |
Etoposide results in decreased expression of COBL mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:12,186,676...12,415,022
Ensembl chr11:12,186,608...12,414,960
|
|
G |
Col15a1 |
collagen, type XV, alpha 1 |
affects response to substance |
ISO |
COL15A1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:47,207,744...47,313,165
Ensembl chr 4:47,208,161...47,313,167
|
|
G |
Col4a1 |
collagen, type IV, alpha 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of COL4A1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:11,248,423...11,362,889
Ensembl chr 8:11,248,423...11,362,826
|
|
G |
Col9a3 |
collagen, type IX, alpha 3 |
affects response to substance |
ISO |
COL9A3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:180,239,895...180,263,985
Ensembl chr 2:180,239,583...180,263,982
|
|
G |
Cox6a2 |
cytochrome c oxidase subunit 6A2 |
decreases expression |
ISO |
Etoposide results in decreased expression of COX6A2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 7:127,804,607...127,805,538
Ensembl chr 7:127,804,607...127,805,559
|
|
G |
Cps1 |
carbamoyl-phosphate synthetase 1 |
affects response to substance |
ISO |
CPS1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:67,151,294...67,270,426
Ensembl chr 1:67,162,185...67,270,418
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of CPT2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 4:107,761,179...107,780,786
Ensembl chr 4:107,761,178...107,780,807
|
|
G |
Crabp2 |
cellular retinoic acid binding protein II |
increases expression |
ISO |
Etoposide results in increased expression of CRABP2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 3:87,856,000...87,860,679
Ensembl chr 3:87,855,973...87,860,683
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP ISO |
Etoposide results in increased expression of and results in increased phosphorylation of CREB1 protein; HIPK2 gene mutant form inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:20573984 |
|
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
|
|
G |
Crem |
cAMP responsive element modulator |
affects response to substance |
ISO |
CREM protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr18:3,263,181...3,337,688
Ensembl chr18:3,266,048...3,337,748
|
|
G |
Crip2 |
cysteine rich protein 2 |
increases expression |
EXP |
Etoposide results in increased expression of CRIP2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr12:113,103,856...113,109,126
Ensembl chr12:113,103,856...113,109,126
|
|
G |
Csgalnact1 |
chondroitin sulfate N-acetylgalactosaminyltransferase 1 |
affects response to substance |
ISO |
CSGALNACT1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:68,809,433...69,188,270
Ensembl chr 8:68,809,433...69,187,798
|
|
G |
Cth |
cystathionine gamma lyase |
affects response to substance |
ISO |
CTH protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:157,599,885...157,630,718
Ensembl chr 3:157,599,885...157,630,714
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide] |
CTD |
PMID:19047049 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
Etoposide results in decreased expression of CXCL12 mRNA; Etoposide results in decreased expression of CXCL12 protein |
CTD |
PMID:22363485 |
|
NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of CXCL8 mRNA; Etoposide results in increased expression of CXCL8 protein SB 203580 inhibits the reaction [Etoposide results in increased expression of CXCL8 protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Etoposide results in increased expression of CXCL8 protein] |
CTD |
PMID:10540334 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
Etoposide affects the localization of CYCS protein |
CTD |
PMID:10759716 |
|
NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; TP53 protein promotes the reaction [Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]]; TP53 protein promotes the reaction [Etoposide results in increased expression of CYP1A1 protein] Etoposide results in increased expression of CYP1A1 mRNA; Etoposide results in increased expression of CYP1A1 protein |
CTD |
PMID:29471073 PMID:31542801 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
ISO |
Etoposide results in increased expression of CYP1A2 mRNA |
CTD |
PMID:31542801 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
decreases response to substance |
ISO |
CYP26A1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:15703382 |
|
NCBI chr19:37,686,186...37,689,984
Ensembl chr19:37,686,246...37,689,984
|
|
G |
Cyp27b1 |
cytochrome P450, family 27, subfamily b, polypeptide 1 |
increases expression |
ISO |
Etoposide results in increased expression of CYP27B1 mRNA |
CTD |
PMID:17716971 |
|
NCBI chr10:126,884,115...126,891,897
Ensembl chr10:126,884,119...126,888,875
|
|
G |
Cyp2c29 |
cytochrome P450, family 2, subfamily c, polypeptide 29 |
increases expression |
EXP |
Etoposide results in increased expression of CYP2C29 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:39,275,541...39,319,157
Ensembl chr19:39,257,849...39,319,157
|
|
G |
Cyp2c55 |
cytochrome P450, family 2, subfamily c, polypeptide 55 |
increases expression |
EXP |
Etoposide results in increased expression of CYP2C55 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:38,995,384...39,031,134
Ensembl chr19:38,995,463...39,031,137
|
|
G |
Cyp2s1 |
cytochrome P450, family 2, subfamily s, polypeptide 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of CYP2S1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:25,501,894...25,515,950
Ensembl chr 7:25,501,900...25,516,338
|
|
G |
Cyp3a13 |
cytochrome P450, family 3, subfamily a, polypeptide 13 |
decreases methylation affects response to substance |
ISO |
CYP3A5 protein results in decreased methylation of Etoposide CYP3A5 gene polymorphism affects the susceptibility to Etoposide |
CTD |
PMID:8114683 PMID:12969965 |
|
NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881
|
|
G |
Cyp3a44 |
cytochrome P450, family 3, subfamily a, polypeptide 44 |
increases expression |
EXP |
Etoposide results in increased expression of CYP3A44 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 5:145,710,793...145,742,701
Ensembl chr 5:145,710,793...145,742,684
|
|
G |
Cyren |
cell cycle regulator of NHEJ |
affects localization |
ISO |
Etoposide affects the localization of CYREN protein alternative form |
CTD |
PMID:24610814 |
|
NCBI chr 6:34,848,706...34,855,024
Ensembl chr 6:34,848,706...34,854,995
|
|
G |
Dab2 |
disabled 2, mitogen-responsive phosphoprotein |
affects response to substance |
ISO |
DAB2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:6,329,269...6,470,196
Ensembl chr15:6,329,269...6,470,193
|
|
G |
Dapk1 |
death associated protein kinase 1 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of DAPK1 protein; Etoposide results in increased expression of DAPK1 protein modified form DAPK1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein modified form]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein] |
CTD |
PMID:30177839 |
|
NCBI chr13:60,749,506...60,911,005
Ensembl chr13:60,749,761...60,911,005
|
|
G |
Dbf4 |
DBF4 zinc finger |
decreases expression |
EXP |
Etoposide results in decreased expression of DBF4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 5:8,446,969...8,472,789
Ensembl chr 5:8,446,973...8,472,716
|
|
G |
Dbn1 |
drebrin 1 |
affects response to substance |
ISO |
DBN1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr13:55,621,241...55,635,874
Ensembl chr13:55,621,242...55,635,924
|
|
G |
Dcaf4 |
DDB1 and CUL4 associated factor 4 |
increases expression |
EXP |
Etoposide results in increased expression of DCAF4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr12:83,567,145...83,588,768
Ensembl chr12:83,567,240...83,588,694
|
|
G |
Dct |
dopachrome tautomerase |
affects response to substance |
ISO |
DCT protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:118,250,202...118,289,658
Ensembl chr14:118,250,202...118,289,656
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
affects response to substance |
ISO |
DDIT4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:59,785,497...59,787,592
Ensembl chr10:59,785,491...59,787,656
|
|
G |
Ddr1 |
discoidin domain receptor family, member 1 |
increases expression |
EXP |
Etoposide results in increased expression of DDR1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr17:35,992,459...36,015,633
Ensembl chr17:35,992,459...36,015,513
|
|
G |
Des |
desmin |
decreases expression |
ISO |
Etoposide results in decreased expression of DES mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:75,336,936...75,345,223
Ensembl chr 1:75,336,973...75,345,223
|
|
G |
Dkk3 |
dickkopf WNT signaling pathway inhibitor 3 |
affects response to substance |
ISO |
DKK3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:111,715,226...111,758,689
Ensembl chr 7:111,715,224...111,758,264
|
|
G |
Dmd |
dystrophin, muscular dystrophy |
affects response to substance decreases expression |
ISO |
DMD protein affects the susceptibility to Etoposide Etoposide results in decreased expression of DMD mRNA |
CTD |
PMID:16217747 PMID:29397400 |
|
NCBI chr X:81,858,244...84,248,656
Ensembl chr X:81,992,476...84,249,747
|
|
G |
Dmrt1 |
doublesex and mab-3 related transcription factor 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of DMRT1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:25,483,070...25,581,692
Ensembl chr19:25,482,982...25,581,693
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
decreases response to substance |
ISO |
DNMT1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:18314485 |
|
NCBI chr 9:20,818,501...20,871,084
Ensembl chr 9:20,818,505...20,871,184
|
|
G |
Dnmt3b |
DNA methyltransferase 3B |
decreases response to substance |
ISO |
DNMT3B protein results in decreased susceptibility to Etoposide |
CTD |
PMID:18314485 |
|
NCBI chr 2:153,491,332...153,529,650
Ensembl chr 2:153,491,370...153,529,650
|
|
G |
Dpp7 |
dipeptidylpeptidase 7 |
multiple interactions |
ISO |
Etoposide promotes the reaction [[DPP7 protein results in increased cleavage of Dipeptides] which results in increased abundance of 4-nitroaniline] |
CTD |
PMID:16725115 |
|
NCBI chr 2:25,242,302...25,246,365
Ensembl chr 2:25,242,288...25,246,371
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of DPYSL2 protein |
CTD |
PMID:29733421 |
|
NCBI chr14:67,040,313...67,148,490
Ensembl chr14:67,040,313...67,148,410
|
|
G |
Dpysl4 |
dihydropyrimidinase-like 4 |
increases expression |
ISO |
Etoposide results in increased expression of DPYSL4 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 7:138,665,917...138,681,711
Ensembl chr 7:138,665,917...138,682,620
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
affects response to substance |
ISO |
DUSP2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:127,178,079...127,180,297
Ensembl chr 2:127,178,079...127,180,296
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
affects response to substance increases expression |
ISO |
DUSP4 protein affects the susceptibility to Etoposide Etoposide results in increased expression of DUSP4 mRNA |
CTD |
PMID:16217747 PMID:29397400 |
|
NCBI chr 8:35,274,448...35,289,106
Ensembl chr 8:35,274,451...35,287,048
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
E2F1 protein affects the reaction [Etoposide results in increased expression of HIC1 mRNA]; Etoposide promotes the reaction [E2F1 protein binds to HIC1 promoter] |
CTD |
PMID:19491197 |
|
NCBI chr 2:154,401,320...154,411,812
Ensembl chr 2:154,401,327...154,411,812
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
EDN1 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:24184161 |
|
NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466
|
|
G |
Ednrb |
endothelin receptor type B |
decreases expression |
EXP |
Etoposide results in decreased expression of EDNRB mRNA |
CTD |
PMID:25270620 |
|
NCBI chr14:104,052,055...104,081,764
Ensembl chr14:104,052,061...104,081,838
|
|
G |
Efs |
embryonal Fyn-associated substrate |
increases expression |
EXP |
Etoposide results in increased expression of EFS mRNA |
CTD |
PMID:25270620 |
|
NCBI chr14:55,154,087...55,164,222
Ensembl chr14:55,153,992...55,163,583
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[EGF protein results in decreased expression of TOP2A protein] which results in decreased susceptibility to Etoposide |
CTD |
PMID:16969495 |
|
NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965
|
|
G |
Egfl8 |
EGF-like domain 8 |
affects response to substance |
ISO |
EGFL8 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:34,832,174...34,835,536
Ensembl chr17:34,832,323...34,834,945
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
Etoposide results in decreased expression of EGFR mRNA; Etoposide results in decreased expression of EGFR protein |
CTD |
PMID:15228094 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Ei24 |
etoposide induced 2.4 mRNA |
increases expression |
ISO |
Etoposide results in increased expression of EI24 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:36,690,449...36,708,630
Ensembl chr 9:36,690,455...36,708,689
|
|
G |
Eif2s2 |
eukaryotic translation initiation factor 2 subunit 2 beta |
decreases expression |
EXP |
Etoposide results in decreased expression of EIF2S2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:154,713,330...154,734,826
Ensembl chr 2:154,713,330...154,734,855
|
|
G |
Eif3a |
eukaryotic translation initiation factor 3, subunit A |
increases response to substance |
ISO EXP |
EIF3A results in increased susceptibility to Etoposide |
CTD |
PMID:21610145 |
|
NCBI chr19:60,749,554...60,779,131
Ensembl chr19:60,749,555...60,779,096
|
|
G |
Emp1 |
epithelial membrane protein 1 |
increases expression |
ISO |
Etoposide results in increased expression of EMP1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 6:135,339,548...135,360,171
Ensembl chr 6:135,339,543...135,360,171
|
|
G |
Emp2 |
epithelial membrane protein 2 |
affects response to substance |
ISO |
EMP2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:10,099,613...10,131,832
Ensembl chr16:10,099,613...10,131,832
|
|
G |
Emp3 |
epithelial membrane protein 3 |
increases expression |
ISO |
Etoposide results in increased expression of EMP3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 7:45,567,447...45,570,850
Ensembl chr 7:45,567,447...45,570,828
|
|
G |
En2 |
engrailed 2 |
affects response to substance |
ISO |
EN2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:28,370,694...28,377,195
Ensembl chr 5:28,370,692...28,377,164
|
|
G |
Eno1 |
enolase 1, alpha non-neuron |
decreases expression |
EXP |
Etoposide results in decreased expression of ENO1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 4:150,321,165...150,333,336
Ensembl chr 4:150,321,178...150,333,336
|
|
G |
Entpd2 |
ectonucleoside triphosphate diphosphohydrolase 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of ENTPD2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:25,285,886...25,291,335
Ensembl chr 2:25,285,886...25,291,333
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide] |
CTD |
PMID:19047049 |
|
NCBI chr15:81,470,329...81,536,273
Ensembl chr15:81,469,552...81,536,278
|
|
G |
Epb41l3 |
erythrocyte membrane protein band 4.1 like 3 |
affects response to substance |
ISO |
EPB41L3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:69,382,642...69,596,986
Ensembl chr17:69,382,678...69,596,984
|
|
G |
Ephx1 |
epoxide hydrolase 1, microsomal |
increases expression |
EXP |
Etoposide results in increased expression of EPHX1 mRNA |
CTD |
PMID:21382384 PMID:25270620 |
|
NCBI chr 1:180,817,121...180,845,134
Ensembl chr 1:180,803,775...180,848,469
|
|
G |
Epm2aip1 |
EPM2A interacting protein 1 |
increases expression |
ISO |
Etoposide results in increased expression of EPM2AIP1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:111,100,913...111,108,161
Ensembl chr 9:111,100,997...111,108,161
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
EPO protein inhibits the reaction [Etoposide results in increased activity of CAT protein]; EPO protein results in increased susceptibility to [Organoplatinum Compounds co-treated with Etoposide] |
CTD |
PMID:18403296 PMID:29069929 |
|
NCBI chr 5:137,481,282...137,484,078
Ensembl chr 5:137,481,282...137,531,504
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions decreases expression decreases response to substance affects response to substance |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; [ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Etoposide; ABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; Curcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Etoposide] Etoposide results in decreased expression of ERBB2 mRNA ERBB2 protein results in decreased susceptibility to Etoposide; ERBB2 results in decreased susceptibility to Etoposide ERBB2 protein affects the susceptibility to Etoposide |
CTD |
PMID:10327070 PMID:15228094 PMID:21712253 PMID:25866362 |
|
NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
affects response to substance decreases expression |
ISO |
ERBB3 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of ERBB3 mRNA |
CTD |
PMID:15228094 PMID:16217747 PMID:29397400 |
|
NCBI chr10:128,403,392...128,425,504
Ensembl chr10:128,403,392...128,425,521
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
decreases expression |
ISO |
Etoposide results in decreased expression of ERBB4 mRNA |
CTD |
PMID:15228094 |
|
NCBI chr 1:68,071,063...69,147,756
Ensembl chr 1:68,071,345...69,147,218
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Etoposide results in increased expression of EREG mRNA |
CTD |
PMID:15228094 |
|
NCBI chr 5:91,222,476...91,241,508
Ensembl chr 5:91,222,481...91,241,505
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
multiple interactions |
ISO |
Etoposide inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:30818834 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
increases response to substance multiple interactions |
ISO |
ESR2 protein results in increased susceptibility to Etoposide TP53 protein inhibits the reaction [ESR2 protein results in increased susceptibility to Etoposide] |
CTD |
PMID:20623183 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
Esrp1 |
epithelial splicing regulatory protein 1 |
affects response to substance |
ISO |
ESRP1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:11,331,933...11,386,783
Ensembl chr 4:11,331,933...11,386,783
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions |
ISO |
Etoposide inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]; Etoposide promotes the reaction [PPARGC1A protein results in increased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr19:6,888,345...6,899,182
Ensembl chr19:6,888,345...6,899,208
|
|
G |
Ets1 |
E26 avian leukemia oncogene 1, 5' domain |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of ETS1 protein DAPK1 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]; ETS1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein] |
CTD |
PMID:30177839 |
|
NCBI chr 9:32,547,501...32,669,116
Ensembl chr 9:32,547,517...32,669,116
|
|
G |
Etv6 |
ets variant 6 |
increases response to substance increases mutagenesis |
ISO |
ETV6 gene mutant form results in increased susceptibility to Etoposide Etoposide results in increased mutagenesis of ETV6 gene |
CTD |
PMID:15217836 PMID:28624474 |
|
NCBI chr 6:134,012,663...134,247,121
Ensembl chr 6:134,012,663...134,247,121
|
|
G |
Exoc4 |
exocyst complex component 4 |
increases expression |
EXP |
Etoposide results in increased expression of EXOC4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 6:33,226,025...33,950,914
Ensembl chr 6:33,226,020...33,950,914
|
|
G |
F11r |
F11 receptor |
increases expression |
ISO |
Etoposide results in increased expression of F11R mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:171,265,129...171,292,161
Ensembl chr 1:171,265,103...171,292,171
|
|
G |
F2r |
coagulation factor II thrombin receptor |
affects response to substance |
ISO |
F2R protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr13:95,738,288...95,754,974
Ensembl chr13:95,738,311...95,754,995
|
|
G |
F3 |
coagulation factor III |
increases expression |
ISO |
Etoposide results in increased expression of F3 mRNA |
CTD |
PMID:12542493 |
|
NCBI chr 3:121,517,186...121,528,701
Ensembl chr 3:121,517,186...121,528,697
|
|
G |
Fads3 |
fatty acid desaturase 3 |
increases expression |
ISO |
Etoposide results in increased expression of FADS3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr19:10,018,189...10,037,477
Ensembl chr19:10,018,933...10,037,474
|
|
G |
Fam171a1 |
family with sequence similarity 171, member A1 |
affects response to substance |
ISO |
FAM171A1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:3,115,261...3,228,843
Ensembl chr 2:3,115,261...3,228,843
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
ISO EXP |
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Etoposide results in increased expression of and affects the localization of FAS protein]; Etoposide results in increased expression of and affects the localization of FAS protein; Lithium inhibits the reaction [Etoposide results in increased expression of and affects the localization of FAS protein] Etoposide results in increased expression of FAS mRNA Etoposide results in increased expression of FAS mRNA; Etoposide results in increased expression of FAS protein |
CTD |
PMID:12513834 PMID:15475000 PMID:16192531 PMID:29397400 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fasl |
Fas ligand |
multiple interactions increases expression increases activity |
ISO EXP |
[linsidomine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [spermine nitric oxide complex results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; Nitric Oxide inhibits the reaction [Etoposide results in increased activity of FASLG promoter] Etoposide results in increased expression of FASL mRNA |
CTD |
PMID:10811113 PMID:12513834 |
|
NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
Etoposide results in increased expression of FASN mRNA |
CTD |
PMID:17089011 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Fbl |
fibrillarin |
affects localization |
ISO |
Etoposide analog affects the localization of FBL protein |
CTD |
PMID:10942594 |
|
NCBI chr 7:27,868,293...27,878,701
Ensembl chr 7:27,869,135...27,878,694
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
affects response to substance |
ISO |
FDFT1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:63,382,599...63,419,136
Ensembl chr14:63,382,599...63,417,027
|
|
G |
Fdxr |
ferredoxin reductase |
increases expression |
ISO |
Etoposide results in increased expression of FDXR mRNA |
CTD |
PMID:17374387 |
|
NCBI chr11:115,158,850...115,167,925
Ensembl chr11:115,158,850...115,167,876
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
affects response to substance |
ISO |
FGF2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
affects response to substance |
ISO |
FHL1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:55,776,569...55,838,704
Ensembl chr X:55,777,147...55,838,706
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of FHL2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:43,162,233...43,237,501
Ensembl chr 1:43,162,234...43,236,144
|
|
G |
Flnc |
filamin C, gamma |
increases expression |
ISO |
Etoposide results in increased expression of FLNC mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 6:29,433,150...29,461,888
Ensembl chr 6:29,433,255...29,461,882
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
decreases response to substance increases expression multiple interactions |
ISO |
FOS protein results in decreased susceptibility to Etoposide Etoposide results in increased expression of FOS [Etoposide co-treated with Cyclic AMP] results in increased expression of FOS mRNA; Acetylcysteine inhibits the reaction [Etoposide results in increased expression of FOS] |
CTD |
PMID:10711420 PMID:18314485 PMID:23824011 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Fosl1 |
fos-like antigen 1 |
increases expression |
EXP |
Etoposide results in increased expression of FOSL1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:5,497,726...5,505,966
Ensembl chr19:5,497,575...5,505,974
|
|
G |
Foxf2 |
forkhead box F2 |
affects response to substance |
ISO |
FOXF2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr13:31,809,686...31,815,390
Ensembl chr13:31,809,799...31,815,386
|
|
G |
Foxj2 |
forkhead box J2 |
decreases expression |
ISO |
Etoposide results in decreased expression of FOXJ2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 6:122,797,143...122,822,325
Ensembl chr 6:122,796,873...122,822,325
|
|
G |
Foxo1 |
forkhead box O1 |
increases phosphorylation multiple interactions |
ISO |
Etoposide results in increased phosphorylation of FOXO1 protein wortmannin inhibits the reaction [Etoposide results in increased phosphorylation of FOXO1 protein] |
CTD |
PMID:17935137 |
|
NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642
|
|
G |
Foxo3 |
forkhead box O3 |
increases phosphorylation increases response to substance multiple interactions |
ISO |
Etoposide results in increased phosphorylation of FOXO3 protein FOXO3 protein results in increased susceptibility to Etoposide [FOXO3 protein results in decreased expression of BIRC5 protein] which results in increased susceptibility to Etoposide; BIRC5 protein inhibits the reaction [FOXO3 protein results in increased susceptibility to Etoposide]; wortmannin inhibits the reaction [Etoposide results in increased phosphorylation of FOXO3 protein] |
CTD |
PMID:17935137 PMID:19211844 |
|
NCBI chr10:42,057,841...42,152,691
Ensembl chr10:42,057,837...42,152,751
|
|
G |
Fth1 |
ferritin heavy polypeptide 1 |
multiple interactions increases expression |
EXP |
HIPK2 protein promotes the reaction [Etoposide results in increased expression of FTH1 mRNA] |
CTD |
PMID:20980392 |
|
NCBI chr19:9,957,964...9,962,475
Ensembl chr19:9,957,962...9,962,462
|
|
G |
Ftl1 |
ferritin light polypeptide 1 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of FTL mRNA; Etoposide results in increased expression of FTL protein 1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine inhibits the reaction [Etoposide results in increased expression of FTL protein]; ARNT protein affects the reaction [Etoposide results in increased expression of FTL protein]; Etoposide promotes the reaction [HIF1A protein binds to FTL promoter]; FTL protein affects the reaction [Etoposide results in increased expression of ALDH1A1 protein]; FTL protein affects the reaction [Etoposide results in increased expression of KLF4 protein]; FTL protein affects the reaction [Etoposide results in increased expression of SOX2 protein]; HIF1A protein affects the reaction [Etoposide results in increased expression of FTL protein] |
CTD |
PMID:33969609 |
|
NCBI chr 7:45,107,368...45,109,310
Ensembl chr 7:45,107,368...45,109,308
|
|
G |
Fut8 |
fucosyltransferase 8 |
affects response to substance |
ISO |
FUT8 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr12:77,284,878...77,522,770
Ensembl chr12:77,284,899...77,523,112
|
|
G |
Fyn |
Fyn proto-oncogene |
affects response to substance decreases expression |
ISO EXP |
FYN protein affects the susceptibility to Etoposide Etoposide results in decreased expression of FYN mRNA |
CTD |
PMID:16217747 PMID:25270620 |
|
NCBI chr10:39,245,735...39,441,377
Ensembl chr10:39,244,851...39,441,377
|
|
G |
Fzd1 |
frizzled class receptor 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of FZD1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 5:4,803,839...4,808,216
Ensembl chr 5:4,803,839...4,808,035
|
|
G |
Fzd5 |
frizzled class receptor 5 |
decreases expression |
EXP |
Etoposide results in decreased expression of FZD5 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:64,769,717...64,776,907
Ensembl chr 1:64,769,717...64,776,910
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible 45 alpha |
increases response to substance multiple interactions increases expression |
ISO |
GADD45A protein results in increased susceptibility to Etoposide IKBKB protein inhibits the reaction [Etoposide results in increased expression of GADD45A protein] Etoposide results in increased expression of GADD45A mRNA; Etoposide results in increased expression of GADD45A protein |
CTD |
PMID:19003803 PMID:21527772 PMID:29397400 PMID:30177839 PMID:31542801 |
|
NCBI chr 6:67,012,080...67,014,391
Ensembl chr 6:67,012,080...67,014,441
|
|
G |
Ganab |
alpha glucosidase 2 alpha neutral subunit |
multiple interactions decreases expression |
EXP |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of GANAB protein Etoposide results in decreased expression of GANAB protein |
CTD |
PMID:29733421 |
|
NCBI chr19:8,875,440...8,894,098
Ensembl chr19:8,875,435...8,894,036
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
increases expression |
EXP |
Etoposide results in increased expression of GAPDH protein |
CTD |
PMID:29733421 |
|
NCBI chr 6:125,138,812...125,143,450
Ensembl chr 6:125,138,678...125,143,430
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[GCLC protein co-treated with GCLM protein] promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; [GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Etoposide |
CTD |
PMID:10900222 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gclm |
glutamate-cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[GCLC protein co-treated with GCLM protein] promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; [GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Etoposide |
CTD |
PMID:10900222 |
|
NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions increases expression |
ISO |
Etoposide promotes the reaction [[TP53 protein binds to GDF15 promoter] which results in increased expression of GDF15 mRNA] [Etoposide results in increased expression of TP53 protein] which results in increased expression of GDF15 protein; Etoposide results in increased expression of GDF15 mRNA; Etoposide results in increased expression of GDF15 protein |
CTD |
PMID:11895857 PMID:16120219 PMID:24211769 PMID:29397400 |
|
NCBI chr 8:71,082,043...71,085,106
Ensembl chr 8:71,082,043...71,085,106
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions increases response to substance |
EXP |
GJA1 protein affects the reaction [Simvastatin results in increased susceptibility to Etoposide]; Tetradecanoylphorbol Acetate affects the reaction [GJA1 protein results in increased susceptibility to Etoposide] |
CTD |
PMID:23978459 |
|
NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609
|
|
G |
Gja5 |
gap junction protein, alpha 5 |
decreases expression |
ISO |
Etoposide results in decreased expression of GJA5 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 3:96,939,718...96,960,950
Ensembl chr 3:96,812,009...96,984,732
|
|
G |
Gls2 |
glutaminase 2 (liver, mitochondrial) |
increases expression |
ISO |
Etoposide results in increased expression of GLS2 mRNA |
CTD |
PMID:21527772 PMID:29397400 |
|
NCBI chr10:128,030,504...128,045,873
Ensembl chr10:128,030,326...128,045,873
|
|
G |
Gm20348 |
predicted gene, 20348 |
increases expression |
ISO |
Etoposide results in increased expression of TP53I3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr12:4,860,475...4,867,155
Ensembl chr12:4,860,494...4,867,142
|
|
G |
Gm40318 |
predicted gene, 40318 |
increases response to substance affects response to substance |
ISO |
S100P protein results in increased susceptibility to Etoposide S100P protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 PMID:18636193 |
|
NCBI chr 5:36,919,848...36,924,763
Ensembl chr 5:36,919,961...36,924,039
|
|
G |
Gpihbp1 |
GPI-anchored HDL-binding protein 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of GPIHBP1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr15:75,468,479...75,470,062
Ensembl chr15:75,468,477...75,471,330
|
|
G |
Gpm6b |
glycoprotein m6b |
affects response to substance |
ISO |
GPM6B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:165,021,911...165,172,028
Ensembl chr X:165,021,907...165,171,984
|
|
G |
Gpnmb |
glycoprotein (transmembrane) nmb |
increases expression |
ISO |
Etoposide results in increased expression of GPNMB mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 6:49,013,449...49,044,413
Ensembl chr 6:49,013,480...49,047,863
|
|
G |
Gpr37 |
G protein-coupled receptor 37 |
affects response to substance |
ISO |
GPR37 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:25,668,522...25,689,979
Ensembl chr 6:25,665,877...25,690,728
|
|
G |
Gpsm2 |
G-protein signalling modulator 2 (AGS3-like, C. elegans) |
affects response to substance |
ISO |
GPSM2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:108,585,954...108,629,637
Ensembl chr 3:108,585,954...108,629,625
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
ISO |
Etoposide results in increased expression of GPX1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression |
EXP |
Etoposide results in increased expression of GPX3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:54,793,680...54,801,213
Ensembl chr11:54,793,279...54,801,203
|
|
G |
Gria3 |
glutamate receptor, ionotropic, AMPA3 (alpha 3) |
increases expression |
EXP |
Etoposide results in increased expression of GRIA3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr X:40,489,351...40,767,478
Ensembl chr X:40,489,731...40,767,478
|
|
G |
Grpel1 |
GrpE-like 1, mitochondrial |
decreases expression |
ISO |
Etoposide results in decreased expression of GRPEL1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 5:36,622,529...36,631,421
Ensembl chr 5:36,622,342...36,631,424
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases activity |
EXP |
BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein] [Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein; Etoposide results in increased activity of GSK3B protein |
CTD |
PMID:19408126 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
Gstm1 |
glutathione S-transferase, mu 1 |
affects response to substance |
ISO |
GSTM1 gene polymorphism affects the susceptibility to Etoposide |
CTD |
PMID:15713801 |
|
NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289
|
|
G |
Gstm4 |
glutathione S-transferase, mu 4 |
affects response to substance |
ISO |
GSTM4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:107,937,887...107,952,495
Ensembl chr 3:107,947,724...107,952,210
|
|
G |
Gstp1 |
glutathione S-transferase, pi 1 |
multiple interactions decreases response to substance affects response to substance |
ISO |
Curcumin inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; Ethacrynic Acid inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Sulfinpyrazone inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; verlukast inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide] GSTP1 gene polymorphism affects the susceptibility to Etoposide |
CTD |
PMID:10900222 PMID:12969965 PMID:15999103 |
|
NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985
|
|
G |
H2-M2 |
histocompatibility 2, M region locus 2 |
affects expression |
ISO |
Etoposide affects the expression of HLA-B mRNA |
CTD |
PMID:25811541 |
|
NCBI chr17:37,791,742...37,794,445
Ensembl chr17:37,791,742...37,794,443
|
|
G |
H2-Q1 |
histocompatibility 2, Q region locus 1 |
affects expression |
ISO |
Etoposide affects the expression of HLA-A mRNA |
CTD |
PMID:25811541 |
|
NCBI chr17:35,539,503...35,547,118
Ensembl chr17:35,539,381...35,544,075
|
|
G |
H2-T23 |
histocompatibility 2, T region locus 23 |
affects expression |
ISO |
Etoposide affects the expression of HLA-E mRNA |
CTD |
PMID:25811541 |
|
NCBI chr17:36,340,869...36,343,593
Ensembl chr17:36,340,665...36,343,747
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions decreases response to substance increases expression increases phosphorylation |
ISO EXP |
Celecoxib inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein]; nimesulide inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein]; palbociclib inhibits the reaction [Etoposide results in increased expression of H2AX protein]; pifithrin promotes the reaction [Etoposide results in increased expression of H2AX protein] H2AX protein results in decreased susceptibility to Etoposide 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Etoposide results in increased expression of H2AX protein]; RAD54B protein affects the reaction [Etoposide results in increased expression of H2AX protein]; TOP2B protein affects the reaction [Etoposide results in increased expression of H2AX protein] 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione inhibits the reaction [Etoposide results in increased expression of H2AX protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Etoposide results in increased expression of H2AX protein]; Bortezomib inhibits the reaction [Etoposide results in increased expression of H2AX protein]; Razoxane inhibits the reaction [Etoposide results in increased expression of H2AX protein] Etoposide results in increased expression of H2AX protein; Etoposide results in increased expression of H2AX protein modified form |
CTD |
PMID:17875725 PMID:20643100 PMID:20978201 PMID:21555580 PMID:21745461 PMID:22302033 PMID:25078064 PMID:26259609 PMID:28343997 PMID:32482060 PMID:33823233 PMID:34510228 PMID:35690182 PMID:37451322 More...
|
|
NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374
|
|
G |
Hal |
histidine ammonia lyase |
decreases expression |
EXP |
Etoposide results in decreased expression of HAL mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:93,324,630...93,352,623
Ensembl chr10:93,324,630...93,355,166
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
decreases expression multiple interactions |
EXP ISO |
Etoposide results in decreased expression of HAMP mRNA Etoposide inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25270620 PMID:25633564 |
|
NCBI chr 7:30,641,793...30,643,454
Ensembl chr 7:30,641,793...30,643,457
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
increases expression |
ISO |
Etoposide results in increased expression of HBEGF mRNA |
CTD |
PMID:15228094 |
|
NCBI chr18:36,637,980...36,648,858
Ensembl chr18:36,637,980...36,648,858
|
|
G |
Hbp1 |
high mobility group box transcription factor 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of HBP1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr12:31,976,449...32,000,529
Ensembl chr12:31,976,253...32,000,534
|
|
G |
Hdac4 |
histone deacetylase 4 |
affects response to substance |
ISO |
HDAC4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:91,856,501...92,123,424
Ensembl chr 1:91,856,501...92,123,421
|
|
G |
Heph |
hephaestin |
affects response to substance |
ISO |
HEPH protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:95,499,042...95,618,091
Ensembl chr X:95,498,965...95,618,091
|
|
G |
Hic1 |
hypermethylated in cancer 1 |
multiple interactions increases expression |
ISO |
E2F1 protein affects the reaction [Etoposide results in increased expression of HIC1 mRNA]; Etoposide promotes the reaction [E2F1 protein binds to HIC1 promoter] |
CTD |
PMID:19491197 |
|
NCBI chr11:75,052,203...75,059,970
Ensembl chr11:75,055,391...75,060,345
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
multiple interactions |
ISO |
Etoposide promotes the reaction [HIF1A protein binds to FTL promoter]; HIF1A mutant form inhibits the reaction [Oxygen deficiency results in decreased susceptibility to Etoposide]; HIF1A protein affects the reaction [Etoposide results in increased expression of FTL protein] |
CTD |
PMID:23144690 PMID:33969609 |
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Hipk2 |
homeodomain interacting protein kinase 2 |
increases activity multiple interactions decreases response to substance |
ISO EXP |
Etoposide results in increased activity of HIPK2 protein HIPK2 gene mutant form inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of CREB1 protein]; HIPK2 gene mutant form promotes the reaction [Etoposide results in increased activity of CASP3 protein]; HIPK2 protein promotes the reaction [Etoposide results in increased expression of FTH1 mRNA]; HIPK2 protein promotes the reaction [Etoposide results in increased expression of NQO1 mRNA] HIPK2 results in decreased susceptibility to Etoposide HIPK2 mutant form inhibits the reaction [Etoposide results in increased expression of BDNF mRNA] |
CTD |
PMID:20573984 PMID:20980392 |
|
NCBI chr 6:38,664,447...38,853,236
Ensembl chr 6:38,671,325...38,853,099
|
|
G |
Hmces |
5-hydroxymethylcytosine (hmC) binding, ES cell specific |
decreases expression |
EXP |
Etoposide results in decreased expression of HMCES mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 6:87,890,889...87,913,603
Ensembl chr 6:87,890,917...87,913,611
|
|
G |
Hmg20b |
high mobility group 20B |
affects response to substance |
ISO |
HMG20B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:81,181,880...81,186,777
Ensembl chr10:81,181,882...81,186,314
|
|
G |
Hmga2 |
high mobility group AT-hook 2 |
affects response to substance |
ISO |
HMGA2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:120,197,173...120,312,374
Ensembl chr10:120,197,180...120,312,374
|
|
G |
Hmgb1 |
high mobility group box 1 |
decreases response to substance increases secretion |
ISO |
HMGB1 protein results in decreased susceptibility to Etoposide Etoposide results in increased secretion of HMGB1 protein |
CTD |
PMID:27807322 |
|
NCBI chr 5:148,983,512...148,989,867
Ensembl chr 5:148,983,512...149,121,299
|
|
G |
Hnrnph2 |
heterogeneous nuclear ribonucleoprotein H2 |
decreases expression |
EXP |
Etoposide results in decreased expression of HNRNPH2 protein |
CTD |
PMID:29733421 |
|
NCBI chr X:133,501,928...133,507,809
Ensembl chr X:133,501,928...133,507,809
|
|
G |
Hoxa5 |
homeobox A5 |
affects response to substance |
ISO |
HOXA5 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:52,178,768...52,181,437
Ensembl chr 6:52,178,734...52,181,567
|
|
G |
Hsp90aa1 |
heat shock protein 90, alpha (cytosolic), class A member 1 |
multiple interactions |
ISO |
[Bleomycin co-treated with Cisplatin co-treated with Etoposide] results in increased expression of HSP90AA1 protein |
CTD |
PMID:24478030 |
|
NCBI chr12:110,657,470...110,662,829
Ensembl chr12:110,657,039...110,669,162
|
|
G |
Hsp90b1 |
heat shock protein 90, beta (Grp94), member 1 |
multiple interactions |
ISO |
[Bleomycin co-treated with Cisplatin co-treated with Etoposide] results in increased expression of HSP90B1 protein |
CTD |
PMID:24478030 |
|
NCBI chr10:86,526,705...86,541,308
Ensembl chr10:86,526,073...86,541,373
|
|
G |
Hspa2 |
heat shock protein 2 |
affects response to substance |
ISO |
HSPA2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr12:76,450,688...76,453,712
Ensembl chr12:76,450,950...76,453,712
|
|
G |
Hspe1 |
heat shock protein 1 (chaperonin 10) |
increases expression |
EXP |
Etoposide results in increased expression of HSPE1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 1:55,127,307...55,130,476
Ensembl chr 1:55,127,291...55,130,466
|
|
G |
Htatip2 |
HIV-1 Tat interactive protein 2 |
affects response to substance increases response to substance multiple interactions |
ISO EXP |
HTATIP2 protein affects the susceptibility to Etoposide HTATIP2 protein results in increased susceptibility to Etoposide HTATIP2 protein promotes the reaction [Etoposide results in increased activity of CASP9 protein]; HTATIP2 protein promotes the reaction [Etoposide results in increased activity of PARP1 protein] |
CTD |
PMID:16217747 PMID:16799960 |
|
NCBI chr 7:49,408,761...49,423,748
Ensembl chr 7:49,408,863...49,423,723
|
|
G |
Htr4 |
5 hydroxytryptamine (serotonin) receptor 4 |
affects response to substance |
ISO |
HTR4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr18:62,456,618...62,636,098
Ensembl chr18:62,457,275...62,629,648
|
|
G |
Ier5 |
immediate early response 5 |
increases expression |
ISO |
Etoposide results in increased expression of IER5 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:154,972,113...154,975,382
Ensembl chr 1:154,972,107...154,975,382
|
|
G |
Ifitm1 |
interferon induced transmembrane protein 1 |
affects response to substance |
ISO |
IFITM1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:140,547,342...140,549,740
Ensembl chr 7:140,547,134...140,549,738
|
|
G |
Igdcc4 |
immunoglobulin superfamily, DCC subclass, member 4 |
increases expression |
EXP |
Etoposide results in increased expression of IGDCC4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:65,008,246...65,045,225
Ensembl chr 9:65,008,768...65,045,222
|
|
G |
Igf1r |
insulin-like growth factor I receptor |
affects response to substance |
ISO |
IGF1R protein affects the susceptibility to Etoposide |
CTD |
PMID:15499378 |
|
NCBI chr 7:67,601,486...67,883,416
Ensembl chr 7:67,602,575...67,883,416
|
|
G |
Igfbp7 |
insulin-like growth factor binding protein 7 |
affects response to substance |
ISO |
IGFBP7 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:77,497,092...77,555,892
Ensembl chr 5:77,497,087...77,555,888
|
|
G |
Igsf11 |
immunoglobulin superfamily, member 11 |
decreases expression |
EXP |
Etoposide results in decreased expression of IGSF11 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr16:38,712,840...38,847,521
Ensembl chr16:38,713,033...38,847,521
|
|
G |
Ikbkb |
inhibitor of kappaB kinase beta |
affects response to substance decreases expression multiple interactions |
EXP ISO |
IKBKB protein affects the susceptibility to Etoposide Etoposide results in decreased expression of IKBKB protein DAPK1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; ETS1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; IKBKB protein inhibits the reaction [Etoposide results in increased expression of GADD45A protein]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein modified form]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein]; TP53 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein] |
CTD |
PMID:20159942 PMID:30177839 |
|
NCBI chr 8:23,149,228...23,196,605
Ensembl chr 8:23,149,228...23,196,605
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
EXP |
Etoposide results in increased expression of IL1B mRNA |
CTD |
PMID:18523641 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il4 |
interleukin 4 |
decreases response to substance multiple interactions |
ISO |
IL4 protein results in decreased susceptibility to Etoposide [IL4 protein co-treated with VCAM1 protein] inhibits the reaction [Etoposide results in decreased folding of BAX protein]; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; [VCAM1 protein co-treated with IL4 protein] results in decreased susceptibility to Etoposide |
CTD |
PMID:10620629 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression increases secretion |
EXP ISO |
(4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine inhibits the reaction [Etoposide results in increased expression of IL6 mRNA]; (4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine inhibits the reaction [Etoposide results in increased secretion of IL6 protein] Etoposide results in increased expression of IL6 mRNA; Etoposide results in increased expression of IL6 protein |
CTD |
PMID:15135310 PMID:17003255 PMID:18523641 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Inka2 |
inka box actin regulator 2 |
increases expression |
EXP |
Etoposide results in increased expression of INKA2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:105,611,915...105,628,158
Ensembl chr 3:105,611,915...105,628,158
|
|
G |
Insig1 |
insulin induced gene 1 |
affects response to substance |
ISO |
INSIG1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:28,276,410...28,283,660
Ensembl chr 5:28,276,361...28,283,660
|
|
G |
Ints15 |
integrator complex subunit 15 |
decreases expression |
ISO |
Etoposide results in decreased expression of INTS15 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 5:143,286,827...143,301,147
Ensembl chr 5:143,286,950...143,301,115
|
|
G |
Ireb2 |
iron responsive element binding protein 2 |
multiple interactions decreases expression |
ISO |
1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine inhibits the reaction [Etoposide results in decreased expression of IREB2 protein] Etoposide results in decreased expression of IREB2 mRNA; Etoposide results in decreased expression of IREB2 protein |
CTD |
PMID:33969609 |
|
NCBI chr 9:54,769,942...54,819,812
Ensembl chr 9:54,771,073...54,819,814
|
|
G |
Irs2 |
insulin receptor substrate 2 |
affects response to substance |
ISO |
IRS2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:11,034,681...11,058,929
Ensembl chr 8:11,034,681...11,058,458
|
|
G |
Irx4 |
Iroquois homeobox 4 |
decreases expression |
ISO |
Etoposide results in decreased expression of IRX4 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr13:73,407,708...73,417,741
Ensembl chr13:73,408,598...73,417,727
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
increases expression |
ISO |
Etoposide results in increased expression of ISG15 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:156,283,881...156,285,275
Ensembl chr 4:156,283,912...156,285,253
|
|
G |
Isg20 |
interferon-stimulated protein |
affects response to substance |
ISO |
ISG20 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:78,561,136...78,570,144
Ensembl chr 7:78,563,172...78,570,144
|
|
G |
Isg20l2 |
interferon stimulated exonuclease gene 20-like 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of ISG20L2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 3:87,837,602...87,847,994
Ensembl chr 3:87,837,621...87,847,993
|
|
G |
Itga2b |
integrin alpha 2b |
increases expression |
ISO |
Etoposide results in increased expression of ITGA2B mRNA |
CTD |
PMID:21527772 |
|
NCBI chr11:102,344,134...102,360,570
Ensembl chr11:102,344,123...102,360,948
|
|
G |
Itgb3 |
integrin beta 3 |
increases response to substance |
ISO |
ITGB3 protein results in increased susceptibility to Etoposide |
CTD |
PMID:21332719 |
|
NCBI chr11:104,498,826...104,561,302
Ensembl chr11:104,498,826...104,561,302
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor 1 |
affects response to substance |
ISO |
ITPR1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:108,190,044...108,528,077
Ensembl chr 6:108,190,057...108,528,070
|
|
G |
Jun |
jun proto-oncogene |
multiple interactions |
ISO |
[Etoposide co-treated with Cyclic AMP] results in increased expression of JUN mRNA |
CTD |
PMID:10711420 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Kcnab2 |
potassium voltage-gated channel, shaker-related subfamily, beta member 2 |
affects response to substance |
ISO |
KCNAB2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:152,475,201...152,561,991
Ensembl chr 4:152,475,199...152,562,367
|
|
G |
Kcne3 |
potassium voltage-gated channel, Isk-related subfamily, gene 3 |
decreases expression |
EXP |
Etoposide results in decreased expression of KCNE3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:99,825,714...99,834,076
Ensembl chr 7:99,825,709...99,834,076
|
|
G |
Kcnn2 |
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of KCNN2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr18:45,401,754...45,818,954
Ensembl chr18:45,401,927...45,818,950
|
|
G |
Keap1 |
kelch-like ECH-associated protein 1 |
decreases response to substance multiple interactions increases response to substance |
ISO |
KEAP1 protein results in decreased susceptibility to Etoposide KEAP1 protein affects the reaction [Etoposide results in increased expression of CDKN1A protein] KEAP1 mRNA results in increased susceptibility to Etoposide |
CTD |
PMID:22684020 PMID:26708503 PMID:27982581 |
|
NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
|
|
G |
Kif1a |
kinesin family member 1A |
increases expression |
ISO |
Etoposide results in increased expression of KIF1A mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:92,943,180...93,029,760
Ensembl chr 1:92,943,186...93,029,673
|
|
G |
Kif20a |
kinesin family member 20A |
decreases expression |
ISO |
Etoposide results in decreased expression of KIF20A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr18:34,757,677...34,766,330
Ensembl chr18:34,757,666...34,766,330
|
|
G |
Kif23 |
kinesin family member 23 |
decreases expression |
EXP |
Etoposide results in decreased expression of KIF23 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:61,824,559...61,854,078
Ensembl chr 9:61,823,187...61,854,056
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
increases expression multiple interactions |
EXP |
Etoposide results in increased expression of KIT protein [Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in increased expression of KIT protein |
CTD |
PMID:29733421 |
|
NCBI chr 5:75,735,647...75,817,382
Ensembl chr 5:75,735,576...75,817,382
|
|
G |
Klf4 |
Kruppel-like transcription factor 4 (gut) |
multiple interactions increases expression |
ISO |
FTL protein affects the reaction [Etoposide results in increased expression of KLF4 protein] Etoposide results in increased expression of KLF4 mRNA; Etoposide results in increased expression of KLF4 protein |
CTD |
PMID:33969609 |
|
NCBI chr 4:55,527,137...55,536,984
Ensembl chr 4:55,527,143...55,532,466
|
|
G |
Klf5 |
Kruppel-like transcription factor 5 |
increases expression |
ISO |
Etoposide results in increased expression of KLF5 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr14:99,536,127...99,550,848
Ensembl chr14:99,536,127...99,552,472
|
|
G |
Klf6 |
Kruppel-like transcription factor 6 |
decreases expression |
ISO |
Etoposide results in decreased expression of KLF6 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr13:5,911,488...5,920,392
Ensembl chr13:5,911,481...5,920,393
|
|
G |
Klhl26 |
kelch-like 26 |
increases expression |
EXP |
Etoposide results in increased expression of KLHL26 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:70,902,868...70,929,660
Ensembl chr 8:70,902,869...70,929,618
|
|
G |
Kmt2a |
lysine (K)-specific methyltransferase 2A |
increases response to substance increases mutagenesis increases cleavage |
ISO |
KMT2A gene mutant form results in increased susceptibility to Etoposide Etoposide results in increased mutagenesis of KMT2A gene Etoposide results in increased cleavage of KMT2A gene |
CTD |
PMID:14712291 PMID:24086652 PMID:28624474 |
|
NCBI chr 9:44,714,652...44,793,492
Ensembl chr 9:44,714,652...44,792,594
|
|
G |
Krt19 |
keratin 19 |
increases expression |
ISO |
Etoposide results in increased expression of KRT19 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr11:100,031,636...100,036,752
Ensembl chr11:100,031,636...100,039,491
|
|
G |
Krt80 |
keratin 80 |
increases expression |
ISO |
Etoposide results in increased expression of KRT80 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr15:101,246,196...101,268,043
Ensembl chr15:101,245,325...101,268,043
|
|
G |
Kynu |
kynureninase |
affects response to substance |
ISO |
KYNU protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:43,445,270...43,572,734
Ensembl chr 2:43,445,341...43,572,734
|
|
G |
Lancl1 |
LanC (bacterial lantibiotic synthetase component C)-like 1 |
affects response to substance |
ISO |
LANCL1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:67,039,676...67,078,049
Ensembl chr 1:67,039,676...67,078,031
|
|
G |
Lap3 |
leucine aminopeptidase 3 |
decreases expression |
EXP |
Etoposide results in decreased expression of LAP3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 5:45,650,716...45,670,033
Ensembl chr 5:45,650,716...45,670,033
|
|
G |
Lcn2 |
lipocalin 2 |
increases response to substance |
ISO |
LCN2 protein results in increased susceptibility to Etoposide |
CTD |
PMID:19860839 |
|
NCBI chr 2:32,274,649...32,277,751
Ensembl chr 2:32,274,645...32,278,264
|
|
G |
Ldb3 |
LIM domain binding 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of LDB3 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr14:34,248,656...34,312,276
Ensembl chr14:34,248,560...34,310,639
|
|
G |
Lgals3 |
lectin, galactose binding, soluble 3 |
affects response to substance |
ISO |
LGALS3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:47,611,317...47,623,624
Ensembl chr14:47,605,208...47,623,617
|
|
G |
Lgals7 |
lectin, galactose binding, soluble 7 |
increases expression |
ISO |
Etoposide results in increased expression of LGALS7 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 7:28,563,258...28,565,711
Ensembl chr 7:28,563,278...28,565,709
|
|
G |
Lhx1 |
LIM homeobox protein 1 |
multiple interactions decreases expression |
EXP |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of LHX1 mRNA Etoposide results in decreased expression of LHX1 mRNA |
CTD |
PMID:29733421 |
|
NCBI chr11:84,408,801...84,416,360
Ensembl chr11:84,409,110...84,416,361
|
|
G |
Lhx2 |
LIM homeobox protein 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of LHX2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 2:38,229,282...38,259,747
Ensembl chr 2:38,229,293...38,259,745
|
|
G |
Lif |
leukemia inhibitory factor |
increases expression |
ISO |
Etoposide results in increased expression of LIF mRNA |
CTD |
PMID:29397400 |
|
NCBI chr11:4,207,587...4,222,514
Ensembl chr11:4,207,557...4,222,514
|
|
G |
Limch1 |
LIM and calponin homology domains 1 |
affects response to substance |
ISO |
LIMCH1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:66,903,232...67,214,502
Ensembl chr 5:66,903,170...67,214,501
|
|
G |
Lipa |
lysosomal acid lipase A |
affects response to substance |
ISO |
LIPA protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr19:34,469,716...34,504,874
Ensembl chr19:34,469,718...34,504,874
|
|
G |
Lrrc47 |
leucine rich repeat containing 47 |
decreases expression |
ISO |
Etoposide results in decreased expression of LRRC47 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 4:154,096,260...154,105,969
Ensembl chr 4:154,096,188...154,105,970
|
|
G |
Ltbr |
lymphotoxin B receptor |
multiple interactions increases expression |
ISO |
Estradiol inhibits the reaction [Etoposide results in increased expression of LTBR mRNA] |
CTD |
PMID:19426747 |
|
NCBI chr 6:125,283,534...125,291,026
Ensembl chr 6:125,283,534...125,290,848
|
|
G |
Lxn |
latexin |
increases response to substance |
EXP |
LXN protein results in increased susceptibility to Etoposide |
CTD |
PMID:25341047 |
|
NCBI chr 3:67,365,332...67,371,240
Ensembl chr 3:67,365,331...67,371,259
|
|
G |
Ly6e |
lymphocyte antigen 6 family member E |
affects response to substance |
ISO |
LY6E protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:74,826,874...74,831,753
Ensembl chr15:74,826,900...74,831,752
|
|
G |
Lyz1 |
lysozyme 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of LYZ1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:117,123,700...117,128,773
Ensembl chr10:117,123,702...117,128,773
|
|
G |
Macf1 |
microtubule-actin crosslinking factor 1 |
affects response to substance |
ISO |
MACF1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:123,243,386...123,581,594
Ensembl chr 4:123,243,426...123,581,331
|
|
G |
Magea6 |
MAGE family member A6 |
affects response to substance |
ISO |
MAGEA6 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:153,706,891...153,719,070
Ensembl chr X:153,707,008...153,718,983
|
|
G |
Man2b1 |
mannosidase 2, alpha B1 |
increases expression |
EXP |
Etoposide results in increased expression of MAN2B1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:85,809,941...85,824,215
Ensembl chr 8:85,809,899...85,824,911
|
|
G |
Map2k3 |
mitogen-activated protein kinase kinase 3 |
increases expression |
ISO |
Etoposide results in increased expression of MAP2K3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr11:60,822,880...60,843,637
Ensembl chr11:60,822,859...60,843,637
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
decreases expression |
ISO |
Etoposide results in decreased expression of MAP3K5 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:19,809,847...20,018,496
Ensembl chr10:19,810,218...20,018,499
|
|
G |
Map7 |
microtubule-associated protein 7 |
affects response to substance |
ISO |
MAP7 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:20,024,666...20,157,336
Ensembl chr10:20,024,217...20,157,336
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased phosphorylation of MAPK1 protein]; Acetylcysteine inhibits the reaction [Etoposide results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Etoposide results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16014620 PMID:19720055 PMID:26046675 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk12 |
mitogen-activated protein kinase 12 |
increases activity affects response to substance multiple interactions |
ISO |
Etoposide results in increased activity of MAPK12 protein MAPK12 protein affects the susceptibility to Etoposide [MAPK12 protein results in increased phosphorylation of TOP2A protein] which results in increased susceptibility to Etoposide; [MAPK12 protein results in increased stability of TOP2A protein] which results in increased susceptibility to Etoposide |
CTD |
PMID:21878638 |
|
NCBI chr15:89,014,787...89,025,270
Ensembl chr15:89,014,787...89,024,906
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased phosphorylation of MAPK3 protein]; Acetylcysteine inhibits the reaction [Etoposide results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Etoposide results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16014620 PMID:19720055 PMID:26046675 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapkapk2 |
MAP kinase-activated protein kinase 2 |
multiple interactions increases phosphorylation |
EXP |
(4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine inhibits the reaction [Etoposide results in increased phosphorylation of MAPKAPK2 protein] |
CTD |
PMID:17003255 |
|
NCBI chr 1:130,981,437...131,025,580
Ensembl chr 1:130,981,437...131,025,563
|
|
G |
Matn2 |
matrilin 2 |
affects response to substance |
ISO |
MATN2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:34,306,827...34,436,388
Ensembl chr15:34,306,823...34,436,419
|
|
G |
Mbp |
myelin basic protein |
affects response to substance |
ISO |
MBP protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr18:82,492,883...82,603,762
Ensembl chr18:82,493,271...82,603,762
|
|
G |
Mcam |
melanoma cell adhesion molecule |
increases expression |
EXP |
Etoposide results in increased expression of MCAM mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:44,045,958...44,054,024
Ensembl chr 9:44,045,766...44,054,024
|
|
G |
Mcl1 |
myeloid cell leukemia sequence 1 |
multiple interactions decreases expression |
ISO |
wortmannin promotes the reaction [Etoposide results in decreased expression of MCL1 protein] |
CTD |
PMID:17935137 |
|
NCBI chr 3:95,564,017...95,583,553
Ensembl chr 3:95,566,099...95,570,487
|
|
G |
Mcm10 |
minichromosome maintenance 10 replication initiation factor |
decreases expression |
ISO |
Etoposide results in decreased expression of MCM10 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 2:4,995,535...5,017,602
Ensembl chr 2:4,994,525...5,017,602
|
|
G |
Mcm2 |
minichromosome maintenance complex component 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of MCM2 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 6:88,860,456...88,875,762
Ensembl chr 6:88,860,456...88,875,762
|
|
G |
Mcm6 |
minichromosome maintenance complex component 6 |
decreases expression |
ISO |
Etoposide results in decreased expression of MCM6 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 1:128,259,312...128,287,442
Ensembl chr 1:128,259,327...128,287,401
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
decreases expression |
ISO |
Etoposide results in decreased expression of MCM7 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 5:138,162,845...138,170,675
Ensembl chr 5:138,162,845...138,170,684
|
|
G |
Mcm8 |
minichromosome maintenance 8 homologous recombination repair factor |
decreases expression |
ISO |
Etoposide results in decreased expression of MCM8 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 2:132,658,061...132,686,117
Ensembl chr 2:132,658,061...132,686,117
|
|
G |
Mdfic |
MyoD family inhibitor domain containing |
affects response to substance |
ISO |
MDFIC protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:15,720,660...15,802,168
Ensembl chr 6:15,720,660...15,802,168
|
|
G |
Mdh2 |
malate dehydrogenase 2, NAD (mitochondrial) |
multiple interactions |
EXP |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of MDH2 protein |
CTD |
PMID:29733421 |
|
NCBI chr 5:135,807,503...135,819,240
Ensembl chr 5:135,807,334...135,819,252
|
|
G |
Mdm2 |
transformed mouse 3T3 cell double minute 2 |
multiple interactions decreases expression increases phosphorylation increases expression decreases response to substance |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]]; Cadmium Chloride affects the reaction [Etoposide results in increased phosphorylation of MDM2 protein]; Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein modified form]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein]; Wortmannin promotes the reaction [Etoposide results in increased phosphorylation of MDM2 protein] Etoposide results in decreased expression of MDM2 protein Etoposide results in increased expression of MDM2 mRNA; Etoposide results in increased expression of MDM2 protein; Etoposide results in increased expression of MDM2 protein modified form Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased expression of MDM2 protein] MDM2 promoter SNP results in decreased susceptibility to Etoposide |
CTD |
PMID:15459018 PMID:16120219 PMID:17575151 PMID:17935137 PMID:18096571 PMID:25078064 PMID:25744307 PMID:26259609 PMID:30177839 PMID:31542801 More...
|
|
NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663
|
|
G |
Me2 |
malic enzyme 2, NAD(+)-dependent, mitochondrial |
decreases expression |
EXP |
Etoposide results in decreased expression of ME2 protein |
CTD |
PMID:29733421 |
|
NCBI chr18:73,898,025...73,949,326
Ensembl chr18:73,902,974...73,948,520
|
|
G |
Mir135b |
microRNA 135b |
increases expression |
ISO |
Etoposide results in increased expression of MIR135B mRNA |
CTD |
PMID:27570640 |
|
NCBI chr 1:132,125,826...132,125,922
Ensembl chr 1:132,125,826...132,125,922
|
|
G |
Mir139 |
microRNA 139 |
increases expression |
ISO |
Etoposide results in increased expression of MIR139 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 7:101,124,583...101,124,650
Ensembl chr 7:101,124,583...101,124,650
|
|
G |
Mir182 |
microRNA 182 |
increases expression |
ISO |
Etoposide results in increased expression of MIR182 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 6:30,165,917...30,165,991
Ensembl chr 6:30,165,917...30,165,991
|
|
G |
Mir196b |
microRNA 196b |
increases expression |
ISO |
Etoposide results in increased expression of MIR196B mRNA |
CTD |
PMID:27570640 |
|
NCBI chr 6:52,207,061...52,207,145
Ensembl chr 6:52,207,061...52,207,145
|
|
G |
Mir34c |
microRNA 34c |
increases expression |
ISO |
Etoposide results in increased expression of MIR34C mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 9:51,014,334...51,014,410
Ensembl chr 9:51,014,334...51,014,410
|
|
G |
Mir654 |
microRNA 654 |
increases response to substance |
ISO |
MIR654 mRNA results in increased susceptibility to Etoposide |
CTD |
PMID:20145152 |
|
NCBI chr12:109,689,652...109,689,735
Ensembl chr12:109,689,652...109,689,735
|
|
G |
Mlana |
melan-A |
affects response to substance |
ISO |
MLANA protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr19:29,674,956...29,685,847
Ensembl chr19:29,675,224...29,686,034
|
|
G |
Mllt11 |
myeloid/lymphoid or mixed-lineage leukemia; translocated to, 11 |
affects response to substance |
ISO |
MLLT11 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:95,125,852...95,139,486
Ensembl chr 3:95,126,446...95,139,482
|
|
G |
Mmp1b |
matrix metallopeptidase 1b (interstitial collagenase) |
decreases expression multiple interactions |
ISO |
Etoposide results in decreased expression of MMP1 protein pifithrin inhibits the reaction [Etoposide results in decreased expression of MMP1 protein] |
CTD |
PMID:18557930 |
|
NCBI chr 9:7,367,670...7,388,026
Ensembl chr 9:7,368,239...7,388,047
|
|
G |
Mocos |
molybdenum cofactor sulfurase |
affects response to substance |
ISO |
MOCOS protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr18:24,786,538...24,834,634
Ensembl chr18:24,786,748...24,834,632
|
|
G |
Mpo |
myeloperoxidase |
increases metabolic processing |
ISO |
MPO protein results in increased metabolism of Etoposide |
CTD |
PMID:16841962 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Mpzl1 |
myelin protein zero-like 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of MPZL1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 1:165,419,745...165,462,144
Ensembl chr 1:165,419,809...165,462,107
|
|
G |
Mr1 |
major histocompatibility complex, class I-related |
increases expression affects expression |
ISO |
Etoposide results in increased expression of MR1 mRNA Etoposide affects the expression of MR1 mRNA |
CTD |
PMID:21527772 PMID:25811541 |
|
NCBI chr 1:155,003,620...155,022,560
Ensembl chr 1:155,003,023...155,022,560
|
|
G |
Mras |
muscle and microspikes RAS |
decreases expression |
EXP |
Etoposide results in decreased expression of MRAS mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:99,267,473...99,319,505
Ensembl chr 9:99,267,473...99,319,434
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of MRC1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:14,234,225...14,336,834
Ensembl chr 2:14,234,203...14,336,868
|
|
G |
Mrm2 |
mitochondrial rRNA methyltransferase 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of MRM2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 5:140,313,429...140,317,653
Ensembl chr 5:140,313,429...140,317,653
|
|
G |
Msc |
musculin |
decreases expression |
EXP |
Etoposide results in decreased expression of MSC mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:14,823,570...14,826,216
Ensembl chr 1:14,823,570...14,826,216
|
|
G |
Msh6 |
mutS homolog 6 |
decreases expression |
ISO |
Etoposide results in decreased expression of MSH6 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr17:88,282,478...88,298,320
Ensembl chr17:88,282,490...88,298,320
|
|
G |
mt-Nd4 |
NADH dehydrogenase 4, mitochondrial |
increases expression |
ISO |
Etoposide results in increased expression of ND4 mRNA |
CTD |
PMID:26259609 |
|
NCBI chr MT:10,167...11,544
Ensembl chr MT:10,167...11,544
|
|
G |
Mt2 |
metallothionein 2 |
multiple interactions decreases expression |
ISO |
XAF1 protein affects the reaction [Etoposide results in decreased expression of MT2A protein] |
CTD |
PMID:28507149 |
|
NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NAD+ dependent), methenyltetrahydrofolate cyclohydrolase |
decreases expression |
EXP |
Etoposide results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 6:83,282,686...83,302,926
Ensembl chr 6:83,282,673...83,302,890
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation |
ISO |
Etoposide results in increased phosphorylation of MTOR protein |
CTD |
PMID:27769712 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Mtus1 |
mitochondrial tumor suppressor 1 |
affects response to substance |
ISO |
MTUS1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:41,443,949...41,587,318
Ensembl chr 8:41,443,951...41,586,763
|
|
G |
Mxi1 |
MAX interactor 1, dimerization protein |
affects response to substance |
ISO |
MXI1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr19:53,298,509...53,361,724
Ensembl chr19:53,298,949...53,364,241
|
|
G |
Myc |
myelocytomatosis oncogene |
decreases expression increases response to substance multiple interactions |
ISO |
Etoposide results in decreased expression of MYC; Etoposide results in decreased expression of MYC mRNA MYC protein results in increased susceptibility to Etoposide MYC protein promotes the reaction [Etoposide results in increased cleavage of CASP9 protein] |
CTD |
PMID:9454737 PMID:21324178 PMID:21527772 |
|
NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
|
|
G |
Mycn |
v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived |
multiple interactions decreases response to substance |
ISO |
[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Etoposide MYCN protein results in decreased susceptibility to Etoposide |
CTD |
PMID:10348353 |
|
NCBI chr12:12,986,094...12,991,837
Ensembl chr12:12,986,094...12,991,915
|
|
G |
Myh7 |
myosin, heavy polypeptide 7, cardiac muscle, beta |
decreases expression |
ISO |
Etoposide results in decreased expression of MYH7 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr14:55,208,141...55,232,083
Ensembl chr14:55,208,141...55,232,083
|
|
G |
Myl2 |
myosin, light polypeptide 2, regulatory, cardiac, slow |
decreases expression |
ISO |
Etoposide results in decreased expression of MYL2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 5:122,230,787...122,251,536
Ensembl chr 5:122,239,014...122,251,535
|
|
G |
Myl3 |
myosin, light polypeptide 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of MYL3 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 9:110,592,746...110,598,870
Ensembl chr 9:110,570,929...110,598,866
|
|
G |
Myom2 |
myomesin 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of MYOM2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 8:15,107,653...15,183,410
Ensembl chr 8:15,107,653...15,183,541
|
|
G |
Myot |
myotilin |
increases expression |
ISO |
Etoposide results in increased expression of MYOT mRNA |
CTD |
PMID:29397400 |
|
NCBI chr18:44,467,126...44,488,795
Ensembl chr18:44,467,141...44,488,791
|
|
G |
Myt1 |
myelin transcription factor 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of MYT1 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 2:181,405,099...181,469,579
Ensembl chr 2:181,405,125...181,469,590
|
|
G |
Nabp2 |
nucleic acid binding protein 2 |
multiple interactions increases acetylation |
ISO |
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid inhibits the reaction [Etoposide results in increased acetylation of NABP2 protein] |
CTD |
PMID:26170237 |
|
NCBI chr10:128,237,263...128,247,426
Ensembl chr10:128,237,264...128,247,361
|
|
G |
Nap1l1 |
nucleosome assembly protein 1-like 1 |
affects response to substance |
ISO |
NAP1L1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:111,308,754...111,334,011
Ensembl chr10:111,309,084...111,334,011
|
|
G |
Nck2 |
non-catalytic region of tyrosine kinase adaptor protein 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of NCK2 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:43,484,643...43,609,678
Ensembl chr 1:43,483,739...43,609,675
|
|
G |
Nectin2 |
nectin cell adhesion molecule 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of NECTIN2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:19,450,569...19,483,498
Ensembl chr 7:19,450,569...19,484,408
|
|
G |
Nedd9 |
neural precursor cell expressed, developmentally down-regulated gene 9 |
affects response to substance |
ISO |
NEDD9 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr13:41,463,392...41,640,836
Ensembl chr13:41,463,057...41,640,838
|
|
G |
Nek2 |
NIMA (never in mitosis gene a)-related expressed kinase 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of NEK2 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 1:191,553,622...191,565,161
Ensembl chr 1:191,553,556...191,565,162
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
decreases response to substance multiple interactions |
ISO |
NFE2L2 mRNA results in decreased susceptibility to Etoposide; NFE2L2 protein results in decreased susceptibility to Etoposide NFE2L2 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein]; NFE2L2 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:26708503 PMID:27982581 PMID:33148531 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
ISO |
NFKB1 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; NFKB1 protein affects the reaction [Etoposide results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:23396362 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions increases degradation |
ISO |
wortmannin inhibits the reaction [Etoposide results in increased degradation of NFKBIA protein] |
CTD |
PMID:12637521 PMID:17935137 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nherf1 |
NHERF family PDZ scaffold protein 1 |
increases expression |
EXP |
Etoposide results in increased expression of NHERF1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:115,054,138...115,072,009
Ensembl chr11:115,054,167...115,072,007
|
|
G |
Niban1 |
niban apoptosis regulator 1 |
affects response to substance |
ISO |
NIBAN1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:151,447,215...151,597,690
Ensembl chr 1:151,446,937...151,597,690
|
|
G |
Nit2 |
nitrilase family, member 2 |
multiple interactions |
EXP |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of NIT2 protein |
CTD |
PMID:29733421 |
|
NCBI chr16:56,977,028...56,987,695
Ensembl chr16:56,977,028...56,987,704
|
|
G |
Nmt2 |
N-myristoyltransferase 2 |
affects response to substance |
ISO |
NMT2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:3,285,249...3,329,914
Ensembl chr 2:3,285,249...3,329,914
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
increases expression |
ISO |
Etoposide results in increased expression of NOS2 mRNA Etoposide results in increased expression of NOS2 protein |
CTD |
PMID:15135310 PMID:26259609 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Npas1 |
neuronal PAS domain protein 1 |
increases expression |
ISO |
Etoposide results in increased expression of NPAS1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 7:16,189,643...16,210,741
Ensembl chr 7:16,189,646...16,211,653
|
|
G |
Npnt |
nephronectin |
increases expression |
EXP |
Etoposide results in increased expression of NPNT mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:132,587,506...132,656,052
Ensembl chr 3:132,587,506...132,656,052
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
affects response to substance increases expression multiple interactions |
ISO EXP |
NQO1 protein affects the susceptibility to Etoposide Etoposide results in increased expression of NQO1 mRNA HIPK2 protein promotes the reaction [Etoposide results in increased expression of NQO1 mRNA] |
CTD |
PMID:16217747 PMID:20980392 PMID:29397400 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of NR0B1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr X:85,235,381...85,239,553
Ensembl chr X:85,235,370...85,239,553
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
affects localization affects response to substance multiple interactions |
ISO |
Etoposide affects the localization of NR1H2 protein NR1H2 protein affects the susceptibility to Etoposide Etoposide promotes the reaction [NR1H2 protein results in increased expression of CETP mRNA]; NR1H2 mutant form inhibits the reaction [Etoposide results in increased expression of CETP mRNA] |
CTD |
PMID:25914138 |
|
NCBI chr 7:44,199,040...44,204,928
Ensembl chr 7:44,199,040...44,203,375
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions affects response to substance increases expression |
ISO |
Etoposide promotes the reaction [NR1H3 protein results in increased expression of CETP mRNA]; Etoposide results in increased expression of and affects the localization of NR1H3 protein; NR1H3 mutant form inhibits the reaction [Etoposide results in increased expression of CETP mRNA] NR1H3 protein affects the susceptibility to Etoposide Etoposide results in increased expression of NR1H3 mRNA |
CTD |
PMID:25914138 |
|
NCBI chr 2:91,014,406...91,033,189
Ensembl chr 2:91,014,406...91,033,179
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
affects response to substance multiple interactions increases activity |
ISO |
NR1I2 protein affects the susceptibility to Etoposide [Etoposide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:17279585 PMID:25455453 |
|
NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
Etoposide inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:171,041,503...171,046,414
Ensembl chr 1:171,041,539...171,048,270
|
|
G |
Nrap |
nebulin-related anchoring protein |
decreases expression |
ISO |
Etoposide results in decreased expression of NRAP mRNA |
CTD |
PMID:29397400 |
|
NCBI chr19:56,308,473...56,378,466
Ensembl chr19:56,308,467...56,378,469
|
|
G |
Nrg1 |
neuregulin 1 |
increases expression |
ISO |
Etoposide results in increased expression of NRG1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 8:32,299,493...33,381,858
Ensembl chr 8:32,304,579...33,374,825 Ensembl chr 8:32,304,579...33,374,825
|
|
G |
Nrip1 |
nuclear receptor interacting protein 1 |
affects response to substance decreases expression |
ISO |
NRIP1 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of NRIP1 mRNA; Etoposide results in decreased expression of NRIP1 protein |
CTD |
PMID:16217747 PMID:25914138 |
|
NCBI chr16:76,084,291...76,170,930
Ensembl chr16:76,084,288...76,170,715
|
|
G |
Nupr1 |
nuclear protein transcription regulator 1 |
affects response to substance decreases expression |
ISO EXP |
NUPR1 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of NUPR1 mRNA |
CTD |
PMID:16217747 PMID:25270620 |
|
NCBI chr 7:126,222,418...126,224,642
Ensembl chr 7:126,222,421...126,230,033
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
EXP |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of OAT protein |
CTD |
PMID:29733421 |
|
NCBI chr 7:132,159,204...132,178,127
Ensembl chr 7:132,159,207...132,178,127
|
|
G |
Oca2 |
oculocutaneous albinism II |
affects response to substance |
ISO |
OCA2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:55,889,341...56,186,266
Ensembl chr 7:55,889,508...56,186,266
|
|
G |
Ogg1 |
8-oxoguanine DNA-glycosylase 1 |
decreases expression multiple interactions |
EXP |
Etoposide results in decreased expression of OGG1 mRNA wogonin inhibits the reaction [Etoposide results in decreased expression of OGG1 mRNA] |
CTD |
PMID:23872129 |
|
NCBI chr 6:113,303,959...113,311,149
Ensembl chr 6:113,303,933...113,312,029
|
|
G |
P2rx7 |
purinergic receptor P2X, ligand-gated ion channel, 7 |
increases expression |
EXP |
Etoposide results in increased expression of P2RX7 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 5:122,781,990...122,830,399
Ensembl chr 5:122,781,974...122,829,495
|
|
G |
Pabpc1 |
poly(A) binding protein, cytoplasmic 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of PABPC1 protein |
CTD |
PMID:29733421 |
|
NCBI chr15:36,595,902...36,609,825
Ensembl chr15:36,595,905...36,609,912
|
|
G |
Palb2 |
partner and localizer of BRCA2 |
decreases expression |
ISO |
Etoposide results in decreased expression of PALB2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 7:121,706,485...121,732,203
Ensembl chr 7:121,706,485...121,732,208
|
|
G |
Papss2 |
3'-phosphoadenosine 5'-phosphosulfate synthase 2 |
increases expression |
EXP |
Etoposide results in increased expression of PAPSS2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:32,573,072...32,644,587
Ensembl chr19:32,573,190...32,644,587
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
increases cleavage multiple interactions increases degradation |
ISO |
Etoposide results in increased cleavage of PARP1 protein 3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of PARP1 protein]; [Colforsin co-treated with Theophylline] inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; [trigonelline co-treated with Etoposide] results in increased cleavage of PARP1 protein; BCL2 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; CD40LG protein inhibits the reaction [Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]; HTATIP2 protein promotes the reaction [Etoposide results in increased activity of PARP1 protein]; Nicotine inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; PTEN protein modified form promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; PTEN protein promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; Wortmannin promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; XAF1 protein affects the reaction [Etoposide results in increased cleavage of PARP1 protein] Niacin deficiency affects the reaction [Etoposide results in increased cleavage of PARP1 protein] |
CTD |
PMID:8840993 PMID:9454737 PMID:12690110 PMID:16014620 PMID:16545138 PMID:16799960 PMID:16807353 PMID:16844113 PMID:17516866 PMID:17935137 PMID:20457658 PMID:21801448 PMID:25447644 PMID:26259609 PMID:28507149 PMID:30890322 PMID:33148531 More...
|
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Pbk |
PDZ binding kinase |
affects response to substance |
ISO |
PBK protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:66,043,337...66,055,271
Ensembl chr14:66,043,286...66,055,271
|
|
G |
Pcbp2 |
poly(rC) binding protein 2 |
multiple interactions |
EXP |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of PCBP2 protein |
CTD |
PMID:29733421 |
|
NCBI chr15:102,378,974...102,408,503
Ensembl chr15:102,378,974...102,408,496
|
|
G |
Pcbp4 |
poly(rC) binding protein 4 |
decreases expression |
EXP |
Etoposide results in decreased expression of PCBP4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:106,330,181...106,341,211
Ensembl chr 9:106,330,490...106,341,211
|
|
G |
Pck2 |
phosphoenolpyruvate carboxykinase 2 (mitochondrial) |
decreases expression |
EXP |
Etoposide results in decreased expression of PCK2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr14:55,777,721...55,787,477
Ensembl chr14:55,777,723...55,788,699
|
|
G |
Pde4b |
phosphodiesterase 4B, cAMP specific |
affects response to substance |
ISO |
PDE4B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:101,944,529...102,464,459
Ensembl chr 4:101,944,740...102,464,456
|
|
G |
Pdgfc |
platelet-derived growth factor, C polypeptide |
affects response to substance |
ISO |
PDGFC protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:80,943,723...81,121,347
Ensembl chr 3:80,943,723...81,121,347
|
|
G |
Pdia3 |
protein disulfide isomerase associated 3 |
multiple interactions |
ISO |
[Bleomycin co-treated with Cisplatin co-treated with Etoposide] results in increased expression of PDIA3 protein |
CTD |
PMID:24478030 |
|
NCBI chr 2:121,244,383...121,269,168
Ensembl chr 2:121,244,256...121,269,168
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase, isoenzyme 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of PDK1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 2:71,703,398...71,734,202
Ensembl chr 2:71,703,568...71,734,202
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase, isoenzyme 4 |
increases expression |
ISO |
Etoposide results in increased expression of PDK4 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 6:5,483,351...5,496,278
Ensembl chr 6:5,483,351...5,496,309
|
|
G |
Pdlim3 |
PDZ and LIM domain 3 |
increases expression |
ISO |
Etoposide results in increased expression of PDLIM3 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 8:46,338,524...46,372,672
Ensembl chr 8:46,338,498...46,372,585
|
|
G |
Pelo |
pelota mRNA surveillance and ribosome rescue factor |
decreases expression |
ISO |
Etoposide results in decreased expression of PELO mRNA |
CTD |
PMID:24211769 |
|
NCBI chr13:115,224,891...115,226,694
Ensembl chr13:115,224,891...115,226,722
|
|
G |
Perp |
PERP, TP53 apoptosis effector |
increases expression |
EXP |
Etoposide results in increased expression of PERP mRNA |
CTD |
PMID:21382384 PMID:25270620 |
|
NCBI chr10:18,720,819...18,732,821
Ensembl chr10:18,720,768...18,732,821
|
|
G |
Phgdh |
3-phosphoglycerate dehydrogenase |
affects response to substance |
ISO |
PHGDH protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:98,220,487...98,247,285
Ensembl chr 3:98,220,486...98,247,306
|
|
G |
Phlda3 |
pleckstrin homology like domain, family A, member 3 |
increases expression |
EXP |
Etoposide results in increased expression of PHLDA3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:135,693,823...135,696,872
Ensembl chr 1:135,693,857...135,696,874
|
|
G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
multiple interactions |
ISO |
[Cisplatin co-treated with Etoposide] results in increased mutagenesis of PIGA |
CTD |
PMID:21826740 |
|
NCBI chr X:163,202,814...163,216,912
Ensembl chr X:163,202,783...163,216,912
|
|
G |
Pip5k1b |
phosphatidylinositol-4-phosphate 5-kinase, type 1 beta |
affects response to substance |
ISO |
PIP5K1B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr19:24,272,158...24,533,236
Ensembl chr19:24,272,158...24,533,236
|
|
G |
Plau |
plasminogen activator, urokinase |
increases expression |
ISO |
Etoposide results in increased expression of PLAU mRNA |
CTD |
PMID:21527772 |
|
NCBI chr14:20,886,730...20,893,456
Ensembl chr14:20,886,728...20,893,453
|
|
G |
Plk1 |
polo like kinase 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of PLK1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:121,758,658...121,769,107
Ensembl chr 7:121,758,662...121,769,096
|
|
G |
Plk2 |
polo like kinase 2 |
increases expression |
ISO |
Etoposide results in increased expression of PLK2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr13:110,531,578...110,537,378
Ensembl chr13:110,531,580...110,537,378
|
|
G |
Plk3 |
polo like kinase 3 |
increases expression |
ISO |
Etoposide results in increased expression of PLK3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 4:116,985,852...116,991,244
Ensembl chr 4:116,985,852...116,991,160
|
|
G |
Plp1 |
proteolipid protein (myelin) 1 |
affects response to substance |
ISO |
PLP1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:135,720,897...135,739,331
Ensembl chr X:135,723,420...135,740,482
|
|
G |
Plpp2 |
phospholipid phosphatase 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of PLPP2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:79,362,258...79,369,621
Ensembl chr10:79,362,264...79,369,630
|
|
G |
Pm20d1 |
peptidase M20 domain containing 1 |
increases expression |
EXP |
Etoposide results in increased expression of PM20D1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:131,725,122...131,749,210
Ensembl chr 1:131,725,119...131,749,211
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
Etoposide results in increased expression of PMAIP1 mRNA |
CTD |
PMID:21801448 |
|
NCBI chr18:66,591,675...66,598,629
Ensembl chr18:66,591,604...66,598,636
|
|
G |
Pmel |
premelanosome protein |
affects response to substance |
ISO |
PMEL protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:128,531,757...128,555,993
Ensembl chr10:128,540,064...128,556,107
|
|
G |
Pmp2 |
peripheral myelin protein 2 |
affects response to substance |
ISO |
PMP2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:10,244,911...10,248,945
Ensembl chr 3:10,244,911...10,248,989
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
affects response to substance |
ISO |
PMP22 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr11:63,019,808...63,050,373
Ensembl chr11:63,019,808...63,050,373
|
|
G |
Polq |
polymerase (DNA directed), theta |
decreases response to substance |
EXP |
POLQ results in decreased susceptibility to Etoposide |
CTD |
PMID:21883722 |
|
NCBI chr16:36,832,104...36,922,321
Ensembl chr16:36,832,148...36,915,779
|
|
G |
Polr1h |
RNA polymerase I subunit H |
decreases response to substance multiple interactions |
ISO |
POLR1H protein results in decreased susceptibility to Etoposide Verapamil inhibits the reaction [POLR1H protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:14726695 |
|
NCBI chr17:37,265,250...37,269,417
Ensembl chr17:37,265,248...37,269,451
|
|
G |
Postn |
periostin, osteoblast specific factor |
increases expression |
ISO |
Etoposide results in increased expression of POSTN mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 3:54,266,688...54,298,462
Ensembl chr 3:54,268,530...54,298,458
|
|
G |
Pou5f1 |
POU domain, class 5, transcription factor 1 |
increases expression |
ISO |
Etoposide results in increased expression of POU5F1 mRNA; Etoposide results in increased expression of POU5F1 protein |
CTD |
PMID:33969609 |
|
NCBI chr17:35,816,929...35,821,674
Ensembl chr17:35,816,915...35,821,669
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of PPARGC1A mRNA Etoposide promotes the reaction [PPARGC1A protein results in increased activity of ESRRA protein] |
CTD |
PMID:26259609 PMID:30818834 |
|
NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068
|
|
G |
Ppargc1b |
peroxisome proliferative activated receptor, gamma, coactivator 1 beta |
increases expression |
ISO |
Etoposide results in increased expression of PPARGC1B mRNA |
CTD |
PMID:26259609 |
|
NCBI chr18:61,424,516...61,533,846
Ensembl chr18:61,431,207...61,533,502
|
|
G |
Ppm1d |
protein phosphatase 1D magnesium-dependent, delta isoform |
increases expression |
ISO |
Etoposide results in increased expression of PPM1D protein |
CTD |
PMID:25078064 |
|
NCBI chr11:85,202,080...85,237,897
Ensembl chr11:85,202,070...85,237,892
|
|
G |
Ppp1r13l |
protein phosphatase 1, regulatory subunit 13 like |
decreases response to substance multiple interactions increases expression |
ISO |
PPP1R13L results in decreased susceptibility to Etoposide Etoposide results in increased expression of and results in increased localization of PPP1R13L protein Etoposide results in increased expression of PPP1R13L mRNA |
CTD |
PMID:17570360 PMID:19299014 |
|
NCBI chr 7:19,093,639...19,112,465
Ensembl chr 7:19,093,674...19,112,458
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of PRC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 7:79,944,224...79,966,007
Ensembl chr 7:79,944,198...79,966,007
|
|
G |
Prdx1 |
peroxiredoxin 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of PRDX1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 4:116,542,796...116,557,196
Ensembl chr 4:116,542,741...116,558,019
|
|
G |
Prkab1 |
protein kinase, AMP-activated, beta 1 non-catalytic subunit |
increases expression |
ISO |
Etoposide results in increased expression of PRKAB1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 5:116,151,654...116,162,449
Ensembl chr 5:116,151,645...116,162,567
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
ISO |
Etoposide results in increased cleavage of and results in increased activity of PRKCD protein |
CTD |
PMID:19662097 |
|
NCBI chr14:30,317,310...30,348,637
Ensembl chr14:30,317,311...30,348,167
|
|
G |
Prkcz |
protein kinase C, zeta |
increases response to substance |
ISO |
PRKCZ protein results in increased susceptibility to Etoposide |
CTD |
PMID:21863889 |
|
NCBI chr 4:155,344,579...155,445,856
Ensembl chr 4:155,344,586...155,445,818
|
|
G |
Prkdc |
protein kinase, DNA activated, catalytic polypeptide |
increases phosphorylation multiple interactions |
ISO |
Etoposide results in increased phosphorylation of PRKDC protein PRKDC protein promotes the reaction [Etoposide results in increased phosphorylation of SP1 protein] |
CTD |
PMID:17441964 |
|
NCBI chr16:15,455,698...15,660,103
Ensembl chr16:15,455,730...15,660,099
|
|
G |
Prkx |
protein kinase, X-linked |
increases expression |
ISO |
Etoposide results in increased expression of PRKX mRNA |
CTD |
PMID:29397400 |
|
NCBI chr X:76,804,578...76,839,545
Ensembl chr X:76,805,017...76,839,884
|
|
G |
Prnp |
prion protein |
decreases response to substance |
ISO |
PRNP protein results in decreased susceptibility to Etoposide |
CTD |
PMID:15386405 |
|
NCBI chr 2:131,751,848...131,780,356
Ensembl chr 2:131,751,848...131,780,349
|
|
G |
Procr |
protein C receptor, endothelial |
increases expression |
ISO |
Etoposide results in increased expression of PROCR mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:155,592,159...155,597,391
Ensembl chr 2:155,593,037...155,597,391
|
|
G |
Psmd13 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 13 |
multiple interactions |
EXP |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of PSMD13 protein |
CTD |
PMID:29733421 |
|
NCBI chr 7:140,462,307...140,478,555
Ensembl chr 7:140,461,881...140,478,556
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions increases response to substance |
ISO |
PTEN protein inhibits the reaction [Etoposide results in increased phosphorylation of and results in increased activity of AKT1 protein]; PTEN protein modified form promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; PTEN protein promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; wortmannin inhibits the reaction [PTEN protein results in increased susceptibility to Etoposide] |
CTD |
PMID:16807353 PMID:17935137 |
|
NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of PTGS2 protein PTGS2 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:24184161 PMID:26259609 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Pus3 |
pseudouridine synthase 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of PUS3 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 9:35,469,856...35,478,697
Ensembl chr 9:35,469,891...35,478,697
|
|
G |
Pygm |
muscle glycogen phosphorylase |
decreases expression |
ISO |
Etoposide results in decreased expression of PYGM mRNA |
CTD |
PMID:29397400 |
|
NCBI chr19:6,434,438...6,448,494
Ensembl chr19:6,434,429...6,448,489
|
|
G |
Rab17 |
RAB17, member RAS oncogene family |
affects response to substance |
ISO |
RAB17 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:90,885,855...90,897,395
Ensembl chr 1:90,885,855...90,897,383
|
|
G |
Rab20 |
RAB20, member RAS oncogene family |
affects response to substance |
ISO |
RAB20 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:11,503,390...11,528,640
Ensembl chr 8:11,503,518...11,528,710
|
|
G |
Rad51 |
RAD51 recombinase |
affects localization |
ISO |
Etoposide affects the localization of RAD51 protein |
CTD |
PMID:9885240 |
|
NCBI chr 2:118,943,295...118,966,554
Ensembl chr 2:118,943,274...118,977,926
|
|
G |
Rad52 |
RAD52 homolog, DNA repair protein |
multiple interactions increases expression |
ISO |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD52 protein] Etoposide results in increased expression of RAD52 mRNA; Etoposide results in increased expression of RAD52 protein |
CTD |
PMID:16417649 PMID:19799994 |
|
NCBI chr 6:119,878,781...119,899,789
Ensembl chr 6:119,879,659...119,899,789
|
|
G |
Rad54b |
RAD54 homolog B (S. cerevisiae) |
multiple interactions |
EXP |
RAD54B protein affects the reaction [Etoposide results in increased expression of H2AX protein] |
CTD |
PMID:33823233 |
|
NCBI chr 4:11,558,930...11,615,806
Ensembl chr 4:11,558,922...11,615,805
|
|
G |
Rad54l |
RAD54 like (S. cerevisiae) |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of RAD54L protein BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD54L protein] |
CTD |
PMID:16417649 |
|
NCBI chr 4:115,951,458...115,980,875
Ensembl chr 4:115,951,461...115,980,887
|
|
G |
Rasip1 |
Ras interacting protein 1 |
affects response to substance |
ISO |
RASIP1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:45,276,961...45,288,516
Ensembl chr 7:45,276,912...45,288,517
|
|
G |
Rassf1 |
Ras association (RalGDS/AF-6) domain family member 1 |
multiple interactions increases response to substance |
ISO |
[RASSF1 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [RASSF1 co-treated with Etoposide] results in increased cleavage of CASP3 protein; [RASSF1 co-treated with Etoposide] results in increased expression of CDKN1A protein; ABT-737 promotes the reaction [RASSF1 results in increased susceptibility to Etoposide] |
CTD |
PMID:21880625 |
|
NCBI chr 9:107,428,752...107,439,460
Ensembl chr 9:107,428,754...107,439,466
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
affects response to substance decreases phosphorylation multiple interactions |
ISO |
RB1 protein affects the susceptibility to Etoposide Etoposide results in decreased phosphorylation of RB1 protein [Colforsin co-treated with Theophylline] inhibits the reaction [Etoposide results in decreased phosphorylation of RB1 protein] |
CTD |
PMID:9454737 PMID:17640669 |
|
NCBI chr14:73,430,298...73,563,446
Ensembl chr14:73,421,113...73,563,262
|
|
G |
Rbm17 |
RNA binding motif protein 17 |
decreases response to substance |
ISO |
RBM17 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:16061639 |
|
NCBI chr 2:11,590,250...11,608,061
Ensembl chr 2:11,590,248...11,608,964
|
|
G |
Rbm34 |
RNA binding motif protein 34 |
decreases expression |
ISO |
Etoposide results in decreased expression of RBM34 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 8:127,673,922...127,697,799
Ensembl chr 8:127,673,922...127,697,821
|
|
G |
Rcan1 |
regulator of calcineurin 1 |
affects response to substance |
ISO |
RCAN1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:92,188,839...92,263,057
Ensembl chr16:92,188,841...92,267,755
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide] |
CTD |
PMID:19047049 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Retsat |
retinol saturase (all trans retinol 13,14 reductase) |
increases expression |
ISO |
Etoposide results in increased expression of RETSAT mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 6:72,575,585...72,584,471
Ensembl chr 6:72,575,458...72,585,408
|
|
G |
Rfc1 |
replication factor C (activator 1) 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of RFC1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 5:65,419,195...65,492,988
Ensembl chr 5:65,419,193...65,493,013
|
|
G |
Rgcc |
regulator of cell cycle |
increases expression |
ISO |
Etoposide results in increased expression of RGCC mRNA |
CTD |
PMID:29397400 |
|
NCBI chr14:79,526,190...79,539,075
Ensembl chr14:79,526,196...79,539,085
|
|
G |
Ripk2 |
receptor (TNFRSF)-interacting serine-threonine kinase 2 |
multiple interactions increases expression |
ISO |
Estradiol inhibits the reaction [Etoposide results in increased expression of RIPK2 mRNA] |
CTD |
PMID:19426747 |
|
NCBI chr 4:16,122,740...16,163,674
Ensembl chr 4:16,122,733...16,163,647
|
|
G |
Ripply3 |
ripply transcriptional repressor 3 |
increases expression |
ISO |
Etoposide results in increased expression of RIPPLY3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr16:94,129,281...94,137,794
Ensembl chr16:94,129,279...94,137,794
|
|
G |
Rnf113a1 |
ring finger protein 113A1 |
decreases expression |
ISO |
Etoposide results in decreased expression of RNF113A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr X:36,454,875...36,456,120
Ensembl chr X:36,454,898...36,456,120
|
|
G |
Robo1 |
roundabout guidance receptor 1 |
affects response to substance |
ISO |
ROBO1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:71,824,406...72,844,379
Ensembl chr16:72,105,194...72,842,983
|
|
G |
Robo3 |
roundabout guidance receptor 3 |
increases expression |
ISO |
Etoposide results in increased expression of ROBO3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 9:37,327,341...37,344,730
Ensembl chr 9:37,326,965...37,344,542
|
|
G |
Ropn1 |
ropporin, rhophilin associated protein 1 |
affects response to substance |
ISO |
ROPN1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:34,470,271...34,498,980
Ensembl chr16:34,470,291...34,498,988
|
|
G |
Rpl6 |
ribosomal protein L6 |
decreases response to substance |
ISO |
RPL6 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:15846068 |
|
NCBI chr 5:121,342,564...121,347,304
Ensembl chr 5:121,342,544...121,347,304
|
|
G |
Rps27l |
ribosomal protein S27-like |
increases expression |
ISO |
Etoposide results in increased expression of RPS27L protein |
CTD |
PMID:18056458 |
|
NCBI chr 9:66,851,906...66,856,804
Ensembl chr 9:66,853,368...66,856,798
|
|
G |
Rps6 |
ribosomal protein S6 |
increases phosphorylation |
ISO |
Etoposide results in increased phosphorylation of RPS6 protein |
CTD |
PMID:23396362 |
|
NCBI chr 4:86,772,336...86,775,604
Ensembl chr 4:86,772,897...86,775,649
|
|
G |
Rras |
related RAS viral (r-ras) oncogene |
increases expression |
ISO |
Etoposide results in increased expression of RRAS mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 7:44,665,686...44,671,070
Ensembl chr 7:44,667,385...44,671,071
|
|
G |
Rrm2b |
ribonucleotide reductase M2 B (TP53 inducible) |
increases expression |
ISO |
Etoposide results in increased expression of RRM2B mRNA |
CTD |
PMID:21704725 |
|
NCBI chr15:37,924,196...37,961,562
Ensembl chr15:37,924,196...37,961,562
|
|
G |
Rtkn |
rhotekin |
increases expression |
EXP |
Etoposide results in increased expression of RTKN mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 6:83,112,485...83,129,560
Ensembl chr 6:83,112,444...83,129,560
|
|
G |
Runx1 |
runt related transcription factor 1 |
increases response to substance increases mutagenesis |
ISO |
RUNX1 gene mutant form results in increased susceptibility to Etoposide Etoposide results in increased mutagenesis of RUNX1 gene |
CTD |
PMID:15217836 PMID:28624474 |
|
NCBI chr16:92,398,354...92,622,962
Ensembl chr16:92,398,354...92,623,037
|
|
G |
Runx3 |
runt related transcription factor 3 |
increases response to substance |
ISO |
RUNX3 protein results in increased susceptibility to Etoposide |
CTD |
PMID:15756676 |
|
NCBI chr 4:134,847,956...134,905,301
Ensembl chr 4:134,847,963...134,905,301
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
Etoposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]; Tretinoin promotes the reaction [Etoposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]] |
CTD |
PMID:25914138 |
|
NCBI chr 2:27,566,457...27,653,331
Ensembl chr 2:27,566,452...27,652,969
|
|
G |
Ryr2 |
ryanodine receptor 2, cardiac |
decreases expression |
ISO |
Etoposide results in decreased expression of RYR2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr13:11,567,985...12,121,831
Ensembl chr13:11,567,988...12,121,831
|
|
G |
Scn3b |
sodium channel, voltage-gated, type III, beta |
increases expression |
EXP |
Etoposide results in increased expression of SCN3B mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:40,180,512...40,202,914
Ensembl chr 9:40,180,513...40,202,914
|
|
G |
Scn4b |
sodium channel, type IV, beta |
increases expression |
ISO |
Etoposide results in increased expression of SCN4B mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 9:45,049,922...45,065,453
Ensembl chr 9:45,049,693...45,065,450
|
|
G |
Sdc1 |
syndecan 1 |
increases expression |
ISO |
Etoposide results in increased expression of SDC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr12:8,821,396...8,843,716
Ensembl chr12:8,821,323...8,843,715
|
|
G |
Sdhaf1 |
succinate dehydrogenase complex assembly factor 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of SDHAF1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 7:30,020,834...30,021,800
Ensembl chr 7:30,020,831...30,023,320
|
|
G |
Serpine2 |
serine (or cysteine) peptidase inhibitor, clade E, member 2 |
increases expression |
EXP |
Etoposide results in increased expression of SERPINE2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:79,772,038...79,836,382
Ensembl chr 1:79,771,914...79,838,897
|
|
G |
Sesn1 |
sestrin 1 |
increases expression |
ISO |
Etoposide results in increased expression of SESN1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr10:41,686,570...41,784,432
Ensembl chr10:41,685,931...41,784,420
|
|
G |
Sfn |
stratifin |
increases expression |
ISO |
Etoposide results in increased expression of SFN mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:133,327,867...133,329,163
Ensembl chr 4:133,327,867...133,329,479
|
|
G |
Slbp |
stem-loop binding protein |
decreases expression |
ISO |
Etoposide results in decreased expression of SLBP mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 5:33,797,399...33,809,918
Ensembl chr 5:33,792,296...33,809,918
|
|
G |
Slc16a6 |
solute carrier family 16 (monocarboxylic acid transporters), member 6 |
affects response to substance |
ISO |
SLC16A6 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr11:109,341,681...109,366,428
Ensembl chr11:109,341,681...109,364,424
|
|
G |
Slc1a5 |
solute carrier family 1 (neutral amino acid transporter), member 5 |
decreases expression |
ISO |
Etoposide results in decreased expression of SLC1A5 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 7:16,515,259...16,532,199
Ensembl chr 7:16,515,265...16,532,199
|
|
G |
Slc22a18 |
solute carrier family 22 (organic cation transporter), member 18 |
affects response to substance |
ISO |
SLC22A18 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:143,027,502...143,053,071
Ensembl chr 7:143,027,473...143,053,071
|
|
G |
Slc27a3 |
solute carrier family 27 (fatty acid transporter), member 3 |
affects response to substance |
ISO |
SLC27A3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:90,292,540...90,298,693
Ensembl chr 3:90,292,546...90,297,245
|
|
G |
Slc2a6 |
solute carrier family 2 (facilitated glucose transporter), member 6 |
increases expression |
ISO |
Etoposide results in increased expression of SLC2A6 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:26,911,375...26,918,011
Ensembl chr 2:26,911,375...26,918,010
|
|
G |
Slc35f2 |
solute carrier family 35, member F2 |
decreases expression |
EXP |
Etoposide results in decreased expression of SLC35F2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:53,678,733...53,725,445
Ensembl chr 9:53,678,822...53,725,438
|
|
G |
Slc45a3 |
solute carrier family 45, member 3 |
multiple interactions |
ISO |
Etoposide inhibits the reaction [Dihydrotestosterone results in increased expression of SLC45A3 mRNA] |
CTD |
PMID:20601956 |
|
NCBI chr 1:131,890,653...131,910,710
Ensembl chr 1:131,890,705...131,910,707
|
|
G |
Slc4a11 |
solute carrier family 4, sodium bicarbonate transporter-like, member 11 |
increases expression |
EXP |
Etoposide results in increased expression of SLC4A11 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:130,526,027...130,539,439
Ensembl chr 2:130,526,033...130,539,439
|
|
G |
Slc7a11 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 |
affects response to substance |
ISO |
SLC7A11 protein affects the susceptibility to Etoposide |
CTD |
PMID:31226288 |
|
NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063
|
|
G |
Slc7a3 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 3 |
decreases expression |
EXP |
Etoposide results in decreased expression of SLC7A3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr X:100,122,752...100,134,058
Ensembl chr X:100,122,816...100,129,626
|
|
G |
Slc7a5 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 |
affects response to substance |
ISO |
SLC7A5 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:122,607,885...122,634,425
Ensembl chr 8:122,607,889...122,634,433
|
|
G |
Slc8a1 |
solute carrier family 8 (sodium/calcium exchanger), member 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of SLC8A1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr17:81,680,534...82,045,816
Ensembl chr17:81,680,534...82,045,806
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions |
ISO |
Etoposide inhibits the reaction [SLCO2B1 protein results in increased uptake of Cascade Blue] |
CTD |
PMID:30863990 |
|
NCBI chr 7:99,307,011...99,360,547
Ensembl chr 7:99,307,011...99,360,547
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions increases phosphorylation |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Etoposide results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:22363485 |
|
NCBI chr18:76,369,898...76,444,819
Ensembl chr18:76,374,651...76,444,034
|
|
G |
Smpdl3a |
sphingomyelin phosphodiesterase, acid-like 3A |
affects response to substance |
ISO |
SMPDL3A protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:57,670,640...57,687,926
Ensembl chr10:57,670,431...57,687,926
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
increases expression decreases response to substance |
ISO |
Etoposide results in increased expression of SOD2 protein SOD2 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:10759716 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Sohlh1 |
spermatogenesis and oogenesis specific basic helix-loop-helix 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of SOHLH1 mRNA |
CTD |
PMID:29733421 |
|
NCBI chr 2:25,733,007...25,737,347
Ensembl chr 2:25,733,007...25,737,260
|
|
G |
Sorbs1 |
sorbin and SH3 domain containing 1 |
affects response to substance |
ISO |
SORBS1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr19:40,280,484...40,502,399
Ensembl chr19:40,283,197...40,502,223
|
|
G |
Sorbs2 |
sorbin and SH3 domain containing 2 |
affects response to substance |
ISO |
SORBS2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:45,960,470...46,280,943
Ensembl chr 8:45,960,825...46,280,943
|
|
G |
Sort1 |
sortilin 1 |
affects response to substance |
ISO |
SORT1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:108,191,272...108,268,835
Ensembl chr 3:108,191,398...108,268,827
|
|
G |
Sox10 |
SRY (sex determining region Y)-box 10 |
affects response to substance |
ISO |
SOX10 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:79,039,113...79,048,690
Ensembl chr15:79,039,108...79,049,440
|
|
G |
Sox2 |
SRY (sex determining region Y)-box 2 |
multiple interactions |
ISO |
FTL protein affects the reaction [Etoposide results in increased expression of SOX2 protein] |
CTD |
PMID:33969609 |
|
NCBI chr 3:34,704,144...34,706,610
Ensembl chr 3:34,704,554...34,706,610
|
|
G |
Sp1 |
trans-acting transcription factor 1 |
increases phosphorylation increases expression increases activity multiple interactions |
ISO |
Etoposide results in increased phosphorylation of SP1 protein Etoposide results in increased expression of SP1 mRNA Etoposide results in increased activity of SP1 protein cordycepin inhibits the reaction [Etoposide results in increased activity of SP1 protein]; cordycepin inhibits the reaction [Etoposide results in increased expression of SP1 mRNA] PRKDC protein promotes the reaction [Etoposide results in increased phosphorylation of SP1 protein]; wortmannin inhibits the reaction [Etoposide results in increased phosphorylation of SP1 protein] |
CTD |
PMID:17441964 PMID:23690541 |
|
NCBI chr15:102,314,751...102,344,839
Ensembl chr15:102,314,578...102,344,839
|
|
G |
Spata18 |
spermatogenesis associated 18 |
increases expression |
ISO |
Etoposide results in increased expression of SPATA18 mRNA |
CTD |
PMID:21527772 PMID:29397400 |
|
NCBI chr 5:73,808,723...73,836,927
Ensembl chr 5:73,808,722...73,836,855
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
affects response to substance decreases expression |
ISO EXP |
SPP1 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of SPP1 mRNA |
CTD |
PMID:16217747 PMID:25270620 |
|
NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916
|
|
G |
Sptssa |
serine palmitoyltransferase, small subunit A |
affects response to substance |
ISO |
SPTSSA protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr12:54,692,159...54,703,357
Ensembl chr12:54,692,177...54,703,358
|
|
G |
Srxn1 |
sulfiredoxin 1 homolog (S. cerevisiae) |
increases expression multiple interactions |
EXP ISO |
Etoposide results in increased expression of SRXN1 mRNA; Etoposide results in increased expression of SRXN1 protein NFE2L2 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein]; TP53 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein] |
CTD |
PMID:22003191 PMID:27358234 PMID:27982581 |
|
NCBI chr 2:151,946,738...151,953,296
Ensembl chr 2:151,947,436...151,953,296
|
|
G |
St3gal5 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 5 |
decreases response to substance |
EXP |
ST3GAL5 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:16571667 |
|
NCBI chr 6:72,074,555...72,131,555
Ensembl chr 6:72,074,576...72,131,555
|
|
G |
St6galnac2 |
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 |
affects response to substance |
ISO |
ST6GALNAC2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr11:116,567,529...116,586,608
Ensembl chr11:116,566,129...116,585,694 Ensembl chr11:116,566,129...116,585,694
|
|
G |
St7 |
suppression of tumorigenicity 7 |
affects response to substance |
ISO |
ST7 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:17,693,579...17,943,022
Ensembl chr 6:17,692,932...17,943,024
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
[STAT1 protein results in increased activity of CASP3 protein] which results in increased susceptibility to Etoposide; [STAT1 protein results in increased activity of CASP7 protein] which results in increased susceptibility to Etoposide |
CTD |
PMID:18649362 |
|
NCBI chr 1:52,158,588...52,201,024
Ensembl chr 1:52,158,599...52,201,024
|
|
G |
Stc1 |
stanniocalcin 1 |
increases expression |
ISO |
Etoposide results in increased expression of STC1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr14:69,266,738...69,278,850
Ensembl chr14:69,266,687...69,279,253
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
increases expression |
EXP |
Etoposide results in increased expression of STIP1 protein |
CTD |
PMID:29733421 |
|
NCBI chr19:6,998,064...7,017,394
Ensembl chr19:6,998,070...7,017,335
|
|
G |
Stmn1 |
stathmin 1 |
affects response to substance |
ISO |
STMN1 affects the susceptibility to Etoposide |
CTD |
PMID:17172428 |
|
NCBI chr 4:134,195,631...134,201,154
Ensembl chr 4:134,195,631...134,201,154
|
|
G |
Stmn2 |
stathmin-like 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of STMN2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:8,574,587...8,626,664
Ensembl chr 3:8,574,420...8,626,666
|
|
G |
Stom |
stomatin |
increases expression |
ISO |
Etoposide results in increased expression of STOM mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:35,204,002...35,227,021
Ensembl chr 2:35,203,998...35,226,988
|
|
G |
Synb |
syncytin b |
affects response to substance |
ISO |
ERVFRD-1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:69,527,827...69,549,857
Ensembl chr14:69,526,793...69,531,748
|
|
G |
Sytl1 |
synaptotagmin-like 1 |
increases expression |
EXP |
Etoposide results in increased expression of SYTL1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:132,980,401...132,990,398
Ensembl chr 4:132,980,401...132,990,424
|
|
G |
Tap1 |
transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) |
increases expression |
ISO |
Etoposide results in increased expression of TAP1 mRNA |
CTD |
PMID:17374387 PMID:21527772 |
|
NCBI chr17:34,406,530...34,416,199
Ensembl chr17:34,406,527...34,416,199
|
|
G |
Tax1bp3 |
Tax1 (human T cell leukemia virus type I) binding protein 3 |
increases expression |
ISO |
Etoposide results in increased expression of TAX1BP3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr11:73,067,909...73,072,872
Ensembl chr11:73,067,909...73,073,988
|
|
G |
Tbc1d8 |
TBC1 domain family, member 8 |
increases expression |
EXP |
Etoposide results in increased expression of TBC1D8 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:39,410,576...39,517,860
Ensembl chr 1:39,410,573...39,517,836
|
|
G |
Tbl1x |
transducin (beta)-like 1 X-linked |
decreases expression |
EXP |
Etoposide results in decreased expression of TBL1X mRNA |
CTD |
PMID:25270620 |
|
NCBI chr X:76,553,053...76,706,591
Ensembl chr X:76,554,619...76,706,589
|
|
G |
Tbpl1 |
TATA box binding protein-like 1 |
affects localization |
EXP |
Etoposide affects the localization of TBPL1 protein |
CTD |
PMID:17085973 |
|
NCBI chr10:22,579,776...22,607,882
Ensembl chr10:22,579,778...22,607,837
|
|
G |
Tcap |
titin-cap |
decreases expression |
ISO |
Etoposide results in decreased expression of TCAP mRNA |
CTD |
PMID:29397400 |
|
NCBI chr11:98,274,637...98,275,779
Ensembl chr11:98,274,637...98,275,779
|
|
G |
Tcfl5 |
transcription factor-like 5 (basic helix-loop-helix) |
affects response to substance |
ISO |
TCFL5 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:180,263,749...180,284,540
Ensembl chr 2:180,263,749...180,284,501
|
|
G |
Tcp1 |
t-complex protein 1 |
multiple interactions |
EXP |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of TCP1 protein |
CTD |
PMID:29733421 |
|
NCBI chr17:13,135,216...13,143,954
Ensembl chr17:13,134,588...13,143,954
|
|
G |
Tdrd3 |
tudor domain containing 3 |
affects response to substance |
ISO |
TDRD3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:87,647,598...87,782,944
Ensembl chr14:87,654,075...87,782,940
|
|
G |
Tent5a |
terminal nucleotidyltransferase 5A |
affects response to substance |
ISO |
TENT5A protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:85,202,492...85,209,203
Ensembl chr 9:85,202,492...85,209,401
|
|
G |
Tex264 |
testis expressed gene 264 ER-phagy receptor |
decreases expression |
EXP |
Etoposide results in decreased expression of TEX264 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:106,535,945...106,563,151
Ensembl chr 9:106,535,945...106,563,126
|
|
G |
Tfam |
transcription factor A, mitochondrial |
increases expression |
ISO |
Etoposide results in increased expression of TFAM mRNA |
CTD |
PMID:26259609 |
|
NCBI chr10:71,061,298...71,074,157
Ensembl chr10:71,061,294...71,074,110
|
|
G |
Tfap2a |
transcription factor AP-2, alpha |
affects response to substance increases response to substance |
ISO |
TFAP2A protein affects the susceptibility to Etoposide TFAP2A protein results in increased susceptibility to Etoposide |
CTD |
PMID:16204029 PMID:16217747 |
|
NCBI chr13:40,867,278...40,891,715
Ensembl chr13:40,868,778...40,891,852
|
|
G |
Tfec |
transcription factor EC |
decreases expression |
ISO |
Etoposide results in decreased expression of TFEC mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 6:16,830,926...16,898,463
Ensembl chr 6:16,833,372...16,898,440
|
|
G |
Tff3 |
trefoil factor 3, intestinal |
affects response to substance |
ISO |
TFF3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:31,344,280...31,348,585
Ensembl chr17:31,344,280...31,348,620
|
|
G |
Tfpi |
tissue factor pathway inhibitor |
affects response to substance |
ISO |
TFPI protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:84,263,199...84,307,119
Ensembl chr 2:84,263,199...84,307,119
|
|
G |
Tfpi2 |
tissue factor pathway inhibitor 2 |
affects response to substance |
ISO |
TFPI2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:3,962,589...3,988,977
Ensembl chr 6:3,962,595...3,988,919
|
|
G |
Tfrc |
transferrin receptor |
decreases expression multiple interactions |
ISO |
Etoposide results in decreased expression of TFRC mRNA; Etoposide results in decreased expression of TFRC protein 1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine inhibits the reaction [Etoposide results in decreased expression of TFRC protein] |
CTD |
PMID:33969609 |
|
NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612
|
|
G |
Tgds |
TDP-glucose 4,6-dehydratase |
affects response to substance |
ISO |
TGDS protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:118,349,323...118,370,177
Ensembl chr14:118,349,323...118,370,167
|
|
G |
Tgfa |
transforming growth factor alpha |
increases expression |
ISO |
Etoposide results in increased expression of TGFA mRNA |
CTD |
PMID:15228094 |
|
NCBI chr 6:86,172,020...86,252,726
Ensembl chr 6:86,172,205...86,252,701
|
|
G |
Tgif2 |
TGFB-induced factor homeobox 2 |
decreases expression |
EXP |
Etoposide results in decreased expression of TGIF2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:156,681,737...156,697,490
Ensembl chr 2:156,681,927...156,697,490
|
|
G |
Thbs4 |
thrombospondin 4 |
increases expression |
ISO |
Etoposide results in increased expression of THBS4 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr13:92,888,094...92,931,326
Ensembl chr13:92,888,098...92,931,326
|
|
G |
Tipin |
timeless interacting protein |
decreases expression |
ISO |
Etoposide results in decreased expression of TIPIN mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 9:64,188,776...64,212,704
Ensembl chr 9:64,188,863...64,212,706
|
|
G |
Tm7sf3 |
transmembrane 7 superfamily member 3 |
increases expression |
EXP |
Etoposide results in increased expression of TM7SF3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 6:146,503,774...146,536,103
Ensembl chr 6:146,503,850...146,544,322
|
|
G |
Tmbim4 |
transmembrane BAX inhibitor motif containing 4 |
increases expression |
EXP |
Etoposide results in increased expression of TMBIM4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:120,044,731...120,060,802
Ensembl chr10:120,037,495...120,060,822
|
|
G |
Tmc6 |
transmembrane channel-like gene family 6 |
affects response to substance |
ISO |
TMC6 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr11:117,656,811...117,673,019
Ensembl chr11:117,656,814...117,673,024
|
|
G |
Tmem185b |
transmembrane protein 185B |
decreases expression |
ISO |
Etoposide results in decreased expression of TMEM185B mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 1:119,453,884...119,456,713
Ensembl chr 1:119,453,890...119,456,713
|
|
G |
Tmem204 |
transmembrane protein 204 |
decreases expression |
EXP |
Etoposide results in decreased expression of TMEM204 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr17:25,276,676...25,300,088
Ensembl chr17:25,276,676...25,302,565
|
|
G |
Tmem47 |
transmembrane protein 47 |
affects response to substance |
ISO |
TMEM47 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:80,114,250...80,141,481
Ensembl chr X:80,114,304...80,141,478
|
|
G |
Tmem97 |
transmembrane protein 97 |
affects response to substance |
ISO |
TMEM97 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr11:78,432,643...78,441,561
Ensembl chr11:78,432,643...78,441,603
|
|
G |
Tmsb4x |
thymosin, beta 4, X chromosome |
multiple interactions decreases response to substance |
ISO |
TMSB4X protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TMSB4X protein inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein] TMSB4X protein results in decreased susceptibility to Etoposide |
CTD |
PMID:16364925 |
|
NCBI chr X:165,990,089...165,996,475
Ensembl chr X:165,990,089...165,992,311
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP ISO |
Etoposide results in increased expression of TNF mRNA |
CTD |
PMID:15135310 PMID:18523641 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfrsf11b |
tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) |
increases expression |
EXP |
Etoposide results in increased expression of TNFRSF11B mRNA |
CTD |
PMID:11459812 |
|
NCBI chr15:54,114,014...54,141,700
Ensembl chr15:54,114,015...54,141,880
|
|
G |
Tnfrsf12a |
tumor necrosis factor receptor superfamily, member 12a |
multiple interactions increases expression |
ISO |
Estradiol inhibits the reaction [Etoposide results in increased expression of TNFRSF12A mRNA] |
CTD |
PMID:19426747 |
|
NCBI chr17:23,894,419...23,896,423
Ensembl chr17:23,894,419...23,896,442
|
|
G |
Tnfrsf14 |
tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator) |
increases expression |
ISO |
Etoposide results in increased expression of TNFRSF14 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:155,002,944...155,013,077
Ensembl chr 4:155,006,390...155,013,020
|
|
G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
affects response to substance |
EXP |
TNFRSF1A protein affects the susceptibility to Etoposide |
CTD |
PMID:20159942 |
|
NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447
|
|
G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
decreases expression |
EXP |
Etoposide results in decreased expression of TNFSF11 mRNA |
CTD |
PMID:11459812 |
|
NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483
|
|
G |
Tnfsf9 |
tumor necrosis factor (ligand) superfamily, member 9 |
increases expression |
ISO |
Etoposide results in increased expression of TNFSF9 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr17:57,412,113...57,414,757
Ensembl chr17:57,412,325...57,414,757
|
|
G |
Tnks |
tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase |
affects response to substance |
ISO |
TNKS protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:35,296,333...35,432,844
Ensembl chr 8:35,293,614...35,432,844
|
|
G |
Top2a |
topoisomerase (DNA) II alpha |
affects binding decreases activity multiple interactions affects activity decreases expression increases response to substance affects response to substance decreases response to substance |
ISO EXP |
Etoposide binds to TOP2A protein Etoposide analog results in decreased activity of TOP2A protein; Etoposide metabolite results in decreased activity of TOP2A protein; Etoposide results in decreased activity of TOP2A protein [Ciprofloxacin binds to TOP2A protein] inhibits the reaction [Etoposide binds to TOP2A protein]; [EGF protein results in decreased expression of TOP2A protein] which results in decreased susceptibility to Etoposide; [MAPK12 protein results in increased phosphorylation of TOP2A protein] which results in increased susceptibility to Etoposide; [MAPK12 protein results in increased stability of TOP2A protein] which results in increased susceptibility to Etoposide; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]]; delphinidin results in decreased susceptibility to [Etoposide affects the activity of TOP2A protein]; Etoposide metabolite inhibits the reaction [TOP2A protein binds to Nucleic Acids, Nucleotides, and Nucleosides]; Etoposide metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]; TOP2A results in decreased susceptibility to [Carboplatin co-treated with Etoposide co-treated with Ifosfamide]; TOP2A results in decreased susceptibility to [Cisplatin co-treated with Etoposide] Etoposide results in decreased expression of TOP2A protein TOP2A protein results in increased susceptibility to Etoposide TOP2A protein modified form affects the susceptibility to Etoposide TOP2A gene mutant form results in decreased susceptibility to Etoposide; TOP2A protein mutant form results in decreased susceptibility to Etoposide |
CTD |
PMID:10856430 PMID:11325482 PMID:11470519 PMID:11531262 PMID:11676865 PMID:12569090 PMID:15211611 PMID:16969495 PMID:17575151 PMID:19182879 PMID:21056033 PMID:21413765 PMID:21878638 PMID:24650156 PMID:26198043 PMID:27422292 PMID:27533850 PMID:31512855 PMID:33760604 PMID:34635930 More...
|
|
NCBI chr11:98,883,773...98,915,037
Ensembl chr11:98,883,769...98,915,015
|
|
G |
Top2b |
topoisomerase (DNA) II beta |
multiple interactions decreases activity affects response to substance decreases response to substance decreases expression increases response to substance |
EXP ISO |
TOP2B protein affects the reaction [Etoposide results in increased expression of H2AX protein] Etoposide results in decreased activity of TOP2B protein TOP2B protein affects the susceptibility to Etoposide TOP2B protein mutant form results in decreased susceptibility to Etoposide Etoposide results in decreased expression of TOP2B protein TOP2B protein mutant form results in increased susceptibility to Etoposide |
CTD |
PMID:10856430 PMID:15322234 PMID:16239602 PMID:17875725 PMID:26198043 PMID:27422292 More...
|
|
NCBI chr14:6,038,976...6,104,585
Ensembl chr14:6,034,301...6,104,584
|
|
G |
Top3a |
topoisomerase (DNA) III alpha |
decreases expression |
ISO |
Etoposide results in decreased expression of TOP3A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr11:60,629,014...60,668,099
Ensembl chr11:60,630,884...60,668,191
|
|
G |
Tor1a |
torsin family 1, member A (torsin A) |
decreases expression |
ISO |
Etoposide results in decreased expression of TOR1A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 2:30,850,573...30,857,930
Ensembl chr 2:30,850,639...30,857,945
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
multiple interactions increases phosphorylation |
ISO |
CDK2 affects the reaction [Etoposide results in increased phosphorylation of TPI1 protein] |
CTD |
PMID:20149834 |
|
NCBI chr 6:124,787,549...124,791,121
Ensembl chr 6:124,787,549...124,791,259
|
|
G |
Tpp2 |
tripeptidyl peptidase II |
multiple interactions affects localization |
ISO EXP |
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Etoposide affects the localization of TPP2 protein]; SB 203580 inhibits the reaction [Etoposide affects the localization of TPP2 protein]; U 0126 inhibits the reaction [Etoposide affects the localization of TPP2 protein] 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Etoposide affects the localization of TPP2 protein]; Sirolimus promotes the reaction [Etoposide affects the localization of TPP2 protein]; U 0126 inhibits the reaction [Etoposide affects the localization of TPP2 protein]; wortmannin promotes the reaction [Etoposide affects the localization of TPP2 protein] |
CTD |
PMID:20643100 |
|
NCBI chr 1:43,973,130...44,042,160
Ensembl chr 1:43,972,807...44,042,160
|
|
G |
Tpt1 |
tumor protein, translationally-controlled 1 |
increases expression multiple interactions |
ISO EXP |
Etoposide results in increased expression of TPT1 mRNA TRP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA]; TRP53 affects the reaction [Etoposide results in increased expression of TPT1 protein] Etoposide results in increased expression of TPT1 mRNA; Etoposide results in increased expression of TPT1 protein TP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA] |
CTD |
PMID:24067374 |
|
NCBI chr14:76,082,771...76,085,743
Ensembl chr14:76,082,533...76,085,965
|
|
G |
Traf2 |
TNF receptor-associated factor 2 |
affects response to substance |
EXP |
TRAF2 protein affects the susceptibility to Etoposide |
CTD |
PMID:20159942 |
|
NCBI chr 2:25,407,994...25,436,952
Ensembl chr 2:25,407,994...25,436,952
|
|
G |
Traj18 |
T cell receptor alpha joining 18 |
increases expression |
EXP |
Etoposide results in increased expression of STK17A mRNA |
CTD |
PMID:21489989 |
|
NCBI chr14:54,438,234...54,438,299
Ensembl chr14:54,438,234...54,438,299
|
|
G |
Trib2 |
tribbles pseudokinase 2 |
affects response to substance |
ISO |
TRIB2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr12:15,841,726...15,866,963
Ensembl chr12:15,841,728...15,866,923
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
decreases expression |
EXP |
Etoposide results in decreased expression of TRIB3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:152,179,345...152,185,980
Ensembl chr 2:152,179,342...152,185,952
|
|
G |
Trim2 |
tripartite motif-containing 2 |
affects response to substance decreases expression |
ISO EXP |
TRIM2 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of TRIM2 mRNA |
CTD |
PMID:16217747 PMID:25270620 |
|
NCBI chr 3:84,067,746...84,215,659
Ensembl chr 3:84,067,746...84,214,184
|
|
G |
Trim38 |
tripartite motif-containing 38 |
decreases expression |
ISO |
Etoposide results in decreased expression of TRIM38 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr13:23,962,483...23,975,721
Ensembl chr13:23,953,896...23,975,511
|
|
G |
Trp53 |
transformation related protein 53 |
increases acetylation affects activity increases expression multiple interactions increases activity increases phosphorylation affects response to substance increases response to substance |
ISO EXP |
Etoposide results in increased acetylation of TP53 protein; Etoposide results in increased acetylation of TP53 protein mutant form Etoposide affects the activity of TP53 protein; Etoposide metabolite affects the activity of TP53 protein Etoposide results in increased expression of TRP53 protein [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of TRP53 protein]; Etoposide results in increased phosphorylation of and results in increased activity of TRP53 protein; TRP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TRP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA]; TRP53 affects the reaction [Etoposide results in increased expression of TPT1 protein]; TRP53 protein affects the reaction [Etoposide results in increased expression of BTG2 mRNA] Etoposide results in increased activity of TP53 protein Etoposide results in increased phosphorylation of TP53 protein TRP53 protein affects the susceptibility to Etoposide Etoposide results in increased expression of TP53 protein [Etoposide results in increased expression of TP53 protein] which results in increased expression of GDF15 protein; Etoposide results in increased expression of TP53 protein 2,4,4'-trichlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein]; 2,4,5,2',5'-pentachlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein]; 3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of CASP3 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of PARP1 protein]; [CASP8 co-treated with TP53] inhibits the reaction [CASP8 protein mutant form results in decreased susceptibility to Etoposide]; [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of TP53 protein; [Etoposide results in increased acetylation of TP53 protein mutant form] which results in increased expression of UBE2C protein; [TP53 protein results in increased susceptibility to Etoposide] which results in decreased chemical synthesis of benzo(a)pyrene 7,8-dihydrodiol; Cadmium Chloride affects the reaction [Etoposide results in increased phosphorylation of TP53 protein]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein modified form]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein]; entinostat promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein]; Etoposide promotes the reaction [[TP53 protein binds to GDF15 promoter] which results in increased expression of GDF15 mRNA]; Etoposide promotes the reaction [entinostat results in increased expression of TP53 protein]; Etoposide promotes the reaction [TP53 protein binds to TNFRSF10B promoter]; Etoposide promotes the reaction [TP53 protein results in increased chemical synthesis of benzo(a)pyrene 7,8-dihydrodiol]; Etoposide promotes the reaction [trichostatin A results in increased expression of TP53 protein]; Etoposide promotes the reaction [UF010 compound results in increased expression of TP53 protein]; Etoposide results in increased expression of and results in increased acetylation of TP53 protein; Etoposide results in increased phosphorylation of and affects the localization of TP53 protein; Etoposide results in increased phosphorylation of and results in increased activity of TP53 protein; NFE2L2 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; NFKB1 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; Oxygen deficiency inhibits the reaction [Etoposide results in increased phosphorylation of TP53 protein]; pifithrin inhibits the reaction [Etoposide results in increased activity of TP53 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased acetylation of TP53 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased phosphorylation of and results in increased activity of TP53 protein]; TP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA]; TP53 promotes the reaction [Etoposide results in increased expression of BTG2 protein]; TP53 promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; TP53 protein affects the reaction [CHEK1 protein affects the susceptibility to Etoposide]; TP53 protein affects the reaction [Etoposide results in decreased expression of UBE2C mRNA]; TP53 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein]; TP53 protein inhibits the reaction [ESR2 protein results in increased susceptibility to Etoposide]; TP53 protein inhibits the reaction [Etoposide results in decreased expression of UBE2C protein]; TP53 protein modified form inhibits the reaction [Etoposide results in increased expression of BBC3 protein]; TP53 protein promotes the reaction [[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]]; TP53 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of CYP1A1 protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein]; UF010 compound promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein] cordycepin promotes the reaction [Etoposide results in increased expression of TP53 protein]; Etoposide promotes the reaction [Acetaminophen results in increased phosphorylation of TP53 protein]; Etoposide results in increased expression of and results in increased phosphorylation of TP53 protein; Niacin deficiency inhibits the reaction [Etoposide results in increased expression of TP53 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of TP53 protein] TP53 protein results in increased susceptibility to Etoposide; TP53 results in increased susceptibility to Etoposide |
CTD |
PMID:9815696 PMID:11895857 PMID:12082016 PMID:15131059 PMID:15459018 PMID:15964798 PMID:16120219 PMID:16330492 PMID:16882877 PMID:17516866 PMID:18698031 PMID:19751709 PMID:20299546 PMID:20477944 PMID:20623183 PMID:20655369 PMID:21212465 PMID:21526190 PMID:21552291 PMID:21801448 PMID:22003191 PMID:22010212 PMID:22242153 PMID:23144690 PMID:23396362 PMID:23690541 PMID:24067374 PMID:25078064 PMID:25699604 PMID:25744307 PMID:26259609 PMID:27129209 PMID:27358234 PMID:27982581 PMID:29471073 PMID:30177839 PMID:30818834 PMID:31542801 PMID:35435491 PMID:37956312 More...
|
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Trp53bp1 |
transformation related protein 53 binding protein 1 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of TP53BP1 protein pifithrin inhibits the reaction [Etoposide results in increased expression of and affects the localization of TP53BP1 protein] |
CTD |
PMID:26259609 PMID:27358234 |
|
NCBI chr 2:121,025,316...121,126,830
Ensembl chr 2:121,023,762...121,101,888
|
|
G |
Trp73 |
transformation related protein 73 |
multiple interactions increases expression |
ISO |
[[Etoposide results in increased expression of TP73 protein] which results in increased expression of VDR protein] which results in increased susceptibility to Calcitriol; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP8 protein]; TP73 protein affects the reaction [Etoposide results in increased expression of VDR mRNA] Etoposide results in increased expression of TP73 mRNA; Etoposide results in increased expression of TP73 protein |
CTD |
PMID:17716971 PMID:21801448 |
|
NCBI chr 4:154,140,706...154,224,332
Ensembl chr 4:154,140,706...154,224,665
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
increases expression |
ISO |
Etoposide results in increased expression of TRPV1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr11:73,124,975...73,152,148
Ensembl chr11:73,125,118...73,152,068
|
|
G |
Ttk |
Ttk protein kinase |
decreases expression |
ISO |
Etoposide results in decreased expression of TTK mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 9:83,716,704...83,754,442
Ensembl chr 9:83,716,742...83,754,442
|
|
G |
Tuba4a |
tubulin, alpha 4A |
increases expression |
ISO |
Etoposide results in increased expression of TUBA4A mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:75,190,867...75,197,905
Ensembl chr 1:75,190,872...75,196,509
|
|
G |
Tufm |
Tu translation elongation factor, mitochondrial |
decreases expression |
EXP |
Etoposide results in decreased expression of TUFM protein |
CTD |
PMID:29733421 |
|
NCBI chr 7:126,086,445...126,089,903
Ensembl chr 7:126,086,533...126,089,903
|
|
G |
Txn2 |
thioredoxin 2 |
decreases response to substance |
ISO |
TXN2 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:12080052 |
|
NCBI chr15:77,799,251...77,813,194
Ensembl chr15:77,799,247...77,813,206
|
|
G |
Txnip |
thioredoxin interacting protein |
increases expression |
ISO |
Etoposide results in increased expression of TXNIP protein |
CTD |
PMID:18270325 |
|
NCBI chr 3:96,465,273...96,469,173
Ensembl chr 3:96,465,273...96,469,199
|
|
G |
Txnl1 |
thioredoxin-like 1 |
decreases expression |
EXP |
Etoposide results in decreased expression of TXNL1 protein |
CTD |
PMID:29733421 |
|
NCBI chr18:63,795,872...63,825,535
Ensembl chr18:63,794,165...63,841,872
|
|
G |
Tyms |
thymidylate synthase |
affects response to substance |
ISO |
TYMS gene polymorphism affects the susceptibility to Etoposide |
CTD |
PMID:15713801 |
|
NCBI chr 5:30,243,544...30,279,261
Ensembl chr 5:30,263,200...30,278,615
|
|
G |
Tyrp1 |
tyrosinase-related protein 1 |
affects response to substance |
ISO |
TYRP1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:80,752,360...80,769,973
Ensembl chr 4:80,752,360...80,769,956
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
decreases expression multiple interactions |
ISO |
Etoposide results in decreased expression of UBE2C mRNA; Etoposide results in decreased expression of UBE2C protein [Etoposide results in increased acetylation of TP53 protein mutant form] which results in increased expression of UBE2C protein; CDKN1A protein affects the reaction [Etoposide results in decreased expression of UBE2C protein]; TP53 protein affects the reaction [Etoposide results in decreased expression of UBE2C mRNA]; TP53 protein inhibits the reaction [Etoposide results in decreased expression of UBE2C protein] |
CTD |
PMID:17374387 PMID:27129209 |
|
NCBI chr 2:164,611,849...164,614,822
Ensembl chr 2:164,611,818...164,620,742
|
|
G |
Ubl3 |
ubiquitin-like 3 |
affects response to substance |
ISO |
UBL3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:148,441,441...148,489,689
Ensembl chr 5:148,441,445...148,489,599
|
|
G |
Ucp2 |
uncoupling protein 2 (mitochondrial, proton carrier) |
decreases expression |
ISO |
Etoposide results in decreased expression of UCP2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 7:100,142,565...100,148,832
Ensembl chr 7:100,142,544...100,151,227
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase 1 family, polypeptide A1 |
affects response to substance increases glucuronidation |
ISO |
UGT1A1 gene polymorphism affects the susceptibility to Etoposide UGT1A1 protein results in increased glucuronidation of Etoposide |
CTD |
PMID:12969965 PMID:17151191 |
|
NCBI chr 1:88,139,681...88,147,724
Ensembl chr 1:88,139,681...88,146,719
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of Etoposide |
CTD |
PMID:17151191 |
|
NCBI chr 1:88,128,333...88,147,724
Ensembl chr 1:88,128,323...88,146,719
|
|
G |
Unc5c |
unc-5 netrin receptor C |
increases response to substance |
ISO |
UNC5C results in increased susceptibility to Etoposide |
CTD |
PMID:21600761 |
|
NCBI chr 3:141,171,360...141,540,685
Ensembl chr 3:141,170,977...141,540,685
|
|
G |
Upp2 |
uridine phosphorylase 2 |
increases expression |
EXP |
Etoposide results in increased expression of UPP2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:58,456,329...58,685,858
Ensembl chr 2:58,457,310...58,682,983
|
|
G |
Utp3 |
UTP3 small subunit processome component |
decreases expression |
ISO |
Etoposide results in decreased expression of UTP3 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 5:88,702,321...88,703,949
Ensembl chr 5:88,702,321...88,703,949
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions decreases response to substance |
ISO |
[IL4 protein co-treated with VCAM1 protein] inhibits the reaction [Etoposide results in decreased folding of BAX protein]; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; [VCAM1 protein co-treated with IL4 protein] results in decreased susceptibility to Etoposide VCAM1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:10620629 |
|
NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337
|
|
G |
Vcan |
versican |
affects response to substance |
ISO |
VCAN protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr13:89,803,429...89,891,146
Ensembl chr13:89,803,431...89,890,628
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions |
ISO |
Etoposide promotes the reaction [VDAC1 protein binds to VDAC1 protein] |
CTD |
PMID:20937774 |
|
NCBI chr11:52,251,905...52,280,224
Ensembl chr11:52,251,687...52,280,224
|
|
G |
Vdr |
vitamin D (1,25-dihydroxyvitamin D3) receptor |
multiple interactions affects response to substance increases expression |
ISO |
[[Etoposide results in increased expression of TP73 protein] which results in increased expression of VDR protein] which results in increased susceptibility to Calcitriol; TP73 protein affects the reaction [Etoposide results in increased expression of VDR mRNA] VDR gene polymorphism affects the susceptibility to Etoposide; VDR intron polymorphism affects the susceptibility to Etoposide |
CTD |
PMID:12969965 PMID:15713801 PMID:17716971 |
|
NCBI chr15:97,752,308...97,806,177
Ensembl chr15:97,752,306...97,808,511
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases response to substance |
ISO |
VEGFA mRNA results in decreased susceptibility to Etoposide |
CTD |
PMID:18494554 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Vegfc |
vascular endothelial growth factor C |
multiple interactions decreases response to substance |
ISO |
EDN1 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide]; PTGS2 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:24184161 |
|
NCBI chr 8:54,530,567...54,639,489
Ensembl chr 8:54,530,641...54,640,131
|
|
G |
Vkorc1 |
vitamin K epoxide reductase complex, subunit 1 |
increases expression |
EXP |
Etoposide results in increased expression of VKORC1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:127,492,235...127,494,833
Ensembl chr 7:127,485,399...127,494,626 Ensembl chr 7:127,485,399...127,494,626
|
|
G |
Wif1 |
Wnt inhibitory factor 1 |
increases response to substance |
ISO |
WIF1 protein results in increased susceptibility to Etoposide |
CTD |
PMID:15389810 |
|
NCBI chr10:120,869,909...120,936,547
Ensembl chr10:120,869,865...120,936,555
|
|
G |
Wipi1 |
WD repeat domain, phosphoinositide interacting 1 |
affects response to substance |
ISO |
WIPI1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr11:109,464,347...109,502,215
Ensembl chr11:109,464,157...109,502,793
|
|
G |
Wnt3a |
wingless-type MMTV integration site family, member 3A |
increases response to substance |
ISO |
WNT3A protein results in increased susceptibility to Etoposide |
CTD |
PMID:19864107 |
|
NCBI chr11:59,138,859...59,181,579
Ensembl chr11:59,138,859...59,181,578
|
|
G |
Wrn |
Werner syndrome RecQ like helicase |
increases response to substance |
ISO |
WRN gene mutant form results in increased susceptibility to Etoposide |
CTD |
PMID:10725663 |
|
NCBI chr 8:33,724,400...33,875,591
Ensembl chr 8:33,724,412...33,875,555
|
|
G |
Xaf1 |
XIAP associated factor 1 |
increases response to substance increases expression multiple interactions |
ISO |
XAF1 protein results in increased susceptibility to Etoposide Etoposide results in increased expression of XAF1 mRNA; Etoposide results in increased expression of XAF1 protein XAF1 protein affects the reaction [Etoposide results in decreased expression of MT2A protein]; XAF1 protein affects the reaction [Etoposide results in increased cleavage of PARP1 protein] |
CTD |
PMID:15843754 PMID:17570219 PMID:28507149 |
|
NCBI chr11:72,192,229...72,204,560
Ensembl chr11:72,192,455...72,204,559
|
|
G |
Xrcc1 |
X-ray repair complementing defective repair in Chinese hamster cells 1 |
multiple interactions affects response to substance increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Etoposide results in increased expression of XRCC1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Etoposide results in increased expression of XRCC1 protein]; resveratrol inhibits the reaction [Etoposide results in increased expression of XRCC1 mRNA]; resveratrol inhibits the reaction [Etoposide results in increased expression of XRCC1 protein]; U 0126 inhibits the reaction [Etoposide results in increased expression of XRCC1 mRNA]; U 0126 inhibits the reaction [Etoposide results in increased expression of XRCC1 protein] XRCC1 protein affects the susceptibility to Etoposide Etoposide results in increased expression of XRCC1 mRNA; Etoposide results in increased expression of XRCC1 protein |
CTD |
PMID:26046675 |
|
NCBI chr 7:24,246,124...24,272,863
Ensembl chr 7:24,245,714...24,272,865
|
|
G |
Xrcc2 |
X-ray repair complementing defective repair in Chinese hamster cells 2 |
multiple interactions increases expression |
ISO |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC2 protein] |
CTD |
PMID:16417649 |
|
NCBI chr 5:25,894,812...25,910,795
Ensembl chr 5:25,894,810...25,910,823
|
|
G |
Xrcc3 |
X-ray repair complementing defective repair in Chinese hamster cells 3 |
multiple interactions increases expression |
ISO |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC3 protein] |
CTD |
PMID:16417649 |
|
NCBI chr12:111,769,626...111,780,326
Ensembl chr12:111,769,626...111,780,307
|
|
G |
Xrcc4 |
X-ray repair complementing defective repair in Chinese hamster cells 4 |
multiple interactions decreases response to substance increases expression |
ISO |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC4 protein] XRCC4 results in decreased susceptibility to Etoposide |
CTD |
PMID:16417649 PMID:21785230 |
|
NCBI chr13:89,997,033...90,237,727
Ensembl chr13:89,922,146...90,237,727
|
|
G |
Xrcc5 |
X-ray repair complementing defective repair in Chinese hamster cells 5 |
affects response to substance |
ISO |
XRCC5 protein affects the susceptibility to Etoposide |
CTD |
PMID:12384553 |
|
NCBI chr 1:72,346,576...72,434,112
Ensembl chr 1:72,346,586...72,434,111
|
|
G |
Zbtb24 |
zinc finger and BTB domain containing 24 |
decreases expression |
ISO |
Etoposide results in decreased expression of ZBTB24 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr10:41,326,354...41,341,578
Ensembl chr10:41,326,379...41,341,570
|
|
G |
Zfp202 |
zinc finger protein 202 |
decreases expression |
ISO |
Etoposide results in decreased expression of ZNF202 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 9:40,103,612...40,124,900
Ensembl chr 9:40,103,612...40,124,900
|
|
G |
Zfp365 |
zinc finger protein 365 |
increases expression |
EXP |
Etoposide results in increased expression of ZFP365 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:67,721,935...67,748,492
Ensembl chr10:67,721,933...67,748,492
|
|
G |
Zfp36l1 |
zinc finger protein 36, C3H type-like 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of ZFP36L1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr12:80,154,534...80,159,787
Ensembl chr12:80,154,528...80,159,787
|
|
G |
Zfp637 |
zinc finger protein 637 |
affects response to substance |
ISO |
ZNF32 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:117,818,165...117,822,917
Ensembl chr 6:117,818,141...117,822,917
|
|
G |
Zfp750 |
zinc finger protein 750 |
increases expression |
EXP |
Etoposide results in increased expression of ZFP750 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:121,401,802...121,410,168
Ensembl chr11:121,401,804...121,410,159
|
|
G |
Zfp94 |
zinc finger protein 94 |
decreases expression |
ISO |
Etoposide results in decreased expression of ZNF45 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 7:24,001,129...24,016,091
Ensembl chr 7:24,001,129...24,016,091
|
|
G |
Zmat3 |
zinc finger matrin type 3 |
increases expression |
ISO |
Etoposide results in increased expression of ZMAT3 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 3:32,388,941...32,419,814
Ensembl chr 3:32,388,941...32,420,163
|
|
|
G |
Ache |
acetylcholinesterase |
increases expression multiple interactions |
ISO |
genistin results in increased expression of ACHE mRNA genistin results in increased expression of and results in increased activity of ACHE protein |
CTD |
PMID:27019979 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of ACSL3 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:78,635,600...78,685,462
Ensembl chr 1:78,635,542...78,685,460
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase family 1, subfamily A2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ALDH1A2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:71,123,071...71,203,525
Ensembl chr 9:71,123,071...71,203,525
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ANPEP mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:79,471,551...79,497,958
Ensembl chr 7:79,471,551...79,510,807
|
|
G |
Atoh8 |
atonal bHLH transcription factor 8 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of ATOH8 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:72,183,158...72,212,765
Ensembl chr 6:72,183,161...72,212,561
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of BCKDK mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:127,503,245...127,508,836
Ensembl chr 7:127,503,254...127,509,393
|
|
G |
Bpgm |
2,3-bisphosphoglycerate mutase |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of BPGM mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:34,453,291...34,482,071
Ensembl chr 6:34,453,142...34,482,548
|
|
G |
Cabp5 |
calcium binding protein 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CABP5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:13,119,885...13,142,812
Ensembl chr 7:13,132,057...13,142,812
|
|
G |
Cacybp |
calcyclin binding protein |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CACYBP mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:160,029,171...160,040,391
Ensembl chr 1:160,029,937...160,040,445
|
|
G |
Casp8ap2 |
caspase 8 associated protein 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CASP8AP2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:32,615,462...32,653,271
Ensembl chr 4:32,615,451...32,653,265
|
|
G |
Cd200r1 |
CD200 receptor 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CD200R1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr16:44,586,141...44,615,341
Ensembl chr16:44,586,099...44,615,341
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
EXP |
genistin inhibits the reaction [Lipopolysaccharides results in increased activity of CEBPB protein] |
CTD |
PMID:15832817 |
|
NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338
|
|
G |
Cfap251 |
cilia and flagella associated protein 251 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CFAP251 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:123,390,196...123,465,547
Ensembl chr 5:123,390,165...123,465,547
|
|
G |
Cybrd1 |
cytochrome b reductase 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CYBRD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:70,948,398...70,973,270
Ensembl chr 2:70,948,267...70,973,270
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306
|
|
G |
Dennd2d |
DENN domain containing 2D |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of DENND2D mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:106,389,745...106,410,346
Ensembl chr 3:106,389,721...106,410,346
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 9:20,818,501...20,871,084
Ensembl chr 9:20,818,505...20,871,184
|
|
G |
Dnmt3a |
DNA methyltransferase 3A |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT3A mRNA |
CTD |
PMID:28964809 |
|
NCBI chr12:3,851,559...3,964,442
Ensembl chr12:3,856,007...3,964,443
|
|
G |
Dpp9 |
dipeptidylpeptidase 9 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of DPP9 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr17:56,493,674...56,525,927
Ensembl chr17:56,493,807...56,525,905
|
|
G |
Edrf1 |
erythroid differentiation regulatory factor 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of EDRF1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:133,239,422...133,274,710
Ensembl chr 7:133,239,272...133,274,700
|
|
G |
Efhd1 |
EF hand domain containing 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of EFHD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:87,192,075...87,238,563
Ensembl chr 1:87,192,085...87,238,561
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of ESR2 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
Fam171a2 |
family with sequence similarity 171, member A2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FAM171A2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr11:102,327,807...102,338,551
Ensembl chr11:102,327,807...102,338,508
|
|
G |
Fam180a |
family with sequence similarity 180, member A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM180A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:35,289,678...35,303,076
Ensembl chr 6:35,289,603...35,303,076
|
|
G |
Fam210b |
family with sequence similarity 210, member B |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM210B mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:172,187,444...172,197,669
Ensembl chr 2:172,187,485...172,197,669
|
|
G |
Fam241b |
family with sequence similarity 241, member B |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of FAM241B mRNA |
CTD |
PMID:27424125 |
|
NCBI chr10:61,943,435...61,946,829
Ensembl chr10:61,943,434...61,979,699
|
|
G |
Fgd6 |
FYVE, RhoGEF and PH domain containing 6 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FGD6 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr10:93,871,862...93,981,201
Ensembl chr10:93,871,863...93,981,201
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FHL2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:43,162,233...43,237,501
Ensembl chr 1:43,162,234...43,236,144
|
|
G |
G6pdx |
glucose-6-phosphate dehydrogenase X-linked |
increases expression |
ISO |
genistin analog results in increased expression of G6PD mRNA |
CTD |
PMID:16719502 |
|
NCBI chr X:73,453,089...73,472,486
Ensembl chr X:73,453,089...73,472,800
|
|
G |
Galnt15 |
polypeptide N-acetylgalactosaminyltransferase 15 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of GALNT15 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr14:31,750,739...31,784,161
Ensembl chr14:31,750,946...31,784,154
|
|
G |
Gng5 |
G protein subunit gamma 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of GNG5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:146,205,591...146,211,298
Ensembl chr 3:146,205,562...146,211,327
|
|
G |
Hipk4 |
homeodomain interacting protein kinase 4 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of HIPK4 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:27,222,686...27,230,605
Ensembl chr 7:27,222,692...27,230,600
|
|
G |
Hmcn1 |
hemicentin 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of HMCN1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:150,438,251...150,869,568
Ensembl chr 1:150,438,275...150,869,186
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of HSD3B1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 3:98,749,672...98,767,110
Ensembl chr 3:98,759,510...98,767,110
|
|
G |
Il6ra |
interleukin 6 receptor, alpha |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of IL6R mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:89,776,631...89,820,503
Ensembl chr 3:89,771,366...89,820,503
|
|
G |
Isg20l2 |
interferon stimulated exonuclease gene 20-like 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ISG20L2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:87,837,602...87,847,994
Ensembl chr 3:87,837,621...87,847,993
|
|
G |
Kdm5a |
lysine demethylase 5A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of KDM5A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:120,341,060...120,421,535
Ensembl chr 6:120,341,085...120,421,535
|
|
G |
Kitl |
kit ligand |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KITLG mRNA |
CTD |
PMID:27424125 |
|
NCBI chr10:99,851,477...99,936,278
Ensembl chr10:99,851,492...99,936,278
|
|
G |
Knstrn |
kinetochore-localized astrin/SPAG5 binding |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KNSTRN mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:118,644,470...118,667,691
Ensembl chr 2:118,644,484...118,684,438
|
|
G |
Ldlrap1 |
low density lipoprotein receptor adaptor protein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LDLRAP1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:134,468,865...134,495,342
Ensembl chr 4:134,468,865...134,495,335
|
|
G |
Lmod1 |
leiomodin 1 (smooth muscle) |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LMOD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:135,252,551...135,295,803
Ensembl chr 1:135,252,545...135,295,803
|
|
G |
Lrg1 |
leucine-rich alpha-2-glycoprotein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of LRG1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr17:56,426,678...56,428,946
Ensembl chr17:56,426,678...56,429,001
|
|
G |
Lsr |
lipolysis stimulated lipoprotein receptor |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LSR mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:30,657,195...30,672,894
Ensembl chr 7:30,657,195...30,672,889
|
|
G |
Ltf |
lactotransferrin |
increases expression |
EXP |
genistin results in increased expression of LTF mRNA |
CTD |
PMID:20049207 |
|
NCBI chr 9:110,848,360...110,871,834
Ensembl chr 9:110,848,339...110,871,835
|
|
G |
Mrpl33 |
mitochondrial ribosomal protein L33 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of MRPL33 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:31,771,295...31,779,988
Ensembl chr 5:31,754,279...31,821,728
|
|
G |
Mt1 |
metallothionein 1 |
increases expression |
ISO |
genistin analog results in increased expression of MT1X mRNA |
CTD |
PMID:16719502 |
|
NCBI chr 8:94,905,214...94,906,955
Ensembl chr 8:94,905,710...94,906,955
|
|
G |
Mt2 |
metallothionein 2 |
increases expression |
ISO |
genistin analog results in increased expression of MT2A mRNA |
CTD |
PMID:16719502 |
|
NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196
|
|
G |
Mtmr11 |
myotubularin related protein 11 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of MTMR11 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:96,069,287...96,079,034
Ensembl chr 3:96,069,321...96,079,034
|
|
G |
Myof |
myoferlin |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of MYOF mRNA |
CTD |
PMID:27424125 |
|
NCBI chr19:37,887,484...38,032,025
Ensembl chr19:37,887,484...38,032,025
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
EXP |
genistin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:15832817 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of NR4A1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr15:101,151,783...101,172,676
Ensembl chr15:101,152,150...101,172,676
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 protein; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased methylation of NR5A1 promoter; decitabine inhibits the reaction [[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA] |
CTD |
PMID:28964809 |
|
NCBI chr 2:38,582,668...38,604,554
Ensembl chr 2:38,582,668...38,604,554
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
increases expression |
ISO |
genistin results in increased expression of PRIMA1 mRNA |
CTD |
PMID:27019979 |
|
NCBI chr12:103,160,712...103,208,967
Ensembl chr12:103,163,167...103,208,409
|
|
G |
Prkaca |
protein kinase, cAMP dependent, catalytic, alpha |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of PRKACA mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 8:84,699,607...84,723,073
Ensembl chr 8:84,699,622...84,723,072
|
|
G |
Prpf40a |
pre-mRNA processing factor 40A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PRPF40A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:53,024,714...53,081,450
Ensembl chr 2:53,024,716...53,081,714
|
|
G |
Pspc1 |
paraspeckle protein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PSPC1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr14:56,959,898...57,015,775
Ensembl chr14:56,958,167...57,015,773
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
genistin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:21341175 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Pth1r |
parathyroid hormone 1 receptor |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of PTH1R mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:110,551,132...110,576,213
Ensembl chr 9:110,551,153...110,576,213
|
|
G |
Rassf5 |
Ras association (RalGDS/AF-6) domain family member 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of RASSF5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:131,104,147...131,172,915
Ensembl chr 1:131,104,147...131,172,995
|
|
G |
Rgs22 |
regulator of G-protein signalling 22 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of RGS22 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr15:35,960,664...36,140,718
Ensembl chr15:36,009,625...36,140,546
|
|
G |
S1pr3 |
sphingosine-1-phosphate receptor 3 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of S1PR3 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:51,562,654...51,576,833
Ensembl chr13:51,562,675...51,576,833
|
|
G |
Selplg |
selectin, platelet (p-selectin) ligand |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SELPLG mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:113,955,859...113,970,576
Ensembl chr 5:113,956,597...113,970,705
|
|
G |
Slc16a1 |
solute carrier family 16 (monocarboxylic acid transporters), member 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SLC16A1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:104,545,980...104,565,778
Ensembl chr 3:104,545,984...104,565,778
|
|
G |
Slc30a1 |
solute carrier family 30 (zinc transporter), member 1 |
increases expression |
ISO |
genistin analog results in increased expression of SLC30A1 mRNA |
CTD |
PMID:16719502 |
|
NCBI chr 1:191,638,810...191,645,359
Ensembl chr 1:191,638,879...191,645,359
|
|
G |
Snx30 |
sorting nexin family member 30 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SNX30 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:59,805,137...59,904,740
Ensembl chr 4:59,805,840...59,904,737
|
|
G |
Ssc5d |
scavenger receptor cysteine rich family, 5 domains |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SSC5D mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:4,928,820...4,947,827
Ensembl chr 7:4,928,784...4,947,825
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR protein |
CTD |
PMID:28964809 |
|
NCBI chr 8:26,298,502...26,306,010
Ensembl chr 8:26,296,583...26,306,010
|
|
G |
Styxl1 |
serine/threonine/tyrosine interacting-like 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of STYXL1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:135,776,074...135,807,277
Ensembl chr 5:135,776,074...135,807,239
|
|
G |
Sumo1 |
small ubiquitin-like modifier 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of SUMO1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:59,678,593...59,709,993
Ensembl chr 1:59,625,717...59,709,993
|
|
G |
Tc2n |
tandem C2 domains, nuclear |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of TC2N mRNA |
CTD |
PMID:27424125 |
|
NCBI chr12:101,611,705...101,685,178
Ensembl chr12:101,611,702...101,684,782
|
|
G |
Trp53i11 |
transformation related protein 53 inducible protein 11 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of TP53I11 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:93,017,694...93,032,102
Ensembl chr 2:93,017,893...93,032,104
|
|
G |
Vcpip1 |
valosin containing protein (p97)/p47 complex interacting protein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of VCPIP1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:9,788,847...9,818,607
Ensembl chr 1:9,788,847...9,818,607
|
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcr1 |
C-X-C motif chemokine receptor 1 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of CXCR1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 1:74,228,862...74,233,867
Ensembl chr 1:74,230,944...74,233,790
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Ifng |
interferon gamma |
decreases expression |
EXP |
ginsenoside M1 results in decreased expression of IFNG mRNA |
CTD |
PMID:15914323 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
EXP |
ginsenoside M1 results in decreased expression of IL1B mRNA |
CTD |
PMID:15914323 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il4 |
interleukin 4 |
decreases expression |
EXP |
ginsenoside M1 results in decreased expression of IL4 mRNA |
CTD |
PMID:15914323 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Itga4 |
integrin alpha 4 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 2:79,084,767...79,163,458
Ensembl chr 2:79,085,770...79,163,467
|
|
G |
Itgal |
integrin alpha L |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 7:126,895,404...126,934,309
Ensembl chr 7:126,895,432...126,934,310
|
|
G |
Itgb1 |
integrin beta 1 (fibronectin receptor beta) |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681
|
|
G |
Itgb2 |
integrin beta 2 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr10:77,366,164...77,401,542
Ensembl chr10:77,366,086...77,401,542
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases secretion |
ISO |
ginsenoside M1 results in decreased secretion of MMP9 protein |
CTD |
PMID:21875580 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
ISO |
ginsenoside M1 results in decreased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:15802804 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
ISO |
ginsenoside M1 results in decreased expression of and results in decreased activity of NOS2 protein |
CTD |
PMID:15802804 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
P2rx4 |
purinergic receptor P2X, ligand-gated ion channel 4 |
multiple interactions |
ISO |
[ginsenoside M1 co-treated with Adenosine Triphosphate] results in increased activity of P2RX4 protein; ginsenoside M1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] |
CTD |
PMID:30545933 |
|
NCBI chr 5:122,845,581...122,867,802
Ensembl chr 5:122,845,607...122,867,801
|
|
G |
P2rx7 |
purinergic receptor P2X, ligand-gated ion channel, 7 |
decreases response to substance |
EXP |
P2RX7 gene mutant form results in decreased susceptibility to ginsenoside M1 |
CTD |
PMID:30545933 |
|
NCBI chr 5:122,781,990...122,830,399
Ensembl chr 5:122,781,974...122,829,495
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
EXP ISO |
ginsenoside M1 results in decreased expression of PTGS2 mRNA ginsenoside M1 results in decreased expression of PTGS2 protein |
CTD |
PMID:15802804 PMID:15914323 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
ginsenoside M1 results in decreased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:15802804 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Sele |
selectin, endothelial cell |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:21875580 |
|
NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression decreases response to substance |
ISO EXP |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of CXCR1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of SELE protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein] ginsenoside M1 results in decreased expression of TNF mRNA ginsenoside M1 results in decreased susceptibility to TNF protein |
CTD |
PMID:15914323 PMID:21875580 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337
|
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions |
ISO |
ginsenoside F1 inhibits the reaction [Galactose results in increased expression of CXCL8 mRNA]; ginsenoside F1 inhibits the reaction [Galactose results in increased secretion of CXCL8 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside F1 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
ginsenoside F1 inhibits the reaction [Galactose affects the localization of RELA protein] |
CTD |
PMID:29412148 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
multiple interactions |
ISO |
ginsenoside F2 analog inhibits the reaction [ABCB1 protein results in increased transport of Digoxin] |
CTD |
PMID:24380838 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:19781563 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Atp6v1a |
ATPase, H+ transporting, lysosomal V1 subunit A |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of ATP6V1A mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr16:43,905,765...43,960,055
Ensembl chr16:43,905,765...43,960,068
|
|
G |
Atp6v1b2 |
ATPase, H+ transporting, lysosomal V1 subunit B2 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of ATP6V1B2 mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr 8:69,541,388...69,566,370
Ensembl chr 8:69,541,298...69,566,363
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions increases expression |
ISO |
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of BMP2 mRNA] ginsenoside Rb1 results in increased expression of BMP2 mRNA |
CTD |
PMID:27470910 |
|
NCBI chr 2:133,394,079...133,404,816
Ensembl chr 2:133,394,079...133,404,805
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein] |
CTD |
PMID:19781563 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Clcn7 |
chloride channel, voltage-sensitive 7 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of CLCN7 mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr17:25,352,353...25,381,077
Ensembl chr17:25,352,365...25,381,078
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of CTSB mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr14:63,359,911...63,383,372
Ensembl chr14:63,359,911...63,383,372
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of CTSD mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
multiple interactions |
EXP |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA] |
CTD |
PMID:22386813 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; ginsenoside Rb1 results in increased expression of and results in increased activity of HMOX1 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein] [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein |
CTD |
PMID:19781563 PMID:25422538 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions increases expression |
ISO |
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of IGF1 mRNA] ginsenoside Rb1 results in increased expression of IGF1 mRNA |
CTD |
PMID:27470910 |
|
NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:17655881 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Itgam |
integrin alpha M |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAM protein] |
CTD |
PMID:17655881 |
|
NCBI chr 7:127,661,812...127,717,663
Ensembl chr 7:127,661,812...127,717,663
|
|
G |
Itgb2 |
integrin beta 2 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGB2 protein] |
CTD |
PMID:17655881 |
|
NCBI chr10:77,366,164...77,401,542
Ensembl chr10:77,366,086...77,401,542
|
|
G |
Kcne1 |
potassium voltage-gated channel, Isk-related subfamily, member 1 |
increases expression |
ISO |
ginsenoside Rb1 results in increased expression of KCNE1 |
CTD |
PMID:24615935 |
|
NCBI chr16:92,142,889...92,156,356
Ensembl chr16:92,142,870...92,156,356
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
affects activity |
ISO |
ginsenoside Rb1 affects the activity of KCNH2 protein |
CTD |
PMID:15842772 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Lamp1 |
lysosomal-associated membrane protein 1 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of LAMP1 mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr 8:13,209,161...13,225,338
Ensembl chr 8:13,209,161...13,225,338
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
EXP |
ginsenoside Rb1 results in increased expression of MAP2 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 1:66,214,337...66,481,742
Ensembl chr 1:66,214,432...66,481,742
|
|
G |
Nfatc1 |
nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1 |
multiple interactions |
EXP |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA] |
CTD |
PMID:22386813 |
|
NCBI chr18:80,649,418...80,756,286
Ensembl chr18:80,649,420...80,756,286
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions affects localization increases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; [ginsenoside Rb1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; ginsenoside Rb1 results in increased activity of and results in increased localization of NFE2L2 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein] ginsenoside Rb1 affects the localization of NFE2L2 protein [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein ginsenoside Rb1 results in increased expression of NFE2L2 mRNA |
CTD |
PMID:19781563 PMID:22780686 PMID:25422538 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
P2rx4 |
purinergic receptor P2X, ligand-gated ion channel 4 |
multiple interactions |
ISO |
ginsenoside Rb1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] |
CTD |
PMID:30545933 |
|
NCBI chr 5:122,845,581...122,867,802
Ensembl chr 5:122,845,607...122,867,801
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
ginsenoside Rb1 results in increased expression of PGR protein |
CTD |
PMID:16204943 |
|
NCBI chr 9:8,890,017...8,968,612
Ensembl chr 9:8,899,834...8,968,612
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
EXP |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein] |
CTD |
PMID:22386813 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Runx2 |
runt related transcription factor 2 |
increases expression multiple interactions |
ISO |
ginsenoside Rb1 results in increased expression of RUNX2 mRNA ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of RUNX2 mRNA] |
CTD |
PMID:27470910 |
|
NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family, member 1b2 |
multiple interactions |
ISO |
ginsenoside Rb1 binds to and results in decreased activity of SLCO1B3 protein |
CTD |
PMID:25297453 |
|
NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression multiple interactions |
ISO |
ginsenoside Rb1 results in decreased expression of SQSTM1 protein ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein] |
CTD |
PMID:34812491 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Tfeb |
transcription factor EB |
multiple interactions |
ISO |
[ginsenoside Rb1 co-treated with alpha-Chlorohydrin] affects the localization of TFEB protein; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of TFEB mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr17:48,047,962...48,103,341
Ensembl chr17:48,047,955...48,103,344
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression |
ISO |
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of TGFB1 mRNA] ginsenoside Rb1 results in increased expression of TGFB1 mRNA |
CTD |
PMID:27470910 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA] |
CTD |
PMID:22386813 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
multiple interactions decreases response to substance |
EXP |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA] ginsenoside Rb1 results in decreased susceptibility to TNFSF11 protein |
CTD |
PMID:22386813 |
|
NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483
|
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
increases expression |
ISO |
ginsenoside Rb2 results in increased expression of ABCC2 mRNA |
CTD |
PMID:23835644 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Lpl |
lipoprotein lipase |
increases secretion decreases secretion |
EXP |
ginsenoside Rb2 results in increased secretion of LPL protein ginsenoside Rb2 results in decreased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100
|
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family, member 1b2 |
multiple interactions |
ISO |
ginsenoside Rc binds to and results in decreased activity of SLCO1B3 protein |
CTD |
PMID:25297453 |
|
NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372
|
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions |
EXP |
ginsenoside Rd results in increased phosphorylation of and results in increased activity of AKT1 protein |
CTD |
PMID:24599032 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
ginsenoside Rd inhibits the reaction [APP protein modified form results in decreased expression of BCL2 mRNA]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of BAX mRNA]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CASP3 protein modified form]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CYCS mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
ISO |
ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of BAX mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
ISO |
ginsenoside Rd inhibits the reaction [APP protein modified form results in decreased expression of BCL2 mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CASP3 protein modified form] |
CTD |
PMID:26111763 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cat |
catalase |
increases expression |
ISO |
ginsenoside Rd results in increased expression of CAT protein |
CTD |
PMID:9933756 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
increases expression multiple interactions |
EXP |
ginsenoside Rd results in increased expression of CDKN1A mRNA staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CDKN1A mRNA] |
CTD |
PMID:24599032 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Chat |
choline O-acetyltransferase |
increases expression multiple interactions |
EXP |
ginsenoside Rd results in increased expression of CHAT mRNA; ginsenoside Rd results in increased expression of CHAT protein staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CHAT mRNA]; staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CHAT protein] |
CTD |
PMID:24599032 |
|
NCBI chr14:32,130,160...32,187,866
Ensembl chr14:32,130,160...32,187,946
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CYCS mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
|
|
G |
Lpl |
lipoprotein lipase |
decreases secretion |
EXP |
ginsenoside Rd results in decreased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
EXP |
ginsenoside Rd results in increased expression of MAP2 mRNA; ginsenoside Rd results in increased expression of MAP2 protein |
CTD |
PMID:24599032 |
|
NCBI chr 1:66,214,337...66,481,742
Ensembl chr 1:66,214,432...66,481,742
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
ginsenoside Rd results in increased phosphorylation of and results in increased activity of MAPK1 protein |
CTD |
PMID:24599032 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
ginsenoside Rd results in increased phosphorylation of and results in increased activity of MAPK3 protein |
CTD |
PMID:24599032 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Ngf |
nerve growth factor |
increases expression |
EXP |
ginsenoside Rd results in increased expression of NGF mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329
|
|
G |
Ngfr |
nerve growth factor receptor (TNFR superfamily, member 16) |
increases expression |
EXP |
ginsenoside Rd results in increased expression of NGFR mRNA; ginsenoside Rd results in increased expression of NGFR protein |
CTD |
PMID:24599032 |
|
NCBI chr11:95,459,644...95,478,524
Ensembl chr11:95,459,644...95,478,561
|
|
G |
P2rx4 |
purinergic receptor P2X, ligand-gated ion channel 4 |
multiple interactions |
ISO |
ginsenoside Rd promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] |
CTD |
PMID:30545933 |
|
NCBI chr 5:122,845,581...122,867,802
Ensembl chr 5:122,845,607...122,867,801
|
|
G |
P2rx7 |
purinergic receptor P2X, ligand-gated ion channel, 7 |
decreases response to substance |
EXP |
P2RX7 gene mutant form results in decreased susceptibility to ginsenoside Rd |
CTD |
PMID:30545933 |
|
NCBI chr 5:122,781,990...122,830,399
Ensembl chr 5:122,781,974...122,829,495
|
|
G |
Slc18a3 |
solute carrier family 18 (vesicular monoamine), member 3 |
increases expression |
EXP |
ginsenoside Rd results in increased expression of SLC18A3 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr14:32,184,394...32,186,807
Ensembl chr14:32,184,395...32,186,807
|
|
G |
Slc5a7 |
solute carrier family 5 (choline transporter), member 7 |
increases expression |
EXP |
ginsenoside Rd results in increased expression of SLC5A7 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr17:54,580,618...54,606,071
Ensembl chr17:54,580,618...54,606,062
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family, member 1b2 |
multiple interactions |
ISO |
ginsenoside Rd binds to and results in decreased activity of SLCO1B3 protein |
CTD |
PMID:25297453 |
|
NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372
|
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
increases transport |
ISO |
ABCB11 protein results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcc1 |
ATP-binding cassette, sub-family C member 1 |
increases transport |
ISO |
ABCC1 protein results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
increases transport |
ISO |
ABCC2 protein results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
increases transport |
ISO |
ABCG2 protein results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression multiple interactions |
EXP |
ginsenoside Re results in increased expression of ADIPOQ mRNA ginsenoside Re results in increased expression of and results in increased secretion of ADIPOQ protein |
CTD |
PMID:23545455 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
multiple interactions decreases expression |
EXP |
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]]; ginsenoside Re affects the reaction [GPX1 protein affects the expression of AIF1 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of AIF1 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]] ginsenoside Re results in decreased expression of AIF1 protein |
CTD |
PMID:29467000 PMID:36682417 |
|
NCBI chr17:35,389,967...35,394,977
Ensembl chr17:35,389,967...35,395,044
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions increases phosphorylation |
EXP ISO |
ginsenoside Re results in increased phosphorylation of and results in increased activity of AKT1 protein ginsenoside Re results in increased phosphorylation of AKT1 protein |
CTD |
PMID:17878692 PMID:17885204 PMID:24599032 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
ginsenoside Re binds to and affects the activity of AR protein |
CTD |
PMID:16985185 |
|
NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821
|
|
G |
Bax |
BCL2-associated X protein |
decreases expression multiple interactions |
EXP ISO |
ginsenoside Re results in decreased expression of BAX mRNA; ginsenoside Re results in decreased expression of BAX protein 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]]; Acetylcysteine inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BAX protein]]; Cyclosporine inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BAX protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BAX protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of BAX protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]] |
CTD |
PMID:12674765 PMID:15621629 PMID:29467000 PMID:37308051 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
increases expression multiple interactions |
EXP |
ginsenoside Re results in increased expression of BCL2 mRNA; ginsenoside Re results in increased expression of BCL2 protein 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]]; 3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2 protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of BCL2 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]] |
CTD |
PMID:15621629 PMID:29467000 PMID:37308051 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l1 |
BCL2-like 1 |
multiple interactions |
EXP |
3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2L1 protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2L1 protein] |
CTD |
PMID:37308051 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]]; 3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of CASP3 protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of CASP3 protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]; ginsenoside Re results in decreased cleavage of and results in decreased activity of CASP3 protein; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]] |
CTD |
PMID:15621629 PMID:23102375 PMID:25523949 PMID:29467000 PMID:37308051 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]] |
CTD |
PMID:24430743 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
increases expression |
EXP |
ginsenoside Re results in increased expression of CDKN1A mRNA |
CTD |
PMID:24599032 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Chat |
choline O-acetyltransferase |
increases expression multiple interactions |
EXP |
ginsenoside Re results in increased expression of CHAT mRNA; ginsenoside Re results in increased expression of CHAT protein staurosporine aglycone inhibits the reaction [ginsenoside Re results in increased expression of CHAT mRNA]; staurosporine aglycone inhibits the reaction [ginsenoside Re results in increased expression of CHAT protein] |
CTD |
PMID:24599032 |
|
NCBI chr14:32,130,160...32,187,866
Ensembl chr14:32,130,160...32,187,946
|
|
G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of CHUK protein] |
CTD |
PMID:17885204 |
|
NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of CLDN1 protein] |
CTD |
PMID:22849695 |
|
NCBI chr16:26,175,395...26,190,589
Ensembl chr16:26,175,392...26,190,591
|
|
G |
Crp |
C-reactive protein, pentraxin-related |
increases expression |
ISO |
ginsenoside Re results in increased expression of CRP protein |
CTD |
PMID:16797897 |
|
NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598
|
|
G |
Cyba |
cytochrome b-245, alpha polypeptide |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of CYBA protein]]; ginsenoside Re inhibits the reaction [Phencyclidine results in increased activity of CYBA protein] |
CTD |
PMID:29037473 |
|
NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669
|
|
G |
Cyp8b1 |
cytochrome P450, family 8, subfamily b, polypeptide 1 |
increases expression |
ISO |
ginsenoside Re results in increased expression of CYP8B1 mRNA |
CTD |
PMID:23835644 |
|
NCBI chr 9:121,743,422...121,745,371
Ensembl chr 9:121,743,422...121,745,371
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
multiple interactions |
ISO |
ginsenoside Re binds to and affects the activity of ESR1 protein |
CTD |
PMID:16985185 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
increases expression |
EXP |
ginsenoside Re results in increased expression of FABP4 mRNA |
CTD |
PMID:23545455 |
|
NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression multiple interactions |
ISO EXP |
ginsenoside Re results in decreased expression of FAS mRNA ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA] |
CTD |
PMID:21971952 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
increases expression |
ISO |
ginsenoside Re results in increased expression of FOS mRNA |
CTD |
PMID:16204943 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
ISO |
ginsenoside Re results in decreased expression of G6PC1 mRNA |
CTD |
PMID:21971952 |
|
NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729
|
|
G |
Gpam |
glycerol-3-phosphate acyltransferase, mitochondrial |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of GPAM mRNA] |
CTD |
PMID:21971952 |
|
NCBI chr19:55,056,067...55,115,666
Ensembl chr19:55,055,700...55,115,670
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
ginsenoside Re affects the reaction [GPX1 protein affects the expression of AIF1 protein]; ginsenoside Re affects the reaction [GPX1 protein affects the expression of and affects the localization of RELA protein]; ginsenoside Re affects the reaction [GPX1 protein affects the expression of PTAFR protein]; ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK1 protein]; ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK3 protein]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine affects the localization of NCF1 protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in decreased activity of SOD2 protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of CYBA protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of SOD1 protein]] |
CTD |
PMID:29037473 PMID:36682417 |
|
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation |
EXP |
ginsenoside Re results in increased phosphorylation of GSK3B protein |
CTD |
PMID:17885204 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
Hspd1 |
heat shock protein 1 (chaperonin) |
increases expression |
EXP |
ginsenoside Re results in increased expression of HSPD1 protein |
CTD |
PMID:23144451 |
|
NCBI chr 1:55,116,992...55,127,402
Ensembl chr 1:55,116,994...55,127,402
|
|
G |
Ifng |
interferon gamma |
decreases expression |
ISO |
ginsenoside Re results in decreased expression of IFNG protein |
CTD |
PMID:20230918 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Ikbkb |
inhibitor of kappaB kinase beta |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IKBKB protein] |
CTD |
PMID:22849695 |
|
NCBI chr 8:23,149,228...23,196,605
Ensembl chr 8:23,149,228...23,196,605
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of IL1B mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1B mRNA] |
CTD |
PMID:16557482 PMID:22494059 PMID:22849695 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [TNF protein results in increased expression of IL6 mRNA] |
CTD |
PMID:17885204 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ins1 |
insulin I |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Dietary Fats inhibits the reaction [INS1 protein results in increased localization of SLC2A4 protein]] |
CTD |
PMID:22571876 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased degradation of IRAK1 protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IRAK1 protein] |
CTD |
PMID:22849695 |
|
NCBI chr X:73,057,520...73,067,527
Ensembl chr X:73,057,520...73,067,524
|
|
G |
Irak4 |
interleukin-1 receptor-associated kinase 4 |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased degradation of IRAK4 protein] |
CTD |
PMID:22849695 |
|
NCBI chr15:94,441,495...94,466,198
Ensembl chr15:94,441,524...94,479,696
|
|
G |
Irgm1 |
immunity-related GTPase family M member 1 |
decreases expression |
ISO |
ginsenoside Re results in decreased expression of IRGM protein |
CTD |
PMID:20230918 |
|
NCBI chr11:48,756,072...48,762,247
Ensembl chr11:48,752,795...48,762,510
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions increases expression increases phosphorylation |
EXP |
ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of IRS1 protein] ginsenoside Re results in increased expression of IRS1 mRNA ginsenoside Re results in increased phosphorylation of IRS1 protein |
CTD |
PMID:17885204 PMID:23545455 |
|
NCBI chr 1:82,210,826...82,269,160
Ensembl chr 1:82,210,822...82,269,137
|
|
G |
Kcne1 |
potassium voltage-gated channel, Isk-related subfamily, member 1 |
increases expression |
ISO |
ginsenoside Re results in increased expression of KCNE1 |
CTD |
PMID:24615935 |
|
NCBI chr16:92,142,889...92,156,356
Ensembl chr16:92,142,870...92,156,356
|
|
G |
Lpl |
lipoprotein lipase |
increases secretion |
EXP |
ginsenoside Re results in increased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100
|
|
G |
Lrpprc |
leucine-rich PPR-motif containing |
increases expression |
EXP |
ginsenoside Re results in increased expression of LRPPRC protein |
CTD |
PMID:23144451 |
|
NCBI chr17:85,012,675...85,098,214
Ensembl chr17:85,012,675...85,098,217
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
EXP |
ginsenoside Re results in increased expression of MAP2 mRNA; ginsenoside Re results in increased expression of MAP2 protein |
CTD |
PMID:24599032 |
|
NCBI chr 1:66,214,337...66,481,742
Ensembl chr 1:66,214,432...66,481,742
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP |
ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK1 protein]; ginsenoside Re results in increased phosphorylation of and results in increased activity of MAPK1 protein ginsenoside Re results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:24599032 PMID:36682417 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP |
ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK3 protein]; ginsenoside Re results in increased phosphorylation of and results in increased activity of MAPK3 protein ginsenoside Re results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:24599032 PMID:36682417 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:22849695 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Myl9 |
myosin, light polypeptide 9, regulatory |
affects phosphorylation |
ISO |
ginsenoside Re affects the phosphorylation of MYL9 protein |
CTD |
PMID:24658813 |
|
NCBI chr 2:156,617,373...156,623,578
Ensembl chr 2:156,617,340...156,623,578
|
|
G |
Mylk |
myosin, light polypeptide kinase |
affects expression |
ISO |
ginsenoside Re affects the expression of MYLK mRNA; ginsenoside Re affects the expression of MYLK protein |
CTD |
PMID:24658813 |
|
NCBI chr16:34,565,569...34,822,806
Ensembl chr16:34,565,580...34,822,790
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine affects the localization of NCF1 protein]]; ginsenoside Re inhibits the reaction [Phencyclidine affects the localization of NCF1 protein] |
CTD |
PMID:29037473 |
|
NCBI chr 5:134,248,907...134,258,479
Ensembl chr 5:134,248,907...134,258,479
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
EXP ISO |
ginsenoside Re inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein] |
CTD |
PMID:17885204 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Ngf |
nerve growth factor |
increases expression |
EXP |
ginsenoside Re results in increased expression of NGF mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329
|
|
G |
Ngfr |
nerve growth factor receptor (TNFR superfamily, member 16) |
increases expression |
EXP |
ginsenoside Re results in increased expression of NGFR mRNA; ginsenoside Re results in increased expression of NGFR protein |
CTD |
PMID:24599032 |
|
NCBI chr11:95,459,644...95,478,524
Ensembl chr11:95,459,644...95,478,561
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
decreases expression multiple interactions |
EXP |
ginsenoside Re results in decreased expression of NOS2 protein ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:15621629 PMID:23102375 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
multiple interactions increases phosphorylation |
ISO |
2-aminoethoxydiphenyl borate inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]; Calcium deficiency inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]; Mifepristone inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein] |
CTD |
PMID:17490654 |
|
NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
ISO |
ginsenoside Re results in increased expression of NR0B2 mRNA |
CTD |
PMID:21971952 |
|
NCBI chr 4:133,280,687...133,283,997
Ensembl chr 4:133,280,687...133,283,847
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions increases activity |
ISO |
[ginsenoside Re results in increased activity of NR3C1 protein] which results in increased abundance of Nitric Oxide |
CTD |
PMID:17490654 |
|
NCBI chr18:39,543,598...39,652,485
Ensembl chr18:39,543,598...39,652,474
|
|
G |
Ocln |
occludin |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of OCLN protein] |
CTD |
PMID:22849695 |
|
NCBI chr13:100,633,012...100,689,226
Ensembl chr13:100,633,015...100,689,226
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Methamphetamine results in increased cleavage of PARP1 protein] |
CTD |
PMID:25523949 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1, cytosolic |
multiple interactions decreases expression |
EXP ISO |
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of PCK1 mRNA] ginsenoside Re results in decreased expression of PCK1 mRNA |
CTD |
PMID:21971952 |
|
NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066
|
|
G |
Pdyn |
prodynorphin |
multiple interactions |
EXP |
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of PDYN mRNA]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]] |
CTD |
PMID:29467000 |
|
NCBI chr 2:129,528,469...129,541,858
Ensembl chr 2:129,528,485...129,541,764
|
|
G |
Pgr |
progesterone receptor |
multiple interactions increases expression |
ISO |
ginsenoside Re binds to and affects the activity of PGR protein ginsenoside Re results in increased expression of PGR protein |
CTD |
PMID:16204943 PMID:16985185 |
|
NCBI chr 9:8,890,017...8,968,612
Ensembl chr 9:8,899,834...8,968,612
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
increases expression |
EXP |
ginsenoside Re results in increased expression of PPARG mRNA |
CTD |
PMID:23545455 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Prkaa1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
increases phosphorylation multiple interactions |
ISO EXP |
ginsenoside Re results in increased phosphorylation of PRKAA1 protein ginsenoside Re inhibits the reaction [Dietary Fats results in decreased phosphorylation of PRKAA1 protein] |
CTD |
PMID:21971952 |
|
NCBI chr15:5,172,641...5,211,380
Ensembl chr15:5,173,343...5,211,380
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions increases response to substance |
EXP ISO |
3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of and results in increased phosphorylation of PRKCD protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of and results in increased phosphorylation of PRKCD protein]; ginsenoside Re inhibits the reaction [Methamphetamine affects the localization of PRKCD protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]] ginsenoside Re inhibits the reaction [Methamphetamine affects the localization of PRKCD protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of and results in increased cleavage of PRKCD protein] PRKCD results in increased susceptibility to ginsenoside Re |
CTD |
PMID:24430743 PMID:25523949 PMID:37308051 |
|
NCBI chr14:30,317,310...30,348,637
Ensembl chr14:30,317,311...30,348,167
|
|
G |
Ptafr |
platelet-activating factor receptor |
multiple interactions decreases expression |
EXP |
ginsenoside Re affects the reaction [GPX1 protein affects the expression of PTAFR protein] ginsenoside Re results in decreased expression of PTAFR protein |
CTD |
PMID:36682417 |
|
NCBI chr 4:132,291,378...132,309,994
Ensembl chr 4:132,291,378...132,309,994
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of PTGS2 mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16557482 PMID:23102375 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
EXP |
ginsenoside Re affects the reaction [GPX1 protein affects the expression of and affects the localization of RELA protein]; ginsenoside Re results in decreased expression of and affects the localization of RELA protein |
CTD |
PMID:36682417 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase, polypeptide 1 |
increases phosphorylation |
EXP |
ginsenoside Re results in increased phosphorylation of RPS6KB1 protein |
CTD |
PMID:17885204 |
|
NCBI chr11:86,389,695...86,435,711
Ensembl chr11:86,389,697...86,435,631
|
|
G |
Scd1 |
stearoyl-Coenzyme A desaturase 1 |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of SCD1 mRNA] |
CTD |
PMID:21971952 |
|
NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318
|
|
G |
Scd2 |
stearoyl-Coenzyme A desaturase 2 |
decreases expression |
ISO |
ginsenoside Re results in decreased expression of SCD mRNA |
CTD |
PMID:21971952 |
|
NCBI chr19:44,282,115...44,295,303
Ensembl chr19:44,282,113...44,295,303
|
|
G |
Slc18a3 |
solute carrier family 18 (vesicular monoamine), member 3 |
increases expression |
EXP |
ginsenoside Re results in increased expression of SLC18A3 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr14:32,184,394...32,186,807
Ensembl chr14:32,184,395...32,186,807
|
|
G |
Slc2a4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
multiple interactions increases localization |
ISO EXP |
ginsenoside Re inhibits the reaction [Dietary Fats inhibits the reaction [INS1 protein results in increased localization of SLC2A4 protein]] ginsenoside Re results in increased localization of SLC2A4 protein |
CTD |
PMID:17885204 PMID:22571876 PMID:23545455 |
|
NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014
|
|
G |
Slc5a7 |
solute carrier family 5 (choline transporter), member 7 |
increases expression |
EXP |
ginsenoside Re results in increased expression of SLC5A7 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr17:54,580,618...54,606,071
Ensembl chr17:54,580,618...54,606,062
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family, member 1b2 |
multiple interactions |
ISO |
SLCO1B3 protein binds to and results in increased transport of ginsenoside Re SLCO1B2 protein binds to and results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [TNF protein results in increased expression of SOCS3 mRNA] |
CTD |
PMID:17885204 |
|
NCBI chr11:117,856,905...117,860,192
Ensembl chr11:117,856,905...117,860,873
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
multiple interactions decreases activity |
EXP |
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of SOD1 protein]]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]] ginsenoside Re results in decreased activity of SOD1 protein |
CTD |
PMID:24430743 PMID:29037473 PMID:36682417 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased activity of SOD2 protein]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in decreased activity of SOD2 protein]] |
CTD |
PMID:29037473 PMID:37308051 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions decreases expression |
EXP ISO |
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA] ginsenoside Re results in decreased expression of SREBF1 mRNA |
CTD |
PMID:21971952 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
G |
Stk11 |
serine/threonine kinase 11 |
increases phosphorylation |
ISO |
ginsenoside Re results in increased phosphorylation of STK11 protein |
CTD |
PMID:21971952 |
|
NCBI chr10:79,951,602...79,966,513
Ensembl chr10:79,951,637...79,966,516
|
|
G |
Tac1 |
tachykinin 1 |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 mRNA]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 protein modified form]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 mRNA]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 protein modified form]] |
CTD |
PMID:29467000 |
|
NCBI chr 6:7,555,061...7,562,978
Ensembl chr 6:7,554,879...7,565,834
|
|
G |
Tbc1d4 |
TBC1 domain family, member 4 |
increases phosphorylation |
EXP |
ginsenoside Re results in increased phosphorylation of TBC1D4 protein |
CTD |
PMID:17885204 |
|
NCBI chr14:101,679,800...101,846,717
Ensembl chr14:101,679,796...101,846,627
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
ginsenoside Re results in increased expression of TFF1 mRNA |
CTD |
PMID:16204943 |
|
NCBI chr17:31,380,369...31,384,034
Ensembl chr17:31,380,369...31,384,251
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
ISO EXP |
ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of and results in decreased activity of TH protein] 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of TH protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]] |
CTD |
PMID:25523949 PMID:29467000 |
|
NCBI chr 7:142,446,516...142,453,732
Ensembl chr 7:142,446,489...142,484,865
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of TJP1 protein] |
CTD |
PMID:22849695 |
|
NCBI chr 7:64,945,913...65,177,629
Ensembl chr 7:64,945,913...65,177,529
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [Lipopolysaccharides binds to TLR4 protein] |
CTD |
PMID:22849695 |
|
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; ginsenoside Re inhibits the reaction [TNF protein results in increased expression of SOCS3 mRNA]; ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of CHUK protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of IRS1 protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of TNF mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA]; ginsenoside Re results in decreased expression of and results in decreased secretion of TNF protein |
CTD |
PMID:16557482 PMID:17885204 PMID:22494059 PMID:22849695 PMID:23545455 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Apoa1 |
apolipoprotein A-I |
multiple interactions decreases expression |
EXP |
ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]; ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 protein]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]] ginsenoside Rf results in decreased expression of APOA1 protein |
CTD |
PMID:16297877 |
|
NCBI chr 9:46,139,928...46,141,767
Ensembl chr 9:46,139,878...46,141,764
|
|
G |
Apoc3 |
apolipoprotein C-III |
multiple interactions decreases expression increases expression |
EXP |
ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]; ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 protein]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf results in increased expression of APOC3 mRNA] ginsenoside Rf results in decreased expression of APOC3 protein |
CTD |
PMID:16297877 |
|
NCBI chr 9:46,144,348...46,146,934
Ensembl chr 9:46,144,231...46,146,934
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
affects activity |
ISO |
ginsenoside Rf affects the activity of KCNH2 protein |
CTD |
PMID:15842772 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions decreases expression |
EXP |
ginsenoside Rf binds to and results in decreased activity of PPARA protein; ginsenoside Rf inhibits the reaction [pirinixic acid results in increased activity of PPARA protein]; ginsenoside Rf inhibits the reaction [pirinixic acid results in increased expression of PPARA mRNA]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf results in increased expression of APOC3 mRNA] ginsenoside Rf results in decreased expression of PPARA mRNA |
CTD |
PMID:16297877 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
increases transport multiple interactions |
ISO EXP |
ABCB11 protein results in increased transport of ginsenoside Rg1 ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 protein] ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCB11 protein] |
CTD |
PMID:25297453 PMID:29964319 PMID:32198087 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcc1 |
ATP-binding cassette, sub-family C member 1 |
increases transport |
ISO |
ABCC1 protein results in increased transport of ginsenoside Rg1 |
CTD |
PMID:25297453 |
|
NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
increases transport multiple interactions increases expression |
ISO EXP |
ABCC2 protein results in increased transport of ginsenoside Rg1 ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 protein] ginsenoside Rg1 results in increased expression of ABCC2 protein ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 protein]; Tretinoin inhibits the reaction [ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 protein]] |
CTD |
PMID:25297453 PMID:29964319 PMID:32198087 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcc3 |
ATP-binding cassette, sub-family C member 3 |
increases expression multiple interactions |
EXP |
ginsenoside Rg1 results in increased expression of ABCC3 protein ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC3 protein]; Tretinoin inhibits the reaction [ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC3 protein]] |
CTD |
PMID:29964319 |
|
NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823
|
|
G |
Abcc4 |
ATP-binding cassette, sub-family C member 4 |
increases expression multiple interactions |
EXP |
ginsenoside Rg1 results in increased expression of ABCC4 protein ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC4 protein] |
CTD |
PMID:29964319 |
|
NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
increases transport |
ISO |
ABCG2 protein results in increased transport of ginsenoside Rg1 |
CTD |
PMID:25297453 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
EXP |
ginsenoside Rg1 results in decreased activity of ACHE protein |
CTD |
PMID:20564503 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
G |
Adam10 |
a disintegrin and metallopeptidase domain 10 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA] |
CTD |
PMID:22484447 |
|
NCBI chr 9:70,586,133...70,687,511
Ensembl chr 9:70,586,279...70,687,511
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions |
EXP ISO |
ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in decreased phosphorylation of AKT1 protein]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of AKT1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased phosphorylation of AKT1 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein] ginsenoside Rg1 inhibits the reaction [Doxorubicin results in increased expression of AKT1 mRNA] |
CTD |
PMID:33331133 PMID:34783124 PMID:34859534 PMID:36811218 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
multiple interactions |
ISO |
ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of APAF1 mRNA] |
CTD |
PMID:34783124 |
|
NCBI chr10:90,825,173...90,918,688
Ensembl chr10:90,825,173...90,918,632
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein alternative form]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA]; ginsenoside Rg1 results in decreased susceptibility to [APP protein alternative form co-treated with Dexamethasone] |
CTD |
PMID:22484447 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of ATF6 protein] |
CTD |
PMID:30918470 |
|
NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340
|
|
G |
Atm |
ataxia telangiectasia mutated |
multiple interactions |
ISO |
ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of ATM mRNA] |
CTD |
PMID:34783124 |
|
NCBI chr 9:53,348,422...53,448,125
Ensembl chr 9:53,350,449...53,448,040
|
|
G |
Bace1 |
beta-site APP cleaving enzyme 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA] |
CTD |
PMID:22484447 |
|
NCBI chr 9:45,749,878...45,775,694
Ensembl chr 9:45,749,878...45,775,697
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]; ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]; Mifepristone inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]; SH-6 compound inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]] |
CTD |
PMID:17123556 |
|
NCBI chr19:6,919,229...6,929,273
Ensembl chr19:6,919,229...6,929,267
|
|
G |
Bax |
BCL2-associated X protein |
increases expression multiple interactions |
EXP ISO |
ginsenoside Rg1 results in increased expression of BAX protein ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of BAX protein] ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of BAX mRNA] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein] |
CTD |
PMID:28371286 PMID:34783124 PMID:34859534 PMID:36811218 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
decreases expression multiple interactions |
EXP ISO |
ginsenoside Rg1 results in decreased expression of BCL2 protein ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in decreased expression of BCL2 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of BCL2 protein] |
CTD |
PMID:26593335 PMID:28371286 PMID:34859534 PMID:36811218 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO EXP |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]; ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CASP3 mRNA] ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased cleavage of CASP3 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein] ginsenoside Rg1 results in increased activity of CASP3 protein |
CTD |
PMID:24386346 PMID:28371286 PMID:34783124 PMID:34859534 PMID:36811218 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
EXP ISO |
ginsenoside Rg1 results in increased activity of CASP9 protein ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased cleavage of CASP9 protein] ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CASP9 mRNA] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein] |
CTD |
PMID:28371286 PMID:34783124 PMID:34859534 PMID:36811218 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein] ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of CAT protein] |
CTD |
PMID:29964319 PMID:37923178 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CCNE1 protein] |
CTD |
PMID:15606011 |
|
NCBI chr 7:37,797,409...37,806,915
Ensembl chr 7:37,797,409...37,806,959
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 protein] |
CTD |
PMID:33331133 |
|
NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDK2 protein] |
CTD |
PMID:15606011 |
|
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
multiple interactions |
ISO |
ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDKN1A protein]; ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CDKN1A mRNA] |
CTD |
PMID:15606011 PMID:34783124 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CREB1 protein] |
CTD |
PMID:33331133 |
|
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
|
|
G |
Cyp2b10 |
cytochrome P450, family 2, subfamily b, polypeptide 10 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 protein] |
CTD |
PMID:32198087 |
|
NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:29964319 |
|
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of DDIT3 protein] |
CTD |
PMID:30918470 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signalling 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of ERN1 protein] |
CTD |
PMID:30918470 |
|
NCBI chr11:106,285,474...106,378,701
Ensembl chr11:106,285,476...106,378,678
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of FOS mRNA |
CTD |
PMID:16204943 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Fshb |
follicle stimulating hormone beta |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in increased expression of FSHB protein] |
CTD |
PMID:33331133 |
|
NCBI chr 2:106,886,331...106,889,996
Ensembl chr 2:106,886,485...106,890,001
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of FSHR protein] |
CTD |
PMID:33331133 |
|
NCBI chr17:89,292,380...89,508,103
Ensembl chr17:89,292,380...89,508,103
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
EXP |
ginsenoside Rg1 results in increased expression of GCLC mRNA ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]] |
CTD |
PMID:29964319 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gclm |
glutamate-cysteine ligase, modifier subunit |
increases expression multiple interactions |
EXP |
ginsenoside Rg1 results in increased expression of GCLM protein ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLM protein] |
CTD |
PMID:29964319 |
|
NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of GJA1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of GJA1 protein] |
CTD |
PMID:33331133 |
|
NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609
|
|
G |
Glud1 |
glutamate dehydrogenase 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in increased expression of GLUD1 protein] |
CTD |
PMID:26593335 |
|
NCBI chr14:34,032,684...34,066,990
Ensembl chr14:34,032,684...34,067,222
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein] |
CTD |
PMID:29964319 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of GSK3B protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:34859534 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of H2AX mRNA] |
CTD |
PMID:34783124 |
|
NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
EXP |
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]] ginsenoside Rg1 results in increased expression of HMOX1 mRNA; ginsenoside Rg1 results in increased expression of HMOX1 protein |
CTD |
PMID:25422538 PMID:29964319 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hspa5 |
heat shock protein 5 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of HSPA5 protein] |
CTD |
PMID:30918470 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IFNG protein] |
CTD |
PMID:32198087 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of IL1B protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B] ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B protein] |
CTD |
PMID:22214447 PMID:29964319 PMID:32198087 PMID:36811218 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in increased expression of IL6 protein] ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:17655881 PMID:29964319 PMID:30918470 PMID:36811218 PMID:37923178 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Inha |
inhibin alpha |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of INHA protein] |
CTD |
PMID:33331133 |
|
NCBI chr 1:75,483,872...75,487,010
Ensembl chr 1:75,483,721...75,487,010
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
affects activity |
ISO |
ginsenoside Rg1 affects the activity of KCNH2 protein |
CTD |
PMID:15842772 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Keap1 |
kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of KEAP1 protein] |
CTD |
PMID:29964319 |
|
NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
|
|
G |
Lhb |
luteinizing hormone beta |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of LHB protein] |
CTD |
PMID:33331133 |
|
NCBI chr 7:45,070,370...45,071,278
Ensembl chr 7:45,070,244...45,071,321
|
|
G |
Lpl |
lipoprotein lipase |
increases secretion |
EXP |
ginsenoside Rg1 results in increased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
EXP |
ginsenoside Rg1 results in increased expression of MAP2 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 1:66,214,337...66,481,742
Ensembl chr 1:66,214,432...66,481,742
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions affects phosphorylation |
EXP |
PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK1 protein] |
CTD |
PMID:22214447 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
affects phosphorylation multiple interactions |
EXP |
ginsenoside Rg1 affects the phosphorylation of MAPK3 protein PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK3 protein] |
CTD |
PMID:22214447 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:24386346 |
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:24386346 |
|
NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248
|
|
G |
Met |
met proto-oncogene |
multiple interactions increases expression |
ISO |
Mifepristone inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]; MIR23A mRNA inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein] |
CTD |
PMID:26115870 |
|
NCBI chr 6:17,463,351...17,573,979
Ensembl chr 6:17,463,799...17,573,979
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 mRNA]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 protein] |
CTD |
PMID:26593335 |
|
NCBI chr 4:147,958,043...147,989,527
Ensembl chr 4:147,958,056...147,989,161
|
|
G |
Mir23a |
microRNA 23a |
decreases expression multiple interactions |
ISO |
ginsenoside Rg1 results in decreased expression of MIR23A mRNA Mifepristone inhibits the reaction [ginsenoside Rg1 results in decreased expression of MIR23A mRNA]; MIR23A mRNA inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein] |
CTD |
PMID:26115870 |
|
NCBI chr 8:84,935,147...84,935,221
Ensembl chr 8:84,935,147...84,935,221
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of MMP2 protein |
CTD |
PMID:23738715 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of MMP9 protein |
CTD |
PMID:23738715 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO EXP |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in decreased activity of [MTOR protein binds to RAPTOR protein]]; ginsenoside Rg1 results in increased activity of [MTOR protein binds to RAPTOR protein] ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of MTOR protein] |
CTD |
PMID:24386346 PMID:33331133 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions affects localization increases expression |
ISO EXP |
[ginsenoside Rg1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein ginsenoside Rg1 affects the localization of NFE2L2 protein [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein]] ginsenoside Rg1 results in increased expression of NFE2L2 mRNA |
CTD |
PMID:22780686 PMID:25422538 PMID:29964319 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
affects phosphorylation multiple interactions |
EXP |
ginsenoside Rg1 affects the phosphorylation of NFKBIA protein PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of NFKBIA protein] |
CTD |
PMID:22214447 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
EXP |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2] |
CTD |
PMID:22214447 PMID:29964319 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 protein]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]] |
CTD |
PMID:29964319 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 protein] |
CTD |
PMID:32198087 |
|
NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of PGR protein |
CTD |
PMID:16204943 |
|
NCBI chr 9:8,890,017...8,968,612
Ensembl chr 9:8,899,834...8,968,612
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of PIK3CA mRNA] |
CTD |
PMID:33331133 |
|
NCBI chr 3:32,451,203...32,520,256
Ensembl chr 3:32,451,820...32,522,635
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
multiple interactions |
EXP |
PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK1 protein]; PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK3 protein]; PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of NFKBIA protein] |
CTD |
PMID:22214447 |
|
NCBI chr 2:160,573,230...160,617,680
Ensembl chr 2:160,573,220...160,617,680
|
|
G |
Prkaa1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased phosphorylation of PRKAA1 protein] |
CTD |
PMID:24386346 |
|
NCBI chr15:5,172,641...5,211,380
Ensembl chr15:5,173,343...5,211,380
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in increased expression of PTEN protein] |
CTD |
PMID:33331133 |
|
NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2] |
CTD |
PMID:22214447 PMID:29964319 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Rad51 |
RAD51 recombinase |
multiple interactions |
ISO |
ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of RAD51 mRNA] |
CTD |
PMID:34783124 |
|
NCBI chr 2:118,943,295...118,966,554
Ensembl chr 2:118,943,274...118,977,926
|
|
G |
Rps6 |
ribosomal protein S6 |
increases phosphorylation |
ISO |
ginsenoside Rg1 results in increased phosphorylation of RPS6 protein |
CTD |
PMID:24386346 |
|
NCBI chr 4:86,772,336...86,775,604
Ensembl chr 4:86,772,897...86,775,649
|
|
G |
Rptor |
regulatory associated protein of MTOR, complex 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in decreased activity of [MTOR protein binds to RAPTOR protein]]; ginsenoside Rg1 results in increased activity of [MTOR protein binds to RAPTOR protein] |
CTD |
PMID:24386346 |
|
NCBI chr11:119,493,731...119,790,417
Ensembl chr11:119,493,731...119,790,402
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of SIRT1 protein] |
CTD |
PMID:30918470 |
|
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
|
|
G |
Slc10a1 |
solute carrier family 10 (sodium/bile acid cotransporter family), member 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 protein] |
CTD |
PMID:32198087 |
|
NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family, member 1b2 |
multiple interactions |
ISO |
SLCO1B2 protein binds to and results in increased transport of ginsenoside Rg1 SLCO1B3 protein binds to and results in increased transport of ginsenoside Rg1 |
CTD |
PMID:25297453 |
|
NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of SOD1 protein] |
CTD |
PMID:37923178 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Sult2a1 |
sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SULT2A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SULT2A1 protein] |
CTD |
PMID:32198087 |
|
NCBI chr 7:13,530,171...13,571,335
Ensembl chr 7:13,530,171...13,571,334
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of TFF1 mRNA |
CTD |
PMID:16204943 |
|
NCBI chr17:31,380,369...31,384,034
Ensembl chr17:31,380,369...31,384,251
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in increased expression of TNF protein] |
CTD |
PMID:22214447 PMID:29964319 PMID:30918470 PMID:32198087 PMID:36811218 PMID:37923178 More...
|
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions |
ISO |
ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of TP53 mRNA] |
CTD |
PMID:34783124 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase 1 family, polypeptide A1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 protein] |
CTD |
PMID:32198087 |
|
NCBI chr 1:88,139,681...88,147,724
Ensembl chr 1:88,139,681...88,146,719
|
|
G |
Xrcc1 |
X-ray repair complementing defective repair in Chinese hamster cells 1 |
multiple interactions |
ISO |
ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of XRCC1 mRNA] |
CTD |
PMID:34783124 |
|
NCBI chr 7:24,246,124...24,272,863
Ensembl chr 7:24,245,714...24,272,865
|
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
increases expression |
ISO |
ginsenoside Rg2 results in increased expression of ABCC2 mRNA |
CTD |
PMID:23835644 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:28756148 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of and results in increased cleavage of CASP3 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased expression of BAX protein] |
CTD |
PMID:28756148 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
ISO |
ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased expression of BAX protein] |
CTD |
PMID:28756148 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
ISO |
ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein] |
CTD |
PMID:28756148 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Becn2 |
beclin 2 |
multiple interactions |
ISO EXP |
ginsenoside Rg2 inhibits the reaction [BECN2 protein binds to GPRASP1 protein] |
CTD |
PMID:27305347 |
|
NCBI chr 1:175,747,895...175,749,791
Ensembl chr 1:175,747,895...175,749,791
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of and results in increased cleavage of CASP3 protein] |
CTD |
PMID:28756148 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Crtc2 |
CREB regulated transcription coactivator 2 |
multiple interactions |
ISO |
[ginsenoside Rg2 results in increased activity of NR0B2 protein] which results in decreased activity of CRTC2 protein |
CTD |
PMID:22062806 |
|
NCBI chr 3:90,161,475...90,171,432
Ensembl chr 3:90,161,470...90,171,432
|
|
G |
G6pc3 |
glucose 6 phosphatase, catalytic, 3 |
decreases expression multiple interactions |
ISO |
ginsenoside Rg2 results in decreased expression of G6PC3 mRNA dorsomorphin inhibits the reaction [ginsenoside Rg2 results in decreased expression of G6PC3 mRNA] |
CTD |
PMID:22062806 |
|
NCBI chr11:102,080,525...102,084,907
Ensembl chr11:102,080,446...102,084,907
|
|
G |
Gprasp1 |
G protein-coupled receptor associated sorting protein 1 |
multiple interactions |
ISO EXP |
ginsenoside Rg2 inhibits the reaction [BECN2 protein binds to GPRASP1 protein] |
CTD |
PMID:27305347 |
|
NCBI chr X:134,643,441...134,704,217
Ensembl chr X:134,643,482...134,704,223
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation multiple interactions |
ISO |
ginsenoside Rg2 results in increased phosphorylation of GSK3B protein [[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose; dorsomorphin inhibits the reaction [ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:22062806 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression multiple interactions |
ISO |
ginsenoside Rg2 results in increased expression of MAP1LC3B protein modified form bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in increased expression of MAP1LC3B protein modified form] |
CTD |
PMID:27305347 |
|
NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions increases expression increases activity |
ISO |
[[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose; [ginsenoside Rg2 results in increased activity of NR0B2 protein] which results in decreased activity of CRTC2 protein |
CTD |
PMID:22062806 |
|
NCBI chr 4:133,280,687...133,283,997
Ensembl chr 4:133,280,687...133,283,847
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1, cytosolic |
multiple interactions decreases expression |
ISO |
dorsomorphin inhibits the reaction [ginsenoside Rg2 results in decreased expression of PCK1 mRNA] |
CTD |
PMID:22062806 |
|
NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
multiple interactions decreases expression |
ISO |
dorsomorphin inhibits the reaction [ginsenoside Rg2 results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:22062806 |
|
NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions decreases expression |
ISO EXP |
bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in decreased expression of SQSTM1 protein] |
CTD |
PMID:27305347 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Stk11 |
serine/threonine kinase 11 |
increases phosphorylation multiple interactions |
ISO |
ginsenoside Rg2 results in increased phosphorylation of STK11 protein dorsomorphin inhibits the reaction [ginsenoside Rg2 results in increased phosphorylation of STK11 protein] |
CTD |
PMID:22062806 |
|
NCBI chr10:79,951,602...79,966,513
Ensembl chr10:79,951,637...79,966,516
|
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions decreases expression |
ISO |
glucobrassicin analog inhibits the reaction [glucoraphanin analog results in increased expression of GPX2 mRNA] glucobrassicin analog results in decreased expression of GPX2 protein |
CTD |
PMID:20868228 |
|
NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions decreases activity |
ISO |
glucobrassicin analog inhibits the reaction [glucoraphanin results in increased activity of NQO1 protein] glucobrassicin analog results in decreased activity of NQO1 protein |
CTD |
PMID:20868228 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
glucoerucin results in increased expression of CYP1A1 protein |
CTD |
PMID:20833222 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
ISO |
glucoerucin results in increased expression of CYP1A2 protein |
CTD |
PMID:20833222 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
glucoerucin results in increased expression of CYP1B1 protein |
CTD |
PMID:20833222 |
|
NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490
|
|
G |
Ephx1 |
epoxide hydrolase 1, microsomal |
increases expression |
ISO |
glucoerucin results in increased expression of EPHX1 protein |
CTD |
PMID:21132492 |
|
NCBI chr 1:180,817,121...180,845,134
Ensembl chr 1:180,803,775...180,848,469
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
increases activity |
ISO |
glucoerucin results in increased activity of NQO1 protein |
CTD |
PMID:20833222 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
glucoraphanin results in increased expression of CYP1A1 protein |
CTD |
PMID:20833222 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
ISO |
glucoraphanin results in increased expression of CYP1A2 protein |
CTD |
PMID:20833222 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
glucoraphanin results in increased expression of CYP1B1 protein |
CTD |
PMID:20833222 |
|
NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490
|
|
G |
Ephx1 |
epoxide hydrolase 1, microsomal |
increases expression |
ISO |
glucoraphanin results in increased expression of EPHX1 protein |
CTD |
PMID:21132492 |
|
NCBI chr 1:180,817,121...180,845,134
Ensembl chr 1:180,803,775...180,848,469
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression |
ISO |
Glucoraphanin decreases expression of Gpx1 mRNA in the jejunum |
RGD |
PMID:23271678 |
RGD:152998882 |
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression increases expression multiple interactions |
ISO |
glucoraphanin analog results in increased expression of GPX2 mRNA; glucoraphanin analog results in increased expression of GPX2 protein Glucoraphanin increases expression of Gpx2 mRNA in the jejunum Benzo(a)pyrene inhibits the reaction [glucoraphanin results in increased expression of GPX2 mRNA]; glucobrassicin analog inhibits the reaction [glucoraphanin analog results in increased expression of GPX2 mRNA] |
CTD RGD |
PMID:20868228 PMID:23271678 |
RGD:152998882 |
NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
affects localization |
ISO |
glucoraphanin analog affects the localization of NFE2L2 protein |
CTD |
PMID:20868228 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions increases activity |
ISO |
glucobrassicin analog inhibits the reaction [glucoraphanin results in increased activity of NQO1 protein] glucoraphanin analog results in increased activity of NQO1 protein |
CTD |
PMID:20833222 PMID:20868228 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of ACSL3 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:78,635,600...78,685,462
Ensembl chr 1:78,635,542...78,685,460
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase family 1, subfamily A2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ALDH1A2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:71,123,071...71,203,525
Ensembl chr 9:71,123,071...71,203,525
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ANPEP mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:79,471,551...79,497,958
Ensembl chr 7:79,471,551...79,510,807
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
glycitin inhibits the reaction [APP protein binds to APP protein] |
CTD |
PMID:17323972 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Atoh8 |
atonal bHLH transcription factor 8 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of ATOH8 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:72,183,158...72,212,765
Ensembl chr 6:72,183,161...72,212,561
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of BCKDK mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:127,503,245...127,508,836
Ensembl chr 7:127,503,254...127,509,393
|
|
G |
Bpgm |
2,3-bisphosphoglycerate mutase |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of BPGM mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:34,453,291...34,482,071
Ensembl chr 6:34,453,142...34,482,548
|
|
G |
Cabp5 |
calcium binding protein 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CABP5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:13,119,885...13,142,812
Ensembl chr 7:13,132,057...13,142,812
|
|
G |
Cacybp |
calcyclin binding protein |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CACYBP mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:160,029,171...160,040,391
Ensembl chr 1:160,029,937...160,040,445
|
|
G |
Casp8ap2 |
caspase 8 associated protein 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CASP8AP2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:32,615,462...32,653,271
Ensembl chr 4:32,615,451...32,653,265
|
|
G |
Cd200r1 |
CD200 receptor 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CD200R1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr16:44,586,141...44,615,341
Ensembl chr16:44,586,099...44,615,341
|
|
G |
Cfap251 |
cilia and flagella associated protein 251 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CFAP251 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:123,390,196...123,465,547
Ensembl chr 5:123,390,165...123,465,547
|
|
G |
Cybrd1 |
cytochrome b reductase 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CYBRD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:70,948,398...70,973,270
Ensembl chr 2:70,948,267...70,973,270
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306
|
|
G |
Dennd2d |
DENN domain containing 2D |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of DENND2D mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:106,389,745...106,410,346
Ensembl chr 3:106,389,721...106,410,346
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 9:20,818,501...20,871,084
Ensembl chr 9:20,818,505...20,871,184
|
|
G |
Dnmt3a |
DNA methyltransferase 3A |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT3A mRNA |
CTD |
PMID:28964809 |
|
NCBI chr12:3,851,559...3,964,442
Ensembl chr12:3,856,007...3,964,443
|
|
G |
Dpp9 |
dipeptidylpeptidase 9 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of DPP9 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr17:56,493,674...56,525,927
Ensembl chr17:56,493,807...56,525,905
|
|
G |
Edrf1 |
erythroid differentiation regulatory factor 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of EDRF1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:133,239,422...133,274,710
Ensembl chr 7:133,239,272...133,274,700
|
|
G |
Efhd1 |
EF hand domain containing 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of EFHD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:87,192,075...87,238,563
Ensembl chr 1:87,192,085...87,238,561
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of ESR2 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
Fam171a2 |
family with sequence similarity 171, member A2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FAM171A2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr11:102,327,807...102,338,551
Ensembl chr11:102,327,807...102,338,508
|
|
G |
Fam180a |
family with sequence similarity 180, member A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM180A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:35,289,678...35,303,076
Ensembl chr 6:35,289,603...35,303,076
|
|
G |
Fam210b |
family with sequence similarity 210, member B |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM210B mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:172,187,444...172,197,669
Ensembl chr 2:172,187,485...172,197,669
|
|
G |
Fam241b |
family with sequence similarity 241, member B |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of FAM241B mRNA |
CTD |
PMID:27424125 |
|
NCBI chr10:61,943,435...61,946,829
Ensembl chr10:61,943,434...61,979,699
|
|
G |
Fgd6 |
FYVE, RhoGEF and PH domain containing 6 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FGD6 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr10:93,871,862...93,981,201
Ensembl chr10:93,871,863...93,981,201
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FHL2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:43,162,233...43,237,501
Ensembl chr 1:43,162,234...43,236,144
|
|
G |
Galnt15 |
polypeptide N-acetylgalactosaminyltransferase 15 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of GALNT15 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr14:31,750,739...31,784,161
Ensembl chr14:31,750,946...31,784,154
|
|
G |
Gng5 |
G protein subunit gamma 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of GNG5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:146,205,591...146,211,298
Ensembl chr 3:146,205,562...146,211,327
|
|
G |
Hipk4 |
homeodomain interacting protein kinase 4 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of HIPK4 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:27,222,686...27,230,605
Ensembl chr 7:27,222,692...27,230,600
|
|
G |
Hmcn1 |
hemicentin 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of HMCN1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:150,438,251...150,869,568
Ensembl chr 1:150,438,275...150,869,186
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of HSD3B1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 3:98,749,672...98,767,110
Ensembl chr 3:98,759,510...98,767,110
|
|
G |
Il6ra |
interleukin 6 receptor, alpha |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of IL6R mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:89,776,631...89,820,503
Ensembl chr 3:89,771,366...89,820,503
|
|
G |
Isg20l2 |
interferon stimulated exonuclease gene 20-like 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ISG20L2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:87,837,602...87,847,994
Ensembl chr 3:87,837,621...87,847,993
|
|
G |
Kdm5a |
lysine demethylase 5A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of KDM5A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:120,341,060...120,421,535
Ensembl chr 6:120,341,085...120,421,535
|
|
G |
Kitl |
kit ligand |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KITLG mRNA |
CTD |
PMID:27424125 |
|
NCBI chr10:99,851,477...99,936,278
Ensembl chr10:99,851,492...99,936,278
|
|
G |
Knstrn |
kinetochore-localized astrin/SPAG5 binding |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KNSTRN mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:118,644,470...118,667,691
Ensembl chr 2:118,644,484...118,684,438
|
|
G |
Ldlrap1 |
low density lipoprotein receptor adaptor protein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LDLRAP1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:134,468,865...134,495,342
Ensembl chr 4:134,468,865...134,495,335
|
|
G |
Lmod1 |
leiomodin 1 (smooth muscle) |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LMOD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:135,252,551...135,295,803
Ensembl chr 1:135,252,545...135,295,803
|
|
G |
Lrg1 |
leucine-rich alpha-2-glycoprotein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of LRG1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr17:56,426,678...56,428,946
Ensembl chr17:56,426,678...56,429,001
|
|
G |
Lsr |
lipolysis stimulated lipoprotein receptor |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LSR mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:30,657,195...30,672,894
Ensembl chr 7:30,657,195...30,672,889
|
|
G |
Mrpl33 |
mitochondrial ribosomal protein L33 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of MRPL33 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:31,771,295...31,779,988
Ensembl chr 5:31,754,279...31,821,728
|
|
G |
Mtmr11 |
myotubularin related protein 11 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of MTMR11 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:96,069,287...96,079,034
Ensembl chr 3:96,069,321...96,079,034
|
|
G |
Myof |
myoferlin |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of MYOF mRNA |
CTD |
PMID:27424125 |
|
NCBI chr19:37,887,484...38,032,025
Ensembl chr19:37,887,484...38,032,025
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of NR4A1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr15:101,151,783...101,172,676
Ensembl chr15:101,152,150...101,172,676
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 protein; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased methylation of NR5A1 promoter; decitabine inhibits the reaction [[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA] |
CTD |
PMID:28964809 |
|
NCBI chr 2:38,582,668...38,604,554
Ensembl chr 2:38,582,668...38,604,554
|
|
G |
Prkaca |
protein kinase, cAMP dependent, catalytic, alpha |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of PRKACA mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 8:84,699,607...84,723,073
Ensembl chr 8:84,699,622...84,723,072
|
|
G |
Prpf40a |
pre-mRNA processing factor 40A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PRPF40A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:53,024,714...53,081,450
Ensembl chr 2:53,024,716...53,081,714
|
|
G |
Pspc1 |
paraspeckle protein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PSPC1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr14:56,959,898...57,015,775
Ensembl chr14:56,958,167...57,015,773
|
|
G |
Pth1r |
parathyroid hormone 1 receptor |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of PTH1R mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:110,551,132...110,576,213
Ensembl chr 9:110,551,153...110,576,213
|
|
G |
Rassf5 |
Ras association (RalGDS/AF-6) domain family member 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of RASSF5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:131,104,147...131,172,915
Ensembl chr 1:131,104,147...131,172,995
|
|
G |
Rgs22 |
regulator of G-protein signalling 22 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of RGS22 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr15:35,960,664...36,140,718
Ensembl chr15:36,009,625...36,140,546
|
|
G |
S1pr3 |
sphingosine-1-phosphate receptor 3 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of S1PR3 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:51,562,654...51,576,833
Ensembl chr13:51,562,675...51,576,833
|
|
G |
Selplg |
selectin, platelet (p-selectin) ligand |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SELPLG mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:113,955,859...113,970,576
Ensembl chr 5:113,956,597...113,970,705
|
|
G |
Slc16a1 |
solute carrier family 16 (monocarboxylic acid transporters), member 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SLC16A1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:104,545,980...104,565,778
Ensembl chr 3:104,545,984...104,565,778
|
|
G |
Snx30 |
sorting nexin family member 30 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SNX30 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:59,805,137...59,904,740
Ensembl chr 4:59,805,840...59,904,737
|
|
G |
Ssc5d |
scavenger receptor cysteine rich family, 5 domains |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SSC5D mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:4,928,820...4,947,827
Ensembl chr 7:4,928,784...4,947,825
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR protein |
CTD |
PMID:28964809 |
|
NCBI chr 8:26,298,502...26,306,010
Ensembl chr 8:26,296,583...26,306,010
|
|
G |
Styxl1 |
serine/threonine/tyrosine interacting-like 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of STYXL1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:135,776,074...135,807,277
Ensembl chr 5:135,776,074...135,807,239
|
|
G |
Sumo1 |
small ubiquitin-like modifier 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of SUMO1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:59,678,593...59,709,993
Ensembl chr 1:59,625,717...59,709,993
|
|
G |
Tc2n |
tandem C2 domains, nuclear |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of TC2N mRNA |
CTD |
PMID:27424125 |
|
NCBI chr12:101,611,705...101,685,178
Ensembl chr12:101,611,702...101,684,782
|
|
G |
Trp53i11 |
transformation related protein 53 inducible protein 11 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of TP53I11 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:93,017,694...93,032,102
Ensembl chr 2:93,017,893...93,032,104
|
|
G |
Vcpip1 |
valosin containing protein (p97)/p47 complex interacting protein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of VCPIP1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:9,788,847...9,818,607
Ensembl chr 1:9,788,847...9,818,607
|
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
increases phosphorylation multiple interactions |
EXP |
gypenoside LXXV results in increased phosphorylation of AKT1 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:35192202 PMID:36325883 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of CCL2 protein] |
CTD |
PMID:35192202 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions increases expression |
EXP |
gypenoside LXXV results in increased expression of and results in increased secretion of CTGF protein gypenoside LXXV results in increased expression of CTGF mRNA |
CTD |
PMID:31018484 |
|
NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of IL1B protein] |
CTD |
PMID:33050067 PMID:35192202 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of IL6 protein] |
CTD |
PMID:35192202 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions decreases phosphorylation |
EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in decreased expression of and results in decreased phosphorylation of IRS1 protein]; gypenoside LXXV results in decreased expression of and results in decreased phosphorylation of IRS1 protein gypenoside LXXV results in decreased phosphorylation of IRS1 protein |
CTD |
PMID:35192202 PMID:36325883 |
|
NCBI chr 1:82,210,826...82,269,160
Ensembl chr 1:82,210,822...82,269,137
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
EXP |
gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of CCL2 protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of IL1B protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of IL6 protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of TNF protein] |
CTD |
PMID:35192202 |
|
NCBI chr 4:101,574,393...101,676,375
Ensembl chr 4:101,574,601...101,672,549
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
multiple interactions |
EXP |
gypenoside LXXV binds to and affects the localization of NR3C2 protein |
CTD |
PMID:31018484 |
|
NCBI chr 8:77,626,422...77,971,641
Ensembl chr 8:77,626,070...77,971,641
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions increases expression |
EXP ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in increased expression of PPARG protein] 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV binds to and results in increased activity of PPARG protein]; gypenoside LXXV binds to and results in increased activity of PPARG protein |
CTD |
PMID:35192202 PMID:36325883 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
EXP |
gypenoside LXXV results in decreased expression of and results in decreased phosphorylation of RELA protein |
CTD |
PMID:33050067 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Slc2a4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
affects localization increases expression multiple interactions |
EXP |
gypenoside LXXV affects the localization of SLC2A4 protein gypenoside LXXV results in increased expression of SLC2A4 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gypenoside LXXV affects the localization of SLC2A4 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV affects the localization of SLC2A4 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in increased expression of SLC2A4 protein] |
CTD |
PMID:35192202 PMID:36325883 |
|
NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression |
EXP |
gypenoside LXXV results in decreased expression of TGFB1 protein |
CTD |
PMID:33050067 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of TNF protein]; gypenoside LXXV inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:33050067 PMID:35192202 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
2200002D01Rik |
RIKEN cDNA 2200002D01 gene |
decreases expression |
ISO |
Arbutin results in decreased expression of C19ORF33 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:28,946,946...28,947,892
Ensembl chr 7:28,945,986...28,947,891
|
|
G |
Abca13 |
ATP-binding cassette, sub-family A member 13 |
decreases expression |
ISO |
Arbutin results in decreased expression of ABCA13 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:9,141,942...9,634,871
Ensembl chr11:9,141,942...9,634,259
|
|
G |
Acmsd |
amino carboxymuconate semialdehyde decarboxylase |
decreases expression |
ISO |
Arbutin results in decreased expression of ACMSD mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:127,657,149...127,695,723
Ensembl chr 1:127,657,150...127,695,715
|
|
G |
Acvrl1 |
activin A receptor, type II-like 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of ACVRL1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr15:101,026,403...101,043,217
Ensembl chr15:101,026,403...101,043,217
|
|
G |
Adam19 |
ADAM metallopeptidase domain 19 |
decreases expression |
ISO |
Arbutin results in decreased expression of ADAM19 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:45,945,329...46,038,174
Ensembl chr11:45,946,819...46,038,170
|
|
G |
Adam20 |
a disintegrin and metallopeptidase domain 20 |
decreases expression |
ISO |
Arbutin results in decreased expression of ADAM20 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:41,246,310...41,250,379
Ensembl chr 8:41,246,310...41,250,340
|
|
G |
Adam7 |
a disintegrin and metallopeptidase domain 7 |
increases expression |
ISO |
Arbutin results in increased expression of ADAM7 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:68,734,785...68,771,138
Ensembl chr14:68,734,785...68,771,190
|
|
G |
Adamts3 |
ADAM metallopeptidase with thrombospondin type 1 motif 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of ADAMTS3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:89,821,700...90,031,521
Ensembl chr 5:89,824,946...90,031,193
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif 9 |
decreases expression |
ISO |
Arbutin results in decreased expression of ADAMTS9 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:92,749,680...92,921,431
Ensembl chr 6:92,749,680...92,920,473
|
|
G |
Adrb3 |
adrenergic receptor, beta 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of ADRB3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:27,715,804...27,720,833
Ensembl chr 8:27,715,804...27,740,644
|
|
G |
Aebp2 |
AE binding protein 2 |
increases expression |
ISO |
Arbutin results in increased expression of AEBP2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:140,567,480...140,624,198
Ensembl chr 6:140,546,644...140,713,010
|
|
G |
Afap1 |
actin filament associated protein 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of AFAP1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:36,050,713...36,161,267
Ensembl chr 5:36,050,663...36,161,267
|
|
G |
Agbl4 |
ATP/GTP binding protein-like 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of AGBL4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:110,254,823...111,521,521
Ensembl chr 4:110,254,858...111,521,521
|
|
G |
Agpat3 |
1-acylglycerol-3-phosphate O-acyltransferase 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of AGPAT3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:78,105,008...78,188,335
Ensembl chr10:78,105,012...78,188,323
|
|
G |
Ahnak |
AHNAK nucleoprotein |
decreases expression |
ISO |
Arbutin results in decreased expression of AHNAK mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:8,966,640...9,054,299
Ensembl chr19:8,966,648...9,054,278
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of AKT1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein binds to and affects the transport of Arbutin |
CTD |
PMID:8831264 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Amtn |
amelotin |
decreases expression |
ISO |
Arbutin results in decreased expression of AMTN mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:88,523,967...88,533,775
Ensembl chr 5:88,523,967...88,533,775
|
|
G |
Ankrd17 |
ankyrin repeat domain 17 |
increases expression |
ISO |
Arbutin results in increased expression of ANKRD17 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:90,375,025...90,517,133
Ensembl chr 5:90,375,025...90,514,436
|
|
G |
Ankrd23 |
ankyrin repeat domain 23 |
increases expression |
ISO |
Arbutin results in increased expression of ANKRD23 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:36,569,269...36,578,380
Ensembl chr 1:36,569,269...36,575,964 Ensembl chr 1:36,569,269...36,575,964
|
|
G |
Ap1s1 |
adaptor protein complex AP-1, sigma 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of AP1S1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:137,063,852...137,074,917
Ensembl chr 5:137,063,847...137,074,989
|
|
G |
Apom |
apolipoprotein M |
increases expression |
ISO |
Arbutin results in increased expression of APOM mRNA |
CTD |
PMID:17103032 |
|
NCBI chr17:35,347,973...35,350,777
Ensembl chr17:35,347,973...35,351,026
|
|
G |
Aptx |
aprataxin |
decreases expression |
ISO |
Arbutin results in decreased expression of APTX mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:40,682,078...40,703,206
Ensembl chr 4:40,682,382...40,703,194
|
|
G |
Arfip2 |
ADP-ribosylation factor interacting protein 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of ARFIP2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:105,283,408...105,289,623
Ensembl chr 7:105,283,410...105,289,623
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of ARHGEF2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:88,500,427...88,556,839
Ensembl chr 3:88,513,273...88,555,359
|
|
G |
Arl2 |
ADP-ribosylation factor-like 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of ARL2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:6,184,419...6,191,167
Ensembl chr19:6,184,404...6,191,578
|
|
G |
Arl6ip1 |
ADP-ribosylation factor-like 6 interacting protein 1 |
increases expression |
ISO |
Arbutin results in increased expression of ARL6IP1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:117,718,113...117,728,848
Ensembl chr 7:117,718,114...117,728,885
|
|
G |
Arx |
aristaless related homeobox |
decreases expression |
ISO |
Arbutin results in decreased expression of ARX mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:92,330,113...92,341,963
Ensembl chr X:92,330,051...92,341,963
|
|
G |
Asap1 |
ArfGAP with SH3 domain, ankyrin repeat and PH domain1 |
increases expression |
ISO |
Arbutin results in increased expression of ASAP1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr15:63,958,704...64,254,922
Ensembl chr15:63,958,706...64,254,768
|
|
G |
Asap3 |
ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of ASAP3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:135,933,662...135,973,888
Ensembl chr 4:135,933,676...135,972,527
|
|
G |
Atf6b |
activating transcription factor 6 beta |
decreases expression |
ISO |
Arbutin results in decreased expression of ATF6B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr17:34,866,120...34,874,048
Ensembl chr17:34,866,120...34,874,048
|
|
G |
B4galnt4 |
beta-1,4-N-acetyl-galactosaminyl transferase 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of B4GALNT4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:140,640,891...140,652,313
Ensembl chr 7:140,641,017...140,652,313
|
|
G |
Bag5 |
BCL2-associated athanogene 5 |
decreases expression |
ISO |
Arbutin results in decreased expression of BAG5 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr12:111,675,922...111,679,690
Ensembl chr12:111,675,922...111,679,691
|
|
G |
Bcas2 |
BCAS2 pre-mRNA processing factor |
increases expression |
ISO |
Arbutin results in increased expression of BCAS2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:103,078,971...103,086,479
Ensembl chr 3:103,078,971...103,086,482
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
decreases expression |
ISO |
Arbutin results in decreased expression of BCKDK mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:127,503,245...127,508,836
Ensembl chr 7:127,503,254...127,509,393
|
|
G |
Bmpr1b |
bone morphogenetic protein receptor, type 1B |
decreases expression |
ISO |
Arbutin results in decreased expression of BMPR1B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:141,540,230...141,875,335
Ensembl chr 3:141,542,897...141,875,186
|
|
G |
Bnip2 |
BCL2/adenovirus E1B interacting protein 2 |
increases expression |
ISO |
Arbutin results in increased expression of BNIP2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:69,896,660...69,918,941
Ensembl chr 9:69,896,748...69,915,599
|
|
G |
Brsk1 |
BR serine/threonine kinase 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of BRSK1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:4,693,635...4,718,996
Ensembl chr 7:4,693,603...4,718,996
|
|
G |
Bst2 |
bone marrow stromal cell antigen 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of BST2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:71,986,899...71,990,116
Ensembl chr 8:71,986,899...71,990,100
|
|
G |
C1qb |
complement component 1, q subcomponent, beta polypeptide |
decreases expression |
ISO |
Arbutin results in decreased expression of C1QB mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:136,607,437...136,613,511
Ensembl chr 4:136,607,440...136,613,498
|
|
G |
Cacng7 |
calcium channel, voltage-dependent, gamma subunit 7 |
decreases expression |
ISO |
Arbutin results in decreased expression of CACNG7 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:3,381,341...3,416,737
Ensembl chr 7:3,381,471...3,416,737
|
|
G |
Capns2 |
calpain, small subunit 2 |
increases expression |
ISO |
Arbutin results in increased expression of CAPNS2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:93,628,023...93,629,037
Ensembl chr 8:93,628,035...93,629,039
|
|
G |
Casp8 |
caspase 8 |
decreases expression |
ISO |
Arbutin results in decreased expression of CASP8 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
Arbutin inhibits the reaction [potassium bromate results in decreased activity of CAT protein] |
CTD |
PMID:36284482 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cbx6 |
chromobox 6 |
decreases expression |
ISO |
Arbutin results in decreased expression of CBX6 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr15:79,708,099...79,718,534
Ensembl chr15:79,708,097...79,718,889
|
|
G |
Ccar1 |
cell division cycle and apoptosis regulator 1 |
increases expression |
ISO |
Arbutin results in increased expression of CCAR1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:62,579,707...62,628,147
Ensembl chr10:62,579,707...62,628,065
|
|
G |
Ccdc170 |
coiled-coil domain containing 170 |
decreases expression |
ISO |
Arbutin results in decreased expression of CCDC170 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:4,432,312...4,514,498
Ensembl chr10:4,432,502...4,512,231
|
|
G |
Ccdc28b |
coiled coil domain containing 28B |
decreases expression |
ISO |
Arbutin results in decreased expression of CCDC28B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:129,513,067...129,517,820
Ensembl chr 4:129,513,067...129,517,740
|
|
G |
Ccnyl1 |
cyclin Y-like 1 |
increases expression |
ISO |
Arbutin results in increased expression of CCNYL1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:64,729,963...64,764,805
Ensembl chr 1:64,729,614...64,764,803
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
increases expression |
ISO |
Arbutin results in increased expression of CCT8 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr16:87,280,213...87,292,757
Ensembl chr16:87,280,214...87,292,761
|
|
G |
Cd151 |
CD151 antigen |
decreases expression |
ISO |
Arbutin results in decreased expression of CD151 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:141,047,275...141,051,394
Ensembl chr 7:141,047,305...141,051,386
|
|
G |
Cd160 |
CD160 antigen |
decreases expression |
ISO |
Arbutin results in decreased expression of CD160 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:96,706,079...96,736,667
Ensembl chr 3:96,706,079...96,736,667
|
|
G |
Cd2bp2 |
CD2 cytoplasmic tail binding protein 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of CD2BP2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:126,790,832...126,795,249
Ensembl chr 7:126,790,832...126,795,222
|
|
G |
Cd3g |
CD3 antigen, gamma polypeptide |
decreases expression |
ISO |
Arbutin results in decreased expression of CD3G mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:44,880,870...44,891,729
Ensembl chr 9:44,880,870...44,891,729
|
|
G |
Cdin1 |
CDAN1 interacting nuclease 1 |
increases expression |
ISO |
Arbutin results in increased expression of CDIN1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:115,411,388...115,609,263
Ensembl chr 2:115,412,197...115,609,249
|
|
G |
Cdk16 |
cyclin dependent kinase 16 |
decreases expression |
ISO |
Arbutin results in decreased expression of CDK16 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:20,554,210...20,566,119
Ensembl chr X:20,554,193...20,566,119
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of CEACAM1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:25,161,127...25,177,072
Ensembl chr 7:25,161,132...25,177,028
|
|
G |
Cfap161 |
cilia and flagella associated protein 161 |
decreases expression |
ISO |
Arbutin results in decreased expression of CFAP161 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:83,424,820...83,447,528
Ensembl chr 7:83,423,309...83,444,088
|
|
G |
Cfap70 |
cilia and flagella associated protein 70 |
decreases expression |
ISO |
Arbutin results in decreased expression of CFAP70 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:20,444,258...20,502,332
Ensembl chr14:20,444,261...20,502,294
|
|
G |
Clec4b1 |
C-type lectin domain family 4, member b1 |
decreases expression |
ISO |
Arbutin results in decreased expression of CLEC4C mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:123,026,921...123,048,514
Ensembl chr 6:123,026,921...123,048,514
|
|
G |
Cnksr2 |
connector enhancer of kinase suppressor of Ras 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of CNKSR2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:156,604,426...156,827,454
Ensembl chr X:156,604,432...156,826,290
|
|
G |
Col17a1 |
collagen, type XVII, alpha 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of COL17A1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:47,634,783...47,680,460
Ensembl chr19:47,634,783...47,680,533
|
|
G |
Cpb1 |
carboxypeptidase B1 |
decreases expression |
ISO |
Arbutin results in decreased expression of CPB1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:20,303,643...20,339,681
Ensembl chr 3:20,302,428...20,329,897
|
|
G |
Cpe |
carboxypeptidase E |
increases expression |
ISO |
Arbutin results in increased expression of CPE mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:65,045,576...65,146,143
Ensembl chr 8:65,045,576...65,146,088
|
|
G |
Cpne5 |
copine V |
increases expression |
ISO |
Arbutin results in increased expression of CPNE5 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr17:29,375,495...29,456,764
Ensembl chr17:29,374,530...29,457,141
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of CYP17A1 mRNA; Arbutin results in decreased expression of CYP17A1 protein |
CTD |
PMID:37783241 |
|
NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611
|
|
G |
Cyp2u1 |
cytochrome P450, family 2, subfamily u, polypeptide 1 |
increases expression |
ISO |
Arbutin results in increased expression of CYP2U1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:131,084,140...131,097,806
Ensembl chr 3:131,082,090...131,096,876
|
|
G |
Cyrib |
CYFIP related Rac1 interactor B |
increases expression |
ISO |
Arbutin results in increased expression of CYRIB mRNA |
CTD |
PMID:17103032 |
|
NCBI chr15:63,800,943...63,932,627
Ensembl chr15:63,800,946...63,932,327
|
|
G |
Ddx46 |
DEAD box helicase 46 |
increases expression |
ISO |
Arbutin results in increased expression of DDX46 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr13:55,782,790...55,829,080
Ensembl chr13:55,782,841...55,829,069
|
|
G |
Diaph2 |
diaphanous related formin 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of DIAPH2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:128,650,409...129,366,583
Ensembl chr X:128,650,491...129,366,583
|
|
G |
Dlgap4 |
DLG associated protein 4 |
increases expression |
ISO |
Arbutin results in increased expression of DLGAP4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:156,455,431...156,606,283
Ensembl chr 2:156,455,625...156,606,283
|
|
G |
Dlx1 |
distal-less homeobox 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of DLX1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:71,358,457...71,364,325
Ensembl chr 2:71,358,457...71,364,325
|
|
G |
Dmxl1 |
Dmx-like 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of DMXL1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr18:49,965,657...50,098,540
Ensembl chr18:49,965,737...50,098,540
|
|
G |
Dnah7b |
dynein, axonemal, heavy chain 7B |
decreases expression |
ISO |
Arbutin results in decreased expression of DNAH7 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:46,105,232...46,412,711
Ensembl chr 1:46,105,475...46,412,710
|
|
G |
Dnai3 |
dynein axonemal intermediate chain 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of DNAI3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:145,746,281...145,813,855
Ensembl chr 3:145,746,281...145,813,885
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
increases expression |
ISO |
Arbutin results in increased expression of DNAJB9 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr12:44,252,680...44,256,851
Ensembl chr12:44,252,342...44,257,109
|
|
G |
Dpp7 |
dipeptidylpeptidase 7 |
decreases expression |
ISO |
Arbutin results in decreased expression of DPP7 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:25,242,302...25,246,365
Ensembl chr 2:25,242,288...25,246,371
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of DPYSL2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:67,040,313...67,148,490
Ensembl chr14:67,040,313...67,148,410
|
|
G |
Ece1 |
endothelin converting enzyme 1 |
increases expression |
ISO |
Arbutin results in increased expression of ECE1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:137,589,548...137,692,540
Ensembl chr 4:137,589,548...137,692,540
|
|
G |
Eepd1 |
endonuclease/exonuclease/phosphatase family domain containing 1 |
increases expression |
ISO |
Arbutin results in increased expression of EEPD1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:25,392,809...25,515,406
Ensembl chr 9:25,392,843...25,515,406
|
|
G |
Efhc2 |
EF-hand domain (C-terminal) containing 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of EFHC2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:16,998,288...17,186,291
Ensembl chr X:16,998,288...17,185,607
|
|
G |
Efl1 |
elongation factor like GTPase 1 |
increases expression |
ISO |
Arbutin results in increased expression of EFL1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:82,297,811...82,427,060
Ensembl chr 7:82,297,822...82,427,060
|
|
G |
Efna3 |
ephrin A3 |
decreases expression |
ISO |
Arbutin results in decreased expression of EFNA3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:89,221,200...89,231,359
Ensembl chr 3:89,221,206...89,230,272
|
|
G |
Efs |
embryonal Fyn-associated substrate |
decreases expression |
ISO |
Arbutin results in decreased expression of EFS mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:55,154,087...55,164,222
Ensembl chr14:55,153,992...55,163,583
|
|
G |
Eid1 |
EP300 interacting inhibitor of differentiation 1 |
increases expression |
ISO |
Arbutin results in increased expression of EID1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:125,515,020...125,517,563
Ensembl chr 2:125,515,015...125,516,705
|
|
G |
Elane |
elastase, neutrophil expressed |
decreases expression |
ISO |
Arbutin results in decreased expression of ELANE mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:79,722,146...79,724,050
Ensembl chr10:79,722,081...79,724,049
|
|
G |
Emx2 |
empty spiracles homeobox 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of EMX2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:59,447,122...59,453,789
Ensembl chr19:59,446,804...59,453,789
|
|
G |
Enpp1 |
ectonucleotide pyrophosphatase/phosphodiesterase 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of ENPP1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:24,513,812...24,588,057
Ensembl chr10:24,513,812...24,588,057
|
|
G |
Eps8 |
epidermal growth factor receptor pathway substrate 8 |
increases expression |
ISO |
Arbutin results in increased expression of EPS8 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:137,454,242...137,626,262
Ensembl chr 6:137,454,243...137,631,874
|
|
G |
Epx |
eosinophil peroxidase |
increases expression |
ISO |
Arbutin results in increased expression of EPX mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:87,754,824...87,766,362
Ensembl chr11:87,754,826...87,766,362
|
|
G |
Erc1 |
ELKS/RAB6-interacting/CAST family member 1 |
increases expression |
ISO |
Arbutin results in increased expression of ERC1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:119,547,757...119,830,985
Ensembl chr 6:119,547,757...119,825,128
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
increases expression |
ISO EXP |
Arbutin results in increased expression of ESR2 protein |
CTD |
PMID:29360751 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
Evi2b |
ecotropic viral integration site 2b |
decreases expression |
ISO |
Arbutin results in decreased expression of EVI2B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:79,404,211...79,414,588
Ensembl chr11:79,405,882...79,414,588
|
|
G |
Exd1 |
exonuclease 3'-5' domain containing 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of EXD1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:119,346,986...119,378,108
Ensembl chr 2:119,346,986...119,378,108
|
|
G |
F13b |
coagulation factor XIII, beta subunit |
decreases expression |
ISO |
Arbutin results in decreased expression of F13B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:139,429,285...139,451,496
Ensembl chr 1:139,429,440...139,451,490
|
|
G |
Fam3d |
FAM3 metabolism regulating signaling molecule D |
decreases expression |
ISO |
Arbutin results in decreased expression of FAM3D mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:14,091,010...14,120,836
Ensembl chr14:14,091,019...14,120,836
|
|
G |
Fancd2os |
Fancd2 opposite strand |
decreases expression |
ISO |
Arbutin results in decreased expression of FANCD2OS mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:113,573,722...113,577,735
Ensembl chr 6:113,573,722...113,577,676
|
|
G |
Fasl |
Fas ligand |
decreases expression |
ISO |
Arbutin results in decreased expression of FASLG mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064
|
|
G |
Fbxo11 |
F-box protein 11 |
increases expression |
ISO |
Arbutin results in increased expression of FBXO11 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr17:88,298,287...88,373,473
Ensembl chr17:88,298,287...88,372,719
|
|
G |
Fbxo16 |
F-box protein 16 |
increases expression |
ISO |
Arbutin results in increased expression of FBXO16 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:65,504,067...65,561,422
Ensembl chr14:65,504,067...65,561,422
|
|
G |
Fgf5 |
fibroblast growth factor 5 |
decreases expression |
ISO |
Arbutin results in decreased expression of FGF5 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:98,402,108...98,424,892
Ensembl chr 5:98,402,043...98,424,889
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of FGFR3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:33,879,068...33,894,412
Ensembl chr 5:33,879,018...33,894,412
|
|
G |
Fmnl3 |
formin-like 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of FMNL3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr15:99,215,091...99,268,375
Ensembl chr15:99,215,106...99,268,363
|
|
G |
Fpgt |
fucose-1-phosphate guanylyltransferase |
decreases expression |
ISO |
Arbutin results in decreased expression of FPGT mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:154,790,552...154,799,024
Ensembl chr 3:154,790,555...154,799,040
|
|
G |
Fras1 |
Fraser extracellular matrix complex subunit 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of FRAS1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:96,518,622...96,932,592
Ensembl chr 5:96,521,814...96,932,587
|
|
G |
Frmpd4 |
FERM and PDZ domain containing 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of FRMPD4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:166,254,297...167,360,230
Ensembl chr X:166,254,305...167,360,227
|
|
G |
Fshb |
follicle stimulating hormone beta |
increases expression |
EXP |
Arbutin results in increased expression of FSHB protein |
CTD |
PMID:29360751 |
|
NCBI chr 2:106,886,331...106,889,996
Ensembl chr 2:106,886,485...106,890,001
|
|
G |
Galc |
galactosylceramidase |
increases expression |
ISO |
Arbutin results in increased expression of GALC mRNA |
CTD |
PMID:17103032 |
|
NCBI chr12:98,168,543...98,226,565
Ensembl chr12:98,168,553...98,225,718
|
|
G |
Garem1 |
GRB2 associated regulator of MAPK1 subtype 1 |
increases expression |
ISO |
Arbutin results in increased expression of GAREM1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr18:21,257,916...21,433,196
Ensembl chr18:21,260,258...21,433,195
|
|
G |
Get3 |
guided entry of tail-anchored proteins factor 3, ATPase |
decreases expression |
ISO |
Arbutin results in decreased expression of GET3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:85,744,558...85,751,916
Ensembl chr 8:85,744,560...85,751,910
|
|
G |
Gipc1 |
GIPC PDZ domain containing family, member 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of GIPC1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:84,376,037...84,391,418
Ensembl chr 8:84,379,306...84,391,323
|
|
G |
Glt8d2 |
glycosyltransferase 8 domain containing 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of GLT8D2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:82,486,262...82,529,846
Ensembl chr10:82,486,267...82,526,484
|
|
G |
Gm12695 |
predicted gene 12695 |
decreases expression |
ISO |
Arbutin results in decreased expression of C1ORF87 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:96,611,818...96,675,067
Ensembl chr 4:96,611,884...96,673,423
|
|
G |
Gm3764 |
predicted gene 3764 |
decreases expression |
ISO |
Arbutin results in decreased expression of MIR9-1HG mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:88,113,980...88,137,266
Ensembl chr 3:88,113,837...88,137,268
|
|
G |
Gmpr |
guanosine monophosphate reductase |
decreases expression |
ISO |
Arbutin results in decreased expression of GMPR mRNA |
CTD |
PMID:17103032 |
|
NCBI chr13:45,660,905...45,699,862
Ensembl chr13:45,660,920...45,707,276
|
|
G |
Gnl2 |
guanine nucleotide binding protein nucleolar 2 |
increases expression |
ISO |
Arbutin results in increased expression of GNL2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:124,920,866...124,949,175
Ensembl chr 4:124,910,378...124,949,173
|
|
G |
Gpc3 |
glypican 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of GPC3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:51,361,303...51,702,851
Ensembl chr X:51,361,303...51,702,827
|
|
G |
Gpd2 |
glycerol phosphate dehydrogenase 2, mitochondrial |
increases expression |
ISO |
Arbutin results in increased expression of GPD2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:57,127,690...57,260,731
Ensembl chr 2:57,127,647...57,260,731
|
|
G |
Gper1 |
G protein-coupled estrogen receptor 1 |
increases expression |
EXP ISO |
Arbutin results in increased expression of GPER1 protein |
CTD |
PMID:29360751 |
|
NCBI chr 5:139,408,905...139,413,555
Ensembl chr 5:139,408,906...139,413,555
|
|
G |
Gpr155 |
G protein-coupled receptor 155 |
decreases expression |
ISO |
Arbutin results in decreased expression of GPR155 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:73,171,850...73,216,842
Ensembl chr 2:73,171,850...73,216,916
|
|
G |
Gpr26 |
G protein-coupled receptor 26 |
decreases expression |
ISO |
Arbutin results in decreased expression of GPR26 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:131,567,891...131,587,362
Ensembl chr 7:131,568,189...131,596,134
|
|
G |
Gpr55 |
G protein-coupled receptor 55 |
decreases expression |
ISO |
Arbutin results in decreased expression of GPR55 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:85,860,927...85,924,781
Ensembl chr 1:85,866,039...85,888,729
|
|
G |
Gprc5d |
G protein-coupled receptor, family C, group 5, member D |
decreases expression |
ISO |
Arbutin results in decreased expression of GPRC5D mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:135,082,989...135,095,281
Ensembl chr 6:135,082,989...135,095,281
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
ISO |
Arbutin inhibits the reaction [Ethanol results in increased expression of GPT protein] |
CTD |
PMID:34346143 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Gsdma |
gasdermin A |
decreases expression |
ISO |
Arbutin results in decreased expression of GSDMA mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:98,555,163...98,568,534
Ensembl chr11:98,555,177...98,568,534
|
|
G |
Gucy1a2 |
guanylate cyclase 1, soluble, alpha 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of GUCY1A2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:3,532,349...3,905,791
Ensembl chr 9:3,532,778...3,894,736
|
|
G |
H1f1 |
H1.1 linker histone, cluster member |
increases expression |
ISO |
Arbutin results in increased expression of H1-1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr13:23,947,651...23,948,395
Ensembl chr13:23,947,649...23,948,389
|
|
G |
Hand1 |
heart and neural crest derivatives expressed 1 |
increases expression |
ISO |
Arbutin results in increased expression of HAND1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:57,719,539...57,722,973
Ensembl chr11:57,719,531...57,723,644
|
|
G |
Hlf |
hepatic leukemia factor |
decreases expression |
ISO |
Arbutin results in decreased expression of HLF mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:90,227,361...90,281,745
Ensembl chr11:90,227,362...90,281,721
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Arbutin inhibits the reaction [Ethanol results in decreased expression of HMOX1 mRNA] |
CTD |
PMID:34346143 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hoxb8 |
homeobox B8 |
decreases expression |
ISO |
Arbutin results in decreased expression of HOXB8 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:96,170,227...96,176,151
Ensembl chr11:96,172,731...96,176,141
|
|
G |
Hps3 |
HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of HPS3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:20,050,109...20,089,478
Ensembl chr 3:20,050,109...20,089,479
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of HSD3B1 mRNA Arbutin results in decreased expression of HSD3B1 mRNA; Arbutin results in decreased expression of HSD3B1 protein |
CTD |
PMID:17103032 PMID:37783241 |
|
NCBI chr 3:98,749,672...98,767,110
Ensembl chr 3:98,759,510...98,767,110
|
|
G |
Htatsf1 |
HIV TAT specific factor 1 |
increases expression |
ISO |
Arbutin results in increased expression of HTATSF1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:56,098,930...56,112,543
Ensembl chr X:56,098,943...56,112,543
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of IFIT3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:34,560,519...34,566,382
Ensembl chr19:34,560,931...34,566,131
|
|
G |
Igdcc3 |
immunoglobulin superfamily, DCC subclass, member 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of IGDCC3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:65,048,404...65,094,313
Ensembl chr 9:65,048,471...65,093,154
|
|
G |
Il23a |
interleukin 23, alpha subunit p19 |
decreases expression |
ISO |
Arbutin results in decreased expression of IL23A mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:128,132,009...128,133,953
Ensembl chr10:128,132,008...128,134,621
|
|
G |
Il3ra |
interleukin 3 receptor, alpha chain |
increases expression |
ISO |
Arbutin results in increased expression of IL3RA mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:8,114,270...8,123,851
Ensembl chr14:8,113,752...8,123,488
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Arbutin inhibits the reaction [Ethanol results in increased expression of IL6 protein] |
CTD |
PMID:34346143 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Il6st |
interleukin 6 signal transducer |
decreases expression |
ISO |
Arbutin results in decreased expression of IL6ST mRNA |
CTD |
PMID:17103032 |
|
NCBI chr13:112,600,604...112,643,394
Ensembl chr13:112,600,604...112,646,620
|
|
G |
Ina |
internexin neuronal intermediate filament protein, alpha |
decreases expression |
ISO |
Arbutin results in decreased expression of INA mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:47,003,120...47,013,766
Ensembl chr19:47,003,137...47,013,766
|
|
G |
Inpp4b |
inositol polyphosphate-4-phosphatase, type II |
increases expression |
ISO |
Arbutin results in increased expression of INPP4B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:82,068,895...82,865,553
Ensembl chr 8:82,069,185...82,854,543
|
|
G |
Jun |
jun proto-oncogene |
decreases expression |
ISO |
Arbutin results in decreased expression of JUN mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Kcnab3 |
potassium voltage-gated channel, shaker-related subfamily, beta member 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of KCNAB3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:69,217,084...69,223,867
Ensembl chr11:69,217,084...69,223,868
|
|
G |
Kctd17 |
potassium channel tetramerisation domain containing 17 |
decreases expression |
ISO |
Arbutin results in decreased expression of KCTD17 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr15:78,312,578...78,323,503
Ensembl chr15:78,312,764...78,323,503
|
|
G |
Kif26b |
kinesin family member 26B |
decreases expression |
ISO |
Arbutin results in decreased expression of KIF26B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:178,356,690...178,766,765
Ensembl chr 1:178,356,690...178,766,765
|
|
G |
Klhl13 |
kelch-like 13 |
increases expression |
ISO |
Arbutin results in increased expression of KLHL13 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:23,085,510...23,231,340
Ensembl chr X:23,085,510...23,231,321
|
|
G |
Lctl |
lactase-like |
decreases expression |
ISO |
Arbutin results in decreased expression of LCTL mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:64,024,399...64,045,400
Ensembl chr 9:64,024,429...64,045,400
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
decreases expression |
ISO |
Arbutin results in decreased expression of LHCGR mRNA; Arbutin results in decreased expression of LHCGR protein |
CTD |
PMID:37783241 |
|
NCBI chr17:89,023,812...89,099,487
Ensembl chr17:89,023,909...89,099,418
|
|
G |
Lrp5 |
low density lipoprotein receptor-related protein 5 |
decreases expression |
ISO |
Arbutin results in decreased expression of LRP5 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:3,634,825...3,736,574
Ensembl chr19:3,634,828...3,736,564
|
|
G |
Lrp6 |
low density lipoprotein receptor-related protein 6 |
decreases expression |
ISO |
Arbutin results in decreased expression of LRP6 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:134,423,439...134,543,876
Ensembl chr 6:134,423,439...134,543,928
|
|
G |
Lrrc4 |
leucine rich repeat containing 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of LRRC4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:28,828,125...28,831,746
Ensembl chr 6:28,661,830...28,831,746
|
|
G |
Lrrtm4 |
leucine rich repeat transmembrane neuronal 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of LRRTM4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:79,995,828...80,787,143
Ensembl chr 6:79,995,860...80,787,124
|
|
G |
Mafk |
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein K (avian) |
decreases expression |
ISO |
Arbutin results in decreased expression of MAFK mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:139,777,291...139,788,409
Ensembl chr 5:139,777,268...139,788,408
|
|
G |
Map4k5 |
mitogen-activated protein kinase kinase kinase kinase 5 |
decreases expression |
ISO |
Arbutin results in decreased expression of MAP4K5 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr12:69,850,531...69,939,937
Ensembl chr12:69,850,524...69,939,974
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
decreases expression |
ISO |
Arbutin results in decreased expression of MAPK8 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mcm8 |
minichromosome maintenance 8 homologous recombination repair factor |
increases expression |
ISO |
Arbutin results in increased expression of MCM8 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:132,658,061...132,686,117
Ensembl chr 2:132,658,061...132,686,117
|
|
G |
Mdfi |
MyoD family inhibitor |
decreases expression |
ISO |
Arbutin results in decreased expression of MDFI mRNA |
CTD |
PMID:17103032 |
|
NCBI chr17:48,126,253...48,145,616
Ensembl chr17:48,126,253...48,145,616
|
|
G |
Mfap4 |
microfibrillar-associated protein 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of MFAP4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:61,376,257...61,379,536
Ensembl chr11:61,376,257...61,379,726
|
|
G |
Midn |
midnolin |
decreases expression |
ISO |
Arbutin results in decreased expression of MIDN mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:79,984,106...79,994,202
Ensembl chr10:79,984,106...79,994,202
|
|
G |
Mki67 |
antigen identified by monoclonal antibody Ki 67 |
increases expression |
ISO |
Arbutin results in increased expression of MKI67 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090
|
|
G |
Mmgt1 |
membrane magnesium transporter 1 |
increases expression |
ISO |
Arbutin results in increased expression of MMGT1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:55,630,872...55,643,304
Ensembl chr X:55,630,872...55,643,429
|
|
G |
Mthfd1l |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like |
decreases expression |
ISO |
Arbutin results in decreased expression of MTHFD1L mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:3,918,282...4,117,081
Ensembl chr10:3,923,118...4,117,081
|
|
G |
Mvd |
mevalonate (diphospho) decarboxylase |
decreases expression |
ISO |
Arbutin results in decreased expression of MVD mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:123,160,335...123,170,161
Ensembl chr 8:123,160,340...123,170,161
|
|
G |
Myo3b |
myosin IIIB |
decreases expression |
ISO |
Arbutin results in decreased expression of MYO3B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:69,869,464...70,259,542
Ensembl chr 2:69,869,470...70,259,542
|
|
G |
Ncald |
neurocalcin delta |
decreases expression |
ISO |
Arbutin results in decreased expression of NCALD mRNA |
CTD |
PMID:17103032 |
|
NCBI chr15:37,366,419...37,792,816
Ensembl chr15:37,366,419...37,792,814
|
|
G |
Negr1 |
neuronal growth regulator 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of NEGR1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:156,266,082...157,022,101
Ensembl chr 3:156,267,431...157,022,082
|
|
G |
Neu4 |
sialidase 4 |
increases expression |
ISO |
Arbutin results in increased expression of NEU4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:93,948,215...93,956,056
Ensembl chr 1:93,948,173...93,956,056
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions |
ISO |
Arbutin inhibits the reaction [Ethanol results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:34346143 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nkd1 |
naked cuticle 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of NKD1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:89,247,961...89,321,515
Ensembl chr 8:89,247,982...89,321,512
|
|
G |
Nmi |
N-myc (and STAT) interactor |
increases expression |
ISO |
Arbutin results in increased expression of NMI mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:51,838,517...51,863,241
Ensembl chr 2:51,838,499...51,863,506
|
|
G |
Noxred1 |
NADP+ dependent oxidoreductase domain containing 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of NOXRED1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr12:87,267,897...87,285,375
Ensembl chr12:87,267,814...87,285,506
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions |
ISO |
Arbutin inhibits the reaction [Ethanol results in increased expression of NQO1 mRNA] |
CTD |
PMID:34346143 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Nr2f1 |
nuclear receptor subfamily 2, group F, member 1 |
increases expression |
ISO |
Arbutin results in increased expression of NR2F1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr13:78,337,090...78,346,954
Ensembl chr13:78,337,092...78,347,876
|
|
G |
Nrp2 |
neuropilin 2 |
increases expression |
ISO |
Arbutin results in increased expression of NRP2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:62,742,476...62,857,851
Ensembl chr 1:62,742,444...62,857,854
|
|
G |
Ntf5 |
neurotrophin 5 |
decreases expression |
ISO |
Arbutin results in decreased expression of NTF4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:45,063,119...45,066,603
Ensembl chr 7:45,063,119...45,066,603
|
|
G |
Olfml1 |
olfactomedin-like 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of OLFML1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:107,166,640...107,190,572
Ensembl chr 7:107,166,653...107,190,301
|
|
G |
Osbp2 |
oxysterol binding protein 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of OSBP2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:3,653,731...3,814,000
Ensembl chr11:3,653,731...3,813,903
|
|
G |
Osbpl11 |
oxysterol binding protein-like 11 |
increases expression |
ISO |
Arbutin results in increased expression of OSBPL11 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr16:33,005,441...33,063,682
Ensembl chr16:33,005,441...33,063,682
|
|
G |
Otx1 |
orthodenticle homeobox 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of OTX1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:21,944,764...21,954,044
Ensembl chr11:21,944,764...21,952,897
|
|
G |
Pacsin2 |
protein kinase C and casein kinase substrate in neurons 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of PACSIN2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr15:83,259,812...83,348,800
Ensembl chr15:83,259,808...83,348,807
|
|
G |
Parg |
poly (ADP-ribose) glycohydrolase |
increases expression |
ISO |
Arbutin results in increased expression of PARG mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:31,923,900...32,020,671
Ensembl chr14:31,923,906...32,019,507
|
|
G |
Pcgf6 |
polycomb group ring finger 6 |
increases expression |
ISO |
Arbutin results in increased expression of PCGF6 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:47,022,056...47,039,379
Ensembl chr19:47,022,056...47,039,345
|
|
G |
Pcmtd2 |
protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 2 |
increases expression |
ISO |
Arbutin results in increased expression of PCMTD2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:181,471,952...181,499,253
Ensembl chr 2:181,479,647...181,499,254
|
|
G |
Pcnx2 |
pecanex homolog 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of PCNX2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:126,478,243...126,625,056
Ensembl chr 8:126,478,247...126,625,056
|
|
G |
Pdzk1 |
PDZ domain containing 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of PDZK1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:96,736,772...96,778,242
Ensembl chr 3:96,736,600...96,778,242
|
|
G |
Perm1 |
PPARGC1 and ESRR induced regulator, muscle 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of PERM1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:156,287,724...156,305,766
Ensembl chr 4:156,300,325...156,305,764
|
|
G |
Pf4 |
platelet factor 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of PF4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:90,920,362...90,921,242
Ensembl chr 5:90,920,294...90,921,242
|
|
G |
Pgm2 |
phosphoglucomutase 2 |
increases expression |
ISO |
Arbutin results in increased expression of PGM2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:64,250,258...64,285,698
Ensembl chr 5:64,250,293...64,285,694
|
|
G |
Pigq |
phosphatidylinositol glycan anchor biosynthesis, class Q |
decreases expression |
ISO |
Arbutin results in decreased expression of PIGQ mRNA |
CTD |
PMID:17103032 |
|
NCBI chr17:26,145,398...26,161,855
Ensembl chr17:26,145,395...26,163,910
|
|
G |
Pin1 |
peptidyl-prolyl cis/trans isomerase, NIMA-interacting 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of PIN1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:20,563,335...20,575,008
Ensembl chr 9:20,563,391...20,577,880
|
|
G |
Pitpnb |
phosphatidylinositol transfer protein, beta |
increases expression |
ISO |
Arbutin results in increased expression of PITPNB mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:111,478,563...111,536,225
Ensembl chr 5:111,478,629...111,536,225
|
|
G |
Pkhd1 |
polycystic kidney and hepatic disease 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of PKHD1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:20,128,003...20,688,306
Ensembl chr 1:20,128,003...20,688,288
|
|
G |
Poglut2 |
protein O-glucosyltransferase 2 |
increases expression |
ISO |
Arbutin results in increased expression of POGLUT2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:44,143,060...44,158,844
Ensembl chr 1:44,145,706...44,157,968
|
|
G |
Pole2 |
polymerase (DNA directed), epsilon 2 (p59 subunit) |
increases expression |
ISO |
Arbutin results in increased expression of POLE2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr12:69,248,547...69,274,979
Ensembl chr12:69,248,547...69,274,969
|
|
G |
Pphln1 |
periphilin 1 |
increases expression |
ISO |
Arbutin results in increased expression of PPHLN1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr15:93,296,243...93,389,794
Ensembl chr15:93,296,231...93,389,391
|
|
G |
Prg2 |
proteoglycan 2, bone marrow |
decreases expression |
ISO |
Arbutin results in decreased expression of PRG2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:84,810,805...84,813,977
Ensembl chr 2:84,810,805...84,813,976
|
|
G |
Prkx |
protein kinase, X-linked |
decreases expression |
ISO |
Arbutin results in decreased expression of PRKX mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:76,804,578...76,839,545
Ensembl chr X:76,805,017...76,839,884
|
|
G |
Prmt2 |
protein arginine N-methyltransferase 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of PRMT2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:76,043,060...76,073,699
Ensembl chr10:76,043,056...76,073,699
|
|
G |
Prr18 |
proline rich 18 |
decreases expression |
ISO |
Arbutin results in decreased expression of PRR18 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr17:8,546,378...8,562,945
Ensembl chr17:8,556,291...8,562,945
|
|
G |
Prrx1 |
paired related homeobox 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of PRRX1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:163,072,688...163,142,714
Ensembl chr 1:163,072,688...163,141,279
|
|
G |
Prss2 |
serine protease 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of PRSS2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:41,498,710...41,502,013
Ensembl chr 6:41,498,721...41,502,013
|
|
G |
Psmd13 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 13 |
decreases expression |
ISO |
Arbutin results in decreased expression of PSMD13 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:140,462,307...140,478,555
Ensembl chr 7:140,461,881...140,478,556
|
|
G |
Psmd3 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of PSMD3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:98,573,380...98,586,804
Ensembl chr11:98,573,380...98,586,805
|
|
G |
Rab3gap1 |
RAB3 GTPase activating protein subunit 1 |
increases expression |
ISO |
Arbutin results in increased expression of RAB3GAP1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:127,796,492...127,871,612
Ensembl chr 1:127,796,510...127,871,605
|
|
G |
Rab6b |
RAB6B, member RAS oncogene family |
decreases expression |
ISO |
Arbutin results in decreased expression of RAB6B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:102,988,866...103,062,475
Ensembl chr 9:102,988,986...103,062,475
|
|
G |
Rasgef1b |
RasGEF domain family, member 1B |
decreases expression |
ISO |
Arbutin results in decreased expression of RASGEF1B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:99,365,279...99,400,786
Ensembl chr 5:99,365,285...99,876,924
|
|
G |
Rnf208 |
ring finger protein 208 |
decreases expression |
ISO |
Arbutin results in decreased expression of RNF208 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:25,132,941...25,134,273
Ensembl chr 2:25,132,941...25,134,274
|
|
G |
Rps6ka3 |
ribosomal protein S6 kinase polypeptide 3 |
increases expression |
ISO |
Arbutin results in increased expression of RPS6KA3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:158,038,652...158,151,240
Ensembl chr X:157,993,303...158,151,240
|
|
G |
Rsbn1 |
rosbin, round spermatid basic protein 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of RSBN1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:103,821,412...103,873,952
Ensembl chr 3:103,821,436...103,873,952
|
|
G |
Saa4 |
serum amyloid A 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of SAA4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:46,377,416...46,382,027
Ensembl chr 7:46,377,422...46,382,027
|
|
G |
Sccpdh |
saccharopine dehydrogenase (putative) |
increases expression |
ISO |
Arbutin results in increased expression of SCCPDH mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:179,495,796...179,514,754
Ensembl chr 1:179,495,775...179,514,754
|
|
G |
Scn1b |
sodium channel, voltage-gated, type I, beta |
increases expression |
ISO |
Arbutin results in increased expression of SCN1B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:30,815,949...30,826,436
Ensembl chr 7:30,815,949...30,826,428
|
|
G |
Sdc4 |
syndecan 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of SDC4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:164,266,167...164,285,512
Ensembl chr 2:164,266,167...164,285,807
|
|
G |
Semg1 |
semenogelin 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of SEMG1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:164,077,849...164,080,261
Ensembl chr 2:164,077,849...164,080,386
|
|
G |
Serpina5 |
serine (or cysteine) peptidase inhibitor, clade A, member 5 |
decreases expression |
ISO |
Arbutin results in decreased expression of SERPINA5 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr12:104,065,572...104,072,397
Ensembl chr12:104,067,372...104,072,396
|
|
G |
Serpind1 |
serine (or cysteine) peptidase inhibitor, clade D, member 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of SERPIND1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr16:17,149,235...17,161,438
Ensembl chr16:17,149,235...17,161,439
|
|
G |
Sf3b1 |
splicing factor 3b, subunit 1 |
increases expression |
ISO |
Arbutin results in increased expression of SF3B1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:55,024,328...55,066,660
Ensembl chr 1:55,024,328...55,066,640
|
|
G |
Sfrp5 |
secreted frizzled-related sequence protein 5 |
decreases expression |
ISO |
Arbutin results in decreased expression of SFRP5 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:42,186,410...42,190,691
Ensembl chr19:42,186,410...42,190,691
|
|
G |
Sfxn2 |
sideroflexin 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of SFXN2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:46,561,798...46,585,340
Ensembl chr19:46,561,804...46,586,505
|
|
G |
Sh3gl2 |
SH3-domain GRB2-like 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of SH3GL2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:85,123,663...85,307,617
Ensembl chr 4:85,123,363...85,557,432
|
|
G |
Sin3b |
transcriptional regulator, SIN3B (yeast) |
decreases expression |
ISO |
Arbutin results in decreased expression of SIN3B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:73,449,898...73,484,831
Ensembl chr 8:73,449,913...73,484,829
|
|
G |
Slc13a2 |
solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of SLC13A2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:78,288,102...78,313,107
Ensembl chr11:78,287,913...78,313,043
|
|
G |
Slc15a3 |
solute carrier family 15, member 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of SLC15A3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:10,819,908...10,835,279
Ensembl chr19:10,817,091...10,836,726
|
|
G |
Slc18a2 |
solute carrier family 18 (vesicular monoamine), member 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of SLC18A2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:59,249,310...59,284,444
Ensembl chr19:59,249,328...59,284,444
|
|
G |
Slc23a3 |
solute carrier family 23 (nucleobase transporters), member 3 |
increases expression |
ISO |
Arbutin results in increased expression of SLC23A3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:75,102,185...75,112,113
Ensembl chr 1:75,102,185...75,110,534
|
|
G |
Slc25a2 |
solute carrier family 25 (mitochondrial carrier, ornithine transporter) member 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of SLC25A2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr18:37,770,431...37,771,776
Ensembl chr18:37,770,431...37,771,776
|
|
G |
Slc27a4 |
solute carrier family 27 (fatty acid transporter), member 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of SLC27A4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:29,692,646...29,707,534
Ensembl chr 2:29,692,646...29,707,534
|
|
G |
Slc7a3 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of SLC7A3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:100,122,752...100,134,058
Ensembl chr X:100,122,816...100,129,626
|
|
G |
Slco5a1 |
solute carrier organic anion transporter family, member 5A1 |
decreases expression |
ISO |
Arbutin results in decreased expression of SLCO5A1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:12,936,773...13,063,043
Ensembl chr 1:12,936,773...13,062,874
|
|
G |
Snip1 |
Smad nuclear interacting protein 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of SNIP1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:124,960,465...124,967,836
Ensembl chr 4:124,960,465...124,967,835
|
|
G |
Socs4 |
suppressor of cytokine signaling 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of SOCS4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:47,514,377...47,533,559
Ensembl chr14:47,514,388...47,533,559
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
multiple interactions |
ISO |
Arbutin inhibits the reaction [potassium bromate results in decreased activity of SOD1 protein] |
CTD |
PMID:36284482 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Spata13 |
spermatogenesis associated 13 |
increases expression |
ISO |
Arbutin results in increased expression of SPATA13 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:60,722,617...61,002,005
Ensembl chr14:60,871,450...61,002,005
|
|
G |
Spata20 |
spermatogenesis associated 20 |
decreases expression |
ISO |
Arbutin results in decreased expression of SPATA20 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:94,369,730...94,376,136
Ensembl chr11:94,369,730...94,377,005
|
|
G |
Sptlc1 |
serine palmitoyltransferase, long chain base subunit 1 |
increases expression |
ISO |
Arbutin results in increased expression of SPTLC1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr13:53,486,784...53,531,401
Ensembl chr13:53,486,784...53,531,433
|
|
G |
Srd5a1 |
steroid 5 alpha-reductase 1 |
decreases activity decreases expression |
ISO |
Arbutin results in decreased activity of SRD5A1 protein Arbutin results in decreased expression of SRD5A1 mRNA; Arbutin results in decreased expression of SRD5A1 protein |
CTD |
PMID:37783241 |
|
NCBI chr13:69,721,568...69,759,611
Ensembl chr13:69,721,568...69,759,561
|
|
G |
Stard8 |
StAR related lipid transfer domain containing 8 |
decreases expression |
ISO |
Arbutin results in decreased expression of STARD8 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:98,046,539...98,118,334
Ensembl chr X:98,046,854...98,118,334
|
|
G |
Syde1 |
synapse defective 1, Rho GTPase, homolog 1 (C. elegans) |
decreases expression |
ISO |
Arbutin results in decreased expression of SYDE1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:78,420,336...78,427,798
Ensembl chr10:78,420,337...78,427,798
|
|
G |
Sympk |
symplekin |
decreases expression |
ISO |
Arbutin results in decreased expression of SYMPK mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:18,758,321...18,788,542
Ensembl chr 7:18,758,302...18,788,543
|
|
G |
Tal1 |
T cell acute lymphocytic leukemia 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of TAL1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:114,913,623...114,928,952
Ensembl chr 4:114,913,623...114,928,952
|
|
G |
Tardbp |
TAR DNA binding protein |
increases expression |
ISO |
Arbutin results in increased expression of TARDBP mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:148,696,839...148,711,672
Ensembl chr 4:148,696,839...148,711,476
|
|
G |
Tcf12 |
transcription factor 12 |
increases expression |
ISO |
Arbutin results in increased expression of TCF12 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:71,751,534...72,019,611
Ensembl chr 9:71,749,970...72,019,153
|
|
G |
Tes |
testin LIM domain protein |
increases expression |
ISO |
Arbutin results in increased expression of TES mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:17,065,148...17,105,824
Ensembl chr 6:17,065,148...17,105,827
|
|
G |
Tex13b |
testis expressed 13B |
decreases expression |
ISO |
Arbutin results in decreased expression of TEX13B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:139,709,056...139,714,182
Ensembl chr X:139,709,056...139,714,182
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of TGFB3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr12:86,103,517...86,125,815
Ensembl chr12:86,103,519...86,125,815
|
|
G |
Tll1 |
tolloid-like |
decreases expression |
ISO |
Arbutin results in decreased expression of TLL1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:64,466,132...64,659,043
Ensembl chr 8:64,467,965...64,659,305
|
|
G |
Tmem59l |
transmembrane protein 59-like |
decreases expression |
ISO |
Arbutin results in decreased expression of TMEM59L mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:70,936,505...70,939,998
Ensembl chr 8:70,936,517...70,940,008
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Arbutin inhibits the reaction [Ethanol results in increased expression of TNF protein] |
CTD |
PMID:34346143 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tor4a |
torsin family 4, member A |
decreases expression |
ISO |
Arbutin results in decreased expression of TOR4A mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:25,082,732...25,086,825
Ensembl chr 2:25,082,978...25,086,898
|
|
G |
Tram2 |
translocating chain-associating membrane protein 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of TRAM2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:21,071,621...21,149,449
Ensembl chr 1:21,066,523...21,149,453
|
|
G |
Treh |
trehalase (brush-border membrane glycoprotein) |
decreases expression |
ISO |
Arbutin results in decreased expression of TREH mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:44,584,530...44,597,602
Ensembl chr 9:44,584,530...44,597,602
|
|
G |
Tsc1 |
TSC complex subunit 1 |
increases expression |
ISO |
Arbutin results in increased expression of TSC1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:28,531,005...28,581,183
Ensembl chr 2:28,531,240...28,581,179
|
|
G |
Tsc22d2 |
TSC22 domain family, member 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of TSC22D2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:58,322,123...58,374,208
Ensembl chr 3:58,322,136...58,374,204
|
|
G |
Tshz2 |
teashirt zinc finger family member 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of TSHZ2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:169,474,430...169,914,671
Ensembl chr 2:169,474,933...169,913,736
|
|
G |
Tspoap1 |
TSPO associated protein 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of TSPOAP1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:87,649,022...87,676,754
Ensembl chr11:87,651,367...87,676,754
|
|
G |
Ttc22 |
tetratricopeptide repeat domain 22 |
decreases expression |
ISO |
Arbutin results in decreased expression of TTC22 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:106,479,646...106,497,393
Ensembl chr 4:106,479,629...106,497,386
|
|
G |
Tulp3 |
TUB like protein 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of TULP3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:128,298,103...128,332,833
Ensembl chr 6:128,298,124...128,332,814
|
|
G |
Tyr |
tyrosinase |
decreases expression decreases activity |
EXP |
Arbutin results in decreased expression of TYR mRNA Arbutin results in decreased activity of TYR protein |
CTD |
PMID:21071833 PMID:22705713 |
|
NCBI chr 7:87,073,979...87,142,637
Ensembl chr 7:87,073,979...87,142,720
|
|
G |
Ube2d4 |
ubiquitin-conjugating enzyme E2D 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of UBE2D4 mRNA |
CTD |
PMID:17103032 |
|
Ensembl chr15:58,718,439...58,719,170
|
|
G |
Ube2m |
ubiquitin-conjugating enzyme E2M |
decreases expression |
ISO |
Arbutin results in decreased expression of UBE2M mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:12,769,047...12,772,202
Ensembl chr 7:12,769,047...12,772,202
|
|
G |
Ubqln1 |
ubiquilin 1 |
increases expression |
ISO |
Arbutin results in increased expression of UBQLN1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr13:58,323,970...58,363,467
Ensembl chr13:58,323,970...58,363,467
|
|
G |
Usp44 |
ubiquitin specific peptidase 44 |
decreases expression |
ISO |
Arbutin results in decreased expression of USP44 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:93,655,831...93,696,792
Ensembl chr10:93,667,417...93,693,950
|
|
G |
Utp11 |
UTP11 small subunit processome component |
increases expression |
ISO |
Arbutin results in increased expression of UTP11 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:124,571,173...124,587,395
Ensembl chr 4:124,571,953...124,587,393
|
|
G |
Vps13b |
vacuolar protein sorting 13B |
decreases expression |
ISO |
Arbutin results in decreased expression of VPS13B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr15:35,371,264...35,931,375
Ensembl chr15:35,371,306...35,931,375
|
|
G |
Vps39 |
VPS39 HOPS complex subunit |
increases expression |
ISO |
Arbutin results in increased expression of VPS39 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:120,146,942...120,183,618
Ensembl chr 2:120,146,942...120,183,618
|
|
G |
Vwa3a |
von Willebrand factor A domain containing 3A |
decreases expression |
ISO |
Arbutin results in decreased expression of VWA3A mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:120,336,554...120,404,769
Ensembl chr 7:120,338,541...120,404,965
|
|
G |
Wnt10a |
wingless-type MMTV integration site family, member 10A |
decreases expression |
ISO |
Arbutin results in decreased expression of WNT10A mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:74,831,178...74,843,335
Ensembl chr 1:74,830,675...74,843,338
|
|
G |
Zbtb20 |
zinc finger and BTB domain containing 20 |
increases expression |
ISO |
Arbutin results in increased expression of ZBTB20 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr16:42,728,008...43,462,981
Ensembl chr16:42,696,244...43,462,965
|
|
G |
Zbtb7b |
zinc finger and BTB domain containing 7B |
decreases expression |
ISO |
Arbutin results in decreased expression of ZBTB7B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:89,284,953...89,300,976
Ensembl chr 3:89,284,951...89,302,083
|
|
G |
Zdhhc2 |
zinc finger, DHHC domain containing 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of ZDHHC2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:40,876,526...40,946,178
Ensembl chr 8:40,876,856...40,963,309
|
|
G |
Zfp354b |
zinc finger protein 354B |
decreases expression |
ISO |
Arbutin results in decreased expression of ZNF354B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:50,812,613...50,822,486
Ensembl chr11:50,812,650...50,822,460
|
|
G |
Zfp414 |
zinc finger protein 414 |
decreases expression |
ISO |
Arbutin results in decreased expression of ZNF414 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr17:33,848,066...33,850,690
Ensembl chr17:33,848,064...33,850,753
|
|
G |
Zfp870 |
zinc finger protein 870 |
increases expression |
ISO |
Arbutin results in increased expression of ZNF670 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr17:33,098,193...33,110,621
Ensembl chr17:33,098,193...33,110,616
|
|
G |
Zkscan16 |
zinc finger with KRAB and SCAN domains 16 |
decreases expression |
ISO |
Arbutin results in decreased expression of ZNF483 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:58,943,568...58,962,624
Ensembl chr 4:58,943,628...58,958,355
|
|
G |
Zkscan7 |
zinc finger with KRAB and SCAN domains 7 |
decreases expression |
ISO |
Arbutin results in decreased expression of ZKSCAN7 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:122,715,883...122,727,684
Ensembl chr 9:122,714,750...122,727,683
|
|
G |
Zp2 |
zona pellucida glycoprotein 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of ZP2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:119,725,985...119,744,514
Ensembl chr 7:119,725,995...119,744,514
|
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in decreased expression of APP protein] |
CTD |
PMID:35537655 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in decreased expression of CAT protein] |
CTD |
PMID:35537655 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA] |
CTD |
PMID:22210036 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
EXP |
astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA] |
CTD |
PMID:22210036 |
|
NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
multiple interactions |
EXP |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of HES1 protein] |
CTD |
PMID:35537655 |
|
NCBI chr16:29,883,259...29,886,614
Ensembl chr16:29,883,202...29,886,614
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in decreased expression of IL10 protein] |
CTD |
PMID:35537655 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of IL1B protein]; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:22210036 PMID:35537655 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of IL6 protein]; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:22210036 PMID:35537655 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
EXP |
astragalin inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein] |
CTD |
PMID:22210036 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
EXP |
astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:22210036 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Notch1 |
notch 1 |
multiple interactions |
EXP |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of NOTCH1 protein] |
CTD |
PMID:35537655 |
|
NCBI chr 2:26,347,914...26,393,834
Ensembl chr 2:26,347,915...26,406,675
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] |
CTD |
PMID:22210036 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Rbpj |
recombination signal binding protein for immunoglobulin kappa J region |
multiple interactions |
EXP |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of RBPJ protein] |
CTD |
PMID:35537655 |
|
NCBI chr 5:53,713,121...53,814,787
Ensembl chr 5:53,623,494...53,814,704
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
EXP |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of and results in increased phosphorylation of RELA protein]; astragalin inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein] |
CTD |
PMID:22210036 PMID:35537655 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of TNF protein]; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:22210036 PMID:35537655 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
multiple interactions |
EXP |
[liquiritin co-treated with 1-Naphthylisothiocyanate] results in increased expression of ABCB11 mRNA |
CTD |
PMID:36008890 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
multiple interactions |
EXP |
[liquiritin co-treated with 1-Naphthylisothiocyanate] results in decreased expression of ABCC2 mRNA |
CTD |
PMID:36008890 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcc3 |
ATP-binding cassette, sub-family C member 3 |
multiple interactions |
EXP |
[liquiritin co-treated with 1-Naphthylisothiocyanate] results in increased expression of ABCC3 mRNA |
CTD |
PMID:36008890 |
|
NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823
|
|
G |
Abcc4 |
ATP-binding cassette, sub-family C member 4 |
multiple interactions |
EXP |
[liquiritin co-treated with 1-Naphthylisothiocyanate] results in increased expression of ABCC4 mRNA |
CTD |
PMID:36008890 |
|
NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP ISO |
liquiritin inhibits the reaction [HSPD1 protein results in increased expression of CCL2 mRNA] liquiritin inhibits the reaction [Monocrotaline results in increased expression of CCL2 mRNA] |
CTD |
PMID:31589899 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
[brucine co-treated with liquiritin] results in decreased activity of CYP2E1 protein |
CTD |
PMID:21800547 |
|
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO |
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of GCLC mRNA] liquiritin results in increased expression of GCLC protein |
CTD |
PMID:29908794 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gclm |
glutamate-cysteine ligase, modifier subunit |
multiple interactions increases expression |
ISO |
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of GCLM mRNA] liquiritin results in increased expression of GCLM protein |
CTD |
PMID:29908794 |
|
NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
ISO EXP |
liquiritin inhibits the reaction [Monocrotaline results in increased activity of GPT protein] liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of GPT protein] |
CTD |
PMID:31589899 PMID:36008890 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Gsr |
glutathione reductase |
multiple interactions |
ISO |
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of GSR mRNA]; liquiritin inhibits the reaction [Monocrotaline results in decreased expression of GSR protein] |
CTD |
PMID:29908794 |
|
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO EXP |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of HMOX1 mRNA] [liquiritin co-treated with 1-Naphthylisothiocyanate] results in increased expression of HMOX1 mRNA; liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of HMOX1 protein] |
CTD |
PMID:29908794 PMID:36008890 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hspd1 |
heat shock protein 1 (chaperonin) |
multiple interactions |
EXP ISO |
liquiritin inhibits the reaction [HSPD1 protein results in increased expression of CCL2 mRNA]; liquiritin inhibits the reaction [HSPD1 protein results in increased expression of IL6 mRNA]; liquiritin inhibits the reaction [HSPD1 protein results in increased expression of NOS2 mRNA]; liquiritin inhibits the reaction [HSPD1 protein results in increased expression of RELA protein] liquiritin inhibits the reaction [Monocrotaline affects the expression of HSPD1 protein] |
CTD |
PMID:31589899 |
|
NCBI chr 1:55,116,992...55,127,402
Ensembl chr 1:55,116,994...55,127,402
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B protein] |
CTD |
PMID:36008890 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
liquiritin inhibits the reaction [HSPD1 protein results in increased expression of IL6 mRNA] liquiritin inhibits the reaction [Monocrotaline results in increased expression of IL6 mRNA] |
CTD |
PMID:31589899 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Keap1 |
kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
liquiritin promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of KEAP1 protein] |
CTD |
PMID:36008890 |
|
NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of MMP9 protein] |
CTD |
PMID:29908794 PMID:31589899 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
liquiritin inhibits the reaction [Monocrotaline results in increased activity of MPO protein] |
CTD |
PMID:31589899 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions decreases response to substance |
ISO EXP |
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of NFE2L2 mRNA] liquiritin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of NFE2L2 protein] NFE2L2 gene mutant form results in decreased susceptibility to liquiritin |
CTD |
PMID:29908794 PMID:36008890 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
ISO EXP |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of NOS2 mRNA] liquiritin inhibits the reaction [HSPD1 protein results in increased expression of NOS2 mRNA] |
CTD |
PMID:31589899 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions |
ISO EXP |
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of NQO1 mRNA] [liquiritin co-treated with 1-Naphthylisothiocyanate] results in increased expression of NQO1 mRNA |
CTD |
PMID:29908794 PMID:36008890 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]; liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 protein] |
CTD |
PMID:36008890 |
|
NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
EXP ISO |
liquiritin inhibits the reaction [HSPD1 protein results in increased expression of RELA protein] liquiritin inhibits the reaction [Monocrotaline results in increased expression of RELA protein] |
CTD |
PMID:31589899 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP |
liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SIRT1 mRNA]; liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SIRT1 protein] |
CTD |
PMID:36008890 |
|
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
|
|
G |
Slc10a1 |
solute carrier family 10 (sodium/bile acid cotransporter family), member 1 |
multiple interactions |
EXP |
liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA] |
CTD |
PMID:36008890 |
|
NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of SQSTM1 protein] |
CTD |
PMID:29908794 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of TLR4 protein] |
CTD |
PMID:31589899 |
|
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF protein] |
CTD |
PMID:36008890 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Txn2 |
thioredoxin 2 |
multiple interactions |
ISO |
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of TXN2 mRNA]; liquiritin inhibits the reaction [Monocrotaline results in decreased expression of TXN2 protein] |
CTD |
PMID:29908794 |
|
NCBI chr15:77,799,251...77,813,194
Ensembl chr15:77,799,247...77,813,206
|
|
G |
Txnrd2 |
thioredoxin reductase 2 |
multiple interactions |
ISO |
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of TXNRD2 mRNA]; liquiritin inhibits the reaction [Monocrotaline results in decreased expression of TXNRD2 protein] |
CTD |
PMID:29908794 |
|
NCBI chr16:18,245,167...18,297,823
Ensembl chr16:18,245,134...18,297,823
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
EXP |
loganin results in decreased activity of ACHE protein |
CTD |
PMID:19666019 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
G |
Acta2 |
actin alpha 2, smooth muscle, aorta |
multiple interactions |
EXP |
loganin inhibits the reaction [Bleomycin results in increased expression of ACTA2 mRNA]; loganin inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein] |
CTD |
PMID:35279615 |
|
NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
increases expression |
EXP |
loganin results in increased expression of BCL2 mRNA |
CTD |
PMID:20966881 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO EXP |
loganin inhibits the reaction [Glucose results in increased expression of CASP1 mRNA]; loganin inhibits the reaction [Glucose results in increased expression of CASP1 protein] loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of CASP1 protein] |
CTD |
PMID:37473909 |
|
NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290
|
|
G |
Casp3 |
caspase 3 |
decreases expression |
EXP |
loganin results in decreased expression of CASP3 mRNA |
CTD |
PMID:20966881 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp9 |
caspase 9 |
decreases expression |
EXP |
loganin results in decreased expression of CASP9 mRNA |
CTD |
PMID:20966881 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
affects expression |
EXP |
loganin affects the expression of CCL2 protein |
CTD |
PMID:21864639 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Cyba |
cytochrome b-245, alpha polypeptide |
affects expression |
EXP |
loganin affects the expression of CYBA protein |
CTD |
PMID:21864639 |
|
NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions |
ISO EXP |
loganin inhibits the reaction [Glucose results in increased expression of GSDMD mRNA]; loganin inhibits the reaction [Glucose results in increased expression of GSDMD protein] loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of GSDMD mRNA]; loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of GSDMD protein] |
CTD |
PMID:37473909 |
|
NCBI chr15:75,733,990...75,739,257
Ensembl chr15:75,734,176...75,739,257
|
|
G |
Hmox1 |
heme oxygenase 1 |
affects expression |
EXP |
loganin affects the expression of HMOX1 protein |
CTD |
PMID:21864639 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO EXP |
loganin inhibits the reaction [Glucose results in increased expression of IL18 mRNA]; loganin inhibits the reaction [Glucose results in increased expression of IL18 protein] loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of and results in increased secretion of IL18 protein]; loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of IL18 mRNA] |
CTD |
PMID:37473909 |
|
NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of and results in increased secretion of IL1B protein]; loganin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] loganin inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; loganin inhibits the reaction [Glucose results in increased expression of IL1B protein] |
CTD |
PMID:35279615 PMID:37473909 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
loganin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:35279615 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Lep |
leptin |
affects expression |
EXP |
loganin affects the expression of LEP protein |
CTD |
PMID:21864639 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
affects expression |
EXP |
loganin affects the expression of NFE2L2 protein |
CTD |
PMID:21864639 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP ISO |
loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of NLRP3 mRNA]; loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of NLRP3 protein] loganin inhibits the reaction [Glucose results in increased expression of NLRP3 mRNA]; loganin inhibits the reaction [Glucose results in increased expression of NLRP3 protein] |
CTD |
PMID:37473909 |
|
NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
affects expression |
EXP |
loganin affects the expression of NOS2 protein |
CTD |
PMID:21864639 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nox4 |
NADPH oxidase 4 |
affects expression |
EXP |
loganin affects the expression of NOX4 protein |
CTD |
PMID:21864639 |
|
NCBI chr 7:86,893,638...87,047,918
Ensembl chr 7:86,895,304...87,047,918
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
affects expression |
EXP |
loganin affects the expression of PTGS2 protein |
CTD |
PMID:21864639 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
affects expression multiple interactions |
EXP ISO |
loganin affects the expression of RELA protein loganin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased phosphorylation of RELA protein] |
CTD |
PMID:21864639 PMID:35279615 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO EXP |
loganin inhibits the reaction [Lipopolysaccharides results in increased expression of STAT3 protein] loganin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:35279615 |
|
NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
loganin inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA] |
CTD |
PMID:35279615 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
loganin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:35279615 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
decreases expression |
EXP |
loganin results in decreased expression of TNFSF11 mRNA |
CTD |
PMID:20966881 |
|
NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483
|
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions decreases phosphorylation |
ISO |
[luteolin-7-glucoside co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein luteolin-7-glucoside results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:31157476 PMID:34165247 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Bax |
BCL2-associated X protein |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of BAX protein |
CTD |
PMID:34165247 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions decreases expression |
ISO |
luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein]; luteolin-7-glucoside inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] luteolin-7-glucoside results in decreased expression of BCL2 protein |
CTD |
PMID:31157476 PMID:31381935 PMID:34165247 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l1 |
BCL2-like 1 |
decreases expression |
ISO |
luteolin-7-glucoside results in decreased expression of BCL2L1 protein |
CTD |
PMID:34165247 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of BID protein alternative form |
CTD |
PMID:34165247 |
|
NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
ISO |
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [luteolin-7-glucoside results in increased cleavage of CASP3 protein]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP3 protein modified form]; luteolin-7-glucoside inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein] |
CTD |
PMID:31157476 PMID:31381935 PMID:34165247 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp8 |
caspase 8 |
increases cleavage |
ISO |
luteolin-7-glucoside results in increased cleavage of CASP8 protein |
CTD |
PMID:34165247 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
increases cleavage |
ISO |
luteolin-7-glucoside results in increased cleavage of CASP9 protein |
CTD |
PMID:34165247 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
luteolin-7-glucoside inhibits the reaction [Hydrogen Peroxide results in decreased activity of CAT protein] |
CTD |
PMID:31157476 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
luteolin-7-glucoside results in decreased expression of CCNA2 protein |
CTD |
PMID:34165247 |
|
NCBI chr 3:36,619,014...36,627,187
Ensembl chr 3:36,619,014...36,626,299
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
luteolin-7-glucoside results in decreased expression of CCNB1 protein |
CTD |
PMID:34165247 |
|
NCBI chr13:100,915,247...100,922,994
Ensembl chr13:100,915,158...100,923,078
|
|
G |
Cdk1 |
cyclin dependent kinase 1 |
decreases phosphorylation |
ISO |
luteolin-7-glucoside results in decreased phosphorylation of CDK1 protein |
CTD |
PMID:34165247 |
|
NCBI chr10:69,170,976...69,188,742
Ensembl chr10:69,170,976...69,188,768
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
luteolin-7-glucoside results in decreased expression of CDK2 protein |
CTD |
PMID:34165247 |
|
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of CDKN1A protein |
CTD |
PMID:34165247 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
multiple interactions increases activity |
ISO |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR1 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR1 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR1 protein] luteolin-7-glucoside results in increased activity of ESR1 protein |
CTD |
PMID:31381935 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
multiple interactions increases activity |
ISO |
4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR2 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR2 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR2 protein] luteolin-7-glucoside results in increased activity of ESR2 protein |
CTD |
PMID:31381935 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of FAS protein |
CTD |
PMID:34165247 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
multiple interactions |
ISO |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein] |
CTD |
PMID:31381935 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
luteolin-7-glucoside inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 protein] |
CTD |
PMID:11123379 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein] luteolin-7-glucoside results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:31381935 PMID:34165247 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein] luteolin-7-glucoside results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:31381935 PMID:34165247 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
increases cleavage multiple interactions |
ISO |
luteolin-7-glucoside results in increased cleavage of PARP1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; SB 203580 promotes the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; U 0126 inhibits the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein] |
CTD |
PMID:34165247 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Ripk1 |
receptor (TNFRSF)-interacting serine-threonine kinase 1 |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of RIPK1 protein |
CTD |
PMID:34165247 |
|
NCBI chr13:34,181,072...34,219,153
Ensembl chr13:34,186,346...34,221,130
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein] |
CTD |
PMID:31381935 |
|
NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
luteolin-7-glucoside inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] |
CTD |
PMID:11123379 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of TNFRSF1A protein |
CTD |
PMID:34165247 |
|
NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447
|
|
|
G |
Aqp3 |
aquaporin 3 |
multiple interactions |
ISO |
[malvidin-3-glucoside co-treated with petunidin-3-glucoside] results in increased expression of AQP3 mRNA |
CTD |
PMID:33294640 |
|
NCBI chr 4:41,092,724...41,098,183
Ensembl chr 4:41,092,722...41,098,183
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases activity |
ISO |
malvidin-3-glucoside results in decreased activity of CA1 protein |
CTD |
PMID:28445001 |
|
NCBI chr 3:14,831,274...14,873,425
Ensembl chr 3:14,831,276...14,873,428
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases activity |
ISO |
malvidin-3-glucoside results in decreased activity of CA2 protein |
CTD |
PMID:28445001 |
|
NCBI chr 3:14,951,329...14,965,830
Ensembl chr 3:14,951,333...14,965,830
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
EXP |
malvidin-3-glucoside inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:23731018 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Pde5a |
phosphodiesterase 5A, cGMP-specific |
decreases activity |
ISO |
malvidin-3-glucoside results in decreased activity of PDE5A protein |
CTD |
PMID:15769121 |
|
NCBI chr 3:122,522,822...122,653,023
Ensembl chr 3:122,522,596...122,653,023
|
|
G |
Sele |
selectin, endothelial cell |
multiple interactions |
ISO |
malvidin-3-glucoside inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:30611791 |
|
NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
malvidin-3-glucoside inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] malvidin-3-glucoside inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:23731018 PMID:30611791 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases activity |
ISO |
malvin results in decreased activity of CA1 protein |
CTD |
PMID:28445001 |
|
NCBI chr 3:14,831,274...14,873,425
Ensembl chr 3:14,831,276...14,873,428
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases activity |
ISO |
malvin results in decreased activity of CA2 protein |
CTD |
PMID:28445001 |
|
NCBI chr 3:14,951,329...14,965,830
Ensembl chr 3:14,951,333...14,965,830
|
|
|
G |
Ikbkb |
inhibitor of kappaB kinase beta |
multiple interactions |
EXP |
monotropein inhibits the reaction [Lipopolysaccharides results in increased activity of IKBKB protein] |
CTD |
PMID:23261679 |
|
NCBI chr 8:23,149,228...23,196,605
Ensembl chr 8:23,149,228...23,196,605
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:23261679 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
monotropein inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein] |
CTD |
PMID:23261679 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
EXP |
monotropein inhibits the reaction [Dextran Sulfate affects the localization of NFKB1 protein]; monotropein inhibits the reaction [Lipopolysaccharides affects the localization of NFKB1 protein] |
CTD |
PMID:23261679 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions decreases degradation |
EXP |
monotropein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; monotropein inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] monotropein results in decreased degradation of NFKBIA protein |
CTD |
PMID:23261679 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
EXP |
monotropein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:23261679 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
monotropein inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] |
CTD |
PMID:23261679 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
EXP |
monotropein inhibits the reaction [Dextran Sulfate affects the localization of RELA protein]; monotropein inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein] |
CTD |
PMID:23261679 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:23261679 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
increases mutagenesis |
ISO |
1-methoxy-3-indolylmethylglucosinolate metabolite results in increased mutagenesis of HPRT1 gene |
CTD |
PMID:20846518 |
|
NCBI chr X:52,076,955...52,110,537
Ensembl chr X:52,077,014...52,110,536
|
|
|
G |
Abca1 |
ATP-binding cassette, sub-family A member 1 |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCA1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
multiple interactions |
EXP |
[Cephalothin co-treated with Neomycin] results in increased expression of ABCB11 mRNA; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCB11 mRNA |
CTD |
PMID:24657338 PMID:36464106 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCB1A mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
multiple interactions |
EXP |
[Cephalothin co-treated with Neomycin] results in increased expression of ABCC2 mRNA; [Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC2 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC2 mRNA |
CTD |
PMID:24657338 PMID:36464106 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcc3 |
ATP-binding cassette, sub-family C member 3 |
multiple interactions |
EXP |
[Cephalothin co-treated with Neomycin] results in increased expression of ABCC3 mRNA; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC3 mRNA |
CTD |
PMID:24657338 PMID:36464106 |
|
NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
multiple interactions |
EXP |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCG2 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCG2 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
EXP |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCG5 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCG5 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr17:84,965,602...84,990,439
Ensembl chr17:84,965,662...84,990,439
|
|
G |
Acaca |
acetyl-Coenzyme A carboxylase alpha |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole co-treated with elemicin] results in increased expression of ACACA mRNA |
CTD |
PMID:34979169 |
|
NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477
|
|
G |
Acat2 |
acetyl-Coenzyme A acetyltransferase 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACAT2 protein |
CTD |
PMID:30545405 |
|
NCBI chr17:13,161,929...13,179,612
Ensembl chr17:13,161,777...13,179,634
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACE2 protein |
CTD |
PMID:30545405 |
|
NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416
|
|
G |
Ada |
adenosine deaminase |
decreases activity multiple interactions |
EXP |
Neomycin results in decreased activity of ADA protein Tetrachlorodibenzodioxin inhibits the reaction [Neomycin results in decreased activity of ADA protein] |
CTD |
PMID:7853360 |
|
NCBI chr 2:163,565,703...163,592,154
Ensembl chr 2:163,568,504...163,592,159
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole co-treated with elemicin] results in increased expression of ADIPOQ mRNA |
CTD |
PMID:34979169 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Ahsg |
alpha-2-HS-glycoprotein |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of AHSG protein |
CTD |
PMID:30545405 |
|
NCBI chr16:22,710,793...22,718,193
Ensembl chr16:22,710,027...22,718,199
|
|
G |
Aldob |
aldolase B, fructose-bisphosphate |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ALDOB protein |
CTD |
PMID:30545405 |
|
NCBI chr 4:49,535,993...49,549,546
Ensembl chr 4:49,535,995...49,549,546
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
multiple interactions increases expression |
EXP |
peoniflorin inhibits the reaction [Neomycin results in increased expression of APAF1 mRNA] |
CTD |
PMID:29292089 |
|
NCBI chr10:90,825,173...90,918,688
Ensembl chr10:90,825,173...90,918,632
|
|
G |
Arg2 |
arginase type II |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of ARG2 protein |
CTD |
PMID:30545405 |
|
NCBI chr12:79,177,562...79,203,075
Ensembl chr12:79,177,551...79,203,075
|
|
G |
Arpc3 |
actin related protein 2/3 complex, subunit 3 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ARPC3 protein |
CTD |
PMID:30545405 |
|
NCBI chr 5:122,529,941...122,544,244
Ensembl chr 5:122,529,941...122,552,247
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of ASAH1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:41,793,683...41,850,681
Ensembl chr 8:41,793,234...41,827,810
|
|
G |
Atp1a1 |
ATPase, Na+/K+ transporting, alpha 1 polypeptide |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP1A1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 3:101,483,535...101,512,023
Ensembl chr 3:101,483,535...101,512,000
|
|
G |
Atp2a3 |
ATPase, Ca++ transporting, ubiquitous |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP2A3 protein |
CTD |
PMID:30545405 |
|
NCBI chr11:72,851,995...72,883,869
Ensembl chr11:72,851,995...72,883,870
|
|
G |
Atp5mf |
ATP synthase membrane subunit f |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5MF protein |
CTD |
PMID:30545405 |
|
NCBI chr 5:145,120,514...145,128,351
Ensembl chr 5:145,120,508...145,128,872
|
|
G |
Atp5pd |
ATP synthase peripheral stalk subunit d |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5PD protein |
CTD |
PMID:30545405 |
|
NCBI chr11:115,306,517...115,310,775
Ensembl chr11:115,306,515...115,310,788
|
|
G |
Atp5pf |
ATP synthase peripheral stalk subunit F6 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5PF protein |
CTD |
PMID:30545405 |
|
NCBI chr16:84,624,754...84,632,495
Ensembl chr16:84,624,754...84,632,513
|
|
G |
B3galt5 |
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of B3GALT5 protein |
CTD |
PMID:30545405 |
|
NCBI chr16:96,037,001...96,121,059
Ensembl chr16:96,037,001...96,121,059
|
|
G |
Bax |
BCL2-associated X protein |
increases expression multiple interactions |
EXP |
Neomycin results in increased expression of BAX mRNA peoniflorin inhibits the reaction [Neomycin results in increased expression of BAX mRNA] |
CTD |
PMID:29292089 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcat1 |
branched chain aminotransferase 1, cytosolic |
decreases expression |
EXP |
Neomycin results in decreased expression of BCAT1 mRNA |
CTD |
PMID:30626089 |
|
NCBI chr 6:144,939,561...145,021,883
Ensembl chr 6:144,939,561...145,021,910
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions decreases expression |
EXP |
peoniflorin inhibits the reaction [Neomycin results in decreased expression of BCL2 mRNA]; peoniflorin inhibits the reaction [Neomycin results in decreased expression of BCL2 protein] Neomycin results in decreased expression of BCL2 mRNA; Neomycin results in decreased expression of BCL2 protein |
CTD |
PMID:29292089 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression affects cleavage |
EXP |
BIX 01294 affects the reaction [Neomycin affects the cleavage of CASP3 protein]; peoniflorin inhibits the reaction [Neomycin results in increased expression of CASP3 mRNA]; peoniflorin inhibits the reaction [Neomycin results in increased expression of CASP3 protein modified form] Neomycin results in increased expression of CASP3 mRNA; Neomycin results in increased expression of CASP3 protein modified form |
CTD |
PMID:23429292 PMID:29292089 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases expression |
EXP |
peoniflorin inhibits the reaction [Neomycin results in increased expression of CASP9 mRNA]; peoniflorin inhibits the reaction [Neomycin results in increased expression of CASP9 protein modified form] Neomycin results in increased expression of CASP9 mRNA; Neomycin results in increased expression of CASP9 protein modified form |
CTD |
PMID:29292089 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Casr |
calcium-sensing receptor |
multiple interactions |
ISO |
CASR protein promotes the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CASR protein promotes the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Neomycin binds to and results in increased activity of CASR protein [Neomycin binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Neomycin binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; Neomycin binds to and results in increased activity of CASR protein |
CTD |
PMID:10231437 PMID:17537980 |
|
NCBI chr16:36,310,947...36,382,605
Ensembl chr16:36,314,058...36,382,503
|
|
G |
Ccng2 |
cyclin G2 |
increases expression |
EXP |
Neomycin results in increased expression of CCNG2 mRNA |
CTD |
PMID:30626089 |
|
NCBI chr 5:93,415,432...93,424,090
Ensembl chr 5:93,415,116...93,424,090
|
|
G |
Cd86 |
CD86 antigen |
increases expression |
ISO |
Neomycin results in increased expression of CD86 protein |
CTD |
PMID:19665512 |
|
NCBI chr16:36,389,318...36,486,439
Ensembl chr16:36,424,231...36,486,443
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression |
EXP |
Neomycin results in decreased expression of CDH1 protein |
CTD |
PMID:15953529 |
|
NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878
|
|
G |
Clca4a |
chloride channel accessory 4A |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CLCA4 protein |
CTD |
PMID:30545405 |
|
NCBI chr 3:144,658,247...144,680,806
Ensembl chr 3:144,658,241...144,680,806
|
|
G |
Cldn5 |
claudin 5 |
multiple interactions |
EXP |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of CLDN5 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of CLDN5 protein] |
CTD |
PMID:35390362 |
|
NCBI chr16:18,595,597...18,597,012
Ensembl chr16:18,595,597...18,597,012
|
|
G |
Cldn7 |
claudin 7 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CLDN7 protein |
CTD |
PMID:30545405 |
|
NCBI chr11:69,855,605...69,858,712
Ensembl chr11:69,855,605...69,858,711
|
|
G |
Cmbl |
carboxymethylenebutenolidase homolog |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CMBL protein |
CTD |
PMID:30545405 |
|
NCBI chr15:31,565,314...31,590,266
Ensembl chr15:31,565,535...31,590,265
|
|
G |
Cndp2 |
CNDP dipeptidase 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CNDP2 protein |
CTD |
PMID:30545405 |
|
NCBI chr18:84,685,590...84,703,827
Ensembl chr18:84,685,590...84,703,827
|
|
G |
Cox5a |
cytochrome c oxidase subunit 5A |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX5A protein |
CTD |
PMID:30545405 |
|
NCBI chr 9:57,423,012...57,439,710
Ensembl chr 9:57,428,557...57,439,709
|
|
G |
Cox6b1 |
cytochrome c oxidase, subunit 6B1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX6B1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 7:30,316,396...30,325,539
Ensembl chr 7:30,316,286...30,325,576
|
|
G |
Cox7a2 |
cytochrome c oxidase subunit 7A2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX7A2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 9:79,662,523...79,667,135
Ensembl chr 9:79,662,643...79,667,160
|
|
G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
multiple interactions |
EXP |
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of CSF2 protein |
CTD |
PMID:31442584 |
|
NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493
|
|
G |
Cth |
cystathionine gamma lyase |
multiple interactions decreases expression |
EXP |
Plant Oils inhibits the reaction [Neomycin results in decreased expression of CTH mRNA] |
CTD |
PMID:30626089 |
|
NCBI chr 3:157,599,885...157,630,718
Ensembl chr 3:157,599,885...157,630,714
|
|
G |
Ctsa |
cathepsin A |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CTSA protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:164,674,792...164,682,952
Ensembl chr 2:164,674,793...164,682,952
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Doxorubicin results in increased expression of CXCL9 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Nanotubes, Carbon promotes the reaction [Doxorubicin results in increased expression of CXCL9 mRNA]] |
CTD |
PMID:32068018 |
|
NCBI chr 5:92,469,190...92,475,938
Ensembl chr 5:92,469,206...92,475,938
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP27A1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 1:74,752,311...74,777,056
Ensembl chr 1:74,752,733...74,777,051
|
|
G |
Cyp2c52-ps |
cytochrome P450, family 2, subfamily c, polypeptide 52, pseudogene |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP2C11 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr19:38,965,106...38,992,071
Ensembl chr19:38,965,091...38,991,733
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
|
|
G |
Cyp7a1 |
cytochrome P450, family 7, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7A1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633
|
|
G |
Cyp7b1 |
cytochrome P450, family 7, subfamily b, polypeptide 1 |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 3:18,126,108...18,298,054
Ensembl chr 3:18,126,114...18,297,502
|
|
G |
Cyp8b1 |
cytochrome P450, family 8, subfamily b, polypeptide 1 |
multiple interactions |
EXP |
[Cephalothin co-treated with Neomycin] results in decreased expression of CYP8B1 mRNA; [Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP8B1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:24657338 PMID:36464106 |
|
NCBI chr 9:121,743,422...121,745,371
Ensembl chr 9:121,743,422...121,745,371
|
|
G |
Epcam |
epithelial cell adhesion molecule |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of EPCAM protein |
CTD |
PMID:30545405 |
|
NCBI chr17:87,943,407...87,958,555
Ensembl chr17:87,943,407...87,958,557
|
|
G |
Etfa |
electron transferring flavoprotein, alpha polypeptide |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ETFA protein |
CTD |
PMID:30545405 |
|
NCBI chr 9:55,361,720...55,419,528
Ensembl chr 9:55,361,792...55,419,527
|
|
G |
Ezr |
ezrin |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of EZR protein |
CTD |
PMID:30545405 |
|
NCBI chr17:7,005,530...7,050,179
Ensembl chr17:7,005,440...7,050,183
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
EXP |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of FASN mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of FASN mRNA; [Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [elemicin results in increased expression of FASN mRNA] |
CTD |
PMID:34979169 PMID:36464106 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Fgf15 |
fibroblast growth factor 15 |
multiple interactions |
EXP |
[Cephalothin co-treated with Neomycin] results in increased expression of FGF15 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 7:144,450,269...144,454,690
Ensembl chr 7:144,450,268...144,454,690
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions increases expression |
EXP |
Plant Oils inhibits the reaction [Neomycin results in increased expression of FOXO1 mRNA] |
CTD |
PMID:30626089 |
|
NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible 45 gamma |
increases expression multiple interactions |
EXP |
Neomycin results in increased expression of GADD45G mRNA Plant Oils inhibits the reaction [Neomycin results in increased expression of GADD45G mRNA] |
CTD |
PMID:30626089 |
|
NCBI chr13:52,000,711...52,002,511
Ensembl chr13:52,000,714...52,002,504
|
|
G |
Gclm |
glutamate-cysteine ligase, modifier subunit |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide analog results in increased expression of GCLM protein] |
CTD |
PMID:36535435 |
|
NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
|
|
G |
Gfpt2 |
glutamine fructose-6-phosphate transaminase 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GFPT2 protein |
CTD |
PMID:30545405 |
|
NCBI chr11:49,684,981...49,729,448
Ensembl chr11:49,685,005...49,729,440
|
|
G |
Gipc2 |
GIPC PDZ domain containing family, member 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GIPC2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 3:151,799,476...151,871,537
Ensembl chr 3:151,799,170...151,871,867
|
|
G |
Gng12 |
guanine nucleotide binding protein (G protein), gamma 12 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GNG12 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:66,873,381...66,998,345
Ensembl chr 6:66,873,381...66,998,334
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
EXP |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased activity of GPT protein]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased activity of GPT protein; [Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [elemicin results in increased activity of GPT protein] |
CTD |
PMID:34979169 PMID:36464106 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Gpt2 |
glutamic pyruvate transaminase (alanine aminotransferase) 2 |
decreases expression |
EXP |
Neomycin results in decreased expression of GPT2 mRNA |
CTD |
PMID:30626089 |
|
NCBI chr 8:86,219,090...86,255,531
Ensembl chr 8:86,219,205...86,254,189
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GPX1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Gstm2 |
glutathione S-transferase, mu 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GSTM2 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 3:107,889,018...107,893,736
Ensembl chr 3:107,889,018...107,893,769
|
|
G |
H2-DMb1 |
histocompatibility 2, class II, locus Mb1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RT1-DMB protein |
CTD |
PMID:30545405 |
|
NCBI chr17:34,372,165...34,379,203
Ensembl chr17:34,372,046...34,379,204
|
|
G |
Hexb |
hexosaminidase B |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of HEXB protein |
CTD |
PMID:30545405 |
|
NCBI chr13:97,312,839...97,334,865
Ensembl chr13:97,312,839...97,334,865
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
multiple interactions |
EXP |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of HMGCR mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of HMGCR mRNA |
CTD |
PMID:36464106 |
|
NCBI chr13:96,785,470...96,807,444
Ensembl chr13:96,785,475...96,807,444
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide analog results in increased expression of HMOX1 protein] |
CTD |
PMID:36535435 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hnrnph2 |
heterogeneous nuclear ribonucleoprotein H2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of HNRNPH2 protein |
CTD |
PMID:30545405 |
|
NCBI chr X:133,501,928...133,507,809
Ensembl chr X:133,501,928...133,507,809
|
|
G |
Hp |
haptoglobin |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of HP protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:110,301,760...110,305,804
Ensembl chr 8:110,301,760...110,305,804
|
|
G |
Hspd1 |
heat shock protein 1 (chaperonin) |
multiple interactions |
ISO |
Neomycin inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein] |
CTD |
PMID:16178011 |
|
NCBI chr 1:55,116,992...55,127,402
Ensembl chr 1:55,116,994...55,127,402
|
|
G |
Htr4 |
5 hydroxytryptamine (serotonin) receptor 4 |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide results in increased expression of HTR4 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in increased expression of HTR4 mRNA |
CTD |
PMID:36535435 |
|
NCBI chr18:62,456,618...62,636,098
Ensembl chr18:62,457,275...62,629,648
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased secretion of IL18 protein] |
CTD |
PMID:35390362 |
|
NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of and results in increased secretion of IL1B protein]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of IL1B mRNA]; [Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Doxorubicin results in increased expression of IL1B protein]; [Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Nanotubes, Carbon promotes the reaction [Doxorubicin results in increased expression of IL1B protein]] |
CTD |
PMID:32068018 PMID:35390362 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of IL6 protein; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of IL6 protein] |
CTD |
PMID:31442584 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Inhba |
inhibin beta-A |
increases expression |
EXP |
Neomycin results in increased expression of INHBA mRNA |
CTD |
PMID:30626089 |
|
NCBI chr13:16,178,841...16,206,194
Ensembl chr13:16,186,436...16,206,206
|
|
G |
Ins2 |
insulin II |
multiple interactions |
ISO |
Neomycin inhibits the reaction [INS protein results in increased uptake of cobaltous chloride] |
CTD |
PMID:14622148 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Irs2 |
insulin receptor substrate 2 |
increases expression |
EXP |
Neomycin results in increased expression of IRS2 mRNA |
CTD |
PMID:30626089 |
|
NCBI chr 8:11,034,681...11,058,929
Ensembl chr 8:11,034,681...11,058,458
|
|
G |
Jun |
jun proto-oncogene |
multiple interactions increases expression |
ISO |
3,9-bis((ethylthio)methyl)-K-252a inhibits the reaction [Neomycin results in increased expression of JUN protein modified form] |
CTD |
PMID:10627579 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Klf2 |
Kruppel-like transcription factor 2 (lung) |
increases expression |
EXP |
Neomycin results in increased expression of KLF2 mRNA |
CTD |
PMID:30626089 |
|
NCBI chr 8:73,072,906...73,075,498
Ensembl chr 8:73,072,877...73,075,500
|
|
G |
Kng2 |
kininogen 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MAP1 protein |
CTD |
PMID:30545405 |
|
NCBI chr16:22,804,602...22,847,851
Ensembl chr16:22,804,604...22,848,232
|
|
G |
Krt16 |
keratin 16 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of KRT16 protein |
CTD |
PMID:30545405 |
|
NCBI chr11:100,136,917...100,139,728
Ensembl chr11:100,136,917...100,139,728
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
EXP |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LDLR mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LDLR mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215
|
|
G |
Lep |
leptin |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole co-treated with elemicin] results in increased expression of LEP mRNA |
CTD |
PMID:34979169 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Lpin1 |
lipin 1 |
multiple interactions |
EXP |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LPIN1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LPIN1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr12:16,585,670...16,697,020
Ensembl chr12:16,585,670...16,696,967
|
|
G |
Lyz2 |
lysozyme 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of LYZ2 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:117,113,446...117,118,177
Ensembl chr10:117,113,236...117,118,226
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions increases expression |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CASR protein promotes the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Neomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein Neomycin results in increased expression of MAPK1 protein modified form peoniflorin inhibits the reaction [Neomycin results in increased expression of MAPK1 protein modified form] |
CTD |
PMID:17537980 PMID:29292089 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions increases expression |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; CASR protein promotes the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Neomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein [Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MAPK3 protein peoniflorin inhibits the reaction [Neomycin results in increased expression of MAPK3 protein modified form] |
CTD |
PMID:17537980 PMID:29292089 PMID:30545405 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mlxip |
MLX interacting protein |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [elemicin results in increased expression of MLXIP mRNA] |
CTD |
PMID:34979169 |
|
NCBI chr 5:123,532,438...123,595,998
Ensembl chr 5:123,532,861...123,595,995
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NAD+ dependent), methenyltetrahydrofolate cyclohydrolase |
decreases expression multiple interactions |
EXP |
Neomycin results in decreased expression of MTHFD2 mRNA Plant Oils inhibits the reaction [Neomycin results in decreased expression of MTHFD2 mRNA] |
CTD |
PMID:30626089 |
|
NCBI chr 6:83,282,686...83,302,926
Ensembl chr 6:83,282,673...83,302,890
|
|
G |
Myd88 |
myeloid differentiation primary response gene 88 |
multiple interactions |
EXP |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of MYD88 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of MYD88 protein] |
CTD |
PMID:35390362 |
|
NCBI chr 9:119,165,000...119,169,084
Ensembl chr 9:119,165,000...119,170,477
|
|
G |
Myh14 |
myosin, heavy polypeptide 14 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MYH14 protein |
CTD |
PMID:30545405 |
|
NCBI chr 7:44,255,227...44,320,296
Ensembl chr 7:44,255,227...44,320,267
|
|
G |
Ndufa13 |
NADH:ubiquinone oxidoreductase subunit A13 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of NDUFA13 protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:70,346,813...70,355,208
Ensembl chr 8:70,346,830...70,355,208
|
|
G |
Ndufab1 |
NADH:ubiquinone oxidoreductase subunit AB1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of NDUFAB1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 7:121,686,038...121,701,071
Ensembl chr 7:121,684,626...121,701,109
|
|
G |
Nog |
noggin |
increases expression |
EXP |
Neomycin results in increased expression of NOG mRNA |
CTD |
PMID:30626089 |
|
NCBI chr11:89,191,464...89,193,385
Ensembl chr11:89,191,464...89,193,158
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Nanotubes, Carbon promotes the reaction [Doxorubicin results in increased expression of NOS2 mRNA]] |
CTD |
PMID:32068018 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
multiple interactions |
EXP |
[Cephalothin co-treated with Neomycin] results in increased expression of NPC1L1 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr11:6,161,011...6,180,245
Ensembl chr11:6,161,013...6,180,143
|
|
G |
Npc2 |
NPC intracellular cholesterol transporter 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of NPC2 protein |
CTD |
PMID:30545405 |
|
NCBI chr12:84,801,333...84,819,886
Ensembl chr12:84,801,336...84,819,926
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions |
EXP |
[Cephalothin co-treated with Neomycin] results in increased expression of NR5A2 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 1:136,770,300...136,888,186
Ensembl chr 1:136,770,309...136,888,186
|
|
G |
Ocln |
occludin |
multiple interactions |
EXP |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of OCLN mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of OCLN protein] |
CTD |
PMID:35390362 |
|
NCBI chr13:100,633,012...100,689,226
Ensembl chr13:100,633,015...100,689,226
|
|
G |
Pfn1 |
profilin 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PFN1 protein |
CTD |
PMID:30545405 |
|
NCBI chr11:70,542,670...70,547,625
Ensembl chr11:70,542,676...70,545,470
|
|
G |
Pgam1 |
phosphoglycerate mutase 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PGAM1 protein |
CTD |
PMID:30545405 |
|
NCBI chr19:41,900,310...41,907,104
Ensembl chr19:41,900,362...41,907,099
|
|
G |
Pmm2 |
phosphomannomutase 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PMM2 protein |
CTD |
PMID:30545405 |
|
NCBI chr16:8,455,467...8,475,472
Ensembl chr16:8,455,538...8,480,331
|
|
G |
Ppp1ca |
protein phosphatase 1 catalytic subunit alpha |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CA protein |
CTD |
PMID:30545405 |
|
NCBI chr19:4,242,173...4,245,418
Ensembl chr19:4,242,064...4,245,419
|
|
G |
Ppp1cb |
protein phosphatase 1 catalytic subunit beta |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CB protein |
CTD |
PMID:30545405 |
|
NCBI chr 5:32,616,192...32,651,057
Ensembl chr 5:32,616,187...32,674,777
|
|
G |
Ppp1cc |
protein phosphatase 1 catalytic subunit gamma |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CC protein |
CTD |
PMID:30545405 |
|
NCBI chr 5:122,296,338...122,313,336
Ensembl chr 5:122,296,341...122,313,336
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
multiple interactions decreases expression |
EXP |
Plant Oils inhibits the reaction [Neomycin results in decreased expression of PSAT1 mRNA] |
CTD |
PMID:30626089 |
|
NCBI chr19:15,882,487...15,902,423
Ensembl chr19:15,882,042...15,924,701
|
|
G |
Psma3 |
proteasome subunit alpha 3 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of PSMA3 protein |
CTD |
PMID:30545405 |
|
NCBI chr12:71,016,082...71,042,651
Ensembl chr12:71,021,395...71,043,121
|
|
G |
Psph |
phosphoserine phosphatase |
decreases expression multiple interactions |
EXP |
Neomycin results in decreased expression of PSPH mRNA Plant Oils inhibits the reaction [Neomycin results in decreased expression of PSPH mRNA] |
CTD |
PMID:30626089 |
|
NCBI chr 5:129,842,622...129,864,318
Ensembl chr 5:129,842,622...129,864,513
|
|
G |
Ralb |
v-ral simian leukemia viral oncogene B |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RALB protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:119,398,035...119,432,512
Ensembl chr 1:119,398,035...119,432,524
|
|
G |
Ran |
RAN, member RAS oncogene family |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RAN protein |
CTD |
PMID:30545405 |
|
NCBI chr 5:129,097,264...129,101,388
Ensembl chr 5:129,097,133...129,101,387
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
EXP |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of RELA mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of RELA protein] |
CTD |
PMID:35390362 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Rida |
reactive intermediate imine deaminase A homolog |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RIDA protein |
CTD |
PMID:30545405 |
|
NCBI chr15:34,484,168...34,495,392
Ensembl chr15:34,484,167...34,495,401
|
|
G |
Rpl30 |
ribosomal protein L30 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPL30 protein |
CTD |
PMID:30545405 |
|
NCBI chr15:34,440,649...34,443,405
Ensembl chr15:34,440,651...34,443,786
|
|
G |
Rpn2 |
ribophorin II |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPN2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:157,121,018...157,168,238
Ensembl chr 2:157,120,937...157,168,239
|
|
G |
Rps23 |
ribosomal protein S23 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPS23 protein |
CTD |
PMID:30545405 |
|
NCBI chr13:91,071,241...91,072,851
Ensembl chr13:91,071,077...91,073,069
|
|
G |
Rps27l |
ribosomal protein S27-like |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPS27L protein |
CTD |
PMID:30545405 |
|
NCBI chr 9:66,851,906...66,856,804
Ensembl chr 9:66,853,368...66,856,798
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase, polypeptide 1 |
affects phosphorylation |
EXP |
Neomycin affects the phosphorylation of RPS6KB1 protein |
CTD |
PMID:16537399 |
|
NCBI chr11:86,389,695...86,435,711
Ensembl chr11:86,389,697...86,435,631
|
|
G |
S100a10 |
S100 calcium binding protein A10 (calpactin) |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of S100A10 protein |
CTD |
PMID:30545405 |
|
NCBI chr 3:93,462,424...93,471,952
Ensembl chr 3:93,462,387...93,471,950
|
|
G |
S100a11 |
S100 calcium binding protein A11 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of S100A11 protein |
CTD |
PMID:30545405 |
|
NCBI chr 3:93,427,803...93,433,595
Ensembl chr 3:93,427,795...93,433,594
|
|
G |
Scarb2 |
scavenger receptor class B, member 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of SCARB2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 5:92,589,170...92,653,516
Ensembl chr 5:92,589,173...92,654,692
|
|
G |
Serpinb6a |
serine (or cysteine) peptidase inhibitor, clade B, member 6a |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SERPINB6 protein |
CTD |
PMID:30545405 |
|
NCBI chr13:34,101,901...34,186,777
Ensembl chr13:34,101,901...34,186,777
|
|
G |
Shmt2 |
serine hydroxymethyltransferase 2 (mitochondrial) |
decreases expression multiple interactions |
EXP ISO |
Neomycin results in decreased expression of SHMT2 mRNA [Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SHMT2 protein |
CTD |
PMID:30545405 PMID:30626089 |
|
NCBI chr10:127,352,992...127,358,313
Ensembl chr10:127,352,992...127,358,313
|
|
G |
Slc10a1 |
solute carrier family 10 (sodium/bile acid cotransporter family), member 1 |
multiple interactions |
EXP |
[Cephalothin co-treated with Neomycin] results in increased expression of SLC10A1 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479
|
|
G |
Slc22a7 |
solute carrier family 22 (organic anion transporter), member 7 |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SLC22A7 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr17:46,743,111...46,749,403
Ensembl chr17:46,743,109...46,749,383
|
|
G |
Slc3a1 |
solute carrier family 3, member 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SLC3A1 protein |
CTD |
PMID:30545405 |
|
NCBI chr17:85,335,775...85,371,669
Ensembl chr17:85,335,804...85,371,664
|
|
G |
Slc51b |
solute carrier family 51, beta subunit |
multiple interactions |
EXP |
[Cephalothin co-treated with Neomycin] results in decreased expression of SLC51B mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 9:65,320,035...65,330,055
Ensembl chr 9:65,319,996...65,330,237
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family, member 1b2 |
multiple interactions |
EXP |
[Cephalothin co-treated with Neomycin] results in increased expression of SLCO1B2 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372
|
|
G |
Smad6 |
SMAD family member 6 |
increases expression |
EXP |
Neomycin results in increased expression of SMAD6 mRNA |
CTD |
PMID:30626089 |
|
NCBI chr 9:63,860,358...63,929,374
Ensembl chr 9:63,860,358...63,929,341
|
|
G |
Smad9 |
SMAD family member 9 |
increases expression |
EXP |
Neomycin results in increased expression of SMAD9 mRNA |
CTD |
PMID:30626089 |
|
NCBI chr 3:54,662,873...54,709,162
Ensembl chr 3:54,663,003...54,708,678
|
|
G |
Smpd2 |
sphingomyelin phosphodiesterase 2, neutral |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SMPD2 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:41,363,168...41,366,410
Ensembl chr10:41,361,638...41,366,365
|
|
G |
Sqle |
squalene epoxidase |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SQLE mRNA |
CTD |
PMID:36464106 |
|
NCBI chr15:59,186,941...59,203,042
Ensembl chr15:59,186,926...59,203,041
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide analog results in increased expression of SQSTM1 protein] |
CTD |
PMID:36535435 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
G |
Srebf2 |
sterol regulatory element binding factor 2 |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF2 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr15:82,031,455...82,089,580
Ensembl chr15:82,031,382...82,089,580
|
|
G |
Sst |
somatostatin |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide results in increased expression of SST mRNA]; [Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in increased expression of SST mRNA |
CTD |
PMID:36535435 |
|
NCBI chr16:23,708,327...23,710,041
Ensembl chr16:23,708,323...23,709,708
|
|
G |
Sstr2 |
somatostatin receptor 2 |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide results in increased expression of SSTR2 mRNA] |
CTD |
PMID:36535435 |
|
NCBI chr11:113,510,153...113,516,854
Ensembl chr11:113,510,168...113,516,854
|
|
G |
Tars1 |
threonyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TARS1 protein |
CTD |
PMID:30545405 |
|
NCBI chr15:11,383,749...11,399,744
Ensembl chr15:11,382,387...11,399,751
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
multiple interactions increases expression |
EXP |
Plant Oils inhibits the reaction [Neomycin results in increased expression of TGFB2 mRNA] |
CTD |
PMID:30626089 |
|
NCBI chr 1:186,354,984...186,441,504
Ensembl chr 1:186,354,989...186,438,186
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
EXP |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of TJP1 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of TJP1 protein] |
CTD |
PMID:35390362 |
|
NCBI chr 7:64,945,913...65,177,629
Ensembl chr 7:64,945,913...65,177,529
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TLR4 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TLR4 protein]; TLR4 gene mutant form results in decreased susceptibility to [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] |
CTD |
PMID:35390362 |
|
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Tm9sf2 |
transmembrane 9 superfamily member 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TM9SF2 protein |
CTD |
PMID:30545405 |
|
NCBI chr14:122,342,290...122,397,015
Ensembl chr14:122,344,450...122,397,016
|
|
G |
Tmed10 |
transmembrane p24 trafficking protein 10 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TMED10 protein |
CTD |
PMID:30545405 |
|
NCBI chr12:85,387,388...85,421,491
Ensembl chr12:85,387,388...85,421,621
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of TNF protein; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of and results in increased secretion of TNF protein]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TNF mRNA]; [Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; [Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Nanotubes, Carbon promotes the reaction [Doxorubicin results in increased expression of TNF protein]]; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of TNF protein] |
CTD |
PMID:31442584 PMID:32068018 PMID:35390362 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Traf6 |
TNF receptor-associated factor 6 |
multiple interactions |
EXP |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TRAF6 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TRAF6 protein] |
CTD |
PMID:35390362 |
|
NCBI chr 2:101,508,765...101,532,013
Ensembl chr 2:101,508,774...101,532,014
|
|
G |
Tubal3 |
tubulin, alpha-like 3 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TUBAL3 protein |
CTD |
PMID:30545405 |
|
NCBI chr13:3,974,695...3,985,277
Ensembl chr13:3,968,274...3,985,277
|
|
G |
Twf1 |
twinfilin actin binding protein 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TWF1 protein |
CTD |
PMID:30545405 |
|
NCBI chr15:94,475,829...94,487,727
Ensembl chr15:94,475,832...94,487,770
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
EXP |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide analog results in increased expression of TXN1 protein] |
CTD |
PMID:36535435 |
|
NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411
|
|
G |
Txndc5 |
thioredoxin domain containing 5 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TXNDC5 protein |
CTD |
PMID:30545405 |
|
NCBI chr13:38,684,242...38,712,800
Ensembl chr13:38,684,055...38,712,800
|
|
G |
Uqcrc1 |
ubiquinol-cytochrome c reductase core protein 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRC1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 9:108,765,716...108,778,709
Ensembl chr 9:108,765,701...108,778,691
|
|
G |
Uqcrfs1 |
ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRFS1 protein |
CTD |
PMID:30545405 |
|
NCBI chr13:30,724,295...30,729,299
Ensembl chr13:30,724,291...30,729,345
|
|
G |
Uqcrh |
ubiquinol-cytochrome c reductase hinge protein |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRH protein |
CTD |
PMID:30545405 |
|
NCBI chr 4:115,924,162...115,932,267
Ensembl chr 4:115,924,162...115,932,268
|
|
G |
Vdr |
vitamin D (1,25-dihydroxyvitamin D3) receptor |
multiple interactions |
EXP |
[Cephalothin co-treated with Neomycin] results in increased expression of VDR mRNA |
CTD |
PMID:24657338 |
|
NCBI chr15:97,752,308...97,806,177
Ensembl chr15:97,752,306...97,808,511
|
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
norswertianolin results in increased expression of GCLC mRNA; norswertianolin results in increased expression of GCLC protein |
CTD |
PMID:30800665 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
norswertianolin results in increased expression of HMOX1 mRNA; norswertianolin results in increased expression of HMOX1 protein |
CTD |
PMID:30800665 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
increases transport |
ISO |
ABCB11 protein results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
multiple interactions increases expression |
ISO EXP |
NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of ABCB1 mRNA] notoginsenoside R1 results in increased expression of ABCB1A mRNA |
CTD |
PMID:25472953 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcc1 |
ATP-binding cassette, sub-family C member 1 |
increases transport |
ISO |
ABCC1 protein results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
increases transport |
ISO |
ABCC2 protein results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
increases transport |
ISO |
ABCG2 protein results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
increases phosphorylation multiple interactions |
EXP |
notoginsenoside R1 results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of AKT1 protein]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:33689844 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased abundance of Glutathione]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased expression of MIR20A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Triglycerides]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IFNG protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL2 protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR126A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR21A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of TNF protein] |
CTD |
PMID:24933211 |
|
NCBI chr 7:19,430,169...19,434,326
Ensembl chr 7:19,430,034...19,433,113
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP ISO |
notoginsenoside R1 inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of APP protein modified form] notoginsenoside R1 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK8 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:24975829 PMID:25714973 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Atp5f1d |
ATP synthase F1 subunit delta |
multiple interactions |
ISO |
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein] |
CTD |
PMID:25305180 |
|
NCBI chr10:79,974,451...79,981,662
Ensembl chr10:79,974,466...79,981,652
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
EXP ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; Cyclosporine inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; notoginsenoside R1 inhibits the reaction [Excitatory Amino Acid Agonists results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein] notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased expression of BAX protein] |
CTD |
PMID:19224577 PMID:24975829 PMID:25305180 PMID:33689844 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions increases expression |
EXP ISO |
notoginsenoside R1 inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein] notoginsenoside R1 results in increased expression of BCL2 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein] |
CTD |
PMID:19224577 PMID:20023602 PMID:23170834 PMID:24975829 PMID:25305180 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bglap |
bone gamma carboxyglutamate protein |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of BGLAP mRNA] |
CTD |
PMID:26362186 |
|
NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of BID protein modified form] |
CTD |
PMID:23170834 |
|
NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]]; 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]]; Cyclosporine inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CASP3 protein modified form]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein] 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein] |
CTD |
PMID:23170834 PMID:24437944 PMID:24720662 PMID:24975829 PMID:25305180 PMID:25738436 PMID:33689844 More...
|
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP8 protein] |
CTD |
PMID:23170834 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP9 protein] |
CTD |
PMID:23170834 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased activity of CAT protein] |
CTD |
PMID:25503068 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein] |
CTD |
PMID:23170834 PMID:25472953 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Chat |
choline O-acetyltransferase |
increases expression |
EXP |
notoginsenoside R1 results in increased expression of CHAT |
CTD |
PMID:25714973 |
|
NCBI chr14:32,130,160...32,187,866
Ensembl chr14:32,130,160...32,187,946
|
|
G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of CHUK protein modified form] |
CTD |
PMID:25472953 |
|
NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
notoginsenoside R1 results in decreased activity of CYP1A2 protein |
CTD |
PMID:25834921 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp3a11 |
cytochrome P450, family 3, subfamily a, polypeptide 11 |
increases expression |
EXP |
notoginsenoside R1 results in increased expression of CYP3A11 mRNA |
CTD |
PMID:25472953 |
|
NCBI chr 5:145,791,417...145,816,664
Ensembl chr 5:145,791,236...145,816,774
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
multiple interactions increases expression |
ISO EXP |
notoginsenoside R1 results in increased phosphorylation of and results in increased activity of ESR1 protein notoginsenoside R1 results in increased expression of ESR1; notoginsenoside R1 results in increased expression of ESR1 mRNA; notoginsenoside R1 results in increased expression of ESR1 protein [1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole results in decreased activity of ESR1 protein] which results in decreased susceptibility to notoginsenoside R1; [notoginsenoside R1 co-treated with Lipopolysaccharides] results in increased expression of ESR1 protein; fulvestrant inhibits the reaction [[notoginsenoside R1 co-treated with Lipopolysaccharides] results in increased expression of ESR1 protein] |
CTD |
PMID:23170834 PMID:24720662 PMID:25738436 PMID:26362186 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
increases expression |
ISO |
notoginsenoside R1 results in increased expression of ESR2 |
CTD |
PMID:24720662 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
F3 |
coagulation factor III |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of F3 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of F3 protein] |
CTD |
PMID:9102164 |
|
NCBI chr 3:121,517,186...121,528,701
Ensembl chr 3:121,517,186...121,528,697
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of FAS mRNA] |
CTD |
PMID:23170834 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased expression of FN1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of FN1 mRNA] |
CTD |
PMID:16632126 |
|
NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO |
Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of GCLC protein] |
CTD |
PMID:24437944 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Grin1 |
glutamate receptor, ionotropic, NMDA1 (zeta 1) |
multiple interactions |
ISO |
[GRIN1 protein co-treated with GRIN2B protein] results in increased susceptibility to notoginsenoside R1 |
CTD |
PMID:19224577 |
|
NCBI chr 2:25,181,189...25,209,199
Ensembl chr 2:25,181,193...25,209,199
|
|
G |
Grin2b |
glutamate receptor, ionotropic, NMDA2B (epsilon 2) |
multiple interactions |
ISO |
[GRIN1 protein co-treated with GRIN2B protein] results in increased susceptibility to notoginsenoside R1 |
CTD |
PMID:19224577 |
|
NCBI chr 6:135,690,219...136,150,658
Ensembl chr 6:135,690,231...136,150,509
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases expression |
EXP ISO |
fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]; wortmannin inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]] notoginsenoside R1 results in increased expression of GSK3B protein modified form |
CTD |
PMID:23170834 PMID:24720662 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
EXP ISO |
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein notoginsenoside R1 results in increased expression of HMOX1; notoginsenoside R1 results in increased expression of HMOX1 protein Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of HMOX1 protein] |
CTD |
PMID:24437944 PMID:24720662 PMID:25422538 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] |
CTD |
PMID:23170834 PMID:25472953 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Ide |
insulin degrading enzyme |
multiple interactions increases expression |
EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [notoginsenoside R1 results in increased expression of IDE] |
CTD |
PMID:25714973 |
|
NCBI chr19:37,246,140...37,341,664
Ensembl chr19:37,246,142...37,340,010
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IFNG protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG protein] |
CTD |
PMID:23170834 PMID:24933211 PMID:25472953 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Ikbkb |
inhibitor of kappaB kinase beta |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IKBKB protein modified form] |
CTD |
PMID:25472953 |
|
NCBI chr 8:23,149,228...23,196,605
Ensembl chr 8:23,149,228...23,196,605
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
notoginsenoside R1 promotes the reaction [Lipopolysaccharides results in increased expression of IL10 protein] |
CTD |
PMID:23170834 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il15 |
interleukin 15 |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL15 mRNA] |
CTD |
PMID:25472953 |
|
NCBI chr 8:83,058,253...83,129,883
Ensembl chr 8:83,058,261...83,129,851
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1A mRNA] |
CTD |
PMID:25472953 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:23170834 PMID:25472953 PMID:25738436 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL2 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL2 mRNA] |
CTD |
PMID:24933211 PMID:25472953 |
|
NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL6 protein] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:17655881 PMID:23170834 PMID:24933211 PMID:25472953 PMID:25738436 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ilk |
integrin linked kinase |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Streptozocin results in increased activity of ILK protein] |
CTD |
PMID:25503068 |
|
NCBI chr 7:105,385,797...105,392,132
Ensembl chr 7:105,385,799...105,392,132
|
|
G |
Itga3 |
integrin alpha 3 |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 mRNA]; notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 protein]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGA3 mRNA]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGA3 protein] |
CTD |
PMID:25503068 |
|
NCBI chr11:94,935,301...94,967,637
Ensembl chr11:94,935,300...94,967,627
|
|
G |
Itgam |
integrin alpha M |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAM protein] |
CTD |
PMID:17655881 |
|
NCBI chr 7:127,661,812...127,717,663
Ensembl chr 7:127,661,812...127,717,663
|
|
G |
Itgb1 |
integrin beta 1 (fibronectin receptor beta) |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGB1 mRNA]; notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGB1 protein]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGB1 mRNA]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGB1 protein] |
CTD |
PMID:25503068 |
|
NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681
|
|
G |
Itgb2 |
integrin beta 2 |
decreases expression multiple interactions |
EXP ISO |
notoginsenoside R1 results in decreased expression of ITGB2 protein notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGB2 protein] |
CTD |
PMID:17655881 PMID:18176958 |
|
NCBI chr10:77,366,164...77,401,542
Ensembl chr10:77,366,086...77,401,542
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein] fulvestrant inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK1 mRNA]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16458614 PMID:16632126 PMID:24437944 PMID:24975829 PMID:25004876 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
fulvestrant inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK3 mRNA]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK3 protein] notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16458614 PMID:16632126 PMID:24437944 PMID:24975829 PMID:25004876 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:24975829 |
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:24975829 |
|
NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248
|
|
G |
Mir126a |
microRNA 126a |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR126A mRNA] |
CTD |
PMID:24933211 |
|
NCBI chr 2:26,481,369...26,481,441
Ensembl chr 2:26,481,369...26,481,441
|
|
G |
Mir20a |
microRNA 20a |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased expression of MIR20A mRNA] |
CTD |
PMID:24933211 |
|
NCBI chr14:115,281,589...115,281,695
Ensembl chr14:115,281,589...115,281,695
|
|
G |
Mir21a |
microRNA 21a |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR21A mRNA] |
CTD |
PMID:24933211 |
|
NCBI chr11:86,474,893...86,474,984
Ensembl chr11:86,474,893...86,474,984
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions decreases expression |
EXP ISO |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] notoginsenoside R1 results in decreased expression of MPO protein |
CTD |
PMID:20023602 PMID:25472953 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
affects localization multiple interactions |
EXP ISO |
notoginsenoside R1 affects the localization of NFE2L2 protein NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide affects the localization of NFE2L2 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased expression of and affects the localization of NFE2L2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 results in increased expression of and affects the localization of NFE2L2 protein]; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased expression of and affects the localization of NFE2L2 protein]; notoginsenoside R1 results in increased expression of and affects the localization of NFE2L2 protein |
CTD |
PMID:24437944 PMID:24720662 PMID:25422538 PMID:33689844 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; notoginsenoside R1 promotes the reaction [Lipopolysaccharides results in increased expression of NFKBIA mRNA] fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]; wortmannin inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]] |
CTD |
PMID:9102164 PMID:23170834 PMID:25472953 PMID:25738436 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
EXP ISO |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] [notoginsenoside R1 results in increased phosphorylation of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; notoginsenoside R1 results in increased phosphorylation of and results in increased activity of NOS2 protein |
CTD |
PMID:23170834 PMID:25472953 PMID:26045775 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NOS3 protein] |
CTD |
PMID:23170834 |
|
NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions increases expression |
ISO |
Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of NQO1 protein] |
CTD |
PMID:24437944 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases activity increases response to substance |
ISO EXP |
notoginsenoside R1 binds to and results in increased activity of NR1I2 protein; NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of UGT1A1 mRNA] notoginsenoside R1 results in increased activity of NR1I2 protein NR1I2 protein results in increased susceptibility to notoginsenoside R1 |
CTD |
PMID:25472953 |
|
NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of PARP1 protein modified form] |
CTD |
PMID:23170834 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Plat |
plasminogen activator, tissue |
increases expression multiple interactions |
ISO |
notoginsenoside R1 results in increased expression of PLAT mRNA; notoginsenoside R1 results in increased expression of PLAT protein notoginsenoside R1 results in increased expression of [PLAT protein binds to SERPINE1 protein] |
CTD |
PMID:8018658 PMID:9220151 |
|
NCBI chr 8:23,247,655...23,272,864
Ensembl chr 8:23,247,743...23,272,860
|
|
G |
Plau |
plasminogen activator, urokinase |
increases expression |
ISO |
notoginsenoside R1 results in increased expression of PLAU mRNA; notoginsenoside R1 results in increased expression of PLAU protein |
CTD |
PMID:9220151 |
|
NCBI chr14:20,886,730...20,893,456
Ensembl chr14:20,886,728...20,893,453
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions increases expression |
EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [notoginsenoside R1 results in increased expression of PPARG] |
CTD |
PMID:25714973 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
multiple interactions |
ISO |
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased phosphorylation of PPP1R12A protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:25305180 |
|
NCBI chr10:107,997,913...108,115,846
Ensembl chr10:107,998,054...108,120,336
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of APP protein modified form] |
CTD |
PMID:25714973 |
|
NCBI chr12:83,734,926...83,781,869
Ensembl chr12:83,734,926...83,781,973
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:25472953 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
EXP ISO |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of RELA protein modified form]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein modified form] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and affects the localization of RELA protein]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and affects the localization of RELA protein] |
CTD |
PMID:23170834 PMID:25472953 PMID:25738436 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of ROCK1 protein] |
CTD |
PMID:25305180 |
|
NCBI chr18:10,064,401...10,182,225
Ensembl chr18:10,064,401...10,182,045
|
|
G |
Runx2 |
runt related transcription factor 2 |
increases expression multiple interactions |
ISO |
notoginsenoside R1 results in increased expression of RUNX2 mRNA fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of RUNX2 mRNA] |
CTD |
PMID:26362186 |
|
NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684
|
|
G |
Sele |
selectin, endothelial cell |
decreases expression |
EXP |
notoginsenoside R1 results in decreased expression of SELE protein |
CTD |
PMID:18176958 |
|
NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246
|
|
G |
Serpine1 |
serine (or cysteine) peptidase inhibitor, clade E, member 1 |
multiple interactions decreases activity |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of SERPINE1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of SERPINE1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of SERPINE1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of SERPINE1 mRNA]; notoginsenoside R1 results in increased expression of [PLAT protein binds to SERPINE1 protein] notoginsenoside R1 results in decreased activity of SERPINE1 protein |
CTD |
PMID:8018658 PMID:9102164 PMID:16458614 |
|
NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family, member 1b2 |
multiple interactions |
ISO |
SLCO1B2 protein binds to and results in increased transport of notoginsenoside R1 SLCO1B3 protein binds to and results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372
|
|
G |
Sp7 |
Sp7 transcription factor 7 |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of SP7 mRNA] |
CTD |
PMID:26362186 |
|
NCBI chr15:102,265,038...102,275,498
Ensembl chr15:102,265,041...102,275,617
|
|
G |
Sparc |
secreted acidic cysteine rich glycoprotein |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of SPARC mRNA] |
CTD |
PMID:26362186 |
|
NCBI chr11:55,284,985...55,310,906
Ensembl chr11:55,285,326...55,314,009
|
|
G |
Sqstm1 |
sequestosome 1 |
affects localization multiple interactions |
EXP |
notoginsenoside R1 affects the localization of SQSTM1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 affects the localization of SQSTM1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate affects the localization of SQSTM1 protein]]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate affects the localization of SQSTM1 protein] |
CTD |
PMID:33689844 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of SERPINE1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of FN1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of SERPINE1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] notoginsenoside R1 results in decreased expression of TNF 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein] |
CTD |
PMID:9102164 PMID:16458614 PMID:16632126 PMID:20023602 PMID:23170834 PMID:24933211 PMID:25472953 PMID:25738436 More...
|
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNFRSF1A mRNA] |
CTD |
PMID:23170834 |
|
NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TRP53 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TRP53 protein] |
CTD |
PMID:23170834 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase 1 family, polypeptide A1 |
increases expression multiple interactions |
ISO EXP |
notoginsenoside R1 results in increased expression of UGT1A1 mRNA NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of UGT1A1 mRNA] |
CTD |
PMID:25472953 |
|
NCBI chr 1:88,139,681...88,147,724
Ensembl chr 1:88,139,681...88,146,719
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein] |
CTD |
PMID:23170834 |
|
NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337
|
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Isoproterenol results in increased activity of ACE protein] |
CTD |
PMID:26056852 |
|
NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790
|
|
G |
Acta2 |
actin alpha 2, smooth muscle, aorta |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Rotenone results in increased expression of ACTA2 protein] |
CTD |
PMID:36774383 |
|
NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Cholesterol, Dietary results in decreased secretion of ADIPOQ protein] |
CTD |
PMID:27019295 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Rotenone results in decreased phosphorylation of AKT1 protein]; oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:34126350 PMID:36774383 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
ISO EXP |
oleuropein inhibits the reaction [Acrolein results in increased expression of BAX mRNA]; oleuropein inhibits the reaction [Acrolein results in increased expression of BAX protein] oleuropein inhibits the reaction [Rotenone results in increased expression of BAX protein] |
CTD |
PMID:29414845 PMID:36774383 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
ISO EXP |
oleuropein inhibits the reaction [Acrolein results in decreased expression of BCL2 mRNA]; oleuropein inhibits the reaction [Acrolein results in decreased expression of BCL2 protein]; oleuropein inhibits the reaction [decamethrin results in decreased expression of BCL2 protein] oleuropein affects the reaction [Rotenone results in decreased expression of BCL2 protein] |
CTD |
PMID:28595958 PMID:29414845 PMID:36774383 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bdnf |
brain derived neurotrophic factor |
multiple interactions |
EXP |
oleuropein affects the reaction [Rotenone results in decreased expression of BDNF protein] |
CTD |
PMID:36774383 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Rotenone results in increased cleavage of CASP3 protein] |
CTD |
PMID:36774383 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cat |
catalase |
increases activity multiple interactions |
ISO EXP |
oleuropein results in increased activity of CAT protein oleuropein inhibits the reaction [Rotenone results in decreased activity of CAT protein] oleuropein inhibits the reaction [decamethrin results in decreased activity of CAT protein] |
CTD |
PMID:18823963 PMID:28595958 PMID:36774383 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Rotenone results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:36774383 |
|
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
multiple interactions |
EXP |
oleuropein inhibits the reaction [TNF protein results in increased export of CSF1R protein] |
CTD |
PMID:34126350 |
|
NCBI chr18:61,238,644...61,264,211
Ensembl chr18:61,233,670...61,265,221
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
ISO |
oleuropein results in decreased activity of CYP19A1 protein |
CTD |
PMID:17910019 |
|
NCBI chr 9:54,073,221...54,175,448
Ensembl chr 9:54,073,221...54,175,394
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Acrolein results in increased expression of DDIT3 protein] |
CTD |
PMID:29414845 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Cholesterol, Dietary results in increased expression of FASN protein] |
CTD |
PMID:27019295 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Cholesterol, Dietary results in increased activity of GPT protein]; oleuropein inhibits the reaction [decamethrin results in increased expression of GPT protein]; oleuropein inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of GPT protein] |
CTD |
PMID:26056852 PMID:27019295 PMID:28595958 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Rotenone results in decreased expression of and results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:36774383 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
Hspa5 |
heat shock protein 5 |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Acrolein results in increased expression of HSPA5 protein] |
CTD |
PMID:29414845 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] |
CTD |
PMID:12615669 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
oleuropein inhibits the reaction [TNF protein results in increased export of IL6 protein] |
CTD |
PMID:34126350 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of LDHA protein] |
CTD |
PMID:26056852 |
|
NCBI chr 7:46,491,698...46,505,051
Ensembl chr 7:46,490,899...46,505,051
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:34126350 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:34126350 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein] |
CTD |
PMID:22595400 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Doxorubicin results in increased expression of NOS2 protein] |
CTD |
PMID:17223128 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Ntrk2 |
neurotrophic tyrosine kinase, receptor, type 2 |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Rotenone results in decreased expression of and results in decreased phosphorylation of NTRK2 protein] |
CTD |
PMID:36774383 |
|
NCBI chr13:58,954,363...59,281,782
Ensembl chr13:58,954,383...59,281,784
|
|
G |
Pnlip |
pancreatic lipase |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Isoproterenol results in increased activity of PNLIP protein] |
CTD |
PMID:26056852 |
|
NCBI chr19:58,658,797...58,670,231
Ensembl chr19:58,640,930...58,670,220
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Cholesterol, Dietary results in increased expression of PPARG protein] |
CTD |
PMID:27019295 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
oleuropein inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA] oleuropein inhibits the reaction [decamethrin results in increased expression of PTGS2 protein] |
CTD |
PMID:22595400 PMID:28595958 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased localization of and results in increased activity of RELA protein] |
CTD |
PMID:22595400 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Sele |
selectin, endothelial cell |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Lipopolysaccharides results in increased expression of SELE protein] |
CTD |
PMID:12615669 |
|
NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Cholesterol, Dietary results in increased expression of SREBF1 protein] |
CTD |
PMID:27019295 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Rotenone results in decreased expression of TH protein] |
CTD |
PMID:36774383 |
|
NCBI chr 7:142,446,516...142,453,732
Ensembl chr 7:142,446,489...142,484,865
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
oleuropein inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] oleuropein inhibits the reaction [TNF protein results in increased export of CSF1R protein]; oleuropein inhibits the reaction [TNF protein results in increased export of IL6 protein]; oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]; oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:12615669 PMID:34126350 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnnt1 |
troponin T1, skeletal, slow |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of TNNT1 protein] |
CTD |
PMID:26056852 |
|
NCBI chr 7:4,507,568...4,518,974
Ensembl chr 7:4,507,569...4,519,381
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions |
ISO |
oleuropein inhibits the reaction [decamethrin results in increased expression of TP53 protein] |
CTD |
PMID:28595958 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 mRNA]; oleuropein inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]; oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of VCAM1 protein]; oleuropein inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:12615669 |
|
NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337
|
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases activity |
ISO |
pelargonidin-3-glucoside results in decreased activity of CA1 protein |
CTD |
PMID:28445001 |
|
NCBI chr 3:14,831,274...14,873,425
Ensembl chr 3:14,831,276...14,873,428
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases activity |
ISO |
pelargonidin-3-glucoside results in decreased activity of CA2 protein |
CTD |
PMID:28445001 |
|
NCBI chr 3:14,951,329...14,965,830
Ensembl chr 3:14,951,333...14,965,830
|
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases activity |
ISO |
pelargonidin-3-glucoside results in decreased activity of CA1 protein |
CTD |
PMID:28445001 |
|
NCBI chr 3:14,831,274...14,873,425
Ensembl chr 3:14,831,276...14,873,428
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases activity |
ISO |
pelargonidin-3-glucoside results in decreased activity of CA2 protein |
CTD |
PMID:28445001 |
|
NCBI chr 3:14,951,329...14,965,830
Ensembl chr 3:14,951,333...14,965,830
|
|
|
G |
Aqp3 |
aquaporin 3 |
multiple interactions |
ISO |
[malvidin-3-glucoside co-treated with petunidin-3-glucoside] results in increased expression of AQP3 mRNA |
CTD |
PMID:33294640 |
|
NCBI chr 4:41,092,724...41,098,183
Ensembl chr 4:41,092,722...41,098,183
|
|
|
G |
Abat |
4-aminobutyrate aminotransferase |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ABAT mRNA |
CTD |
PMID:22538082 |
|
NCBI chr16:8,331,293...8,439,432
Ensembl chr16:8,331,293...8,439,432
|
|
G |
Acaa1b |
acetyl-Coenzyme A acyltransferase 1B |
increases expression |
EXP |
Phlorhizin results in increased expression of ACAA1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:118,977,111...118,986,149
Ensembl chr 9:118,977,091...118,986,161
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ACAA2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr18:74,912,283...74,939,278
Ensembl chr18:74,912,268...74,939,279
|
|
G |
Acad8 |
acyl-Coenzyme A dehydrogenase family, member 8 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ACAD8 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:26,885,434...26,910,872
Ensembl chr 9:26,885,431...26,910,862
|
|
G |
Acad9 |
acyl-Coenzyme A dehydrogenase family, member 9 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ACAD9 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:36,120,128...36,147,006
Ensembl chr 3:36,120,128...36,147,002
|
|
G |
Acadl |
acyl-Coenzyme A dehydrogenase, long-chain |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ACADL mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:66,869,998...66,902,468
Ensembl chr 1:66,869,998...66,902,436
|
|
G |
Acadm |
acyl-Coenzyme A dehydrogenase, medium chain |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ACADM mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:153,627,990...153,650,280
Ensembl chr 3:153,627,994...153,650,269
|
|
G |
Acat1 |
acetyl-Coenzyme A acetyltransferase 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ACAT1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:53,491,822...53,521,650
Ensembl chr 9:53,491,822...53,521,682
|
|
G |
Aco1 |
aconitase 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ACO1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:40,143,429...40,199,011
Ensembl chr 4:40,143,081...40,198,338
|
|
G |
Acox1 |
acyl-Coenzyme A oxidase 1, palmitoyl |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ACOX1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr11:116,062,714...116,089,605
Ensembl chr11:116,062,714...116,089,871
|
|
G |
Acox2 |
acyl-Coenzyme A oxidase 2, branched chain |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ACOX2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr14:14,210,406...14,244,262
Ensembl chr14:14,210,420...14,244,262
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ACSL1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:46,924,214...46,989,088
Ensembl chr 8:46,924,074...46,989,088
|
|
G |
Actb |
actin, beta |
increases expression |
EXP |
Phlorhizin results in increased expression of ACTB mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:142,888,870...142,892,509
Ensembl chr 5:142,888,870...142,892,509
|
|
G |
Adh5 |
alcohol dehydrogenase 5 (class III), chi polypeptide |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ADH5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:138,142,961...138,161,260
Ensembl chr 3:138,148,854...138,161,260
|
|
G |
Adhfe1 |
alcohol dehydrogenase, iron containing, 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ADHFE1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:9,618,173...9,648,195
Ensembl chr 1:9,618,173...9,650,898
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of ADIPOQ mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of ADIPOQ mRNA]; [cobaltous chloride co-treated with Phlorhizin] affects the expression of ADIPOQ mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of ADIPOQ mRNA |
CTD |
PMID:32408695 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Akr1a1 |
aldo-keto reductase family 1, member A1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of AKR1A1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:116,493,707...116,508,871
Ensembl chr 4:116,493,707...116,508,877
|
|
G |
Akr7a5 |
aldo-keto reductase family 7, member A5 |
increases expression |
EXP |
Phlorhizin results in increased expression of AKR7A2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:139,038,005...139,046,097
Ensembl chr 4:139,038,055...139,045,737
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
Phlorhizin inhibits the reaction [Glucose results in decreased uptake of ALB protein] |
CTD |
PMID:16313995 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Aldh1a7 |
aldehyde dehydrogenase family 1, subfamily A7 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ALDH1A7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr19:20,670,318...20,704,920
Ensembl chr19:20,670,317...20,704,926
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2, mitochondrial |
decreases expression increases expression |
EXP |
Phlorhizin results in decreased expression of ALDH2 mRNA Phlorhizin results in increased expression of ALDH2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:121,704,090...121,731,887
Ensembl chr 5:121,704,090...121,731,887
|
|
G |
Aldh3a2 |
aldehyde dehydrogenase family 3, subfamily A2 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ALDH3A2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr11:61,114,240...61,158,267
Ensembl chr11:61,114,243...61,158,290
|
|
G |
Aldh4a1 |
aldehyde dehydrogenase 4 family, member A1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ALDH4A1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:139,348,404...139,377,002
Ensembl chr 4:139,350,177...139,377,001
|
|
G |
Aldh6a1 |
aldehyde dehydrogenase family 6, subfamily A1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ALDH6A1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr12:84,477,491...84,497,798
Ensembl chr12:84,477,491...84,497,778
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase family 7, member A1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ALDH7A1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr18:56,657,794...56,706,112
Ensembl chr18:56,642,759...56,706,023
|
|
G |
Anapc2 |
anaphase promoting complex subunit 2 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ANAPC2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:25,162,469...25,175,928
Ensembl chr 2:25,162,490...25,175,927
|
|
G |
Anapc5 |
anaphase-promoting complex subunit 5 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ANAPC5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:122,925,522...122,960,402
Ensembl chr 5:122,925,522...122,959,402
|
|
G |
Aox1 |
aldehyde oxidase 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of AOX1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:58,068,963...58,145,569
Ensembl chr 1:58,069,090...58,145,572
|
|
G |
Aox3 |
aldehyde oxidase 3 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of AOX3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:58,152,294...58,241,380
Ensembl chr 1:58,152,289...58,239,857
|
|
G |
Aph1b |
aph1 homolog B, gamma secretase subunit |
increases expression |
EXP |
Phlorhizin results in increased expression of APH1B mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:66,682,484...66,704,671
Ensembl chr 9:66,682,484...66,702,772
|
|
G |
App |
amyloid beta precursor protein |
decreases expression |
EXP |
Phlorhizin results in decreased expression of APP mRNA |
CTD |
PMID:22538082 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Atf3 |
activating transcription factor 3 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ATF3 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236
|
|
G |
Atp2a2 |
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 |
increases expression |
EXP |
Phlorhizin results in increased expression of ATP2A2 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr 5:122,591,576...122,640,288
Ensembl chr 5:122,591,576...122,640,288
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ATP5F1A mRNA |
CTD |
PMID:22538082 |
|
NCBI chr18:77,861,468...77,870,569
Ensembl chr18:77,861,429...77,870,569
|
|
G |
Atp5f1c |
ATP synthase F1 subunit gamma |
increases expression |
EXP |
Phlorhizin results in increased expression of ATP5F1C mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:10,060,841...10,085,321
Ensembl chr 2:10,060,827...10,085,321
|
|
G |
Auh |
AU RNA binding protein/enoyl-coenzyme A hydratase |
decreases expression |
EXP |
Phlorhizin results in decreased expression of AUH mRNA |
CTD |
PMID:22538082 |
|
NCBI chr13:52,989,155...53,083,742
Ensembl chr13:52,989,155...53,083,717
|
|
G |
B2m |
beta-2 microglobulin |
increases expression |
EXP |
Phlorhizin results in increased expression of B2M mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:121,978,168...121,983,563
Ensembl chr 2:121,978,167...121,983,564
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
EXP |
[2,2-bis(4-glycidyloxyphenyl)propane co-treated with Phlorhizin] promotes the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of BAD protein] |
CTD |
PMID:32408695 |
|
NCBI chr19:6,919,229...6,929,273
Ensembl chr19:6,919,229...6,929,267
|
|
G |
Bag1 |
BCL2-associated athanogene 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of BAG1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:40,936,398...40,948,294
Ensembl chr 4:40,936,398...40,948,294
|
|
G |
Bckdhb |
branched chain ketoacid dehydrogenase E1, beta polypeptide |
decreases expression |
EXP |
Phlorhizin results in decreased expression of BCKDHB mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:83,807,190...84,006,293
Ensembl chr 9:83,807,198...84,006,293
|
|
G |
Bcl2l1 |
BCL2-like 1 |
multiple interactions |
EXP |
[2,2-bis(4-glycidyloxyphenyl)propane co-treated with Phlorhizin] promotes the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of BCL2L1 protein] |
CTD |
PMID:32408695 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Birc6 |
baculoviral IAP repeat-containing 6 |
increases expression |
EXP |
Phlorhizin results in increased expression of BIRC6 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr17:74,835,247...75,010,351
Ensembl chr17:74,835,290...75,010,351
|
|
G |
Cat |
catalase |
increases expression |
EXP |
Phlorhizin results in increased expression of CAT mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of CCL2 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of CCL2 mRNA]; [cobaltous chloride co-treated with Phlorhizin] affects the expression of CCL2 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of CCL2 mRNA |
CTD |
PMID:32408695 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Cct7 |
chaperonin containing TCP1 subunit 7 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of CCT7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:85,428,487...85,445,459
Ensembl chr 6:85,428,496...85,445,457
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2, cardiac |
multiple interactions |
ISO |
Phlorhizin inhibits the reaction [Streptozocin results in increased expression of CHRM2 mRNA]; Phlorhizin inhibits the reaction [Streptozocin results in increased expression of CHRM2 protein] |
CTD |
PMID:18715473 |
|
NCBI chr 6:36,364,928...36,505,573
Ensembl chr 6:36,365,019...36,505,349
|
|
G |
Clybl |
citrate lyase beta like |
decreases expression |
EXP |
Phlorhizin results in decreased expression of CLYBL mRNA |
CTD |
PMID:22538082 |
|
NCBI chr14:122,408,289...122,639,646
Ensembl chr14:122,419,116...122,639,646
|
|
G |
Cox15 |
cytochrome c oxidase assembly protein 15 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of COX15 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr19:43,721,693...43,741,439
Ensembl chr19:43,721,693...43,741,439
|
|
G |
Cox17 |
cytochrome c oxidase assembly protein 17, copper chaperone |
decreases expression |
EXP |
Phlorhizin results in decreased expression of COX17 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr16:38,167,332...38,173,125
Ensembl chr16:38,167,353...38,182,659
|
|
G |
Cox7c |
cytochrome c oxidase subunit 7C |
increases expression |
EXP |
Phlorhizin results in increased expression of COX7C mRNA |
CTD |
PMID:22538082 |
|
NCBI chr13:86,192,917...86,194,914
Ensembl chr13:86,192,935...86,195,023
|
|
G |
Cox8a |
cytochrome c oxidase subunit 8A |
decreases expression |
EXP |
Phlorhizin results in decreased expression of COX8A mRNA |
CTD |
PMID:22538082 |
|
NCBI chr19:7,192,523...7,194,981
Ensembl chr19:7,192,518...7,194,981
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1a, liver |
decreases expression |
EXP |
Phlorhizin results in decreased expression of CPT1A mRNA |
CTD |
PMID:16123366 PMID:22538082 |
|
NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of CPT2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:107,761,179...107,780,786
Ensembl chr 4:107,761,178...107,780,807
|
|
G |
Crebbp |
CREB binding protein |
decreases expression |
EXP |
Phlorhizin results in decreased expression of CREBBP mRNA |
CTD |
PMID:22538082 |
|
NCBI chr16:3,899,198...4,031,864
Ensembl chr16:3,899,192...4,031,861
|
|
G |
Cs |
citrate synthase |
decreases expression |
EXP |
Phlorhizin results in decreased expression of CS mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:128,173,596...128,198,351
Ensembl chr10:128,173,603...128,198,348
|
|
G |
Cul1 |
cullin 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of CUL1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:47,430,516...47,503,078
Ensembl chr 6:47,430,332...47,503,073
|
|
G |
Cyb5r3 |
cytochrome b5 reductase 3 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of CYB5R3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr15:83,037,696...83,060,641
Ensembl chr15:83,037,695...83,056,793
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp2b10 |
cytochrome P450, family 2, subfamily b, polypeptide 10 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of CYP2B6 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049
|
|
G |
Cyp2d13 |
cytochrome P450, family 2, subfamily d, polypeptide 13 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of CYP2D13 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr15:82,520,951...82,526,246
Ensembl chr15:82,520,388...82,526,247
|
|
G |
Cyp2d22 |
cytochrome P450, family 2, subfamily d, polypeptide 22 |
increases expression |
EXP |
Phlorhizin results in increased expression of CYP2D6 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461
|
|
G |
Cyp2j5 |
cytochrome P450, family 2, subfamily j, polypeptide 5 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of CYP2J5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:96,517,010...96,552,391
Ensembl chr 4:96,517,010...96,552,391
|
|
G |
Cyp3a13 |
cytochrome P450, family 3, subfamily a, polypeptide 13 |
decreases expression increases expression |
EXP |
Phlorhizin results in decreased expression of CYP3A7 mRNA Phlorhizin results in increased expression of CYP3A7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881
|
|
G |
Cyp4a31 |
cytochrome P450, family 4, subfamily a, polypeptide 31 |
increases expression |
EXP |
Phlorhizin results in increased expression of CYP4A11 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:115,420,824...115,436,212
Ensembl chr 4:115,420,846...115,436,212
|
|
G |
Cyp4f14 |
cytochrome P450, family 4, subfamily f, polypeptide 14 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of CYP4F12 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr17:33,122,331...33,136,353
Ensembl chr17:33,124,044...33,136,316
|
|
G |
Dhrs4 |
dehydrogenase/reductase 4 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of DHRS4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr14:55,715,880...55,727,797
Ensembl chr14:55,716,215...55,727,797
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
decreases expression |
EXP |
Phlorhizin results in decreased expression of DLD mRNA |
CTD |
PMID:22538082 |
|
NCBI chr12:31,381,561...31,401,470
Ensembl chr12:31,381,276...31,401,452
|
|
G |
Dnaja2 |
DnaJ heat shock protein family (Hsp40) member A2 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of DNAJA2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:86,264,262...86,281,990
Ensembl chr 8:86,264,262...86,281,973
|
|
G |
Dnaja3 |
DnaJ heat shock protein family (Hsp40) member A3 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of DNAJA3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr16:4,501,934...4,525,559
Ensembl chr16:4,457,853...4,525,559
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
decreases expression increases expression |
EXP |
Phlorhizin results in decreased expression of DNAJB1 mRNA Phlorhizin results in increased expression of DNAJB1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:84,334,804...84,339,282
Ensembl chr 8:84,334,822...84,339,282
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of DNAJB4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:151,887,217...151,915,720
Ensembl chr 3:151,884,148...151,915,939
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
increases expression |
EXP |
Phlorhizin results in increased expression of DNAJB6 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:29,940,896...29,991,476
Ensembl chr 5:29,940,686...30,023,132
|
|
G |
Dnajc1 |
DnaJ heat shock protein family (Hsp40) member C1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of DNAJC1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:18,210,445...18,402,025
Ensembl chr 2:18,200,465...18,397,641
|
|
G |
Dnajc13 |
DnaJ heat shock protein family (Hsp40) member C13 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of DNAJC13 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:104,028,796...104,140,807
Ensembl chr 9:104,028,481...104,140,129
|
|
G |
Dnajc14 |
DnaJ heat shock protein family (Hsp40) member C14 |
increases expression |
EXP |
Phlorhizin results in increased expression of DNAJC14 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:128,641,423...128,655,317
Ensembl chr10:128,639,931...128,655,315
|
|
G |
Dnajc19 |
DnaJ heat shock protein family (Hsp40) member C19 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of DNAJC19 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:34,111,429...34,135,503
Ensembl chr 3:34,110,169...34,135,470
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of DNAJC3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr14:119,175,371...119,219,114
Ensembl chr14:119,175,388...119,219,109
|
|
G |
Dnajc4 |
DnaJ heat shock protein family (Hsp40) member C4 |
increases expression |
EXP |
Phlorhizin results in increased expression of DNAJC4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr19:6,965,279...6,969,954
Ensembl chr19:6,965,279...6,969,940
|
|
G |
Dnajc5 |
DnaJ heat shock protein family (Hsp40) member C5 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of DNAJC5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:181,162,141...181,194,679
Ensembl chr 2:181,162,278...181,196,926
|
|
G |
Echs1 |
enoyl Coenzyme A hydratase, short chain, 1, mitochondrial |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ECHS1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:139,685,623...139,696,334
Ensembl chr 7:139,685,623...139,696,389
|
|
G |
Ep300 |
E1A binding protein p300 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of EP300 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr15:81,470,329...81,536,273
Ensembl chr15:81,469,552...81,536,278
|
|
G |
Ephx1 |
epoxide hydrolase 1, microsomal |
decreases expression |
EXP |
Phlorhizin results in decreased expression of EPHX1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:180,817,121...180,845,134
Ensembl chr 1:180,803,775...180,848,469
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
EXP |
Phlorhizin results in decreased expression of FAS mRNA |
CTD |
PMID:16123366 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fbxw7 |
F-box and WD-40 domain protein 7 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of FBXW7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:84,721,901...84,886,505
Ensembl chr 3:84,722,575...84,886,505
|
|
G |
Fh1 |
fumarate hydratase 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of FH mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:175,428,944...175,453,201
Ensembl chr 1:175,427,940...175,453,201
|
|
G |
Fis1 |
fission, mitochondrial 1 |
increases expression |
EXP |
Phlorhizin results in increased expression of FIS1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:136,982,129...136,995,088
Ensembl chr 5:136,982,129...136,995,088
|
|
G |
Fkbp5 |
FK506 binding protein 5 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of FKBP5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr17:28,617,727...28,705,123
Ensembl chr17:28,618,068...28,736,501
|
|
G |
Fmo1 |
flavin containing monooxygenase 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of FMO1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:162,657,130...162,694,170
Ensembl chr 1:162,657,130...162,694,179
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
Phlorhizin inhibits the reaction [Streptozocin results in increased expression of G6PC1 mRNA] |
CTD |
PMID:12446591 |
|
NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
decreases expression |
EXP |
Phlorhizin results in decreased expression of GCLC mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gclm |
glutamate-cysteine ligase, modifier subunit |
decreases expression |
EXP |
Phlorhizin results in decreased expression of GCLM mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
|
|
G |
Glrx2 |
glutaredoxin 2 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of GLRX2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:143,614,787...143,625,416
Ensembl chr 1:143,592,076...143,625,414
|
|
G |
Gpd2 |
glycerol phosphate dehydrogenase 2, mitochondrial |
increases expression decreases expression |
EXP |
Phlorhizin results in increased expression of GPD2 mRNA Phlorhizin results in decreased expression of GPD2 mRNA |
CTD |
PMID:16123366 PMID:22538082 |
|
NCBI chr 2:57,127,690...57,260,731
Ensembl chr 2:57,127,647...57,260,731
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of GPX1 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Gpx7 |
glutathione peroxidase 7 |
increases expression |
EXP |
Phlorhizin results in increased expression of GPX7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:108,257,414...108,263,910
Ensembl chr 4:108,257,587...108,264,158
|
|
G |
Gsta1 |
glutathione S-transferase, alpha 1 (Ya) |
decreases expression |
EXP |
Phlorhizin results in decreased expression of GSTA5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:78,137,951...78,149,965
Ensembl chr 9:78,137,938...78,149,966
|
|
G |
Gstk1 |
glutathione S-transferase kappa 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of GSTK1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:42,222,869...42,227,375
Ensembl chr 6:42,222,869...42,227,381
|
|
G |
Gstm1 |
glutathione S-transferase, mu 1 |
decreases expression increases expression |
EXP |
Phlorhizin results in decreased expression of GSTM1 mRNA; Phlorhizin results in decreased expression of GSTM5 mRNA Phlorhizin results in increased expression of GSTM5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289
|
|
G |
Gstm2 |
glutathione S-transferase, mu 2 |
increases expression |
EXP |
Phlorhizin results in increased expression of GSTM2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:107,889,018...107,893,736
Ensembl chr 3:107,889,018...107,893,769
|
|
G |
Gstm4 |
glutathione S-transferase, mu 4 |
increases expression |
EXP |
Phlorhizin results in increased expression of GSTM4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:107,937,887...107,952,495
Ensembl chr 3:107,947,724...107,952,210
|
|
G |
Gstp1 |
glutathione S-transferase, pi 1 |
increases expression |
EXP |
Phlorhizin results in increased expression of GSTP1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985
|
|
G |
Gstt1 |
glutathione S-transferase, theta 1 |
decreases expression increases expression |
EXP |
Phlorhizin results in decreased expression of GSTT1 mRNA Phlorhizin results in increased expression of GSTT1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:75,619,647...75,634,418
Ensembl chr10:75,619,647...75,634,418
|
|
G |
Gstt2 |
glutathione S-transferase, theta 2 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of GSTT2B mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:75,667,676...75,673,253
Ensembl chr10:75,666,948...75,673,258
|
|
G |
Hacd3 |
3-hydroxyacyl-CoA dehydratase 3 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of HACD3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:64,894,265...64,929,014
Ensembl chr 9:64,894,265...64,928,975
|
|
G |
Hadhb |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta |
increases expression |
EXP |
Phlorhizin results in increased expression of HADHB mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:30,360,251...30,389,591
Ensembl chr 5:30,360,246...30,389,591
|
|
G |
Herpud1 |
homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of HERPUD1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:95,113,057...95,121,999
Ensembl chr 8:95,113,066...95,122,005
|
|
G |
Hibadh |
3-hydroxyisobutyrate dehydrogenase |
decreases expression |
EXP |
Phlorhizin results in decreased expression of HIBADH mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:52,523,215...52,617,285
Ensembl chr 6:52,523,213...52,617,374
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of HMGCS1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr13:120,151,887...120,169,796
Ensembl chr13:120,151,915...120,169,796
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of HMOX1 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hras |
Harvey rat sarcoma virus oncogene |
increases expression |
EXP |
Phlorhizin results in increased expression of HRAS mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:140,770,839...140,773,938
Ensembl chr 7:140,769,018...140,773,918
|
|
G |
Hsd17b10 |
hydroxysteroid (17-beta) dehydrogenase 10 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of HSD17B10 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr X:150,784,892...150,787,438
Ensembl chr X:150,784,841...150,787,438
|
|
G |
Hsd17b4 |
hydroxysteroid (17-beta) dehydrogenase 4 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of HSD17B4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr18:50,261,268...50,329,337
Ensembl chr18:50,261,268...50,329,336
|
|
G |
Hsp90aa1 |
heat shock protein 90, alpha (cytosolic), class A member 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of HSP90AA1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr12:110,657,470...110,662,829
Ensembl chr12:110,657,039...110,669,162
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha (cytosolic), class B member 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of HSP90AB1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr17:45,878,704...45,884,187
Ensembl chr17:45,878,701...45,884,197
|
|
G |
Hspa13 |
heat shock protein 70 family, member 13 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of HSPA13 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr16:75,552,078...75,564,575
Ensembl chr16:75,542,319...75,563,992
|
|
G |
Hspa5 |
heat shock protein 5 |
increases expression |
EXP |
Phlorhizin results in increased expression of HSPA5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Hspa8 |
heat shock protein 8 |
increases expression |
EXP |
Phlorhizin results in increased expression of HSPA8 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383
|
|
G |
Hspa9 |
heat shock protein 9 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of HSPA9 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr18:35,070,467...35,087,404
Ensembl chr18:35,070,467...35,087,410
|
|
G |
Hspb1 |
heat shock protein 1 |
increases expression |
EXP |
Phlorhizin results in increased expression of HSPB1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:135,916,773...135,918,417
Ensembl chr 5:135,916,773...135,918,417
|
|
G |
Hspb8 |
heat shock protein 8 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of HSPB8 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:116,546,550...116,560,923
Ensembl chr 5:116,546,550...116,560,923
|
|
G |
Hspd1 |
heat shock protein 1 (chaperonin) |
decreases expression |
EXP |
Phlorhizin results in decreased expression of HSPD1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:55,116,992...55,127,402
Ensembl chr 1:55,116,994...55,127,402
|
|
G |
Hspe1 |
heat shock protein 1 (chaperonin 10) |
decreases expression |
EXP |
Phlorhizin results in decreased expression of HSPE1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:55,127,307...55,130,476
Ensembl chr 1:55,127,291...55,130,466
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of HTRA2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:83,028,247...83,031,552
Ensembl chr 6:83,028,247...83,032,254
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
decreases expression |
EXP |
Phlorhizin results in decreased expression of ID1 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr 2:152,578,171...152,579,330
Ensembl chr 2:152,578,171...152,579,330
|
|
G |
Idh2 |
isocitrate dehydrogenase 2 (NADP+), mitochondrial |
increases expression |
EXP |
Phlorhizin results in increased expression of IDH2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140
|
|
G |
Idh3a |
isocitrate dehydrogenase 3 (NAD+) alpha |
decreases expression |
EXP |
Phlorhizin results in decreased expression of IDH3A mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:54,493,795...54,511,946
Ensembl chr 9:54,493,618...54,511,945
|
|
G |
Idh3b |
isocitrate dehydrogenase 3 (NAD+) beta |
decreases expression |
EXP |
Phlorhizin results in decreased expression of IDH3B mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:130,121,229...130,126,371
Ensembl chr 2:130,121,229...130,126,467
|
|
G |
Idh3g |
isocitrate dehydrogenase 3 (NAD+), gamma |
decreases expression |
EXP |
Phlorhizin results in decreased expression of IDH3G mRNA |
CTD |
PMID:22538082 |
|
NCBI chr X:72,822,569...72,830,471
Ensembl chr X:72,822,569...72,830,503
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of IL1B mRNA]; [cobaltous chloride co-treated with Phlorhizin] affects the expression of IL1B mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of IL1B mRNA |
CTD |
PMID:32408695 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of IL6 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of IL6 mRNA]; [cobaltous chloride co-treated with Phlorhizin] affects the expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of IL6 mRNA |
CTD |
PMID:32408695 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ivd |
isovaleryl coenzyme A dehydrogenase |
decreases expression |
EXP |
Phlorhizin results in decreased expression of IVD mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:118,692,475...118,713,388
Ensembl chr 2:118,692,435...118,713,390
|
|
G |
Junb |
jun B proto-oncogene |
decreases expression |
EXP |
Phlorhizin results in decreased expression of JUNB mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:85,703,538...85,705,377
Ensembl chr 8:85,701,113...85,705,347
|
|
G |
Jund |
jun D proto-oncogene |
increases expression |
EXP |
Phlorhizin results in increased expression of JUND mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:71,150,389...71,153,265
Ensembl chr 8:71,151,599...71,153,265
|
|
G |
Kcnj11 |
potassium inwardly rectifying channel, subfamily J, member 11 |
increases expression |
EXP |
Phlorhizin results in increased expression of KCNJ11 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr 7:45,746,545...45,750,215
Ensembl chr 7:45,743,377...45,750,188
|
|
G |
Keap1 |
kelch-like ECH-associated protein 1 |
increases expression |
EXP |
Phlorhizin results in increased expression of KEAP1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
|
|
G |
Kras |
Kirsten rat sarcoma viral oncogene homolog |
decreases expression |
EXP |
Phlorhizin results in decreased expression of KRAS mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:145,162,425...145,197,631
Ensembl chr 6:145,162,425...145,195,965
|
|
G |
Lep |
leptin |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of LEP mRNA]; [2,2-bis(4-glycidyloxyphenyl)propane co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of LEP mRNA; [cobaltous chloride co-treated with Phlorhizin] affects the expression of LEP mRNA |
CTD |
PMID:32408695 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Maf |
MAF bZIP transcription factor |
decreases expression |
EXP |
Phlorhizin results in decreased expression of MAF mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:116,429,992...116,433,633
Ensembl chr 8:116,409,681...116,434,533
|
|
G |
Mafg |
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein G (avian) |
decreases expression |
EXP |
Phlorhizin results in decreased expression of MAFG mRNA |
CTD |
PMID:22538082 |
|
NCBI chr11:120,515,943...120,525,771
Ensembl chr11:120,515,943...120,524,426
|
|
G |
Maob |
monoamine oxidase B |
decreases expression |
EXP |
Phlorhizin results in decreased expression of MAOB mRNA |
CTD |
PMID:22538082 |
|
NCBI chr X:16,575,520...16,683,605
Ensembl chr X:16,575,521...16,683,605
|
|
G |
Map2k2 |
mitogen-activated protein kinase kinase 2 |
increases expression |
EXP |
Phlorhizin results in increased expression of MAP2K2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:80,941,749...80,960,531
Ensembl chr10:80,941,749...80,969,809
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
increases expression |
EXP |
Phlorhizin results in increased expression of MAP2K6 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr11:110,289,928...110,416,348
Ensembl chr11:110,289,948...110,416,348
|
|
G |
Map2k7 |
mitogen-activated protein kinase kinase 7 |
increases expression |
EXP |
Phlorhizin results in increased expression of MAP2K7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:4,288,740...4,297,897
Ensembl chr 8:4,288,740...4,297,897 Ensembl chr 8:4,288,740...4,297,897
|
|
G |
Map3k7 |
mitogen-activated protein kinase kinase kinase 7 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of MAP3K7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:31,963,659...32,023,470
Ensembl chr 4:31,964,097...32,023,467
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
increases expression |
EXP |
Phlorhizin results in increased expression of MAPK3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of MAPK9 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248
|
|
G |
Mccc2 |
methylcrotonoyl-Coenzyme A carboxylase 2 (beta) |
decreases expression |
EXP |
Phlorhizin results in decreased expression of MCCC2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr13:100,085,040...100,152,147
Ensembl chr13:100,085,038...100,152,147
|
|
G |
Mdm2 |
transformed mouse 3T3 cell double minute 2 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of MDM2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663
|
|
G |
Med20 |
mediator complex subunit 20 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of MED20 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr17:47,922,510...47,935,176
Ensembl chr17:47,922,507...47,935,343
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
increases expression |
EXP |
Phlorhizin results in increased expression of MGST1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:138,117,525...138,133,753
Ensembl chr 6:138,117,314...138,133,753
|
|
G |
Mmut |
methylmalonyl-Coenzyme A mutase |
decreases expression |
EXP |
Phlorhizin results in decreased expression of MMUT mRNA |
CTD |
PMID:22538082 |
|
NCBI chr17:41,245,576...41,272,880
Ensembl chr17:41,245,576...41,272,879
|
|
G |
Myl9 |
myosin, light polypeptide 9, regulatory |
decreases phosphorylation |
ISO |
Phlorhizin results in decreased phosphorylation of MYL9 protein |
CTD |
PMID:17272349 |
|
NCBI chr 2:156,617,373...156,623,578
Ensembl chr 2:156,617,340...156,623,578
|
|
G |
Ndufa12 |
NADH:ubiquinone oxidoreductase subunit A12 |
increases expression |
EXP |
Phlorhizin results in increased expression of NDUFA12 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:94,034,897...94,057,302
Ensembl chr10:94,034,582...94,057,305
|
|
G |
Ndufa2 |
NADH:ubiquinone oxidoreductase subunit A2 |
increases expression |
EXP |
Phlorhizin results in increased expression of NDUFA2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr18:36,875,385...36,877,640
Ensembl chr18:36,875,385...36,877,610
|
|
G |
Ndufa3 |
NADH:ubiquinone oxidoreductase subunit A3 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of NDUFA3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:3,620,372...3,623,162
Ensembl chr 7:3,620,372...3,623,326
|
|
G |
Ndufa7 |
NADH:ubiquinone oxidoreductase subunit A7 |
increases expression |
EXP |
Phlorhizin results in increased expression of NDUFA7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr17:34,043,546...34,057,290
Ensembl chr17:34,043,546...34,057,291
|
|
G |
Ndufab1 |
NADH:ubiquinone oxidoreductase subunit AB1 |
increases expression |
EXP |
Phlorhizin results in increased expression of NDUFAB1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:121,686,038...121,701,071
Ensembl chr 7:121,684,626...121,701,109
|
|
G |
Ndufaf1 |
NADH:ubiquinone oxidoreductase complex assembly factor 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of NDUFAF1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:119,485,927...119,493,302
Ensembl chr 2:119,485,927...119,493,308
|
|
G |
Ndufb6 |
NADH:ubiquinone oxidoreductase subunit B6 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of NDUFB6 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:40,270,591...40,279,421
Ensembl chr 4:40,270,591...40,279,421
|
|
G |
Ndufs1 |
NADH:ubiquinone oxidoreductase core subunit S1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of NDUFS1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:63,182,751...63,215,981
Ensembl chr 1:63,182,755...63,215,992
|
|
G |
Ndufs4 |
NADH:ubiquinone oxidoreductase core subunit S4 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of NDUFS4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr13:114,424,331...114,524,630
Ensembl chr13:114,424,331...114,524,794
|
|
G |
Ndufs5 |
NADH:ubiquinone oxidoreductase core subunit S5 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of NDUFS5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:123,606,503...123,611,979
Ensembl chr 4:123,606,503...123,611,995
|
|
G |
Ndufs8 |
NADH:ubiquinone oxidoreductase core subunit S8 |
increases expression |
EXP |
Phlorhizin results in increased expression of NDUFS8 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr19:3,958,863...3,962,774
Ensembl chr19:3,958,863...3,962,774
|
|
G |
Nedd4 |
neural precursor cell expressed, developmentally down-regulated 4 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of NEDD4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:72,569,613...72,657,133
Ensembl chr 9:72,569,628...72,657,134
|
|
G |
Neurod1 |
neurogenic differentiation 1 |
increases expression |
EXP |
Phlorhizin results in increased expression of NEUROD1 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr 2:79,282,981...79,286,980
Ensembl chr 2:79,282,865...79,287,095
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of NFE2L2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
EXP |
[Phlorhizin co-treated with 2,2-bis(4-glycidyloxyphenyl)propane co-treated with cobaltous chloride] affects the expression of NFKB1 mRNA |
CTD |
PMID:32408695 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nkx6-1 |
NK6 homeobox 1 |
increases expression |
EXP |
Phlorhizin results in increased expression of NKX6-1 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr 5:101,807,050...101,812,577
Ensembl chr 5:101,806,005...101,812,862
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
multiple interactions decreases expression |
ISO |
Phlorhizin inhibits the reaction [Hydrogen Peroxide results in increased expression of NOS3 mRNA] Phlorhizin results in decreased expression of NOS3 mRNA |
CTD |
PMID:20021702 |
|
NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472
|
|
G |
Nras |
neuroblastoma ras oncogene |
decreases expression |
EXP |
Phlorhizin results in decreased expression of NRAS mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:102,965,643...102,975,230
Ensembl chr 3:102,965,601...102,975,230
|
|
G |
Ogdh |
oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) |
decreases expression |
EXP |
Phlorhizin results in decreased expression of OGDH mRNA |
CTD |
PMID:22538082 |
|
NCBI chr11:6,241,597...6,309,094
Ensembl chr11:6,241,633...6,306,642
|
|
G |
Park7 |
Parkinson disease (autosomal recessive, early onset) 7 |
increases expression |
EXP |
Phlorhizin results in increased expression of PARK7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:150,981,590...150,994,378
Ensembl chr 4:150,981,590...150,998,894
|
|
G |
Pcca |
propionyl-Coenzyme A carboxylase, alpha polypeptide |
decreases expression |
EXP |
Phlorhizin results in decreased expression of PCCA mRNA |
CTD |
PMID:22538082 |
|
NCBI chr14:122,721,822...123,127,372
Ensembl chr14:122,771,736...123,128,512
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1, cytosolic |
decreases expression |
EXP |
Phlorhizin results in decreased expression of PCK1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066
|
|
G |
Pcx |
pyruvate carboxylase |
increases expression decreases expression |
EXP |
Phlorhizin results in increased expression of PCX mRNA Phlorhizin results in decreased expression of PC mRNA |
CTD |
PMID:16123366 PMID:22538082 |
|
NCBI chr19:4,560,500...4,671,780
Ensembl chr19:4,560,500...4,671,780
|
|
G |
Pecr |
peroxisomal trans-2-enoyl-CoA reductase |
increases expression decreases expression |
EXP |
Phlorhizin results in increased expression of PECR mRNA Phlorhizin results in decreased expression of PECR mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:72,298,331...72,323,480
Ensembl chr 1:72,298,326...72,323,473
|
|
G |
Pik3c2a |
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha |
decreases expression |
EXP |
Phlorhizin results in decreased expression of PIK3C2A mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:115,936,500...116,042,693
Ensembl chr 7:115,936,500...116,042,684
|
|
G |
Pik3c3 |
phosphatidylinositol 3-kinase catalytic subunit type 3 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of PIK3C3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr18:30,390,441...30,481,179
Ensembl chr18:30,405,800...30,481,179
|
|
G |
Pink1 |
PTEN induced putative kinase 1 |
increases expression |
EXP |
Phlorhizin results in increased expression of PINK1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:138,040,718...138,053,631
Ensembl chr 4:138,040,720...138,053,618
|
|
G |
Prdx1 |
peroxiredoxin 1 |
increases expression |
EXP |
Phlorhizin results in increased expression of PRDX1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:116,542,796...116,557,196
Ensembl chr 4:116,542,741...116,558,019
|
|
G |
Prdx5 |
peroxiredoxin 5 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of PRDX5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr19:6,884,065...6,887,474
Ensembl chr19:6,884,065...6,887,474
|
|
G |
Prkch |
protein kinase C, eta |
increases expression |
EXP |
Phlorhizin results in increased expression of PRKCH mRNA |
CTD |
PMID:22538082 |
|
NCBI chr12:73,631,570...73,824,959
Ensembl chr12:73,631,570...73,824,959
|
|
G |
Prkci |
protein kinase C, iota |
decreases expression |
EXP |
Phlorhizin results in decreased expression of PRKCI mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:31,049,893...31,106,889
Ensembl chr 3:31,049,896...31,107,108
|
|
G |
Prkd3 |
protein kinase D3 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of PRKD3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr17:79,256,834...79,328,245
Ensembl chr17:79,256,834...79,328,245
|
|
G |
Psma4 |
proteasome subunit alpha 4 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of PSMA4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:54,858,074...54,865,316
Ensembl chr 9:54,858,074...54,865,314
|
|
G |
Psmb1 |
proteasome (prosome, macropain) subunit, beta type 1 |
increases expression |
EXP |
Phlorhizin results in increased expression of PSMB1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr17:15,695,983...15,718,538
Ensembl chr17:15,695,283...15,720,013
|
|
G |
Psmb2 |
proteasome (prosome, macropain) subunit, beta type 2 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of PSMB2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:126,571,460...126,603,503
Ensembl chr 4:126,571,423...126,603,507
|
|
G |
Psmc1 |
protease (prosome, macropain) 26S subunit, ATPase 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of PSMC1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr12:100,076,461...100,089,623
Ensembl chr12:100,076,413...100,089,664
|
|
G |
Psmc4 |
proteasome (prosome, macropain) 26S subunit, ATPase, 4 |
increases expression decreases expression |
EXP |
Phlorhizin results in increased expression of PSMC4 mRNA Phlorhizin results in decreased expression of PSMC4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:27,741,127...27,749,517
Ensembl chr 7:27,741,132...27,749,526
|
|
G |
Psmc6 |
proteasome (prosome, macropain) 26S subunit, ATPase, 6 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of PSMC6 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr14:45,567,285...45,587,150
Ensembl chr14:45,567,245...45,587,162
|
|
G |
Psmd10 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 10 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of PSMD10 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr X:139,849,174...139,857,460
Ensembl chr X:139,849,178...139,857,477
|
|
G |
Psmd12 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 12 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of PSMD12 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr11:107,370,354...107,388,862
Ensembl chr11:107,370,310...107,395,188
|
|
G |
Psmd14 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of PSMD14 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:61,542,038...61,630,720
Ensembl chr 2:61,542,038...61,630,720
|
|
G |
Psmd4 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 4 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of PSMD4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:94,939,999...94,949,880
Ensembl chr 3:94,940,005...94,949,925
|
|
G |
Psmd6 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 6 |
increases expression |
EXP |
Phlorhizin results in increased expression of PSMD6 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr14:8,348,818...8,357,578
Ensembl chr14:8,348,779...8,357,589
|
|
G |
Psmd7 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 7 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of PSMD7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:108,307,012...108,315,114
Ensembl chr 8:108,307,013...108,315,096
|
|
G |
Psmd9 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 9 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of PSMD9 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:123,366,253...123,388,189
Ensembl chr 5:123,307,476...123,388,194
|
|
G |
Raf1 |
v-raf-leukemia viral oncogene 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of RAF1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:115,595,530...115,653,596
Ensembl chr 6:115,595,028...115,653,596
|
|
G |
Rdh14 |
retinol dehydrogenase 14 (all-trans and 9-cis) |
increases expression |
EXP |
Phlorhizin results in increased expression of RDH14 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr12:10,440,752...10,445,562
Ensembl chr12:10,440,772...10,445,562
|
|
G |
S100a6 |
S100 calcium binding protein A6 (calcyclin) |
decreases expression |
EXP |
Phlorhizin results in decreased expression of S100A6 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr 3:90,520,491...90,531,797
Ensembl chr 3:90,520,189...90,531,488
|
|
G |
Sdha |
succinate dehydrogenase complex, subunit A, flavoprotein (Fp) |
decreases expression |
EXP |
Phlorhizin results in decreased expression of SDHA mRNA |
CTD |
PMID:22538082 |
|
NCBI chr13:74,470,374...74,498,359
Ensembl chr13:74,470,373...74,498,399
|
|
G |
Sdhb |
succinate dehydrogenase complex, subunit B, iron sulfur (Ip) |
increases expression |
EXP |
Phlorhizin results in increased expression of SDHB mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:140,688,582...140,706,509
Ensembl chr 4:140,688,514...140,706,504
|
|
G |
Sds |
serine dehydratase |
decreases expression |
EXP |
Phlorhizin results in decreased expression of SDS mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:120,614,612...120,621,997
Ensembl chr 5:120,614,591...120,621,997
|
|
G |
Slc2a2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
increases expression |
EXP |
Phlorhizin results in increased expression of SLC2A2 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr 3:28,752,052...28,782,510
Ensembl chr 3:28,752,052...28,785,508
|
|
G |
Slc35a2 |
solute carrier family 35 (UDP-galactose transporter), member A2 |
increases expression |
EXP |
Phlorhizin results in increased expression of SLC35A2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr X:7,750,189...7,760,699
Ensembl chr X:7,750,267...7,760,731
|
|
G |
Slc5a1 |
solute carrier family 5 (sodium/glucose cotransporter), member 1 |
multiple interactions decreases activity affects binding |
ISO EXP |
Phlorhizin inhibits the reaction [[Sodium co-treated with SLC5A1 protein] results in increased uptake of methylglucoside]; Phlorhizin inhibits the reaction [SLC5A1 protein results in increased uptake of methylglucoside] [Phlorhizin results in decreased activity of SLC5A1 protein] which results in decreased uptake of spiraeoside [Phlorhizin results in decreased activity of SLC5A1 protein] which results in decreased uptake of Glucose SLC5A1 protein binds to Phlorhizin |
CTD |
PMID:12663055 PMID:12927799 PMID:16300400 PMID:17288452 PMID:17983207 |
|
NCBI chr 5:33,261,563...33,320,043
Ensembl chr 5:33,261,563...33,320,214
|
|
G |
Slc5a2 |
solute carrier family 5 (sodium/glucose cotransporter), member 2 |
decreases activity |
ISO |
Phlorhizin results in decreased activity of SLC5A2 protein |
CTD |
PMID:21128592 |
|
NCBI chr 7:127,864,855...127,871,602
Ensembl chr 7:127,864,829...127,871,602
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
increases expression |
EXP |
Phlorhizin results in increased expression of SOD1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
decreases expression |
EXP |
Phlorhizin results in decreased expression of SOD2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of STIP1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr19:6,998,064...7,017,394
Ensembl chr19:6,998,070...7,017,335
|
|
G |
Sucla2 |
succinate-Coenzyme A ligase, ADP-forming, beta subunit |
decreases expression |
EXP |
Phlorhizin results in decreased expression of SUCLA2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr14:73,790,226...73,833,584
Ensembl chr14:73,762,759...73,833,582
|
|
G |
Suclg2 |
succinate-Coenzyme A ligase, GDP-forming, beta subunit |
decreases expression |
EXP |
Phlorhizin results in decreased expression of SUCLG2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:95,449,992...95,695,799
Ensembl chr 6:95,449,990...95,695,781
|
|
G |
Sugt1 |
SGT1, suppressor of G2 allele of SKP1 (S. cerevisiae) |
decreases expression |
EXP |
Phlorhizin results in decreased expression of SUGT1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr14:79,825,100...79,868,237
Ensembl chr14:79,825,131...79,872,636
|
|
G |
Txn1 |
thioredoxin 1 |
decreases expression increases expression |
EXP |
Phlorhizin results in decreased expression of TXN mRNA Phlorhizin results in increased expression of TXN mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411
|
|
G |
Txn2 |
thioredoxin 2 |
increases expression |
EXP |
Phlorhizin results in increased expression of TXN2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr15:77,799,251...77,813,194
Ensembl chr15:77,799,247...77,813,206
|
|
G |
Ubb |
ubiquitin B |
increases expression |
EXP |
Phlorhizin results in increased expression of UBB mRNA |
CTD |
PMID:22538082 |
|
NCBI chr11:62,442,329...62,444,037
Ensembl chr11:62,441,997...62,444,039
|
|
G |
Ubc |
ubiquitin C |
decreases expression |
EXP |
Phlorhizin results in decreased expression of UBC mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:125,463,029...125,467,081
Ensembl chr 5:125,463,029...125,467,266
|
|
G |
Ube2b |
ubiquitin-conjugating enzyme E2B |
decreases expression |
EXP |
Phlorhizin results in decreased expression of UBE2B mRNA |
CTD |
PMID:22538082 |
|
NCBI chr11:51,875,965...51,894,972
Ensembl chr11:51,876,324...51,891,589
|
|
G |
Ube2f |
ubiquitin-conjugating enzyme E2F (putative) |
decreases expression |
EXP |
Phlorhizin results in decreased expression of UBE2F mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:91,177,412...91,214,243
Ensembl chr 1:91,178,026...91,218,059
|
|
G |
Ube2h |
ubiquitin-conjugating enzyme E2H |
decreases expression |
EXP |
Phlorhizin results in decreased expression of UBE2H mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:30,211,288...30,304,538
Ensembl chr 6:30,211,288...30,304,538
|
|
G |
Ube2i |
ubiquitin-conjugating enzyme E2I |
decreases expression |
EXP |
Phlorhizin results in decreased expression of UBE2I mRNA |
CTD |
PMID:22538082 |
|
NCBI chr17:25,479,484...25,494,965
Ensembl chr17:25,479,482...25,493,856
|
|
G |
Ube2l3 |
ubiquitin-conjugating enzyme E2L 3 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of UBE2L3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr16:16,969,879...17,019,363
Ensembl chr16:16,969,877...17,020,513
|
|
G |
Ube2m |
ubiquitin-conjugating enzyme E2M |
increases expression |
EXP |
Phlorhizin results in increased expression of UBE2M mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:12,769,047...12,772,202
Ensembl chr 7:12,769,047...12,772,202
|
|
G |
Ube2n |
ubiquitin-conjugating enzyme E2N |
decreases expression |
EXP |
Phlorhizin results in decreased expression of UBE2N mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:95,351,024...95,381,520
Ensembl chr10:95,351,007...95,381,519
|
|
G |
Ube2q1 |
ubiquitin-conjugating enzyme E2Q family member 1 |
increases expression |
EXP |
Phlorhizin results in increased expression of UBE2Q1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:89,680,905...89,691,304
Ensembl chr 3:89,680,923...89,691,307
|
|
G |
Ube2r2 |
ubiquitin-conjugating enzyme E2R 2 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of UBE2R2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:41,136,021...41,193,370
Ensembl chr 4:41,135,743...41,193,380
|
|
G |
Ube2v2 |
ubiquitin-conjugating enzyme E2 variant 2 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of UBE2V2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr16:15,368,850...15,412,382
Ensembl chr16:15,369,941...15,413,637
|
|
G |
Ube4a |
ubiquitination factor E4A |
increases expression |
EXP |
Phlorhizin results in increased expression of UBE4A mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:44,834,425...44,877,021
Ensembl chr 9:44,834,425...44,876,898
|
|
G |
Ubr2 |
ubiquitin protein ligase E3 component n-recognin 2 |
increases expression |
EXP |
Phlorhizin results in increased expression of UBR2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr17:47,239,217...47,321,812
Ensembl chr17:47,239,221...47,321,482
|
|
G |
Uchl3 |
ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase) |
decreases expression |
EXP |
Phlorhizin results in decreased expression of UCHL3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr14:101,891,387...101,933,561
Ensembl chr14:101,891,403...101,933,561
|
|
G |
Uchl5 |
ubiquitin carboxyl-terminal esterase L5 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of UCHL5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:143,652,993...143,683,204
Ensembl chr 1:143,653,010...143,683,204
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase 1 family, polypeptide A1 |
decreases activity |
ISO |
Phlorhizin results in decreased activity of UGT1A1 protein |
CTD |
PMID:35868516 |
|
NCBI chr 1:88,139,681...88,147,724
Ensembl chr 1:88,139,681...88,146,719
|
|
G |
Ugt1a10 |
UDP glycosyltransferase 1 family, polypeptide A10 |
decreases activity |
ISO |
Phlorhizin results in decreased activity of UGT1A10 protein |
CTD |
PMID:35868516 |
|
NCBI chr 1:87,983,133...88,147,724
Ensembl chr 1:87,983,110...88,146,726
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
decreases activity |
ISO |
Phlorhizin results in decreased activity of UGT1A3 protein |
CTD |
PMID:35868516 |
|
NCBI chr 1:88,128,333...88,147,724
Ensembl chr 1:88,128,323...88,146,719
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase 1 family, polypeptide A9 |
decreases activity |
ISO |
Phlorhizin results in decreased activity of UGT1A9 protein |
CTD |
PMID:35868516 |
|
NCBI chr 1:87,998,501...88,147,724
Ensembl chr 1:87,998,522...88,146,719
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
decreases activity |
ISO |
Phlorhizin results in decreased activity of UGT2B17 protein |
CTD |
PMID:35868516 |
|
NCBI chr 5:87,064,498...87,074,362
Ensembl chr 5:87,064,497...87,074,389
|
|
G |
Ugt2b34 |
UDP glucuronosyltransferase 2 family, polypeptide B34 |
decreases activity |
ISO |
Phlorhizin results in decreased activity of UGT2B7 protein |
CTD |
PMID:35868516 |
|
NCBI chr 5:87,037,613...87,054,805
Ensembl chr 5:87,037,626...87,054,796
|
|
G |
Uqcrc2 |
ubiquinol cytochrome c reductase core protein 2 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of UQCRC2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:120,234,412...120,258,746
Ensembl chr 7:120,234,399...120,258,747
|
|
G |
Usp1 |
ubiquitin specific peptidase 1 |
increases expression |
EXP |
Phlorhizin results in increased expression of USP1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:98,812,047...98,823,780
Ensembl chr 4:98,812,047...98,823,780
|
|
G |
Usp14 |
ubiquitin specific peptidase 14 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of USP14 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr18:9,993,615...10,030,149
Ensembl chr18:9,993,066...10,045,119
|
|
G |
Usp19 |
ubiquitin specific peptidase 19 |
increases expression |
EXP |
Phlorhizin results in increased expression of USP19 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:108,367,806...108,379,536
Ensembl chr 9:108,367,801...108,379,536
|
|
G |
Usp24 |
ubiquitin specific peptidase 24 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of USP24 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:106,173,179...106,303,798
Ensembl chr 4:106,173,417...106,298,519
|
|
G |
Usp33 |
ubiquitin specific peptidase 33 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of USP33 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:152,051,797...152,099,254
Ensembl chr 3:152,052,115...152,099,254
|
|
G |
Usp4 |
ubiquitin specific peptidase 4 (proto-oncogene) |
increases expression |
EXP |
Phlorhizin results in increased expression of USP4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:108,223,763...108,269,744
Ensembl chr 9:108,225,052...108,269,744
|
|
G |
Usp45 |
ubiquitin specific petidase 45 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of USP45 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:21,767,161...21,837,872
Ensembl chr 4:21,767,156...21,837,872
|
|
G |
Usp46 |
ubiquitin specific peptidase 46 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of USP46 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:74,159,387...74,229,070
Ensembl chr 5:74,159,114...74,229,092
|
|
G |
Usp7 |
ubiquitin specific peptidase 7 |
decreases expression |
EXP |
Phlorhizin results in decreased expression of USP7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr16:8,506,586...8,574,931
Ensembl chr16:8,507,459...8,610,172
|
|
G |
Usp9x |
ubiquitin specific peptidase 9, X chromosome |
decreases expression |
EXP |
Phlorhizin results in decreased expression of USP9X mRNA |
CTD |
PMID:22538082 |
|
NCBI chr X:12,937,221...13,039,567
Ensembl chr X:12,937,737...13,039,567
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] results in increased expression of VEGFA mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of VEGFA mRNA]; [cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] results in increased expression of VEGFA mRNA; [cobaltous chloride co-treated with Phlorhizin] affects the expression of VEGFA mRNA |
CTD |
PMID:32408695 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
EXP |
Phlorhizin results in decreased expression of XIAP mRNA |
CTD |
PMID:22538082 |
|
NCBI chr X:41,148,483...41,198,541
Ensembl chr X:41,148,556...41,198,533
|
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
isosalipurposide results in increased expression of HMOX1 protein |
CTD |
PMID:26028482 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions |
ISO |
MAPK1 protein affects the reaction [isosalipurposide affects the localization of NFE2L2 protein] |
CTD |
PMID:26028482 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions |
ISO |
MAPK3 protein affects the reaction [isosalipurposide affects the localization of NFE2L2 protein] |
CTD |
PMID:26028482 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
affects localization multiple interactions |
ISO |
isosalipurposide affects the localization of NFE2L2 protein MAPK1 protein affects the reaction [isosalipurposide affects the localization of NFE2L2 protein]; MAPK3 protein affects the reaction [isosalipurposide affects the localization of NFE2L2 protein] |
CTD |
PMID:26028482 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
multiple interactions increases activity |
ISO |
2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide inhibits the reaction [picrocrocin results in increased activity of TRPA1 protein] |
CTD |
PMID:30636360 |
|
NCBI chr 1:14,942,868...14,989,086
Ensembl chr 1:14,942,872...14,989,086
|
|
|
G |
Acat2 |
acetyl-Coenzyme A acetyltransferase 2 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of ACAT2 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr17:13,161,929...13,179,612
Ensembl chr17:13,161,777...13,179,634
|
|
G |
Apoa1 |
apolipoprotein A-I |
increases secretion |
ISO |
isoquercitrin results in increased secretion of APOA1 protein |
CTD |
PMID:24963805 |
|
NCBI chr 9:46,139,928...46,141,767
Ensembl chr 9:46,139,878...46,141,764
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression |
ISO |
isoquercitrin results in increased expression of ATF6 mRNA |
CTD |
PMID:30365939 |
|
NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340
|
|
G |
Atxn2 |
ataxin 2 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of ATXN2 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 5:121,849,794...121,954,372
Ensembl chr 5:121,849,400...121,954,556
|
|
G |
Atxn3 |
ataxin 3 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of ATXN3 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr12:101,885,160...101,928,139
Ensembl chr12:101,885,160...101,924,505
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
decreases expression |
ISO |
isoquercitrin results in decreased expression of BCL2 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Casp3 |
caspase 3 |
affects expression |
ISO |
isoquercitrin affects the expression of CASP3 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp8 |
caspase 8 |
decreases expression |
ISO |
isoquercitrin results in decreased expression of CASP8 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid co-treated with isoquercitrin analog] results in increased expression of CAT mRNA; isoquercitrin inhibits the reaction [Streptozocin results in decreased activity of CAT protein] |
CTD |
PMID:30298849 PMID:30817903 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CCL2 mRNA] |
CTD |
PMID:21295105 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Carrageenan results in increased expression of CCL5 protein] |
CTD |
PMID:14654164 |
|
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Cdkn2b |
cyclin dependent kinase inhibitor 2B |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CDKN2B mRNA] |
CTD |
PMID:21295105 |
|
NCBI chr 4:89,224,526...89,229,269
Ensembl chr 4:89,224,536...89,229,276
|
|
G |
Ctnnb1 |
catenin beta 1 |
affects expression |
ISO |
isoquercitrin affects the expression of CTNNB1 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
increases expression |
ISO |
isoquercitrin results in increased expression of CXCL8 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Carrageenan results in increased expression of CXCL2 protein] |
CTD |
PMID:14654164 |
|
NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity |
ISO |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of CYP1A1 mRNA isoquercitrin results in decreased activity of CYP1A1 protein |
CTD |
PMID:16271822 PMID:20033131 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of CYP1A2 mRNA |
CTD |
PMID:20033131 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
isoquercitrin results in decreased activity of CYP1B1 protein |
CTD |
PMID:16271822 |
|
NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490
|
|
G |
Cyp2b13 |
cytochrome P450, family 2, subfamily b, polypeptide 13 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP2B2 mRNA] |
CTD |
PMID:20033131 |
|
NCBI chr 7:25,760,813...25,795,622
Ensembl chr 7:25,760,922...25,795,622
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of CYP51A1 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 5:4,130,674...4,154,697
Ensembl chr 5:4,131,145...4,154,746
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of DHCR7 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 7:143,376,827...143,402,147
Ensembl chr 7:143,376,882...143,402,147
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:26109002 |
|
NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:26109002 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Egln1 |
egl-9 family hypoxia-inducible factor 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of EGLN1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 8:125,635,325...125,676,063
Ensembl chr 8:125,635,326...125,676,063
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of FDFT1 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr14:63,382,599...63,419,136
Ensembl chr14:63,382,599...63,417,027
|
|
G |
Fdps |
farnesyl diphosphate synthetase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of FDPS mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 3:89,000,895...89,009,274
Ensembl chr 3:89,000,895...89,009,266
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
multiple interactions |
ISO |
[isoquercitrin analog co-treated with Propylthiouracil] results in decreased expression of FOS mRNA |
CTD |
PMID:31068541 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of GPX2 mRNA |
CTD |
PMID:20033131 |
|
NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273
|
|
G |
Gria3 |
glutamate receptor, ionotropic, AMPA3 (alpha 3) |
multiple interactions |
ISO |
isoquercitrin analog inhibits the reaction [Propylthiouracil results in increased expression of GRIA3 mRNA] |
CTD |
PMID:31068541 |
|
NCBI chr X:40,489,351...40,767,478
Ensembl chr X:40,489,731...40,767,478
|
|
G |
Gsta1 |
glutathione S-transferase, alpha 1 (Ya) |
multiple interactions |
ISO |
[isoquercitrin co-treated with oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of GSTA5 mRNA] |
CTD |
PMID:20033131 PMID:20045035 |
|
NCBI chr 9:78,137,951...78,149,965
Ensembl chr 9:78,137,938...78,149,966
|
|
G |
Gstm1 |
glutathione S-transferase, mu 1 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of GSTM1 mRNA; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of GSTM1 mRNA] |
CTD |
PMID:20033131 PMID:20045035 |
|
NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of HMGCR mRNA |
CTD |
PMID:18032389 |
|
NCBI chr13:96,785,470...96,807,444
Ensembl chr13:96,785,475...96,807,444
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of HMGCS1 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr13:120,151,887...120,169,796
Ensembl chr13:120,151,915...120,169,796
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [beta-Naphthoflavone results in increased expression of HMOX1 protein]; isoquercitrin inhibits the reaction [Streptozocin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:21295105 PMID:30817903 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Ibsp |
integrin binding sialoprotein |
increases expression |
ISO |
isoquercitrin results in increased expression of IBSP mRNA |
CTD |
PMID:30365939 |
|
NCBI chr 5:104,447,153...104,459,338
Ensembl chr 5:104,447,037...104,459,335
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
[isoquercitrin analog co-treated with Propylthiouracil] results in increased expression of IL1A mRNA; [isoquercitrin co-treated with Diethylnitrosamine co-treated with beta-Naphthoflavone] results in decreased expression of IL1A mRNA |
CTD |
PMID:21295105 PMID:31068541 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of IL1B mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of IL6 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ins1 |
insulin I |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of INS1 protein] |
CTD |
PMID:30817903 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Insig1 |
insulin induced gene 1 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of INSIG1 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 5:28,276,410...28,283,660
Ensembl chr 5:28,276,361...28,283,660
|
|
G |
Jak1 |
Janus kinase 1 |
increases expression |
ISO |
isoquercitrin results in increased expression of JAK1 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 4:101,009,171...101,122,493
Ensembl chr 4:101,009,564...101,122,479
|
|
G |
Jak2 |
Janus kinase 2 |
increases expression |
ISO |
isoquercitrin results in increased expression of JAK2 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr19:29,229,006...29,290,495
Ensembl chr19:29,229,228...29,290,480
|
|
G |
Keap1 |
kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Streptozocin results in decreased expression of KEAP1 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
|
|
G |
Lct |
lactase |
multiple interactions |
ISO |
[migalastat results in decreased activity of LCT protein] which results in decreased hydrolysis of isoquercitrin |
CTD |
PMID:12663055 |
|
NCBI chr 1:128,212,493...128,256,055
Ensembl chr 1:128,212,493...128,256,055
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of LDLR mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:26109002 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:26109002 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mcl1 |
myeloid cell leukemia sequence 1 |
affects expression |
ISO |
isoquercitrin affects the expression of MCL1 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 3:95,564,017...95,583,553
Ensembl chr 3:95,566,099...95,570,487
|
|
G |
Me1 |
malic enzyme 1, NADP(+)-dependent, cytosolic |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of ME1 mRNA] |
CTD |
PMID:20033131 |
|
NCBI chr 9:86,463,416...86,577,967
Ensembl chr 9:86,463,424...86,578,006
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
isoquercitrin results in decreased expression of and results in decreased activity of MMP2 protein |
CTD |
PMID:18715546 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
isoquercitrin results in decreased expression of and results in decreased activity of MMP9 protein |
CTD |
PMID:18715546 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
ISO |
[isoquercitrin analog co-treated with Propylthiouracil] results in decreased expression of NFKB1 mRNA |
CTD |
PMID:31068541 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of NFKBIA mRNA] |
CTD |
PMID:20045035 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of NOS2 mRNA] |
CTD |
PMID:21295105 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of NQO1 mRNA; isoquercitrin analog inhibits the reaction [Propylthiouracil results in increased expression of NQO1 mRNA] |
CTD |
PMID:20033131 PMID:31068541 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid co-treated with isoquercitrin analog] results in increased expression of NR3C2 mRNA |
CTD |
PMID:30298849 |
|
NCBI chr 8:77,626,422...77,971,641
Ensembl chr 8:77,626,070...77,971,641
|
|
G |
Nsf |
N-ethylmaleimide sensitive fusion protein |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of NSF mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr11:103,712,608...103,844,882
Ensembl chr11:103,712,608...103,844,882
|
|
G |
Nsg1 |
neuron specific gene family member 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of NSG1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 5:38,294,537...38,317,087
Ensembl chr 5:38,294,536...38,317,251
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of OPA1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr16:29,398,099...29,481,924
Ensembl chr16:29,398,152...29,473,702
|
|
G |
Otx2 |
orthodenticle homeobox 2 |
multiple interactions |
ISO |
isoquercitrin analog inhibits the reaction [Propylthiouracil results in increased expression of OTX2 mRNA] |
CTD |
PMID:31068541 |
|
NCBI chr14:48,894,238...48,905,101
Ensembl chr14:48,895,134...48,911,276
|
|
G |
Park7 |
Parkinson disease (autosomal recessive, early onset) 7 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PARK7 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 4:150,981,590...150,994,378
Ensembl chr 4:150,981,590...150,998,894
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
affects expression |
ISO |
isoquercitrin affects the expression of PIK3CA mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 3:32,451,203...32,520,256
Ensembl chr 3:32,451,820...32,522,635
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
increases expression |
ISO |
isoquercitrin results in increased expression of PIK3R1 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr13:101,817,269...101,904,725
Ensembl chr13:101,817,071...101,904,725
|
|
G |
Ppid |
peptidylprolyl isomerase D (cyclophilin D) |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PPID mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 3:79,498,644...79,511,117
Ensembl chr 3:79,498,649...79,510,957
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr17:11,059,227...12,282,257
Ensembl chr17:11,059,271...12,282,248
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 mRNA]; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 protein]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; isoquercitrin inhibits the reaction [Streptozocin results in increased expression of PTGS2 mRNA] |
CTD |
PMID:14654164 PMID:20045035 PMID:30817903 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Ptk2 |
PTK2 protein tyrosine kinase 2 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:26109002 |
|
NCBI chr15:73,076,951...73,297,192
Ensembl chr15:73,076,951...73,295,129
|
|
G |
Relb |
avian reticuloendotheliosis viral (v-rel) oncogene related B |
increases expression |
ISO |
isoquercitrin results in increased expression of RELB mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 7:19,340,142...19,363,352
Ensembl chr 7:19,340,142...19,363,363
|
|
G |
Runx2 |
runt related transcription factor 2 |
increases expression |
ISO |
isoquercitrin results in increased expression of RUNX2 mRNA |
CTD |
PMID:30365939 |
|
NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684
|
|
G |
Sc5d |
sterol-C5-desaturase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of SC5D mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 9:42,162,888...42,175,607
Ensembl chr 9:42,162,891...42,175,552
|
|
G |
Serpine1 |
serine (or cysteine) peptidase inhibitor, clade E, member 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:20045035 |
|
NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122
|
|
G |
Slc5a1 |
solute carrier family 5 (sodium/glucose cotransporter), member 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [SLC5A1 protein results in increased uptake of methylglucoside] |
CTD |
PMID:17495124 |
|
NCBI chr 5:33,261,563...33,320,043
Ensembl chr 5:33,261,563...33,320,214
|
|
G |
Sqle |
squalene epoxidase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of SQLE mRNA |
CTD |
PMID:18032389 |
|
NCBI chr15:59,186,941...59,203,042
Ensembl chr15:59,186,926...59,203,041
|
|
G |
Srebf2 |
sterol regulatory element binding factor 2 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased cleavage of and results in increased activity of SREBF2 protein; [isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of SREBF2 mRNA; SREBF2 protein affects the susceptibility to [isoquercitrin co-treated with Hydrogen Peroxide] |
CTD |
PMID:18032389 |
|
NCBI chr15:82,031,455...82,089,580
Ensembl chr15:82,031,382...82,089,580
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases expression |
ISO |
isoquercitrin results in increased expression of STAT3 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366
|
|
G |
Stat6 |
signal transducer and activator of transcription 6 |
increases expression |
ISO |
isoquercitrin results in increased expression of STAT6 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr10:127,478,855...127,496,856
Ensembl chr10:127,478,855...127,496,826
|
|
G |
Stub1 |
STIP1 homology and U-Box containing protein 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of STUB1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr17:26,049,608...26,051,893
Ensembl chr17:26,049,479...26,052,378
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
ISO |
isoquercitrin promotes the reaction [Oxidopamine results in decreased expression of TH mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 7:142,446,516...142,453,732
Ensembl chr 7:142,446,489...142,484,865
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
increases expression |
ISO |
isoquercitrin results in increased expression of TIMP1 protein |
CTD |
PMID:18715546 |
|
NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of TNF mRNA]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; isoquercitrin inhibits the reaction [Streptozocin results in increased expression of TNF mRNA] |
CTD |
PMID:14654164 PMID:21295105 PMID:30817903 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of TNFRSF1A protein] |
CTD |
PMID:21295105 |
|
NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447
|
|
G |
Tradd |
TNFRSF1A-associated via death domain |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of TRADD protein] |
CTD |
PMID:21295105 |
|
NCBI chr 8:105,985,207...105,991,226
Ensembl chr 8:105,984,918...105,991,241
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of TP53 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
ISO |
isoquercitrin analog inhibits the reaction [Propylthiouracil results in increased expression of TXN1 mRNA] |
CTD |
PMID:31068541 |
|
NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411
|
|
G |
Tyk2 |
tyrosine kinase 2 |
affects expression |
ISO |
isoquercitrin affects the expression of TYK2 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 9:21,015,364...21,042,689
Ensembl chr 9:21,015,364...21,042,539
|
|
G |
Uchl1 |
ubiquitin carboxy-terminal hydrolase L1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of UCHL1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 5:66,833,464...66,844,577
Ensembl chr 5:66,833,434...66,844,577
|
|
|
G |
Acat2 |
acetyl-Coenzyme A acetyltransferase 2 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of ACAT2 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr17:13,161,929...13,179,612
Ensembl chr17:13,161,777...13,179,634
|
|
G |
Apoa1 |
apolipoprotein A-I |
increases secretion |
ISO |
isoquercitrin results in increased secretion of APOA1 protein |
CTD |
PMID:24963805 |
|
NCBI chr 9:46,139,928...46,141,767
Ensembl chr 9:46,139,878...46,141,764
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression |
ISO |
isoquercitrin results in increased expression of ATF6 mRNA |
CTD |
PMID:30365939 |
|
NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340
|
|
G |
Atxn2 |
ataxin 2 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of ATXN2 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 5:121,849,794...121,954,372
Ensembl chr 5:121,849,400...121,954,556
|
|
G |
Atxn3 |
ataxin 3 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of ATXN3 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr12:101,885,160...101,928,139
Ensembl chr12:101,885,160...101,924,505
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
decreases expression |
ISO |
isoquercitrin results in decreased expression of BCL2 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Casp3 |
caspase 3 |
affects expression |
ISO |
isoquercitrin affects the expression of CASP3 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp8 |
caspase 8 |
decreases expression |
ISO |
isoquercitrin results in decreased expression of CASP8 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid co-treated with isoquercitrin analog] results in increased expression of CAT mRNA; isoquercitrin inhibits the reaction [Streptozocin results in decreased activity of CAT protein] |
CTD |
PMID:30298849 PMID:30817903 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CCL2 mRNA] |
CTD |
PMID:21295105 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Carrageenan results in increased expression of CCL5 protein] |
CTD |
PMID:14654164 |
|
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Cdkn2b |
cyclin dependent kinase inhibitor 2B |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CDKN2B mRNA] |
CTD |
PMID:21295105 |
|
NCBI chr 4:89,224,526...89,229,269
Ensembl chr 4:89,224,536...89,229,276
|
|
G |
Ctnnb1 |
catenin beta 1 |
affects expression |
ISO |
isoquercitrin affects the expression of CTNNB1 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
increases expression |
ISO |
isoquercitrin results in increased expression of CXCL8 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Carrageenan results in increased expression of CXCL2 protein] |
CTD |
PMID:14654164 |
|
NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity multiple interactions |
ISO |
isoquercitrin results in decreased activity of CYP1A1 protein [Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of CYP1A1 mRNA |
CTD |
PMID:16271822 PMID:20033131 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of CYP1A2 mRNA |
CTD |
PMID:20033131 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
isoquercitrin results in decreased activity of CYP1B1 protein |
CTD |
PMID:16271822 |
|
NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490
|
|
G |
Cyp2b13 |
cytochrome P450, family 2, subfamily b, polypeptide 13 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP2B2 mRNA] |
CTD |
PMID:20033131 |
|
NCBI chr 7:25,760,813...25,795,622
Ensembl chr 7:25,760,922...25,795,622
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of CYP51A1 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 5:4,130,674...4,154,697
Ensembl chr 5:4,131,145...4,154,746
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of DHCR7 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 7:143,376,827...143,402,147
Ensembl chr 7:143,376,882...143,402,147
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:26109002 |
|
NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:26109002 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Egln1 |
egl-9 family hypoxia-inducible factor 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of EGLN1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 8:125,635,325...125,676,063
Ensembl chr 8:125,635,326...125,676,063
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of FDFT1 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr14:63,382,599...63,419,136
Ensembl chr14:63,382,599...63,417,027
|
|
G |
Fdps |
farnesyl diphosphate synthetase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of FDPS mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 3:89,000,895...89,009,274
Ensembl chr 3:89,000,895...89,009,266
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
multiple interactions |
ISO |
[isoquercitrin analog co-treated with Propylthiouracil] results in decreased expression of FOS mRNA |
CTD |
PMID:31068541 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of GPX2 mRNA |
CTD |
PMID:20033131 |
|
NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273
|
|
G |
Gria3 |
glutamate receptor, ionotropic, AMPA3 (alpha 3) |
multiple interactions |
ISO |
isoquercitrin analog inhibits the reaction [Propylthiouracil results in increased expression of GRIA3 mRNA] |
CTD |
PMID:31068541 |
|
NCBI chr X:40,489,351...40,767,478
Ensembl chr X:40,489,731...40,767,478
|
|
G |
Gsta1 |
glutathione S-transferase, alpha 1 (Ya) |
multiple interactions |
ISO |
[isoquercitrin co-treated with oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of GSTA5 mRNA] |
CTD |
PMID:20033131 PMID:20045035 |
|
NCBI chr 9:78,137,951...78,149,965
Ensembl chr 9:78,137,938...78,149,966
|
|
G |
Gstm1 |
glutathione S-transferase, mu 1 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of GSTM1 mRNA; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of GSTM1 mRNA] |
CTD |
PMID:20033131 PMID:20045035 |
|
NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of HMGCR mRNA |
CTD |
PMID:18032389 |
|
NCBI chr13:96,785,470...96,807,444
Ensembl chr13:96,785,475...96,807,444
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of HMGCS1 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr13:120,151,887...120,169,796
Ensembl chr13:120,151,915...120,169,796
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [beta-Naphthoflavone results in increased expression of HMOX1 protein]; isoquercitrin inhibits the reaction [Streptozocin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:21295105 PMID:30817903 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Ibsp |
integrin binding sialoprotein |
increases expression |
ISO |
isoquercitrin results in increased expression of IBSP mRNA |
CTD |
PMID:30365939 |
|
NCBI chr 5:104,447,153...104,459,338
Ensembl chr 5:104,447,037...104,459,335
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
[isoquercitrin analog co-treated with Propylthiouracil] results in increased expression of IL1A mRNA; [isoquercitrin co-treated with Diethylnitrosamine co-treated with beta-Naphthoflavone] results in decreased expression of IL1A mRNA |
CTD |
PMID:21295105 PMID:31068541 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of IL1B mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of IL6 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ins1 |
insulin I |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of INS1 protein] |
CTD |
PMID:30817903 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Insig1 |
insulin induced gene 1 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of INSIG1 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 5:28,276,410...28,283,660
Ensembl chr 5:28,276,361...28,283,660
|
|
G |
Jak1 |
Janus kinase 1 |
increases expression |
ISO |
isoquercitrin results in increased expression of JAK1 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 4:101,009,171...101,122,493
Ensembl chr 4:101,009,564...101,122,479
|
|
G |
Jak2 |
Janus kinase 2 |
increases expression |
ISO |
isoquercitrin results in increased expression of JAK2 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr19:29,229,006...29,290,495
Ensembl chr19:29,229,228...29,290,480
|
|
G |
Keap1 |
kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Streptozocin results in decreased expression of KEAP1 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
|
|
G |
Lct |
lactase |
multiple interactions |
ISO |
[migalastat results in decreased activity of LCT protein] which results in decreased hydrolysis of isoquercitrin |
CTD |
PMID:12663055 |
|
NCBI chr 1:128,212,493...128,256,055
Ensembl chr 1:128,212,493...128,256,055
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of LDLR mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:26109002 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:26109002 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mcl1 |
myeloid cell leukemia sequence 1 |
affects expression |
ISO |
isoquercitrin affects the expression of MCL1 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 3:95,564,017...95,583,553
Ensembl chr 3:95,566,099...95,570,487
|
|
G |
Me1 |
malic enzyme 1, NADP(+)-dependent, cytosolic |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of ME1 mRNA] |
CTD |
PMID:20033131 |
|
NCBI chr 9:86,463,416...86,577,967
Ensembl chr 9:86,463,424...86,578,006
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
isoquercitrin results in decreased expression of and results in decreased activity of MMP2 protein |
CTD |
PMID:18715546 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
isoquercitrin results in decreased expression of and results in decreased activity of MMP9 protein |
CTD |
PMID:18715546 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
ISO |
[isoquercitrin analog co-treated with Propylthiouracil] results in decreased expression of NFKB1 mRNA |
CTD |
PMID:31068541 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of NFKBIA mRNA] |
CTD |
PMID:20045035 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of NOS2 mRNA] |
CTD |
PMID:21295105 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of NQO1 mRNA; isoquercitrin analog inhibits the reaction [Propylthiouracil results in increased expression of NQO1 mRNA] |
CTD |
PMID:20033131 PMID:31068541 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid co-treated with isoquercitrin analog] results in increased expression of NR3C2 mRNA |
CTD |
PMID:30298849 |
|
NCBI chr 8:77,626,422...77,971,641
Ensembl chr 8:77,626,070...77,971,641
|
|
G |
Nsf |
N-ethylmaleimide sensitive fusion protein |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of NSF mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr11:103,712,608...103,844,882
Ensembl chr11:103,712,608...103,844,882
|
|
G |
Nsg1 |
neuron specific gene family member 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of NSG1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 5:38,294,537...38,317,087
Ensembl chr 5:38,294,536...38,317,251
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of OPA1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr16:29,398,099...29,481,924
Ensembl chr16:29,398,152...29,473,702
|
|
G |
Otx2 |
orthodenticle homeobox 2 |
multiple interactions |
ISO |
isoquercitrin analog inhibits the reaction [Propylthiouracil results in increased expression of OTX2 mRNA] |
CTD |
PMID:31068541 |
|
NCBI chr14:48,894,238...48,905,101
Ensembl chr14:48,895,134...48,911,276
|
|
G |
Park7 |
Parkinson disease (autosomal recessive, early onset) 7 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PARK7 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 4:150,981,590...150,994,378
Ensembl chr 4:150,981,590...150,998,894
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
affects expression |
ISO |
isoquercitrin affects the expression of PIK3CA mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 3:32,451,203...32,520,256
Ensembl chr 3:32,451,820...32,522,635
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
increases expression |
ISO |
isoquercitrin results in increased expression of PIK3R1 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr13:101,817,269...101,904,725
Ensembl chr13:101,817,071...101,904,725
|
|
G |
Ppid |
peptidylprolyl isomerase D (cyclophilin D) |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PPID mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 3:79,498,644...79,511,117
Ensembl chr 3:79,498,649...79,510,957
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr17:11,059,227...12,282,257
Ensembl chr17:11,059,271...12,282,248
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 mRNA]; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 protein]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; isoquercitrin inhibits the reaction [Streptozocin results in increased expression of PTGS2 mRNA] |
CTD |
PMID:14654164 PMID:20045035 PMID:30817903 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Ptk2 |
PTK2 protein tyrosine kinase 2 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:26109002 |
|
NCBI chr15:73,076,951...73,297,192
Ensembl chr15:73,076,951...73,295,129
|
|
G |
Relb |
avian reticuloendotheliosis viral (v-rel) oncogene related B |
increases expression |
ISO |
isoquercitrin results in increased expression of RELB mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 7:19,340,142...19,363,352
Ensembl chr 7:19,340,142...19,363,363
|
|
G |
Runx2 |
runt related transcription factor 2 |
increases expression |
ISO |
isoquercitrin results in increased expression of RUNX2 mRNA |
CTD |
PMID:30365939 |
|
NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684
|
|
G |
Sc5d |
sterol-C5-desaturase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of SC5D mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 9:42,162,888...42,175,607
Ensembl chr 9:42,162,891...42,175,552
|
|
G |
Serpine1 |
serine (or cysteine) peptidase inhibitor, clade E, member 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:20045035 |
|
NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122
|
|
G |
Slc5a1 |
solute carrier family 5 (sodium/glucose cotransporter), member 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [SLC5A1 protein results in increased uptake of methylglucoside] |
CTD |
PMID:17495124 |
|
NCBI chr 5:33,261,563...33,320,043
Ensembl chr 5:33,261,563...33,320,214
|
|
G |
Sqle |
squalene epoxidase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of SQLE mRNA |
CTD |
PMID:18032389 |
|
NCBI chr15:59,186,941...59,203,042
Ensembl chr15:59,186,926...59,203,041
|
|
G |
Srebf2 |
sterol regulatory element binding factor 2 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased cleavage of and results in increased activity of SREBF2 protein; [isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of SREBF2 mRNA; SREBF2 protein affects the susceptibility to [isoquercitrin co-treated with Hydrogen Peroxide] |
CTD |
PMID:18032389 |
|
NCBI chr15:82,031,455...82,089,580
Ensembl chr15:82,031,382...82,089,580
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases expression |
ISO |
isoquercitrin results in increased expression of STAT3 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366
|
|
G |
Stat6 |
signal transducer and activator of transcription 6 |
increases expression |
ISO |
isoquercitrin results in increased expression of STAT6 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr10:127,478,855...127,496,856
Ensembl chr10:127,478,855...127,496,826
|
|
G |
Stub1 |
STIP1 homology and U-Box containing protein 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of STUB1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr17:26,049,608...26,051,893
Ensembl chr17:26,049,479...26,052,378
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
ISO |
isoquercitrin promotes the reaction [Oxidopamine results in decreased expression of TH mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 7:142,446,516...142,453,732
Ensembl chr 7:142,446,489...142,484,865
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
increases expression |
ISO |
isoquercitrin results in increased expression of TIMP1 protein |
CTD |
PMID:18715546 |
|
NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of TNF mRNA]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; isoquercitrin inhibits the reaction [Streptozocin results in increased expression of TNF mRNA] |
CTD |
PMID:14654164 PMID:21295105 PMID:30817903 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of TNFRSF1A protein] |
CTD |
PMID:21295105 |
|
NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447
|
|
G |
Tradd |
TNFRSF1A-associated via death domain |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of TRADD protein] |
CTD |
PMID:21295105 |
|
NCBI chr 8:105,985,207...105,991,226
Ensembl chr 8:105,984,918...105,991,241
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of TP53 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
ISO |
isoquercitrin analog inhibits the reaction [Propylthiouracil results in increased expression of TXN1 mRNA] |
CTD |
PMID:31068541 |
|
NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411
|
|
G |
Tyk2 |
tyrosine kinase 2 |
affects expression |
ISO |
isoquercitrin affects the expression of TYK2 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 9:21,015,364...21,042,689
Ensembl chr 9:21,015,364...21,042,539
|
|
G |
Uchl1 |
ubiquitin carboxy-terminal hydrolase L1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of UCHL1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 5:66,833,464...66,844,577
Ensembl chr 5:66,833,434...66,844,577
|
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; spiraeoside inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:32602595 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Ap5m1 |
adaptor-related protein complex 5, mu 1 subunit |
decreases expression |
ISO |
spiraeoside results in decreased expression of AP5M1 protein |
CTD |
PMID:34116102 |
|
NCBI chr14:49,303,869...49,331,681
Ensembl chr14:49,303,554...49,331,691
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in increased expression of BAX protein]]; spiraeoside inhibits the reaction [Glucose results in increased expression of BAX protein] |
CTD |
PMID:32602595 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased expression of BCL2 protein]]; spiraeoside inhibits the reaction [Glucose results in decreased expression of BCL2 protein] spiraeoside results in decreased expression of BCL2 protein |
CTD |
PMID:32602595 PMID:34116102 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bid |
BH3 interacting domain death agonist |
decreases expression |
ISO |
spiraeoside results in decreased expression of BID protein |
CTD |
PMID:34116102 |
|
NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814
|
|
G |
Casp3 |
caspase 3 |
decreases expression |
ISO |
spiraeoside results in decreased expression of CASP3 protein |
CTD |
PMID:34116102 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp9 |
caspase 9 |
decreases expression |
ISO |
spiraeoside results in decreased expression of CASP9 protein |
CTD |
PMID:34116102 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in increased activity of CAT protein]]; spiraeoside inhibits the reaction [Glucose results in increased activity of CAT protein] |
CTD |
PMID:32602595 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
spiraeoside results in decreased expression of CDK2 protein |
CTD |
PMID:34116102 |
|
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
|
|
G |
Cryz |
crystallin, zeta |
increases activity |
EXP |
spiraeoside results in increased activity of CRYZ protein |
CTD |
PMID:8968052 |
|
NCBI chr 3:154,302,348...154,328,819
Ensembl chr 3:154,302,348...154,328,819
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased expression of HMOX1 protein]]; spiraeoside inhibits the reaction [Glucose results in decreased expression of HMOX1 protein] |
CTD |
PMID:32602595 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Lct |
lactase |
multiple interactions |
ISO |
[migalastat results in decreased activity of LCT protein] which results in decreased hydrolysis of spiraeoside |
CTD |
PMID:12663055 |
|
NCBI chr 1:128,212,493...128,256,055
Ensembl chr 1:128,212,493...128,256,055
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased expression of NFE2L2 protein]]; spiraeoside inhibits the reaction [Glucose results in decreased expression of NFE2L2 protein] |
CTD |
PMID:32602595 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Plcg2 |
phospholipase C, gamma 2 |
decreases phosphorylation |
ISO |
spiraeoside results in decreased phosphorylation of PLCG2 protein |
CTD |
PMID:15613018 |
|
NCBI chr 8:118,225,014...118,361,881
Ensembl chr 8:118,225,030...118,361,881
|
|
G |
Slc5a1 |
solute carrier family 5 (sodium/glucose cotransporter), member 1 |
multiple interactions |
ISO |
[Phlorhizin results in decreased activity of SLC5A1 protein] which results in decreased uptake of spiraeoside spiraeoside inhibits the reaction [SLC5A1 protein results in increased uptake of methylglucoside] |
CTD |
PMID:12663055 PMID:17495124 |
|
NCBI chr 5:33,261,563...33,320,043
Ensembl chr 5:33,261,563...33,320,214
|
|
G |
Syk |
spleen tyrosine kinase |
decreases phosphorylation |
ISO |
spiraeoside results in decreased phosphorylation of SYK protein |
CTD |
PMID:15613018 |
|
NCBI chr13:52,736,670...52,802,828
Ensembl chr13:52,737,209...52,802,828
|
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases expression |
ISO |
rebaudioside A results in decreased expression of ACE mRNA |
CTD |
PMID:31655124 |
|
NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790
|
|
G |
Acox1 |
acyl-Coenzyme A oxidase 1, palmitoyl |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of ACOX1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr11:116,062,714...116,089,605
Ensembl chr11:116,062,714...116,089,871
|
|
G |
Acta2 |
actin alpha 2, smooth muscle, aorta |
multiple interactions |
ISO |
rebaudioside A inhibits the reaction [Thioacetamide results in increased expression of ACTA2 protein] |
CTD |
PMID:30883860 |
|
NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression |
ISO |
rebaudioside A results in increased expression of AGTR1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
increases expression |
ISO |
rebaudioside A results in increased expression of ALOX5 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 6:116,387,030...116,438,139
Ensembl chr 6:116,387,038...116,438,139
|
|
G |
Bax |
BCL2-associated X protein |
decreases expression |
ISO |
rebaudioside A results in decreased expression of BAX mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Calca |
calcitonin/calcitonin-related polypeptide, alpha |
increases expression |
ISO |
rebaudioside A results in increased expression of CALCA mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 7:114,225,223...114,236,145
Ensembl chr 7:114,230,713...114,235,592
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CAT mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cav1 |
caveolin 1, caveolae protein |
decreases expression |
ISO |
rebaudioside A results in decreased expression of CAV1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 6:17,306,387...17,341,323
Ensembl chr 6:17,306,334...17,341,451
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
rebaudioside A results in decreased expression of CCL2 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression |
ISO |
rebaudioside A results in decreased expression of CFLAR mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 1:58,750,353...58,798,043
Ensembl chr 1:58,750,667...58,798,043
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1a, liver |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CPT1A mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of DGAT2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 7:98,802,870...98,831,920
Ensembl chr 7:98,802,865...98,831,926
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
ISO |
rebaudioside A results in decreased expression of EDN1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466
|
|
G |
Ednra |
endothelin receptor type A |
increases expression |
ISO |
rebaudioside A results in increased expression of EDNRA mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 8:78,389,658...78,451,081
Ensembl chr 8:78,389,660...78,451,093
|
|
G |
F2r |
coagulation factor II thrombin receptor |
decreases expression |
ISO |
rebaudioside A results in decreased expression of F2R mRNA |
CTD |
PMID:31655124 |
|
NCBI chr13:95,738,288...95,754,974
Ensembl chr13:95,738,311...95,754,995
|
|
G |
Fasl |
Fas ligand |
increases expression |
ISO |
rebaudioside A results in increased expression of FASLG mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
increases expression |
ISO |
rebaudioside A results in increased expression of FGF1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr18:38,971,725...39,062,532
Ensembl chr18:38,971,726...39,062,525
|
|
G |
Flt1 |
FMS-like tyrosine kinase 1 |
decreases expression |
ISO |
rebaudioside A results in decreased expression of FLT1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 5:147,498,414...147,663,419
Ensembl chr 5:147,498,414...147,662,821
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of FOXO1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of G6PC1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
rebaudioside A inhibits the reaction [Thioacetamide results in increased expression of IL10 protein] |
CTD |
PMID:30883860 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
rebaudioside A inhibits the reaction [Thioacetamide results in increased expression of IL6 protein] |
CTD |
PMID:30883860 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Insr |
insulin receptor |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of INSR mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 8:3,200,922...3,329,649
Ensembl chr 8:3,172,061...3,329,617
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 1:82,210,826...82,269,160
Ensembl chr 1:82,210,822...82,269,137
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 8:11,034,681...11,058,929
Ensembl chr 8:11,034,681...11,058,458
|
|
G |
Itgav |
integrin alpha V |
decreases expression |
ISO |
rebaudioside A results in decreased expression of ITGAV mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 2:83,554,796...83,637,261
Ensembl chr 2:83,554,741...83,637,260
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression |
ISO |
rebaudioside A results in decreased expression of KIT mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 5:75,735,647...75,817,382
Ensembl chr 5:75,735,576...75,817,382
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of ACOX1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CAT mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CPT1A mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of DGAT2 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of FOXO1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of G6PC1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of INSR mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS2 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of LIPC mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of MTOR mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKB1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKBIA mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PCK1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARA mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARD mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARG mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARGC1A mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SCD1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SIRT1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC27A1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC2A2 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SOD2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215
|
|
G |
Lep |
leptin |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of ACOX1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CAT mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CPT1A mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of DGAT2 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of FOXO1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of G6PC1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of INSR mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS2 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of LIPC mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of MTOR mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKB1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKBIA mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PCK1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARA mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARD mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARG mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARGC1A mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SCD1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SIRT1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC27A1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC2A2 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SOD2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Lipc |
lipase, hepatic |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of LIPC mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 9:70,705,410...70,859,503
Ensembl chr 9:70,705,410...70,859,508
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
ISO |
rebaudioside A inhibits the reaction [Thioacetamide results in increased expression of MMP13 protein] |
CTD |
PMID:30883860 |
|
NCBI chr 9:7,272,514...7,283,333
Ensembl chr 9:7,272,514...7,283,331
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
rebaudioside A inhibits the reaction [Thioacetamide results in increased activity of MMP2 protein] |
CTD |
PMID:30883860 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions |
ISO |
rebaudioside A results in increased expression of MMP9 mRNA rebaudioside A inhibits the reaction [Thioacetamide results in increased activity of MMP9 protein] |
CTD |
PMID:30883860 PMID:31655124 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of MTOR mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions |
ISO |
rebaudioside A inhibits the reaction [Thioacetamide results in decreased expression of NFE2L2 protein] |
CTD |
PMID:30883860 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKB1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKBIA mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1, cytosolic |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PCK1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066
|
|
G |
Pf4 |
platelet factor 4 |
increases expression |
ISO |
rebaudioside A results in increased expression of PF4 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 5:90,920,362...90,921,242
Ensembl chr 5:90,920,294...90,921,242
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARA mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Ppard |
peroxisome proliferator activator receptor delta |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARD mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr17:28,451,715...28,520,446
Ensembl chr17:28,451,674...28,520,448
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARG mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARGC1A mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
rebaudioside A results in decreased expression of PTGS2 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
rebaudioside A inhibits the reaction [Thioacetamide results in increased expression of RELA protein] |
CTD |
PMID:30883860 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Scd1 |
stearoyl-Coenzyme A desaturase 1 |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SCD1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318
|
|
G |
Sele |
selectin, endothelial cell |
decreases expression |
ISO |
rebaudioside A results in decreased expression of SELE mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SIRT1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
|
|
G |
Slc27a1 |
solute carrier family 27 (fatty acid transporter), member 1 |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC27A1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 8:72,021,372...72,039,951
Ensembl chr 8:72,021,526...72,039,946
|
|
G |
Slc2a2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC2A2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 3:28,752,052...28,782,510
Ensembl chr 3:28,752,052...28,785,508
|
|
G |
Smad7 |
SMAD family member 7 |
multiple interactions |
ISO |
rebaudioside A inhibits the reaction [Thioacetamide results in decreased expression of SMAD7 protein] |
CTD |
PMID:30883860 |
|
NCBI chr18:75,500,436...75,529,006
Ensembl chr18:75,500,600...75,529,006
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
multiple interactions |
EXP |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SOD2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
rebaudioside A inhibits the reaction [Thioacetamide results in increased expression of TGFB1 protein] |
CTD |
PMID:30883860 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
rebaudioside A inhibits the reaction [Thioacetamide results in increased expression of TNF protein] |
CTD |
PMID:30883860 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
decreases expression |
ISO |
rebaudioside A results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 3:27,371,226...27,393,814
Ensembl chr 3:27,371,177...27,396,576
|
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein binds to and affects the transport of salicin |
CTD |
PMID:8831264 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Tas2r118 |
taste receptor, type 2, member 118 |
multiple interactions increases activity |
ISO |
4-((diethylamino)sulfonyl)benzoic acid inhibits the reaction [salicin results in increased activity of TAS2R16 protein]; Probenecid inhibits the reaction [salicin results in increased activity of TAS2R16 protein] |
CTD |
PMID:21629661 |
|
NCBI chr 6:23,969,160...23,970,059
Ensembl chr 6:23,969,160...23,970,059
|
|
|
G |
Ide |
insulin degrading enzyme |
multiple interactions |
ISO |
scopolin binds to and affects the activity of IDE protein |
CTD |
PMID:23146021 |
|
NCBI chr19:37,246,140...37,341,664
Ensembl chr19:37,246,142...37,340,010
|
|
G |
Urod |
uroporphyrinogen decarboxylase |
multiple interactions |
ISO |
scopolin binds to and affects the activity of UROD protein |
CTD |
PMID:23209648 |
|
NCBI chr 4:116,847,161...116,851,561
Ensembl chr 4:116,847,162...116,851,610
|
|
|
G |
Gsta1 |
glutathione S-transferase, alpha 1 (Ya) |
increases activity |
ISO |
sinigrin results in increased activity of GSTA5 protein |
CTD |
PMID:9328168 |
|
NCBI chr 9:78,137,951...78,149,965
Ensembl chr 9:78,137,938...78,149,966
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
EXP |
sinigrin inhibits the reaction [TNF protein affects the localization of RELA protein] |
CTD |
PMID:28483571 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
sinigrin inhibits the reaction [TNF protein affects the localization of RELA protein]; sinigrin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; sinigrin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:28483571 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP |
sinigrin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; sinigrin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:28483571 |
|
NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337
|
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases expression |
ISO |
stevioside results in decreased expression of ACE mRNA |
CTD |
PMID:31655124 |
|
NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO |
stevioside inhibits the reaction [Scopolamine results in increased activity of ACHE protein] |
CTD |
PMID:20871768 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
G |
Acox1 |
acyl-Coenzyme A oxidase 1, palmitoyl |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of ACOX1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr11:116,062,714...116,089,605
Ensembl chr11:116,062,714...116,089,871
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
decreases secretion |
ISO |
stevioside results in decreased secretion of ACP5 protein |
CTD |
PMID:21089163 |
|
NCBI chr 9:22,038,023...22,047,042
Ensembl chr 9:22,038,023...22,047,007
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression |
ISO |
stevioside results in increased expression of AGTR1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
increases expression |
ISO |
stevioside results in increased expression of ALOX5 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 6:116,387,030...116,438,139
Ensembl chr 6:116,387,038...116,438,139
|
|
G |
Bax |
BCL2-associated X protein |
decreases expression |
ISO |
stevioside results in decreased expression of BAX mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Calca |
calcitonin/calcitonin-related polypeptide, alpha |
increases expression |
ISO |
stevioside results in increased expression of CALCA mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 7:114,225,223...114,236,145
Ensembl chr 7:114,230,713...114,235,592
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CAT mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
stevioside results in decreased expression of CCL2 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression |
ISO |
stevioside results in decreased expression of CFLAR mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 1:58,750,353...58,798,043
Ensembl chr 1:58,750,667...58,798,043
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1a, liver |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CPT1A mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
stevioside results in increased expression of CYP1A1 mRNA |
CTD |
PMID:28887089 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
ISO |
stevioside results in increased expression of CYP1A2 mRNA; stevioside results in increased expression of CYP1A2 protein |
CTD |
PMID:28887089 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
stevioside results in increased expression of CYP1B1 mRNA |
CTD |
PMID:28887089 |
|
NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490
|
|
G |
Cyp2c65 |
cytochrome P450, family 2, subfamily c, polypeptide 65 |
decreases expression |
ISO |
stevioside results in decreased expression of CYP2C9 mRNA |
CTD |
PMID:28887089 |
|
NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of DGAT2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 7:98,802,870...98,831,920
Ensembl chr 7:98,802,865...98,831,926
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
ISO |
stevioside results in decreased expression of EDN1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466
|
|
G |
Ednra |
endothelin receptor type A |
increases expression |
ISO |
stevioside results in increased expression of EDNRA mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 8:78,389,658...78,451,081
Ensembl chr 8:78,389,660...78,451,093
|
|
G |
F2r |
coagulation factor II thrombin receptor |
decreases expression |
ISO |
stevioside results in decreased expression of F2R mRNA |
CTD |
PMID:31655124 |
|
NCBI chr13:95,738,288...95,754,974
Ensembl chr13:95,738,311...95,754,995
|
|
G |
Fasl |
Fas ligand |
increases expression |
ISO |
stevioside results in increased expression of FASLG mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
increases expression |
ISO |
stevioside results in increased expression of FGF1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr18:38,971,725...39,062,532
Ensembl chr18:38,971,726...39,062,525
|
|
G |
Flt1 |
FMS-like tyrosine kinase 1 |
decreases expression |
ISO |
stevioside results in decreased expression of FLT1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 5:147,498,414...147,663,419
Ensembl chr 5:147,498,414...147,662,821
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of FOXO1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of G6PC1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729
|
|
G |
Insr |
insulin receptor |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of INSR mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 8:3,200,922...3,329,649
Ensembl chr 8:3,172,061...3,329,617
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 1:82,210,826...82,269,160
Ensembl chr 1:82,210,822...82,269,137
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 8:11,034,681...11,058,929
Ensembl chr 8:11,034,681...11,058,458
|
|
G |
Itgav |
integrin alpha V |
decreases expression |
ISO |
stevioside results in decreased expression of ITGAV mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 2:83,554,796...83,637,261
Ensembl chr 2:83,554,741...83,637,260
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression |
ISO |
stevioside results in decreased expression of KIT mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 5:75,735,647...75,817,382
Ensembl chr 5:75,735,576...75,817,382
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of ACOX1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CAT mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CPT1A mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of DGAT2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of FOXO1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of G6PC1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of INSR mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of LIPC mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of MTOR mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKB1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKBIA mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PCK1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PLIN2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARA mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARD mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARG mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARGC1A mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SCD1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SIRT1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC27A1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC2A2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SOD2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215
|
|
G |
Lep |
leptin |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of ACOX1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CAT mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CPT1A mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of DGAT2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of FOXO1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of G6PC1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of INSR mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of LIPC mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of MTOR mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKB1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKBIA mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PCK1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PLIN2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARA mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARD mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARG mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARGC1A mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SCD1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SIRT1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC27A1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC2A2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SOD2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Lipc |
lipase, hepatic |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of LIPC mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 9:70,705,410...70,859,503
Ensembl chr 9:70,705,410...70,859,508
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression |
ISO |
stevioside results in increased expression of MMP9 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of MTOR mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKB1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKBIA mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1, cytosolic |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PCK1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066
|
|
G |
Pf4 |
platelet factor 4 |
increases expression |
ISO |
stevioside results in increased expression of PF4 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 5:90,920,362...90,921,242
Ensembl chr 5:90,920,294...90,921,242
|
|
G |
Plin2 |
perilipin 2 |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PLIN2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 4:86,545,147...86,588,518
Ensembl chr 4:86,566,623...86,588,297
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARA mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Ppard |
peroxisome proliferator activator receptor delta |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARD mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr17:28,451,715...28,520,446
Ensembl chr17:28,451,674...28,520,448
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARG mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARGC1A mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
stevioside results in decreased expression of PTGS2 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Scd1 |
stearoyl-Coenzyme A desaturase 1 |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SCD1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318
|
|
G |
Sele |
selectin, endothelial cell |
decreases expression |
ISO |
stevioside results in decreased expression of SELE mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SIRT1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
|
|
G |
Slc27a1 |
solute carrier family 27 (fatty acid transporter), member 1 |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC27A1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 8:72,021,372...72,039,951
Ensembl chr 8:72,021,526...72,039,946
|
|
G |
Slc2a2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC2A2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 3:28,752,052...28,782,510
Ensembl chr 3:28,752,052...28,785,508
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
multiple interactions |
EXP |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SOD2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
decreases expression |
ISO |
stevioside results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 3:27,371,226...27,393,814
Ensembl chr 3:27,371,177...27,396,576
|
|
|
G |
Bax |
BCL2-associated X protein |
increases expression |
ISO |
syringin results in increased expression of BAX protein |
CTD |
PMID:35580997 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
decreases expression |
ISO |
syringin results in decreased expression of BCL2 protein |
CTD |
PMID:35580997 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
syringin results in decreased expression of BIRC5 protein |
CTD |
PMID:35580997 |
|
NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
multiple interactions |
EXP |
syringin inhibits the reaction [Ovalbumin results in increased expression of CCL11 protein] |
CTD |
PMID:33146439 |
|
NCBI chr11:81,948,658...81,953,781
Ensembl chr11:81,948,649...81,953,781
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO |
syringin results in increased expression of CCND1 protein |
CTD |
PMID:35580997 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
syringin results in increased expression of CDH1 protein |
CTD |
PMID:35580997 |
|
NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
syringin inhibits the reaction [Ovalbumin results in increased expression of IFNG protein] |
CTD |
PMID:33146439 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
EXP |
syringin inhibits the reaction [Ovalbumin results in increased expression of IL13 protein] |
CTD |
PMID:33146439 |
|
NCBI chr11:53,522,150...53,525,529
Ensembl chr11:53,522,151...53,525,529
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
EXP |
syringin inhibits the reaction [Ovalbumin results in increased expression of IL4 protein] |
CTD |
PMID:33146439 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
EXP |
syringin inhibits the reaction [Ovalbumin results in increased expression of IL5 protein] |
CTD |
PMID:33146439 |
|
NCBI chr11:53,611,621...53,615,930
Ensembl chr11:53,611,621...53,615,933
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
syringin inhibits the reaction [Ovalbumin results in increased expression of IL6 protein] |
CTD |
PMID:33146439 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
syringin inhibits the reaction [Ovalbumin results in increased activity of MPO protein] |
CTD |
PMID:33146439 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
EXP |
syringin inhibits the reaction [Ovalbumin results in increased expression of and results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:33146439 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases phosphorylation |
ISO |
syringin results in increased phosphorylation of PPARA protein |
CTD |
PMID:23691032 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Prkaa1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
decreases phosphorylation |
ISO |
syringin results in decreased phosphorylation of PRKAA1 protein |
CTD |
PMID:23691032 |
|
NCBI chr15:5,172,641...5,211,380
Ensembl chr15:5,173,343...5,211,380
|
|
G |
Prkaa2 |
protein kinase, AMP-activated, alpha 2 catalytic subunit |
decreases phosphorylation |
ISO |
syringin results in decreased phosphorylation of PRKAA2 protein |
CTD |
PMID:23691032 |
|
NCBI chr 4:104,886,846...104,967,095
Ensembl chr 4:104,887,071...104,967,087
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
EXP |
syringin inhibits the reaction [Ovalbumin results in increased expression of and results in increased phosphorylation of RELA protein] |
CTD |
PMID:33146439 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression |
ISO |
syringin results in decreased expression of SQSTM1 protein |
CTD |
PMID:35580997 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
syringin inhibits the reaction [Ovalbumin results in increased expression of TNF protein] |
CTD |
PMID:33146439 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Trp53 |
transformation related protein 53 |
increases expression |
ISO |
syringin results in increased expression of TP53 protein |
CTD |
PMID:35580997 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
|
G |
Acadm |
acyl-Coenzyme A dehydrogenase, medium chain |
multiple interactions |
EXP |
tectoridin inhibits the reaction [Ethanol results in decreased expression of ACADM mRNA] |
CTD |
PMID:20637825 |
|
NCBI chr 3:153,627,990...153,650,280
Ensembl chr 3:153,627,994...153,650,269
|
|
G |
Acox1 |
acyl-Coenzyme A oxidase 1, palmitoyl |
multiple interactions |
EXP |
tectoridin inhibits the reaction [Ethanol results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:20637825 |
|
NCBI chr11:116,062,714...116,089,605
Ensembl chr11:116,062,714...116,089,871
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1a, liver |
multiple interactions |
EXP |
tectoridin inhibits the reaction [Ethanol results in decreased expression of CPT1A mRNA] |
CTD |
PMID:20637825 |
|
NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733
|
|
G |
Cyp4a10 |
cytochrome P450, family 4, subfamily a, polypeptide 10 |
multiple interactions |
EXP |
tectoridin inhibits the reaction [Ethanol results in decreased expression of CYP4A10 mRNA] |
CTD |
PMID:20637825 |
|
NCBI chr 4:115,375,484...115,390,846
Ensembl chr 4:115,375,461...115,390,846
|
|
G |
Cyp4a14 |
cytochrome P450, family 4, subfamily a, polypeptide 14 |
multiple interactions |
EXP |
tectoridin inhibits the reaction [Ethanol results in decreased expression of CYP4A14 mRNA] |
CTD |
PMID:20637825 |
|
NCBI chr 4:115,343,397...115,353,355
Ensembl chr 4:115,343,397...115,353,339
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
EXP |
tectoridin inhibits the reaction [Ethanol results in increased expression of DGAT1 mRNA] |
CTD |
PMID:20637825 |
|
NCBI chr15:76,386,215...76,396,167
Ensembl chr15:76,386,215...76,396,153
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
multiple interactions |
EXP |
tectoridin inhibits the reaction [Ethanol results in increased expression of DGAT2 mRNA] |
CTD |
PMID:20637825 |
|
NCBI chr 7:98,802,870...98,831,920
Ensembl chr 7:98,802,865...98,831,926
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
multiple interactions |
EXP |
[Xiao-Ke-An results in increased abundance of tectoridin] which results in decreased activity of DPP4 protein |
CTD |
PMID:32535096 |
|
NCBI chr 2:62,160,417...62,242,635
Ensembl chr 2:62,160,417...62,242,575
|
|
G |
Gpam |
glycerol-3-phosphate acyltransferase, mitochondrial |
multiple interactions |
EXP |
tectoridin inhibits the reaction [Ethanol results in increased expression of GPAM mRNA] |
CTD |
PMID:20637825 |
|
NCBI chr19:55,056,067...55,115,666
Ensembl chr19:55,055,700...55,115,670
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
tectoridin inhibits the reaction [Ethanol results in decreased expression of PPARA mRNA] |
CTD |
PMID:20637825 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
|
G |
Abcc1 |
ATP-binding cassette, sub-family C member 1 |
decreases response to substance |
EXP |
ABCC1 results in decreased susceptibility to Teniposide |
CTD |
PMID:8968083 |
|
NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Teniposide binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
increases expression |
ISO |
Teniposide results in increased expression of CDKN1A mRNA; Teniposide results in increased expression of CDKN1A protein |
CTD |
PMID:25914138 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cyp3a13 |
cytochrome P450, family 3, subfamily a, polypeptide 13 |
decreases methylation |
ISO |
CYP3A5 protein results in decreased methylation of Teniposide |
CTD |
PMID:8114683 |
|
NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
multiple interactions |
ISO |
Teniposide binds to and results in decreased activity of ESR1 protein |
CTD |
PMID:25752796 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
multiple interactions |
ISO |
Teniposide binds to and results in decreased activity of ESR2 protein |
CTD |
PMID:25752796 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
decreases response to substance |
ISO |
FGF2 protein results in decreased susceptibility to Teniposide |
CTD |
PMID:20221717 |
|
NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257
|
|
G |
Gstp1 |
glutathione S-transferase, pi 1 |
multiple interactions |
ISO |
Teniposide inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985
|
|
G |
Mir135b |
microRNA 135b |
decreases response to substance |
ISO |
MIR135B mRNA results in decreased susceptibility to Teniposide |
CTD |
PMID:27570640 |
|
NCBI chr 1:132,125,826...132,125,922
Ensembl chr 1:132,125,826...132,125,922
|
|
G |
Mir196b |
microRNA 196b |
decreases response to substance |
ISO |
MIR196B mRNA results in decreased susceptibility to Teniposide |
CTD |
PMID:27570640 |
|
NCBI chr 6:52,207,061...52,207,145
Ensembl chr 6:52,207,061...52,207,145
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
decreases expression multiple interactions |
EXP |
Teniposide results in decreased expression of MTTP mRNA Teniposide promotes the reaction [CETP protein results in decreased expression of MTTP mRNA] |
CTD |
PMID:25914138 |
|
NCBI chr 3:137,795,616...137,849,179
Ensembl chr 3:137,795,615...137,850,729
|
|
G |
Myc |
myelocytomatosis oncogene |
decreases expression |
ISO |
Teniposide results in decreased expression of MYC mRNA; Teniposide results in decreased expression of MYC protein |
CTD |
PMID:11585056 |
|
NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
multiple interactions affects localization affects response to substance |
ISO |
NR1H2 mutant form inhibits the reaction [Teniposide results in increased expression of CETP mRNA]; Teniposide promotes the reaction [NR1H2 protein results in increased expression of CETP mRNA] Teniposide affects the localization of NR1H2 protein NR1H2 protein affects the susceptibility to Teniposide |
CTD |
PMID:25914138 |
|
NCBI chr 7:44,199,040...44,204,928
Ensembl chr 7:44,199,040...44,203,375
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions increases expression affects response to substance |
ISO |
NR1H3 mutant form inhibits the reaction [Teniposide results in increased expression of CETP mRNA]; Teniposide promotes the reaction [NR1H3 protein results in increased expression of CETP mRNA]; Teniposide results in increased expression of and affects the localization of NR1H3 protein Teniposide results in increased expression of NR1H3 mRNA NR1H3 protein affects the susceptibility to Teniposide |
CTD |
PMID:25914138 |
|
NCBI chr 2:91,014,406...91,033,189
Ensembl chr 2:91,014,406...91,033,179
|
|
G |
Nrip1 |
nuclear receptor interacting protein 1 |
decreases expression |
ISO |
Teniposide results in decreased expression of NRIP1 mRNA; Teniposide results in decreased expression of NRIP1 protein |
CTD |
PMID:25914138 |
|
NCBI chr16:76,084,291...76,170,930
Ensembl chr16:76,084,288...76,170,715
|
|
G |
Odc1 |
ornithine decarboxylase, structural 1 |
decreases expression |
ISO |
Teniposide results in decreased expression of ODC1 protein |
CTD |
PMID:11585056 |
|
NCBI chr12:17,594,906...17,601,503
Ensembl chr12:17,594,795...17,601,506
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Teniposide binds to and results in decreased activity of PGR protein |
CTD |
PMID:25752796 |
|
NCBI chr 9:8,890,017...8,968,612
Ensembl chr 9:8,899,834...8,968,612
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
Teniposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]; Tretinoin promotes the reaction [Teniposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]] |
CTD |
PMID:25914138 |
|
NCBI chr 2:27,566,457...27,653,331
Ensembl chr 2:27,566,452...27,652,969
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions |
ISO |
Teniposide inhibits the reaction [SLCO2B1 protein results in increased uptake of Cascade Blue] |
CTD |
PMID:30863990 |
|
NCBI chr 7:99,307,011...99,360,547
Ensembl chr 7:99,307,011...99,360,547
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
Teniposide binds to and results in decreased activity of THRA protein |
CTD |
PMID:25752796 |
|
NCBI chr11:98,631,539...98,659,832
Ensembl chr11:98,631,464...98,659,832
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
Teniposide binds to and results in decreased activity of THRB protein |
CTD |
PMID:25752796 |
|
NCBI chr14:4,429,599...4,810,538
Ensembl chr14:4,431,611...4,809,435
|
|
G |
Top2a |
topoisomerase (DNA) II alpha |
multiple interactions |
ISO |
TOP2A results in decreased susceptibility to [Cisplatin co-treated with Teniposide] |
CTD |
PMID:11325482 |
|
NCBI chr11:98,883,773...98,915,037
Ensembl chr11:98,883,769...98,915,015
|
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
affects export |
ISO |
ABCC2 protein affects the export of polydatin |
CTD |
PMID:15686436 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
multiple interactions |
EXP |
polydatin inhibits the reaction [potassium oxonate results in increased expression of ABCG2 protein] |
CTD |
PMID:22865646 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
polydatin inhibits the reaction [AGT protein modified form results in increased expression of CYBB mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of CYBB protein]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of MYH7 mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NOX4 mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NOX4 protein]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NPPA mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of TGFB1 protein] |
CTD |
PMID:25488910 |
|
NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
decreases localization multiple interactions |
ISO |
polydatin results in decreased localization of AHR protein polydatin promotes the reaction [6-formylindolo(3,2-b)carbazole results in increased localization of AHR protein] |
CTD |
PMID:21756928 |
|
NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
increases localization |
ISO |
polydatin results in increased localization of ARNT protein |
CTD |
PMID:21756928 |
|
NCBI chr 3:95,341,674...95,404,551
Ensembl chr 3:95,341,699...95,404,551
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
ISO |
polydatin inhibits the reaction [Rotenone results in decreased expression of ATG5 protein] |
CTD |
PMID:31926197 |
|
NCBI chr10:44,144,325...44,240,295
Ensembl chr10:44,144,354...44,240,287
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
EXP ISO |
cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BCL2 mRNA]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BCL2 mRNA] polydatin inhibits the reaction [Dopamine results in decreased expression of BCL2 protein] |
CTD |
PMID:27481074 PMID:28980048 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
cyclopamine inhibits the reaction [polydatin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein]]; polydatin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein] polydatin inhibits the reaction [Arsenic Trioxide results in decreased activity of CAT protein] |
CTD |
PMID:27481074 PMID:29130132 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases secretion decreases expression |
ISO |
polydatin inhibits the reaction [leptomycin B results in increased secretion of CCL2 protein]; polydatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA]; polydatin inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA] polydatin results in decreased secretion of CCL2 protein polydatin results in decreased expression of CCL2 mRNA |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
EXP |
cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND1 mRNA]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND1 mRNA] |
CTD |
PMID:27481074 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
EXP |
cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND2 mRNA]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND2 mRNA] |
CTD |
PMID:27481074 |
|
NCBI chr 6:127,102,125...127,131,913
Ensembl chr 6:127,102,125...127,129,156
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions decreases secretion decreases expression |
ISO |
[polydatin co-treated with TGFA protein] results in increased expression of CXCL10 mRNA; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; polydatin inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA] polydatin results in decreased secretion of CXCL10 protein polydatin results in decreased expression of CXCL10 mRNA |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions increases secretion decreases expression |
ISO |
[polydatin co-treated with TGFA protein] results in increased expression of CXCL8 mRNA; polydatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CXCL8 mRNA]; polydatin promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] polydatin results in increased secretion of CXCL8 protein polydatin results in decreased expression of CXCL8 mRNA |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cybb |
cytochrome b-245, beta polypeptide |
multiple interactions |
ISO |
polydatin inhibits the reaction [AGT protein modified form results in increased expression of CYBB mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of CYBB protein] |
CTD |
PMID:25488910 |
|
NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
polydatin results in increased expression of CYP1A1 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
polydatin inhibits the reaction [TGFA protein affects the localization of EGFR protein] |
CTD |
PMID:21967610 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
multiple interactions |
EXP |
ESR2 gene mutant form inhibits the reaction [polydatin results in increased expression of SOD2 protein] |
CTD |
PMID:24361291 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
G6pdx |
glucose-6-phosphate dehydrogenase X-linked |
decreases activity |
ISO |
polydatin results in decreased activity of G6PD protein |
CTD |
PMID:25130191 |
|
NCBI chr X:73,453,089...73,472,486
Ensembl chr X:73,453,089...73,472,800
|
|
G |
Gli1 |
GLI-Kruppel family member GLI1 |
multiple interactions |
EXP |
cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GLI1 mRNA]]; cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased localization of GLI1 protein]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GLI1 mRNA]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased localization of GLI1 protein] |
CTD |
PMID:27481074 |
|
NCBI chr10:127,165,751...127,177,448
Ensembl chr10:127,165,751...127,177,843
|
|
G |
Hlcs |
holocarboxylase synthetase (biotin- [propriony-Coenzyme A-carboxylase (ATP-hydrolysing)] ligase) |
decreases activity |
ISO |
polydatin results in decreased activity of HLCS protein |
CTD |
PMID:26303405 |
|
NCBI chr16:93,930,054...94,116,098
Ensembl chr16:93,929,741...94,114,430
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; polydatin promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] |
CTD |
PMID:21756928 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
polydatin inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B mRNA] |
CTD |
PMID:29130132 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
polydatin inhibits the reaction [OVAL protein results in increased secretion of IL4 protein] |
CTD |
PMID:23840142 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO |
polydatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA] polydatin results in decreased expression of IL6 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Keap1 |
kelch-like ECH-associated protein 1 |
multiple interactions |
ISO EXP |
polydatin inhibits the reaction [Hydrogen Peroxide results in increased expression of KEAP1 protein] polydatin inhibits the reaction [TSHR protein results in increased expression of KEAP1 protein] |
CTD |
PMID:31705858 |
|
NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
|
|
G |
Lct |
lactase |
increases hydrolysis |
ISO |
LCT protein results in increased hydrolysis of polydatin analog |
CTD |
PMID:17009167 |
|
NCBI chr 1:128,212,493...128,256,055
Ensembl chr 1:128,212,493...128,256,055
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation decreases phosphorylation |
ISO |
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [polydatin results in increased phosphorylation of MAPK1 protein] polydatin results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:21756928 PMID:28980048 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation decreases phosphorylation |
ISO |
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [polydatin results in increased phosphorylation of MAPK3 protein] polydatin results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:21756928 PMID:28980048 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk7 |
mitogen-activated protein kinase 7 |
multiple interactions increases phosphorylation |
ISO |
XMD 8-92 inhibits the reaction [polydatin results in increased phosphorylation of MAPK7 protein] |
CTD |
PMID:28980048 |
|
NCBI chr11:61,379,638...61,385,101
Ensembl chr11:61,379,638...61,385,232
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
ISO |
polydatin inhibits the reaction [Rotenone results in increased expression of MFN2 protein] |
CTD |
PMID:31926197 |
|
NCBI chr 4:147,958,043...147,989,527
Ensembl chr 4:147,958,056...147,989,161
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
polydatin inhibits the reaction [Rotenone results in increased phosphorylation of MTOR protein] |
CTD |
PMID:31926197 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Myh7 |
myosin, heavy polypeptide 7, cardiac muscle, beta |
multiple interactions |
ISO |
polydatin inhibits the reaction [AGT protein modified form results in increased expression of MYH7 mRNA] |
CTD |
PMID:25488910 |
|
NCBI chr14:55,208,141...55,232,083
Ensembl chr14:55,208,141...55,232,083
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions |
ISO EXP |
[polydatin co-treated with Hydrogen Peroxide] results in increased expression of NFE2L2 protein; NFE2L2 protein affects the reaction [[polydatin co-treated with Hydrogen Peroxide] results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [polydatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NQO1 protein]] polydatin inhibits the reaction [TSHR protein results in decreased expression of NFE2L2 protein] |
CTD |
PMID:31705858 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
ISO |
polydatin inhibits the reaction [AGT protein modified form results in increased expression of NOX4 mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NOX4 protein] |
CTD |
PMID:25488910 |
|
NCBI chr 7:86,893,638...87,047,918
Ensembl chr 7:86,895,304...87,047,918
|
|
G |
Nppa |
natriuretic peptide type A |
multiple interactions |
ISO |
polydatin inhibits the reaction [2,2'-dipyridyl disulfide results in increased expression of NPPA protein]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NPPA mRNA]; polydatin inhibits the reaction [Phenylephrine results in increased expression of NPPA protein] |
CTD |
PMID:25449040 PMID:25488910 |
|
NCBI chr 4:148,085,179...148,086,531
Ensembl chr 4:148,085,179...148,086,536
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions |
ISO EXP |
NFE2L2 protein affects the reaction [polydatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NQO1 protein]]; polydatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NQO1 protein] polydatin inhibits the reaction [TSHR protein results in decreased expression of NQO1 protein] |
CTD |
PMID:31705858 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Orai1 |
ORAI calcium release-activated calcium modulator 1 |
affects response to substance |
EXP |
ORAI1 protein affects the susceptibility to polydatin |
CTD |
PMID:22959927 |
|
NCBI chr 5:123,153,078...123,168,515
Ensembl chr 5:123,153,137...123,168,519
|
|
G |
Park7 |
Parkinson disease (autosomal recessive, early onset) 7 |
multiple interactions |
ISO |
[PRKN protein affects the susceptibility to polydatin] which results in increased expression of PARK7 protein; polydatin inhibits the reaction [Rotenone results in increased expression of PARK7 protein] |
CTD |
PMID:31926197 |
|
NCBI chr 4:150,981,590...150,994,378
Ensembl chr 4:150,981,590...150,998,894
|
|
G |
Pde5a |
phosphodiesterase 5A, cGMP-specific |
decreases activity |
ISO |
polydatin results in decreased activity of PDE5A protein |
CTD |
PMID:15769121 |
|
NCBI chr 3:122,522,822...122,653,023
Ensembl chr 3:122,522,596...122,653,023
|
|
G |
Ppargc1b |
peroxisome proliferative activated receptor, gamma, coactivator 1 beta |
decreases expression |
ISO |
polydatin results in decreased expression of PPARGC1B protein |
CTD |
PMID:31926197 |
|
NCBI chr18:61,424,516...61,533,846
Ensembl chr18:61,431,207...61,533,502
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
multiple interactions |
ISO |
polydatin inhibits the reaction [2,2'-dipyridyl disulfide results in increased phosphorylation of PPP1R12A protein]; polydatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:25449040 |
|
NCBI chr10:107,997,913...108,115,846
Ensembl chr10:107,998,054...108,120,336
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
affects response to substance multiple interactions |
ISO |
PRKN protein affects the susceptibility to polydatin [PRKN protein affects the susceptibility to polydatin] which results in increased expression of PARK7 protein |
CTD |
PMID:31926197 |
|
NCBI chr17:11,059,227...12,282,257
Ensembl chr17:11,059,271...12,282,248
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
decreases activity |
EXP |
polydatin results in decreased activity of PTGS1 protein |
CTD |
PMID:11962253 |
|
NCBI chr 2:36,106,758...36,142,287
Ensembl chr 2:36,120,438...36,142,284
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases activity |
ISO EXP |
[polydatin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of PTGS2 mRNA polydatin results in decreased activity of PTGS2 protein |
CTD |
PMID:11962253 PMID:21756928 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; polydatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein] polydatin inhibits the reaction [Arsenic Trioxide results in increased expression of RELA mRNA] |
CTD |
PMID:21756928 PMID:29130132 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
ISO |
polydatin inhibits the reaction [Phenylephrine results in increased activity of RHOA protein] |
CTD |
PMID:25449040 |
|
NCBI chr 9:108,183,359...108,215,142
Ensembl chr 9:108,183,328...108,215,133
|
|
G |
Shh |
sonic hedgehog |
multiple interactions |
EXP |
polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and results in increased secretion of SHH protein] |
CTD |
PMID:27481074 |
|
NCBI chr 5:28,661,838...28,672,099
Ensembl chr 5:28,661,813...28,672,254
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
polydatin inhibits the reaction [Rotenone results in decreased expression of SIRT1 protein] |
CTD |
PMID:31926197 |
|
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
|
|
G |
Slc22a1 |
solute carrier family 22 (organic cation transporter), member 1 |
multiple interactions |
EXP |
polydatin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A1 protein] |
CTD |
PMID:22865646 |
|
NCBI chr17:12,867,761...12,894,725
Ensembl chr17:12,867,756...12,894,716
|
|
G |
Slc22a12 |
solute carrier family 22 (organic anion/cation transporter), member 12 |
multiple interactions |
EXP |
polydatin inhibits the reaction [potassium oxonate results in increased expression of SLC22A12 protein] |
CTD |
PMID:22865646 |
|
NCBI chr19:6,585,884...6,593,100
Ensembl chr19:6,585,875...6,593,062
|
|
G |
Slc22a4 |
solute carrier family 22 (organic cation transporter), member 4 |
multiple interactions |
EXP |
polydatin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A4 protein] |
CTD |
PMID:22865646 |
|
NCBI chr11:53,873,941...53,920,866
Ensembl chr11:53,873,949...53,918,916
|
|
G |
Slc22a5 |
solute carrier family 22 (organic cation transporter), member 5 |
multiple interactions |
EXP |
polydatin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A5 protein] |
CTD |
PMID:22865646 |
|
NCBI chr11:53,755,368...53,782,609
Ensembl chr11:53,755,368...53,782,486
|
|
G |
Slc22a6 |
solute carrier family 22 (organic anion transporter), member 6 |
multiple interactions |
EXP |
polydatin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A6 protein] |
CTD |
PMID:22865646 |
|
NCBI chr19:8,595,360...8,605,663
Ensembl chr19:8,595,403...8,605,663
|
|
G |
Slc2a9 |
solute carrier family 2 (facilitated glucose transporter), member 9 |
multiple interactions |
EXP |
polydatin inhibits the reaction [potassium oxonate results in increased expression of SLC2A9 protein] |
CTD |
PMID:22865646 |
|
NCBI chr 5:38,506,616...38,660,488
Ensembl chr 5:38,506,616...38,660,486
|
|
G |
Slc5a1 |
solute carrier family 5 (sodium/glucose cotransporter), member 1 |
affects uptake |
ISO |
SLC5A1 protein affects the uptake of polydatin |
CTD |
PMID:15686436 |
|
NCBI chr 5:33,261,563...33,320,043
Ensembl chr 5:33,261,563...33,320,214
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
multiple interactions increases expression |
ISO EXP |
polydatin results in increased expression of and results in increased activity of SOD2 protein polydatin results in increased expression of SOD2 protein ESR2 gene mutant form inhibits the reaction [polydatin results in increased expression of SOD2 protein]; fulvestrant inhibits the reaction [polydatin results in increased expression of SOD2 protein] |
CTD |
PMID:24361291 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
polydatin promotes the reaction [Rotenone results in decreased expression of SQSTM1 protein] |
CTD |
PMID:31926197 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
ISO |
[polydatin co-treated with TGFA protein] results in increased expression of CXCL10 mRNA; [polydatin co-treated with TGFA protein] results in increased expression of CXCL8 mRNA; polydatin inhibits the reaction [TGFA protein affects the localization of EGFR protein] |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr 6:86,172,020...86,252,726
Ensembl chr 6:86,172,205...86,252,701
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
polydatin inhibits the reaction [AGT protein modified form results in increased expression of TGFB1 protein] |
CTD |
PMID:25488910 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO |
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; polydatin promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] polydatin inhibits the reaction [Arsenic Trioxide results in increased expression of TNF mRNA] polydatin results in decreased expression of TNF mRNA |
CTD |
PMID:21756928 PMID:29130132 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions |
ISO |
polydatin inhibits the reaction [Arsenic Trioxide results in increased expression of TP53 mRNA] |
CTD |
PMID:29130132 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
multiple interactions |
EXP |
polydatin inhibits the reaction [TSHR protein results in decreased expression of NFE2L2 protein]; polydatin inhibits the reaction [TSHR protein results in decreased expression of NQO1 protein]; polydatin inhibits the reaction [TSHR protein results in increased expression of KEAP1 protein] |
CTD |
PMID:31705858 |
|
NCBI chr12:91,367,767...91,507,283
Ensembl chr12:91,351,337...91,516,582
|
|
G |
Tug1 |
taurine upregulated gene 1 |
decreases expression |
ISO |
polydatin results in decreased expression of TUG1 mRNA |
CTD |
PMID:30974157 |
|
NCBI chr11:3,589,313...3,599,021
Ensembl chr11:3,589,785...3,599,673
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase 1 family, polypeptide A1 |
increases hydrolysis |
ISO |
UGT1A1 protein results in increased hydrolysis of polydatin metabolite |
CTD |
PMID:17009167 |
|
NCBI chr 1:88,139,681...88,147,724
Ensembl chr 1:88,139,681...88,146,719
|
|
G |
Ulk1 |
unc-51 like kinase 1 |
multiple interactions |
ISO |
polydatin inhibits the reaction [Rotenone results in increased phosphorylation of ULK1 protein] |
CTD |
PMID:31926197 |
|
NCBI chr 5:110,932,355...110,957,991
Ensembl chr 5:110,932,354...110,957,963
|
|
G |
Umod |
uromodulin |
multiple interactions |
EXP |
polydatin inhibits the reaction [potassium oxonate results in increased expression of and results in decreased secretion of UMOD protein] |
CTD |
PMID:22865646 |
|
NCBI chr 7:119,061,931...119,078,485
Ensembl chr 7:119,061,934...119,078,505
|
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
rhapontin inhibits the reaction [Streptozocin results in decreased activity of CAT protein] |
CTD |
PMID:32662907 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
rhapontin inhibits the reaction [Streptozocin results in decreased expression of HMOX1 mRNA]; rhapontin inhibits the reaction [Streptozocin results in decreased expression of HMOX1 protein] |
CTD |
PMID:32662907 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
rhapontin inhibits the reaction [Streptozocin results in decreased expression of IL10 mRNA]; rhapontin inhibits the reaction [Streptozocin results in decreased expression of IL10 protein] |
CTD |
PMID:32662907 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Ins1 |
insulin I |
multiple interactions |
ISO |
rhapontin inhibits the reaction [Streptozocin results in decreased expression of INS1 protein] |
CTD |
PMID:32662907 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Keap1 |
kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
rhapontin inhibits the reaction [Streptozocin results in increased expression of KEAP1 mRNA]; rhapontin inhibits the reaction [Streptozocin results in increased expression of KEAP1 protein] |
CTD |
PMID:32662907 |
|
NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
rhapontin inhibits the reaction [Streptozocin results in increased expression of MMP2 mRNA] |
CTD |
PMID:32662907 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions |
ISO |
rhapontin inhibits the reaction [Streptozocin results in decreased expression of NFE2L2 mRNA]; rhapontin inhibits the reaction [Streptozocin results in decreased expression of NFE2L2 protein] |
CTD |
PMID:32662907 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions |
ISO |
rhapontin inhibits the reaction [Streptozocin results in decreased expression of NQO1 mRNA] |
CTD |
PMID:32662907 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
multiple interactions |
ISO |
rhapontin inhibits the reaction [Streptozocin results in decreased expression of TIMP1 mRNA] |
CTD |
PMID:32662907 |
|
NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
rhapontin inhibits the reaction [Streptozocin results in increased expression of TNF mRNA] |
CTD |
PMID:32662907 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Hydrogen Peroxide affects the localization of BAX protein] |
CTD |
PMID:30104959 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] |
CTD |
PMID:30104959 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
NFE2L2 protein affects the reaction [trilobatin inhibits the reaction [Isoflurane results in decreased activity of CAT protein]]; trilobatin inhibits the reaction [Isoflurane results in decreased activity of CAT protein] |
CTD |
PMID:32663520 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of ESRRA protein] |
CTD |
PMID:30104959 |
|
NCBI chr19:6,888,345...6,899,182
Ensembl chr19:6,888,345...6,899,208
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of FOXO3 protein] |
CTD |
PMID:30104959 |
|
NCBI chr10:42,057,841...42,152,691
Ensembl chr10:42,057,837...42,152,751
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of GPX1 protein] |
CTD |
PMID:30104959 |
|
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP ISO |
trilobatin promotes the reaction [Isoflurane results in increased expression of HMOX1 mRNA]; trilobatin promotes the reaction [Isoflurane results in increased expression of HMOX1 protein] trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of HMOX1 protein] |
CTD |
PMID:30104959 PMID:32663520 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Idh2 |
isocitrate dehydrogenase 2 (NADP+), mitochondrial |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased activity of IDH2 protein]; trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of IDH2 protein] |
CTD |
PMID:30104959 |
|
NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; trilobatin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] |
CTD |
PMID:25053100 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; trilobatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; trilobatin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:25053100 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Keap1 |
kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Hydrogen Peroxide results in increased expression of KEAP1 protein] |
CTD |
PMID:30104959 |
|
NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
|
|
G |
mt-Atp6 |
ATP synthase 6, mitochondrial |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of ATP6 mRNA] |
CTD |
PMID:30104959 |
|
NCBI chr MT:7,927...8,607
Ensembl chr MT:7,927...8,607
|
|
G |
mt-Co1 |
cytochrome c oxidase I, mitochondrial |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX1 mRNA] |
CTD |
PMID:30104959 |
|
NCBI chr MT:5,328...6,872
Ensembl chr MT:5,328...6,872
|
|
G |
mt-Cytb |
cytochrome b, mitochondrial |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of CYTB mRNA] |
CTD |
PMID:30104959 |
|
NCBI chr MT:14,145...15,288
Ensembl chr MT:14,145...15,288
|
|
G |
mt-Nd2 |
NADH dehydrogenase 2, mitochondrial |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of ND2 mRNA] |
CTD |
PMID:30104959 |
|
NCBI chr MT:3,914...4,951
Ensembl chr MT:3,914...4,951
|
|
G |
mt-Nd5 |
NADH dehydrogenase 5, mitochondrial |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of ND5 mRNA] |
CTD |
PMID:30104959 |
|
NCBI chr MT:11,742...13,565
Ensembl chr MT:11,742...13,565
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions |
ISO EXP |
trilobatin promotes the reaction [Hydrogen Peroxide affects the localization of NFE2L2 protein] NFE2L2 protein affects the reaction [trilobatin inhibits the reaction [Isoflurane results in decreased activity of CAT protein]]; trilobatin promotes the reaction [Isoflurane results in increased expression of NFE2L2 protein] |
CTD |
PMID:30104959 PMID:32663520 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein] |
CTD |
PMID:25053100 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions |
EXP ISO |
trilobatin promotes the reaction [Isoflurane results in increased expression of NQO1 mRNA]; trilobatin promotes the reaction [Isoflurane results in increased expression of NQO1 protein] trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NQO1 protein] |
CTD |
PMID:30104959 PMID:32663520 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of PPARGC1A protein] |
CTD |
PMID:30104959 |
|
NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein] |
CTD |
PMID:25053100 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Sirt3 |
sirtuin 3 |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of SIRT3 mRNA]; trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of SIRT3 protein] |
CTD |
PMID:30104959 |
|
NCBI chr 7:140,443,576...140,462,222
Ensembl chr 7:140,443,579...140,462,222
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased activity of SOD2 protein]; trilobatin inhibits the reaction [Hydrogen Peroxide results in increased acetylation of SOD2 protein] |
CTD |
PMID:30104959 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; trilobatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; trilobatin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:25053100 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Ucp2 |
uncoupling protein 2 (mitochondrial, proton carrier) |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Hydrogen Peroxide results in increased expression of UCP2 protein] |
CTD |
PMID:30104959 |
|
NCBI chr 7:100,142,565...100,148,832
Ensembl chr 7:100,142,544...100,151,227
|
|